<SEC-DOCUMENT>0001213900-22-012161.txt : 20220314
<SEC-HEADER>0001213900-22-012161.hdr.sgml : 20220314
<ACCEPTANCE-DATETIME>20220314161636
ACCESSION NUMBER:		0001213900-22-012161
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		17
FILED AS OF DATE:		20220314
DATE AS OF CHANGE:		20220314

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Helix Acquisition Corp
		CENTRAL INDEX KEY:			0001821586
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			E9
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-262643
		FILM NUMBER:		22736780

	BUSINESS ADDRESS:	
		STREET 1:		C/O CORMORANT ASSET MANAGEMENT, LLP
		STREET 2:		200 CLARENDON STREET FL 52
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		857 702 0370

	MAIL ADDRESS:	
		STREET 1:		C/O CORMORANT ASSET MANAGEMENT, LLP
		STREET 2:		200 CLARENDON STREET FL 52
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>ea156790-s1a2_helixacq.htm
<DESCRIPTION>AMENDMENT NO. 2 TO FORM S-1
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:HLXA="http://helixacquisitioncorp.com/20211231">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_03B_HLXA_helixacquisitioncorp.com_20211231 -->
<!-- Field: Set; Name: xdx; ID: xdx_046_20210101_20211231 -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DEntityCentralIndexKey_0001821586 -->
<!-- Field: Set; Name: xdx; ID: xdx_055_edei%2D%2DAmendmentFlag_true -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:EntityCentralIndexKey">0001821586</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt:booleantrue" name="dei:AmendmentFlag">true</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0010" name="dei:DocumentType">S-1/A</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0012" name="dei:EntityRegistrantName">Helix Acquisition Corp</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt-sec:entityfilercategoryen" id="xdx2ixbrl0015" name="dei:EntityFilerCategory">Non-accelerated Filer</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="hlxa-20211231.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-01-01to2021-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001821586</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>As filed with the
Securities and Exchange Commission on March 14, 2022</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><b>Registration No.&#160;333-262643</b></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-size: 6pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>SECURITIES AND EXCHANGE
COMMISSION<br />
Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-size: 6pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-size: 6pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>AMENDMENT NO. 2<br />
TO<br />
FORM&#160;<span id="xdx_909_edei--DocumentType_dxL_c20210101__20211231_zuecYKt8U3Q5" title="Document Type::XDX::S-1%2FA"><span style="-sec-ix-hidden: xdx2ixbrl0010">S-1</span></span><br />
REGISTRATION STATEMENT<br />
UNDER<br />
THE SECURITIES ACT OF 1933</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-size: 6pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-size: 6pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b><span id="xdx_906_edei--EntityRegistrantName_dxL_c20210101__20211231_zK4R4rqsXQf1" title="Entity Registrant Name::XDX::Helix%20Acquisition%20Corp"><span style="-sec-ix-hidden: xdx2ixbrl0012">HELIX ACQUISITION CORP.</span></span>*<br />
</b>(Exact name of registrant as specified in its charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-size: 6pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-size: 6pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; padding: 0; width: 32%; text-align: center; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--EntityIncorporationStateCountryCode_c20210101__20211231_zXfG4siq54X"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode">Cayman Islands</ix:nonNumeric></span></b></span></td>
    <td style="padding: 0; white-space: nowrap; width: 2%; text-indent: 0">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; padding: 0; width: 32%; text-align: center; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>6770</b></span></td>
    <td style="padding: 0; white-space: nowrap; width: 2%; text-indent: 0">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; padding: 0; width: 32%; text-align: center; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>N/A</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding: 0; text-align: center; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction of<br />
incorporation or organization)</span></td>
    <td style="padding: 0; white-space: nowrap; text-indent: 0">&#160;</td>
    <td style="padding: 0; text-align: center; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Primary Standard Industrial<br />
Classification Code Number)</span></td>
    <td style="padding: 0; white-space: nowrap; text-indent: 0">&#160;</td>
    <td style="padding: 0; text-align: center; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.&#160;Employer<br />
Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-size: 6pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>c/o Cormorant Asset
Management, LLP<br />
200 Clarendon Street, FL&#160;52<br />
Boston, MA&#160;02116<br />
(857)&#160;702-0370<br />
</b>(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-size: 6pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>Maples Fiduciary Services
(Delaware) Inc.<br />
4001 Kennett Pike, Suite 302<br />
Wilmington, Delaware 19807<br />
+1 (302)-338-9130<br />
</b>(Name, address, including zip code, and telephone number, including area code, of agent for service)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-size: 6pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>Copies to:</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding: 0; width: 32%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: center; text-indent: -10pt"><b>Joel L.&#160;Rubinstein</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: center; text-indent: -10pt"><b>Elliott Smith</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: center; text-indent: -10pt"><b>White&#160;&amp;
    Case LLP</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: center; text-indent: -10pt"><b>1221 Avenue of
    the Americas</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: center; text-indent: -10pt"><b>New&#160;York,
    NY&#160;10020</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 10pt; text-align: center; text-indent: -10pt"><b>(212)&#160;819-8200</b></p></td>
    <td style="padding: 0; white-space: nowrap; width: 2%">&#160;</td>
    <td style="padding: 0; width: 32%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Matthew Gardner</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Michael Johns</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Maples and Calder<br />
    P.O.&#160;Box 309, Ugland House</b>,</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Grand Cayman</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Cayman Islands</b>,&#160;<b>KY1-1104</b><br />
    <b>+1 (345)&#160;949-8066</b></p></td>
    <td style="padding: 0; white-space: nowrap; width: 2%">&#160;</td>
    <td style="padding: 0; width: 32%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Ryan A.&#160;Murr</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Branden C.&#160;Berns</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Gibson, Dunn&#160;&amp; Crutcher LLP</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>555 Mission Street, Suite 3000</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>San Francisco, CA&#160;94105</b></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(415)&#160;393-8200</b></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><span style="font-size: 6pt">&#160;</span></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Approximate date of
commencement of proposed sale to the public:&#160;</b>From time to time after this Registration Statement becomes effective.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-size: 6pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">If any of the securities
being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&#160;415 under the Securities Act&#160;of&#160;1933
check the following box:&#160;&#9746;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-size: 6pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">If this form is filed
to register additional securities for an offering pursuant to Rule&#160;462(b)&#160;under the Securities Act, check the following box
and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#160;&#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-size: 6pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">If this form is a post-effective
amendment filed pursuant to Rule&#160;462(c)&#160;under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering.&#160;&#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-size: 6pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">If this form is a post-effective
amendment filed pursuant to Rule&#160;462(d)&#160;under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering.&#160;&#9744;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-size: 6pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Indicate by check mark
whether the registrant is a large accelerated filer, an accelerated filer, a&#160;non-accelerated&#160;filer, smaller reporting company,
or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller
reporting company,&#8221; and &#8220;emerging growth company&#8221; in&#160;Rule&#160;12b-2&#160;of the Exchange&#160;Act.</p>

<p style="margin-top: 0; margin-bottom: 0"><span style="font-size: 6pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 5%; padding-bottom: 2.25pt">&#160;</td>
    <td style="width: 17%; padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large&#160;accelerated&#160;filer</span></td>
    <td style="white-space: nowrap; width: 1%; padding-bottom: 2.25pt">&#160;</td>
    <td style="width: 21%; padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td>
    <td style="white-space: nowrap; width: 1%; padding-bottom: 2.25pt">&#160;</td>
    <td style="width: 21%; padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated&#160;filer</span></td>
    <td style="white-space: nowrap; width: 1%; padding-bottom: 2.25pt">&#160;</td>
    <td style="width: 33%; padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 2.25pt">&#160;</td>
    <td style="padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--EntityFilerCategory_dxL_c20210101__20211231_zSROuVuNiaMk" title="Entity Filer Category::XDX::Non-accelerated%20Filer"><span style="-sec-ix-hidden: xdx2ixbrl0015">Non-accelerated&#160;filer</span></span></span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller&#160;reporting&#160;company</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_edei--EntitySmallBusiness_c20210101__20211231_z1LHRHBOzCsl"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 2.25pt">&#160;</td>
    <td style="padding-bottom: 2.25pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="padding-bottom: 2.25pt">&#160;</td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging&#160;growth&#160;company</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_edei--EntityEmergingGrowthCompany_c20210101__20211231_zPi7kaG6n6n7"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-size: 6pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">If an emerging growth
company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B)&#160;of the Securities Act.&#160;<span id="xdx_90A_edei--EntityExTransitionPeriod_c20210101__20211231_zx3HWbHhg5Ia" title="Entity Ex Transition Period"><ix:nonNumeric contextRef="From2021-01-01to2021-12-31" format="ixt:booleanfalse" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-size: 6pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left"><b>*</b></td><td style="text-align: justify"><b>All ordinary shares being registered for resale hereunder
will be issued by Helix in connection with the business combination with MoonLake Immunotherapeutics AG.&#160;Upon the closing of the
business combination, Helix will change its name to MoonLake Immunotherapeutics.</b></td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font-size: 6pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>The registrant hereby
amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file
a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section&#160;8(a)&#160;of
the Securities Act&#160;of&#160;1933 or until this registration statement shall become effective on such date as the Securities and Exchange
Commission, acting pursuant to said Section&#160;8(a), may determine.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt; background-color: white"><span style="font-size: 6pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt; background-color: white"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt; background-color: white"><span style="font-size: 6pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt; background-color: white"></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>EXPLANATORY NOTE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<div id="xdx_987_edei--AmendmentDescription_c20210101__20211231_z8MAtkuhKQQk">

<ix:nonNumeric contextRef="From2021-01-01to2021-12-31" name="dei:AmendmentDescription"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">This registration statement
registers the resale of up to 11,500,000 Class&#160;A Ordinary Shares (the &#8220;<b><i>PIPE Shares</i></b>&#8221;), par value $0.0001
per share, of Helix Acquisition Corp., a Cayman Islands exempted company (&#8220;<b><i>Helix</i></b>&#8221;), by the selling shareholders
named in this prospectus (or their permitted transferees) (the &#8220;<b><i>Selling Shareholders</i></b>&#8221;). The Selling Shareholders
are expected to be issued the PIPE Shares in private placements immediately prior to or substantially concurrently with the consummation
of the proposed business combination (the &#8220;<b><i>Business Combination</i></b>&#8221;) by and among Helix, MoonLake Immunotherapeutics
AG, a Swiss stock corporation (&#8220;<b><i>MoonLake</i></b>&#8221;), the existing securityholders of MoonLake (collectively, the &#8220;<b><i>ML
Parties</i></b>&#8221;), Helix Holdings LLC, a Cayman Islands limited liability company and the sponsor of Helix, and the representative
of the ML Parties.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The PIPE Shares will
not be issued and outstanding at the time of the extraordinary general meeting of Helix&#8217;s shareholders relating to the Business
Combination and, accordingly, will not be entitled to vote at the extraordinary general meeting and will not have redemption rights in
connection therewith. Further, the holders of the PIPE Shares will not receive any proceeds from the trust account established in connection
with Helix&#8217;s initial public offering in the event Helix does not consummate an initial business combination by the October&#160;22,
2022 deadline set forth in its amended and restated memorandum and articles of association. In the event the Business Combination is not
approved by Helix shareholders or the other conditions precedent to the consummation of the Business Combination are not met or waived,
the PIPE Shares will not be issued and Helix will seek to withdraw this registration statement prior to its effectiveness.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Helix is filing this
Amendment No. 2 to the registration statement as an exhibits-only filing to file the exhibits attached hereto. Accordingly, this amendment
consists only of the facing page, this explanatory note, Part II of the registration statement, the signature pages to the registration
statement, and the filed exhibits.</p></ix:nonNumeric>

</div>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>PART&#160;II</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>INFORMATION NOT REQUIRED
IN PROSPECTUS</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Item&#160;13.&#160;Other
Expenses of Issuance and Distribution.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The following table sets
forth the estimated expenses to be borne by the registrant in connection with the issuance and distribution of the Class&#160;A Ordinary
Shares being registered hereby.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold">Expense</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Estimated<br /> Amount</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left; text-indent: -10pt; padding-left: 10pt">Securities and Exchange Commission registration fee</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10,532.57</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Accounting fees and expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">15,000.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -10pt; padding-left: 10pt">Legal fees and expenses</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">75,000.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt">Financial printing and miscellaneous expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20,000.00</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">120,532.57</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We will bear all costs,
expenses and fees in connection with the registration of the Class&#160;A Ordinary Shares being registered hereby, including with regard
to compliance with state securities or &#8220;blue sky&#8221; laws. The Selling Shareholders, however, will bear all underwriting commissions
and discounts, if any, attributable to their sale of the Class&#160;A Ordinary Shares. All amounts are estimates except the SEC registration
fee.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Item&#160;14.&#160;Indemnification
of Directors and Officers.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Cayman Islands law does
not limit the extent to which a company&#8217;s memorandum and articles of association may provide for indemnification of officers and
directors, except to the extent any such provision may be held by the Cayman Islands courts to be contrary to public policy, such as to
provide indemnification against willful default, willful neglect, civil fraud or the consequences of committing a crime. The Proposed
MAA provide for indemnification of our officers and directors to the maximum extent permitted by law, including for any liability incurred
in their capacities as such, except through their own actual fraud, willful default or willful neglect. We purchased a policy of directors&#8217;
and officers&#8217; liability insurance that insures our officers and directors against the cost of defense, settlement or payment of
a judgment in some circumstances and insures us against our obligations to indemnify our officers and directors.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">We have entered into
indemnification agreements with each of our directors and officers in which we have agreed to indemnify, defend and hold harmless, and
also advance expenses as incurred, to the fullest extent permitted under applicable law, from damage arising from the fact that such person
is or was an officer or director of our company or our subsidiaries.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The indemnification rights
set forth above shall not be exclusive of any other right which an indemnified person may have or hereafter acquire under any statute,
our amended and restated certificate of incorporation, our amended and restated bylaws, any agreement, any vote of stockholders or disinterested
directors or otherwise.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Our indemnification obligations
may discourage shareholders from bringing a lawsuit against our officers or directors for breach of their fiduciary duty. These provisions
also may have the effect of reducing the likelihood of derivative litigation against our officers and directors, even though such an action,
if successful, might otherwise benefit us and our shareholders. Furthermore, a shareholder&#8217;s investment may be adversely affected
to the extent we pay the costs of settlement and damage awards against our officers and directors pursuant to these indemnification provisions.
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers, or control persons,
in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b></b></p>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Item&#160;15.&#160;Recent
Sales of Unregistered Securities.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In connection with Helix&#8217;s
formation on August&#160;13, 2020, the Sponsor paid $25,000, or approximately $0.007 per share, to cover certain of our offering costs
in exchange 3,593,750 founder shares. Such securities were issued in connection with our organization pursuant to the exemption from registration
contained in Section&#160;4(a)(2)&#160;of the Securities Act. On September&#160;30, 2020, the Sponsor surrendered, for no consideration,
718,750 Class&#160;B Ordinary Shares, resulting in our Sponsor holding 2,875,000 founder shares with a value of approximately $0.009 per
share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Simultaneously with the
closing of Helix&#8217;s IPO on October&#160;22, 2020, the Sponsor purchased an aggregate of 430,000 private placement shares, at a price
of $10.00 per share, for an aggregate of $4,300,000, in a private placement exempt from registration pursuant to Section&#160;4(a)(2)&#160;of
the Securities Act.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Item&#160;16.&#160;Exhibits
and Financial Statement Schedules.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The following exhibits
are filed as part of this registration statement:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; padding-top: 0; padding-right: 0; padding-left: 0; width: 9%; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Exhibit</b></span></td>
    <td style="padding: 0 0 1.5pt; white-space: nowrap; width: 1%; text-indent: 0">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; padding-top: 0; padding-right: 0; padding-left: 0; width: 90%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Description</b></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.1&#8224;</span></td>
    <td style="padding: 0; white-space: nowrap; text-indent: 0">&#160;</td>
    <td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1821586/000121390021051257/ea147872ex2-1_helixacq.htm">Business Combination Agreement, dated as of October&#160;4, 2021, by and among Helix Acquisition Corp., MoonLake Immunotherapeutics AG, the existing shareholders and option rights holders of MoonLake Immunotherapeutics AG, Helix Holdings LLC, and Matthias Bodenstedt (incorporated by reference to Exhibit 2.1 of Helix&#8217;s Form&#160;8-K, filed with the SEC on October&#160;4, 2021).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</span></td>
    <td style="padding: 0; white-space: nowrap; text-indent: 0">&#160;</td>
    <td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1821586/000121390020032858/ea128762ex3-1_helixacq.htm">Amended and Restated Memorandum and Articles of Association of Helix Acquisition Corp. (incorporated&#160;by reference to Exhibit 3.1 to Helix&#8217;s Form&#160;8-K, filed with the SEC on October&#160;22, 2020).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</span></td>
    <td style="padding: 0; white-space: nowrap; text-indent: 0">&#160;</td>
    <td style="padding: 0; text-align: justify; text-indent: 0"><a href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022007163/defm14a4_helixacq.htm#T725"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proposed Memorandum and Articles of Association of MoonLake Immunotherapeutics (incorporated by reference to Annex B of Helix&#8217;s Definitive Proxy Statement, filed with the SEC on February 14, 2022).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</span></td>
    <td style="padding: 0; white-space: nowrap; text-indent: 0">&#160;</td>
    <td style="padding: 0; text-align: justify; text-indent: 0"><a href="http://www.sec.gov/Archives/edgar/data/1821586/000121390020031188/ea128089ex4-1_helixacquis.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Specimen Ordinary Share Certificate (incorporated by reference to Exhibit 4.1 of Helix&#8217;s Form&#160;S-1/A&#160;(File&#160;No.&#160;333-249197),&#160;filed with the SEC on October&#160;14, 2021).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1*</span></td>
    <td style="padding: 0; white-space: nowrap; text-indent: 0">&#160;</td>
    <td style="padding: 0; text-align: justify; text-indent: 0"><a href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022011107/fs12022a1ex5-1_helixacqu.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Maples and Calder.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</span></td>
    <td style="padding: 0; white-space: nowrap; text-indent: 0">&#160;</td>
    <td style="padding: 0; text-align: justify; text-indent: 0"><a href="http://www.sec.gov/Archives/edgar/data/1821586/000121390021051257/ea147872ex10-1_helixacq.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investment Agreement, dated as of October&#160;4, 2021, by and among Helix Acquisition Corp., MoonLake Immunotherapeutics AG and the existing shareholders and option rights holders of MoonLake Immunotherapeutics AG (incorporated by reference to Exhibit 10.1 of Helix&#8217;s Form&#160;8-K, filed with the SEC on October&#160;4, 2021).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</span></td>
    <td style="padding: 0; white-space: nowrap; text-indent: 0">&#160;</td>
    <td style="padding: 0; text-align: justify; text-indent: 0"><a href="http://www.sec.gov/Archives/edgar/data/1821586/000121390021051257/ea147872ex10-2_helixacq.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Amended and Restated Shareholders&#8217; Agreement (incorporated by reference to Exhibit 10.2 of Helix&#8217;s Form&#160;8-K, filed with the SEC on October&#160;4, 2021).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</span></td>
    <td style="padding: 0; white-space: nowrap; text-indent: 0">&#160;</td>
    <td style="padding: 0; text-align: justify; text-indent: 0"><a href="http://www.sec.gov/Archives/edgar/data/1821586/000121390020032858/ea128762ex10-1_helixacq.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Letter Agreement, dated October&#160;19, 2020, among Helix Acquisition Corp., Helix Holdings LLC and each of the officers and directors of Helix (incorporated by reference to Exhibit 10.1 of Helix&#8217;s Form&#160;8-K, filed with the SEC on October&#160;22, 2020).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</span></td>
    <td style="padding: 0; white-space: nowrap; text-indent: 0">&#160;</td>
    <td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="http://www.sec.gov/Archives/edgar/data/1821586/000121390021051257/ea147872ex10-4_helixacq.htm">Amended Sponsor Agreement, dated as of October&#160;4, 2021, by and among Helix Acquisition Corp., Helix Holdings LLC, and the officers and directors of Helix Acquisition Corp (incorporated by reference to Exhibit 10.4 of Helix&#8217;s Form&#160;8-K, filed with the SEC on October&#160;4, 2021).</a></span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</span></td>
    <td style="padding: 0; white-space: nowrap; text-indent: 0">&#160;</td>
    <td style="padding: 0; text-align: justify; text-indent: 0"><a href="http://www.sec.gov/Archives/edgar/data/1821586/000121390020032858/ea128762ex10-3_helixacqu.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration Rights Agreement, dated October&#160;19, 2020, among the Company, Helix Holdings LLC and the Holders signatory thereto (incorporated by reference to Exhibit 10.3 of Helix&#8217;s Form&#160;8-K, filed with the SEC on October&#160;22, 2020).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</span></td>
    <td style="padding: 0; white-space: nowrap; text-indent: 0">&#160;</td>
    <td style="padding: 0; text-align: justify; text-indent: 0"><a href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022007163/defm14a4_helixacq.htm#T728"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Amended and Restated Registration Rights Agreement (incorporated by reference to Annex&#160;E of Helix&#8217;s Definitive Proxy Statement, filed with the SEC on February 14, 2022).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</span></td>
    <td style="padding: 0; white-space: nowrap; text-indent: 0">&#160;</td>
    <td style="padding: 0; text-align: justify; text-indent: 0"><a href="http://www.sec.gov/Archives/edgar/data/1821586/000121390021051257/ea147872ex10-3_helixacq.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Subscription Agreement (incorporated by reference to Exhibit 10.3 of Helix&#8217;s Form&#160;8-K, filed with the SEC on October&#160;4, 2021).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8+</span></td>
    <td style="padding: 0; white-space: nowrap; text-indent: 0">&#160;</td>
    <td style="padding: 0; text-align: justify; text-indent: 0"><a href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022007163/defm14a4_helixacq.htm#T726"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of MoonLake Immunotherapeutics 2022 Equity Incentive Plan (incorporated by reference to Annex&#160;C of Helix&#8217;s Definitive Proxy Statement,&#160;filed with the SEC on February 14, 2022).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9**&#8224;#</span></td>
    <td style="padding: 0; white-space: nowrap; text-indent: 0">&#160;</td>
    <td style="padding: 0; text-align: justify; text-indent: 0"><a href="ea156790ex10-9_helixacq.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">License Agreement, dated April 29, 2021, by and between MoonLake Immunotherapeutics AG and MERCK Healthcare KGaA.</span></a></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 0; text-align: justify; text-indent: 0; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10**</span></td>
    <td style="padding: 0; white-space: nowrap; text-indent: 0; width: 1%">&#160;</td>
    <td style="padding: 0; text-align: justify; width: 90%"><a href="ea156790ex10-10_helixacq.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Side Letter to License Agreement, dated April 29, 2021, by and between MoonLake Immunotherapeutics AG and MERCK Healthcare KGaA.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11**&#8224;#</span></td>
    <td style="padding: 0; white-space: nowrap; text-indent: 0">&#160;</td>
    <td style="padding: 0; text-align: justify"><a href="ea156790ex10-11_helixacq.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contract Manufacturing Agreement, dated October 15, 2018, by and between MoonLake Immunotherapeutics AG, as assignee of MERCK Healthcare KGaA, and Richter-Helm Biologics GmbH &amp; Co.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12**#</span></td>
    <td style="padding: 0; white-space: nowrap; text-indent: 0">&#160;</td>
    <td style="padding: 0; text-align: justify"><a href="ea156790ex10-12_helixacq.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment No. 2 to Contract Manufacturing Agreement, by and between MoonLake Immunotherapeutics AG, as assignee of MERCK Healthcare KGaA, and Richter-Helm Biologics GmbH &amp; Co.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13**</span></td>
    <td style="padding: 0; white-space: nowrap; text-indent: 0">&#160;</td>
    <td style="padding: 0; text-align: justify"><a href="ea156790ex10-13_helixacq.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assignment of Contract Manufacturing Agreement, dated July 1, 2021, by and among MoonLake Immunotherapeutics AG, MERCK Healthcare KGaA, and Richter-Helm Biologics GmbH &amp; Co.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14*+</span></td>
    <td style="padding: 0; white-space: nowrap; text-indent: 0">&#160;</td>
    <td style="padding: 0; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022011107/fs12022a1ex10-14_helixacqu.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement, dated April 30, 2021, by and between MoonLake Immunotherapeutics AG and Dr. Jorge Santos da Silva.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15*+</span></td>
    <td style="padding: 0; white-space: nowrap; text-indent: 0">&#160;</td>
    <td style="padding: 0; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022011107/fs12022a1ex10-15_helixacqu.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to Employment Agreement, dated September 9, 2021, by and between MoonLake Immunotherapeutics AG and Dr. Jorge Santos da Silva.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding: 0; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16*+</span></td>
    <td style="padding: 0; white-space: nowrap; text-indent: 0">&#160;</td>
    <td style="padding: 0; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022011107/fs12022a1ex10-16_helixacqu.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement, dated April 30, 2021, by and between MoonLake Immunotherapeutics AG and Prof. Dr. Kristian Reich.</span></a></td></tr>

<tr style="vertical-align: top; background-color: White">
    <td style="width: 8%; padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17*+</span></td>
    <td style="white-space: nowrap; width: 1%; padding-bottom: 2.25pt">&#160;</td>
    <td style="width: 91%; padding-bottom: 2.25pt; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022011107/fs12022a1ex10-17_helixacqu.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to Employment Agreement, dated November 8, 2021, by and between MoonLake Immunotherapeutics AG and Prof. Dr. Kristian Reich.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18*+</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="padding-bottom: 2.25pt; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022011107/fs12022a1ex10-18_helixacqu.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement, dated May 10, 2021, by and between MoonLake Immunotherapeutics AG and Matthias Bodenstedt.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19*+</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="padding-bottom: 2.25pt; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022011107/fs12022a1ex10-19_helixacqu.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to Employment Agreement, dated June 22, 2021, by and between MoonLake Immunotherapeutics AG and Matthias Bodenstedt.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20*+</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="padding-bottom: 2.25pt; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022011107/fs12022a1ex10-20_helixacqu.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employment Agreement, dated April 30, 2021, by and between MoonLake Immunotherapeutics AG and Jonkheer Arnout Michiel Ploos van Amstel.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21*+</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="padding-bottom: 2.25pt; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022011107/fs12022a1ex10-21_helixacqu.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to Employment Agreement, dated September 9, 2021, by and between MoonLake Immunotherapeutics AG and Jonkheer Arnout Michiel Ploos van Amstel.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22*&#8224;+</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="padding-bottom: 2.25pt; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022011107/fs12022a1ex10-22_helixacqu.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Termination Agreement, dated December 13, 2021, by and between MoonLake Immunotherapeutics AG and Jonkheer Arnout Michiel Ploos van Amstel.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23*&#8224;+</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="padding-bottom: 2.25pt; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022011107/fs12022a1ex10-23_helixacqu.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board Member Agreement, dated September 25, 2021, by and between MoonLake Immunotherapeutics AG and Simon Sturge.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24*+</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="padding-bottom: 2.25pt; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022011107/fs12022a1ex10-24_helixacqu.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee Share Participation Plan of MoonLake Immunotherapeutics AG, dated July 23, 2021.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25*+</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="padding-bottom: 2.25pt; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022011107/fs12022a1ex10-25_helixacqu.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee Stock Option Plan of MoonLake Immunotherapeutics AG, dated July 23, 2021.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26*+</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="padding-bottom: 2.25pt; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022011107/fs12022a1ex10-27_helixacqu.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee Share Participation Plan of MoonLake Immunotherapeutics AG, dated December 14, 2021.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27*+</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="padding-bottom: 2.25pt; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022011107/fs12022a1ex10-27_helixacqu.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employee Stock Option Plan of MoonLake Immunotherapeutics AG, dated December 14, 2021.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28*</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="padding-bottom: 2.25pt; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022011107/fs12022a1ex10-28_helixacqu.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loan Agreement, dated October 15, 2021, by and among MoonLake Immunotherapeutics AG and the Lenders named therein.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29*</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="padding-bottom: 2.25pt; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022011107/fs12022a1ex10-29_helixacqu.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amendment to the Loan Amendment, dated January 18, 2022, by and among MoonLake Immunotherapeutics AG and the Lenders named therein.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30*</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="padding-bottom: 2.25pt; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022011107/fs12022a1ex10-30_helixacqu.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Second Amendment to the Loan Agreement, dated February 15, 2022, by and among MoonLake Immunotherapeutics AG and the Lenders named therein.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="padding-bottom: 2.25pt; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022009481/ea156204ex10-1_helixacq.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Convertible Loan Agreement, dated as of February 20, 2022, by and among Cormorant Private Healthcare Fund IV. L.P., MoonLake Immunotherapeutics AG, Biotechnology Value Fund, L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS, L.P. and Helix Acquisition Corp. (incorporated by reference to Exhibit 10.1 of Helix&#8217;s Form 8-K, filed with the SEC on February 25, 2022).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.32*+</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="padding-bottom: 2.25pt; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022011107/fs12022a1ex10-32_helixacqu.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form of Indemnification Agreement for directors and executive officers.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1*</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="padding-bottom: 2.25pt; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022011107/fs12022a1ex23-1_helixacqu.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of WithumSmith+Brown, PC.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.2*</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="padding-bottom: 2.25pt; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022011107/fs12022a1ex23-2_helixacqu.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Baker Tilly US, LLP.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.3*</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="padding-bottom: 2.25pt; text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1821586/000121390022011107/fs12022a1ex5-1_helixacqu.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Maples and Calder (included in Exhibit 5.1 hereto).</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">104</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">107*</span></td>
    <td style="white-space: nowrap; padding-bottom: 2.25pt">&#160;</td>
    <td style="padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><a href="https://www.sec.gov/Archives/edgar/data/1821586/000121390022011107/fs12022a1ex-fee_helixacqu.htm" style="-sec-extract: exhibit">Filing Fee Table.</a></span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="margin-top: 0; margin-bottom: 0"></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">Previously filed.</td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">**</td><td style="text-align: justify">Filed herewith.</td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">&#8224;</td><td style="text-align: justify">The annexes, schedules, and certain exhibits to this Exhibit
have been omitted pursuant to Item&#160;601(a)(5).</td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">+</td><td style="text-align: justify">Indicates a management contract of compensatory plan.</td>
</tr></table>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">#</td><td style="text-align: justify">Portions of the Exhibit have been omitted because they are both
(i) not material and (ii) would be competitively harmful if publicly disclosed.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Item&#160;17.&#160;Undertakings.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The undersigned registrant
hereby undertakes:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">To file, during any period in which offers or sales are being
made, a post-effective&#160;amendment to this registration statement:</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left">(i)</td><td style="text-align: justify">To include any prospectus required by Section&#160;10(a)(3)&#160;of
the Securities Act&#160;of&#160;1933, as amended;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left">(ii)</td><td style="text-align: justify">To reflect in the prospectus any facts or events arising
after the effective date of the registration statement (or the most recent post-effective&#160;amendment thereof) which, individually
or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing,
any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which
was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus
filed with the SEC pursuant to Rule&#160;424(b)&#160;if, in the aggregate, the changes in volume and price represent no more than a 20%
change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective
registration statement; and</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left">(iii)</td><td style="text-align: justify">To include any material information with respect to the plan
of distribution not previously disclosed in the registration statement or any material change to such information in the registration
statement.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">(2)</td><td style="text-align: justify">That, for the purpose of determining any liability under the
Securities Act, each such post-effective&#160;amendment shall be deemed to be a new registration statement relating to the securities
offered therein, and the offering of such securities at that time shall be deemed to be the initial&#160;<i>bona fide</i>&#160;offering
thereof.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">(3)</td><td style="text-align: justify">To remove from registration by means of a post-effective&#160;amendment
any of the securities being registered which remain unsold at the termination of the offering.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">(4)</td><td style="text-align: justify">That, for the purpose of determining liability under the Securities
Act to any purchaser, each prospectus filed pursuant to Rule&#160;424(b)&#160;as part of a registration statement relating to an offering,
other than registration statements relying on Rule&#160;430B or other than prospectuses filed in reliance on Rule&#160;430A, shall be
deemed to be part of and included in the registration statement as of the date it is first used after effectiveness.&#160;<i>Provided</i>,&#160;<i>however</i>,&#160;<i>that</i>&#160;no
statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated
or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as
to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration
statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first
use.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">(5)</td><td style="text-align: justify">That, for the purpose of determining liability of the registrant
under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in
a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting
method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following
communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities
to such purchaser:</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left">(i)</td><td style="text-align: justify">Any preliminary prospectus or prospectus of the undersigned
registrant relating to the offering required to be filed pursuant to Rule&#160;424;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left">(ii)</td><td style="text-align: justify">Any free writing prospectus relating to the offering prepared
by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant;</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left">(iii)</td><td style="text-align: justify">The portion of any other free writing prospectus relating
to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned
registrant; and</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -24pt; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left">(iv)</td><td style="text-align: justify">Any other communication that is an offer in the offering
made by the undersigned registrant to the purchaser.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt; background-color: white">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">(6)</td><td style="text-align: justify">Insofar as indemnification for liabilities arising under the
Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions,
or otherwise, the registrant has been advised that in the opinion of the SEC such indemnification is against public policy as expressed
in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other
than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the
successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with
the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling
precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as
expressed in the Securities Act and will be governed by the final adjudication of such issue.</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b></b></p>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Pursuant to the requirements
of the Securities Act&#160;of&#160;1933, the registrant has duly caused this registration statement to be signed on its behalf by the
undersigned, thereunto duly authorized, in the City of New&#160;York, State of New&#160;York, on the 14th day of March, 2022.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="padding-bottom: 2.25pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HELIX ACQUISITION CORP.</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 2.25pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 2.25pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%; padding-bottom: 2.25pt">&#160;</td>
    <td style="width: 5%; padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 35%; padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Bihua Chen&#160;</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 2.25pt">&#160;</td>
    <td style="padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</span>&#160;</td>
    <td style="padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bihua Chen</span></td></tr>
  <tr style="vertical-align: top">
    <td style="padding-bottom: 2.25pt">&#160;</td>
    <td style="padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</span></td>
    <td style="padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and Chairwoman</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Pursuant to the requirements
of the Securities Act&#160;of&#160;1933, as amended, this Registration Statement has been signed below by the following persons in the
capacities and on the dates indicated.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; padding: 0; width: 31%; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name</b></span></td>
    <td style="padding: 0; white-space: nowrap; width: 1%; text-indent: 0">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; padding: 0; width: 44%; text-align: center; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title</b></span></td>
    <td style="padding: 0; white-space: nowrap; width: 1%; text-indent: 0">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; padding: 0; width: 23%; text-align: center; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Date</b></span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding: 0; text-indent: 0">&#160;</td>
    <td style="padding: 0; white-space: nowrap; text-indent: 0">&#160;</td>
    <td style="padding: 0; text-align: center; text-indent: 0">&#160;</td>
    <td style="padding: 0; white-space: nowrap; text-indent: 0">&#160;</td>
    <td style="padding: 0; text-align: center; text-indent: 0">&#160;</td></tr>
  <tr>
    <td style="border-bottom: Black 1.5pt solid; padding: 0; vertical-align: bottom; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="padding: 0; white-space: nowrap; vertical-align: bottom; text-indent: 0">&#160;</td>
    <td rowspan="2" style="padding: 0; vertical-align: top; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer and Chairwoman (Principal Executive Officer)</span></td>
    <td rowspan="2" style="padding: 0; white-space: nowrap; vertical-align: top; text-indent: 0">&#160;</td>
    <td style="padding: 0; vertical-align: top; text-align: center; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March&#160;14, 2022</span></td></tr>
  <tr>
    <td style="padding: 0; vertical-align: bottom; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bihua Chen</span></td>
    <td style="padding: 0; white-space: nowrap; vertical-align: bottom; text-indent: 0">&#160;</td>
    <td style="padding: 0; vertical-align: top; text-indent: 0">&#160;</td></tr>
  <tr>
    <td style="padding: 0; vertical-align: bottom; text-align: justify; text-indent: 0">&#160;</td>
    <td style="padding: 0; white-space: nowrap; vertical-align: bottom; text-indent: 0">&#160;</td>
    <td style="padding: 0; vertical-align: top; text-indent: 0">&#160;</td></tr>
  <tr>
    <td style="border-bottom: Black 1.5pt solid; padding: 0; vertical-align: bottom; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Dr. Andrew J. Phillips&#160;</span></td>
    <td style="padding: 0; white-space: nowrap; vertical-align: bottom; text-indent: 0">&#160;</td>
    <td rowspan="2" style="padding: 0; vertical-align: top; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer (Principal Financial and Accounting Officer)</span></td>
    <td rowspan="2" style="padding: 0; white-space: nowrap; vertical-align: top; text-indent: 0">&#160;</td>
    <td style="padding: 0; vertical-align: top; text-align: center; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March&#160;14, 2022</span></td></tr>
  <tr>
    <td style="padding: 0; vertical-align: bottom; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.&#160;Andrew J.&#160;Phillips</span></td>
    <td style="padding: 0; white-space: nowrap; vertical-align: bottom; text-indent: 0">&#160;</td>
    <td style="padding: 0; vertical-align: top; text-indent: 0">&#160;</td></tr>
  <tr>
    <td style="padding: 0; vertical-align: bottom; text-align: justify; text-indent: 0">&#160;</td>
    <td style="padding: 0; white-space: nowrap; vertical-align: bottom; text-indent: 0">&#160;</td>
    <td style="padding: 0; vertical-align: top; text-indent: 0">&#160;</td></tr>
  <tr>
    <td style="border-bottom: Black 1.5pt solid; padding: 0; vertical-align: bottom; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="padding: 0; white-space: nowrap; vertical-align: bottom; text-indent: 0">&#160;</td>
    <td style="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="padding: 0; white-space: nowrap; vertical-align: top; text-indent: 0">&#160;</td>
    <td style="padding: 0; vertical-align: top; text-align: center; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March&#160;14, 2022</span></td></tr>
  <tr>
    <td style="padding: 0; vertical-align: bottom; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.&#160;Nancy Chang</span></td>
    <td style="padding: 0; white-space: nowrap; vertical-align: bottom; text-indent: 0">&#160;</td>
    <td style="padding: 0; vertical-align: top; text-indent: 0">&#160;</td>
    <td style="padding: 0; white-space: nowrap; vertical-align: top; text-indent: 0">&#160;</td>
    <td style="padding: 0; vertical-align: top; text-indent: 0">&#160;</td></tr>
  <tr>
    <td style="padding: 0; vertical-align: bottom; text-align: justify; text-indent: 0">&#160;</td>
    <td style="padding: 0; white-space: nowrap; vertical-align: bottom; text-indent: 0">&#160;</td>
    <td style="padding: 0; vertical-align: top; text-indent: 0">&#160;</td>
    <td style="padding: 0; white-space: nowrap; vertical-align: top; text-indent: 0">&#160;</td>
    <td style="padding: 0; vertical-align: top; text-indent: 0">&#160;</td></tr>
  <tr>
    <td style="border-bottom: Black 1.5pt solid; padding: 0; vertical-align: bottom; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="padding: 0; white-space: nowrap; vertical-align: bottom; text-indent: 0">&#160;</td>
    <td style="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="padding: 0; white-space: nowrap; vertical-align: top; text-indent: 0">&#160;</td>
    <td style="padding: 0; vertical-align: top; text-align: center; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March&#160;14, 2022</span></td></tr>
  <tr>
    <td style="padding: 0; vertical-align: bottom; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Will Lewis</span></td>
    <td style="padding: 0; white-space: nowrap; vertical-align: bottom; text-indent: 0">&#160;</td>
    <td style="padding: 0; vertical-align: top; text-indent: 0">&#160;</td>
    <td style="padding: 0; white-space: nowrap; vertical-align: top; text-indent: 0">&#160;</td>
    <td style="padding: 0; vertical-align: top; text-indent: 0">&#160;</td></tr>
  <tr>
    <td style="padding: 0; vertical-align: bottom; text-align: justify; text-indent: 0">&#160;</td>
    <td style="padding: 0; white-space: nowrap; vertical-align: bottom; text-indent: 0">&#160;</td>
    <td style="padding: 0; vertical-align: top; text-indent: 0">&#160;</td>
    <td style="padding: 0; white-space: nowrap; vertical-align: top; text-indent: 0">&#160;</td>
    <td style="padding: 0; vertical-align: top; text-indent: 0">&#160;</td></tr>
  <tr>
    <td style="border-bottom: Black 1.5pt solid; padding: 0; vertical-align: bottom; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td>
    <td style="padding: 0; white-space: nowrap; vertical-align: bottom; text-indent: 0">&#160;</td>
    <td style="padding: 0; vertical-align: top; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</span></td>
    <td style="padding: 0; white-space: nowrap; vertical-align: top; text-indent: 0">&#160;</td>
    <td style="padding: 0; vertical-align: top; text-align: center; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">March&#160;14, 2022</span></td></tr>
  <tr>
    <td style="padding: 0; vertical-align: bottom; text-align: justify; text-indent: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">John Schmid</span></td>
    <td style="padding: 0; white-space: nowrap; vertical-align: bottom; text-indent: 0">&#160;</td>
    <td style="padding: 0; vertical-align: top; text-indent: 0">&#160;</td>
    <td style="padding: 0; white-space: nowrap; vertical-align: top; text-indent: 0">&#160;</td>
    <td style="padding: 0; vertical-align: top; text-indent: 0">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="width: 4%; padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; width: 36%; padding-bottom: 2.25pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Dr. Andrew J. Phillips</span></td>
    <td style="width: 60%; padding-bottom: 2.25pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 2.25pt">&#160;</td>
    <td style="padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr. Andrew J. Phillips</span></td>
    <td style="padding-bottom: 2.25pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 2.25pt">&#160;</td>
    <td style="padding-bottom: 2.25pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attorney-in-fact</span></td>
    <td style="padding-bottom: 2.25pt">&#160;</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">II-5</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjU0KwjAQhU/QOwxZiyYRN11atIhVpBRxG+0owTZTJvGnR/KW1nThMDA83nvzCTEROa1tgwynZVlAhW3XmIBQ4hUZ3QWHRLbZpjDcEm/WBzYuRJlTrCymSp8HGQNP67FOQc5nSs+0BqVTKeGwE8nPz8hdbY0uWNOAcTUcmDq2GAz344fKvMlR20fAEdlbcimoqRztD2ipNOzpaV7Edw9FkYlkEicROdOj+2EePlALqwbbgeXH6n+TL1LxRSo= -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>2
<FILENAME>ea156790ex10-9_helixacq.htm
<DESCRIPTION>LICENSE AGREEMENT, DATED APRIL 29, 2021, BY AND BETWEEN MOONLAKE IMMUNOTHERAPEUTICS AG AND MERCK HEALTHCARE KGAA
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 10.9</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">Execution Copy</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Certain confidential information contained in this document, marked
by brackets as [***], has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
In addition, certain personally identifiable information contained in this document, marked by brackets as [***], has been omitted from
this exhibit pursuant to Item 601(a)(6) under Regulation S-K.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>LICENSE AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>dated April 29, 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>by and between</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Merck Healthcare KGaA, Darmstadt, Germany</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>and</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>MoonLake Immunotherapeutics AG </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center"><U>LICENSE AGREEMENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>THIS LICENSE AGREEMENT
</B>(the &ldquo;<B>Agreement</B>&rdquo;) is dated as of April 29, 2021 (the &ldquo;<B>Effective Date</B>&rdquo;) by and between <B>MERCK
Healthcare KGaA</B>, a corporation with general partners organized under German law, having a place of business at Frankfurter Strasse
250, 64293 Darmstadt, Germany (&ldquo;<B>Licensor</B>&rdquo;) and MoonLake Immunotherapeutics AG, a corporation organized under the laws
of Switzerland, having a place of business at Unterm&uuml;li 7 / Postfach 7444, 6302 Zug, Switzerland (&ldquo;<B>Licensee</B>&rdquo;).
Licensor and Licensee may be referred to herein as a &ldquo;<B>Party</B>&rdquo; or, collectively, as &ldquo;<B>Parties</B>&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>RECITALS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS</B>, Licensor is engaged, among other
activities, in the development, manufacture and commercialization of pharmaceutical products;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS</B>, Licensee is a newly established
legal entity whose specific purposes are to develop, manufacture and subsequently commercialize the proprietary compound that is the subject
of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS</B>, pursuant to the Initial License
Agreement (as hereinafter defined), Licensor has developed a proprietary compound known as M1095 (an anti-IL17A/F nanobody) in a collaboration
with the Initial Licensor (as hereinafter defined) and has obtained rights under certain platform intellectual property owned or controlled
by the Initial Licensor;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS</B>, Initial Licensor has opted out
of the Initial Project (as hereinafter defined) in accordance with the Initial License Agreement and thereafter has assigned to Licensor
a patent family seeking to protect M1095, and Licensor has all necessary rights to further develop and commercialize M1095 and products
containing M1095, including the right to grant a sublicense of such development and commercialization rights (subject to the Initial License
Agreement and Underlying GMP License), all to the extent set out in greater detail in this Agreement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS</B>, Licensor wishes to license and
sublicense to Licensee, on an exclusive or non-exclusive basis, as applicable and further defined hereinafter, the right to Develop (as
hereinafter defined) and Commercialize (as hereinafter defined) M1095 and products containing M1095.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOW, THEREFORE</B>, in consideration of the
promises and mutual covenants contained herein, the Parties agree as follows.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
1 - DEFINITIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In this Agreement the following terms, when capitalized,
shall have the following meanings, and such meanings shall apply equally to both the singular and plural forms of the terms defined:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.1. &ldquo;<B>Accounting
Standards</B>&rdquo; means either IFRS or U.S. GAAP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.2. &ldquo;<B>Affiliate</B>&rdquo;
means a Person that now or in the future, directly or indirectly, controls, is controlled by or is under common control with another Person,
but only for so long as such control exists. For the purposes of this <U>Section 1.1</U>, the word &ldquo;control&rdquo; (including, with
correlative meaning, the terms &ldquo;controlled by&rdquo; or &ldquo;under the common control with&rdquo;) means the actual power, either
directly or indirectly through one or more intermediaries, to direct, or cause the direction of, the management and policies of such Person,
whether by the ownership of more than fifty percent (50%) of the voting stock of such entity, or by contract or otherwise, entitled to
vote in the election of its directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.3. &ldquo;<B>Applicable
Laws</B>&rdquo; means any supranational, federal, state, local or foreign law, statute, ordinance or principle of common law, or any rule,
regulation, standard, judgment, order, writ, injunction, decree, arbitration award, agency guidelines or other requirement, license or
permit of any Governmental Body, which may be in effect from time to time, to the extent applicable under or in connection with this Agreement
or any activities related to this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.4. &ldquo;<B>Business
Day</B>&rdquo; means a day other than Saturday or Sunday, and other than national holidays in the United States, Switzerland or Germany,
on which banking institutions in New York, New York, United States, as well as Zug, Switzerland, and Frankfurt, Germany, are open for
business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.5. &ldquo;<B>Calendar
Quarter</B>&rdquo; means each three (3) month period commencing January&nbsp;1, April 1, July 1 or October 1; <I>provided</I>, <I>however</I>,
that (a) the first Calendar Quarter of the Term shall extend from the Effective Date to the end of the first full Calendar Quarter thereafter,
and (b) the last Calendar Quarter of the Term shall end on the date of termination or expiration of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.6. &ldquo;<B>Calendar
Year</B>&rdquo; means the period beginning on January&nbsp;1 and ending on December&nbsp;31 of the same year; <I>provided</I>, <I>however</I>,
that (a) the first Calendar Year of the Term shall commence on the Effective Date and end on December&nbsp;31 of the same year and (b)
the last Calendar Year of the Term shall commence on January&nbsp;1 of the Calendar Year in which this Agreement terminates or expires
and end on the date of termination or expiration of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.7. &ldquo;<B>Change
of Control</B>&rdquo; means, with respect to a Person or one or more of its Affiliates, whether in one transaction or a series of related
transactions: (a) the acquisition by any third party of beneficial ownership of fifty percent (50%) or more of the then-outstanding shares
or voting power of such Party; (b) the consummation of a business combination involving such Party with any third party, unless, following
such business combination, the stockholders of such Party immediately prior to such business combination beneficially own, directly or
indirectly, more than fifty percent (50%) of the then-outstanding shares or voting power of the entity resulting from such business combination;
or (c) the sale of all or substantially all of such Party&rsquo;s assets or business relating to the subject matter of the Agreement to
any third party (whether by asset sale, stock sale, merger, exclusive license or otherwise).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.8. &ldquo;<B>Clinical
Trial</B>&rdquo; means a clinical trial in which a pharmaceutical product is administered in human subjects that has been approved by
a Regulatory Authority and Institutional Review Board or Ethics Committee, and is designed to measure the safety or therapeutic efficacy
of the pharmaceutical product in such subjects. Clinical Trials shall include Phase I Trials, Phase II Trials and Phase III Trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.9.
&ldquo;<B>Combination Product</B>&rdquo; means a Licensed Product that (a) includes one or more active ingredients in addition to the
Compounds or (b) is combined with one or more products, devices, pieces of equipment or components.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.10. &ldquo;<B>Commercialization</B>&rdquo;
or &ldquo;<B>Commercialize</B>&rdquo; means, with respect to a product, any and all activities undertaken before or after Regulatory Approval
of an NDA for such product and directed to the commercial exploitation of such product, including the marketing, promoting, distributing,
importing or exporting for sale, offering for sale, and selling of such product, and interacting with Regulatory Authorities regarding
the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.11. &ldquo;<B>Commercially
Reasonable Efforts</B>&rdquo; means, (a) with respect to the efforts to be expended by any Party with respect to any objective under this
Agreement (other than as provided under clause (b)), such reasonable, diligent, and good faith efforts as such Party would normally use
to accomplish a similar objective under similar circumstances, and (b) with respect to any objective relating to Development or Commercialization
of a Licensed Product by Licensee, the level of efforts and resources (measured as of the time that such efforts and resources are required
to be used under this Agreement) that are commonly devoted by similarly situated biotechnology companies or pharmaceutical companies (measured
in terms of size and resources), as the case may be, to Develop or Commercialize, as the case may be, a comparable product for the same
Indications, at a similar stage in its development (including taking into consideration factors such as, safety, efficacy, regulatory
status and applicable regulatory requirements) or product life. If a Party assigns its rights or obligations under this Agreement to an
Affiliate or marketing partner, if and to the extent permitted under this Agreement, then, with respect to such Affiliate or marketing
partner, Commercially Reasonable Efforts shall mean at least (i)&nbsp;the efforts and resources as required from the assigning Party pursuant
to the first part of this <U>Section 1.11</U> or (ii)&nbsp;such reasonable, good-faith efforts and resources as such Affiliate or marketing
partner would normally devote to the accomplishment of a similar objective under similar circumstances, whatever is more beneficial for
the non-assigning Party, again taking into account all relevant factors. For clarity, it is understood that Commercially Reasonable Efforts
shall be evaluated on a country-by-country basis based on factors relevant to the particular country (including, size of market, availability
and enforcement of market exclusivity (whether by Patent Right, regulatory exclusivity or otherwise), anticipated or approved labeling,
pricing strategies, likelihood of gray-market goods, Applicable Laws, and likelihood of Regulatory Approval) and it is expected that the
level of efforts required may be different for different countries and may change over time for particular countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.12. &ldquo;<B>Competing
Product</B>&rdquo; means, with respect to a Licensed Product that is being sold in a country or jurisdiction in the Territory, any product
that: (a) is sold in such country or jurisdiction by a Third Party that (i) has not obtained the rights to market or sell such product
as a Sublicensee or distributor of Licensee and (ii) did not purchase such product in a chain of distribution that included Licensee or
any of its Affiliates or Sublicensees; and (b) the Commercialization of which would be Covered by a Pending Claim of a Licensor Patent
(for purposes of determining whether a Pending Claim of a Licensor Patent would be infringed, such Pending Claim shall be treated as if
issued in the form then being prosecuted).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.13. &ldquo;<B>Competing
Biologic Product</B>&rdquo; means any product that contains any of the following: an inhibitor of IL-17 or an inhibitor of any receptor
of IL-17.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.14. &ldquo;<B>Competitor</B>&rdquo;
means a Third Party that owns or controls a Competing Biologic Product that (i) has completed a Phase I Trial and is entering or is then
in, or has completed, a Phase II Trial or Phase III Trial or (ii) is then being commercialized in one or more countries in the Territory
(any such Competing Biologic Product an &ldquo;<B>Acquired Competing Biologic Product</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.15. &ldquo;<B>Compound</B>&rdquo;
means the compound described as Anti-IL17A/F Nanobody (also known to the Parties as &ldquo;M1095&rdquo; or &ldquo;sonelokimab&rdquo;)
having the sequence set forth on <U>Schedule&nbsp;1.15</U> and, all modifications, derivatives, fragments or variants thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.16. &ldquo;<B>Confidential
Information</B>&rdquo; of a Party means information relating to the business, operations or products of such Party or any of its Affiliates,
including any Know-How, marketing plans, strategies, customer lists, or other information that such Party discloses to the other Party
under this Agreement, or otherwise becomes known to the other Party by virtue of this Agreement, regardless of whether any of the foregoing
are marked &ldquo;confidential&rdquo; or &ldquo;proprietary&rdquo; or communicated to the other by the disclosing Party or Affiliate in
oral, written, graphic, or electronic form. For purposes of this Agreement, confidential information of the Initial Licensor shall be
Confidential Information of Licensor. For clarity, such confidential information of the Initial Licensor may be subject to additional
restrictions based on the Initial License Agreement; <I>provided</I> that Licensor identifies in writing such confidential information
of the Initial Licensor to Licensee. For the avoidance of doubt, the Development Plan and any updates thereto shall be considered the
Confidential Information of Licensee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.17. &ldquo;<B>Controlled</B>&rdquo;
means, with respect to (a) Patent Rights, (b) Know-How or (c) biological, chemical or physical material, that the Person or one of its
Affiliates owns or has a license or sublicense to such right, item, or material (or in the case of material, has the right to physical
possession of such material) and has the ability to grant a license or sublicense to, or assign its right, title and interest in and to,
such right, item or material as provided for in this Agreement without violating the terms of any agreement or other arrangement with
any Third Party, in particular such Third Party that has assigned or licensed such Patent Rights, Know-How or material to such Party (or
any Affiliate of such Party). For the avoidance of doubt, Licensor shall not be deemed to &ldquo;Control&rdquo; any Patent Rights, Know-How
or material owned by a Third Party (including, for greater clarity, the Initial Licensor) for which Licensor or any of its Licensor Affiliates
have no rights to license or sublicense any rights under such Patent Rights, Know-How or material to Licensee in accordance with the terms
herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.18. &ldquo;<B>Cover</B>&rdquo;
means, with respect to any claim of any Patent Right and product in any jurisdiction, that such claim would be infringed, absent a license
granted under such Patent Right, by the Development, Manufacture, distribution, offering for sale, sale, importation, exportation or other
Commercialization of such product (or any element thereof) in such jurisdiction; <I>provided</I> that in determining whether a claim of
a pending Patent application would be infringed, it shall be treated as if issued in the form then being prosecuted. &ldquo;<B>Covered</B>&rdquo;
and &ldquo;<B>Covering</B>&rdquo; have correlative meanings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.19.
&ldquo;<B>Data Protection Law</B>&rdquo; means Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016
on the protection of natural persons with regard to the processing of Personal Data and on the free movement of such data, and repealing
Directive 95/46/EC (the &ldquo;<B>GDPR</B>&rdquo;) as well as, to the extent applicable, any other data protection laws of the country
in which Licensee is established and any other data protection laws applicable to Licensee in connection with this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.20. &ldquo;<B>Development</B>&rdquo;
means, with respect to a compound or product, the performance of all pre-clinical and clinical development, including toxicology, pharmacology,
test method development and stability testing, process development, formulation development, quality control development, statistical
analysis, Clinical Trials (excluding Clinical Trials conducted after Regulatory Approval for such compound or product), manufacturing
and regulatory activities that are required to obtain Regulatory Approval for such compound or product in the Territory under this Agreement,
and interacting with Regulatory Authorities regarding the foregoing. For the avoidance of doubt, Development shall include all research
activities. When used as a verb, &ldquo;<B>Develop</B>&rdquo;, &ldquo;<B>Developed</B>&rdquo;, or &ldquo;<B>Developing</B>&rdquo; means
to engage in Development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.21. &ldquo;<B>Drug
Product</B>&rdquo; means the final formulation containing Drug Substance filled in naked syringes for use in Clinical Trials.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.22. &ldquo;<B>Drug
Substance</B>&rdquo; means the drug substance required for the manufacturing of the drug product form of the Licensed Products, which
is on stock at Licensor on the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.23. &ldquo;<B>EMA</B>&rdquo;
means the European Medicines Agency, or any successor agency thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.24. &ldquo;<B>Equity
Documentation</B>&rdquo; means the investment agreement between certain investors, the Licensor, the founders of the Licensee and the
Licensee, dated on or around the date hereof and the share purchase agreement between the Licensee and the Licensor dated on or around
the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.25. &ldquo;<B>EU</B>&rdquo;
or &ldquo;<B>European Union</B>&rdquo; means the European Union, as its membership may be altered from time to time, and any successor
thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.26. &ldquo;<B>European
Commission</B>&rdquo; means the authority within the European Union that has the legal authority to grant Regulatory Approvals in the
European Union based on input received from the EMA or other competent Regulatory Authorities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.27. &ldquo;<B>FDA</B>&rdquo;
means the United States Food and Drug Administration, or any successor agency thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.28. &ldquo;<B>Field</B>&rdquo;
means the diagnosis, treatment, palliation, or prevention of any disease or condition in humans or animals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.29. &ldquo;<B>First
Commercial Sale</B>&rdquo; means, with respect to any Licensed Product in a country in the Territory, the first sale or commercial transfer
or disposition for value of the Licensed Product to a Third Party by Licensee or its Affiliates in such country after Regulatory Approval
of such Licensed Product has been granted in such country, or such sale is otherwise permitted, by the applicable Regulatory Authority
of such country; <I>provided</I> that any sale, transfer or disposition of the type described in the last paragraph of <U>Section 1.61</U>
shall not constitute a First Commercial Sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.30. &ldquo;<B>FTE</B>&rdquo;
means one thousand six hundred (1600) hours of work per annum devoted to the specified activities that are carried out by one or more
qualified professional employees of Licensor or its Affiliates, such as scientists, research and manufacturing staff, quality control
and assurance personnel, technicians or the like, but excluding non-technical, non-professional personnel such as secretarial or administrative
staff.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.31. &ldquo;<B>GLP</B>&rdquo;
means all applicable Good Laboratory Practice standards, including, as applicable, as set forth in the then current good laboratory practice
standards promulgated or endorsed by the FDA as defined in 21 C.F.R. Part 58, or the equivalent laws in any country or jurisdiction within
the Territory, each as may be amended and applicable from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.32. &ldquo;<B>GMP</B>&rdquo;
means all applicable current Good Manufacturing Practices, including, as applicable, (a) the principles detailed in the U.S. Current Good
Manufacturing Practices, 21 C.F.R. Parts 4, 210, 211, (b) European Directive 2003/94/EC and Eudralex 4, (c) the principles detailed in
the ICH Q7 guidelines, and (d) the equivalent Applicable Law in any relevant country, each as may be amended and applicable from time
to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.33. &ldquo;<B>Governmental
Body</B>&rdquo; means any: (a) nation, principality, state, commonwealth, province, territory, county, municipality, district or other
jurisdiction of any nature; (b) federal, state, local, municipal, foreign or other government; (c) governmental or quasi-governmental
authority of any nature (including any governmental division, subdivision, department, agency, bureau, branch, office, commission, council,
board, instrumentality, officer, official, representative, organization, unit, body or entity and any court or other tribunal); (d) multi-national
or supranational organization or body; or (e) individual, entity, or body exercising, or entitled to exercise, any executive, legislative,
judicial, administrative, regulatory, police, military or taxing authority or power of any nature.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.34. &ldquo;<B>ICC</B>&rdquo;
means the International Chamber of Commerce.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.35. &ldquo;<B>IFRS</B>&rdquo;
or &ldquo;<B>International Financial Reporting Standards</B>&rdquo; means the set of accounting standards and interpretations and the
framework in force on the Effective Date and adopted by the European Union as issued by the International Accounting Standards Board (&ldquo;<B>IASB</B>&rdquo;)
and the International Financial Reporting Interpretations Committee (&ldquo;<B>IFRIC</B>&rdquo;), as such accounting standards may be
amended from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.36. &ldquo;<B>IND</B>&rdquo;
means an investigational new drug application filed with the FDA for approval to commence Clinical Trials or the equivalent application
or filing filed with any equivalent agency or Governmental Body outside the United States (including any supra-national entity such as
in the European Union) for approval to commence Clinical Trials in such jurisdiction, and including all regulations at 21 U.S. C.F.R.
&sect; 312 et seq. and equivalent foreign regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.37. &ldquo;<B>Indication</B>&rdquo;
means a separate and distinct disease or medical condition, a significant manifestation of a disease or medical condition, or symptoms
associated with a disease or medical condition, or a risk for a disease or medical condition; <I>provided </I>that an Indication is only
distinct from another Indication if the diseases associated with such Indications are (a) listed in two different blocks of the ICD-10
or any successor publication (by way of example, any neoplasm under C15 is in a different block from any neoplasm under block C16, whereas
C15.0 and C15.1 belong to the same block) and (b) studied by Licensee or any of its Affiliates or Sublicensees under separate Clinical
Trials; <I>provided further</I>, that, notwithstanding the foregoing, psoriatic arthritis, ankylosing spondylitis and hidradenitis suppurativa
shall be separate Indications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.38. &ldquo;<B>Initial
License Agreement</B>&rdquo; means the Agreement for Joint Discovery and Development by and between Initial Licensor and Licensor, dated
September 3, 2008.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.39. &ldquo;<B>Initial
Licensor</B>&rdquo; means Ablynx N.V., Belgium.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.40. &ldquo;<B>Initial
Project</B>&rdquo; means the Anti-IL17A/F Nanobody project pursued by Initial Licensor and Licensor together which led to the development
of M1095.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.41.
&ldquo;<B>Initiation</B>&rdquo; or <B>&ldquo;Initiate&rdquo;</B> means, when used with respect to any Clinical Trial, the first dosing
of the first patient in such Clinical Trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.42.
&ldquo;<B>Inlicensed Know-How</B>&rdquo; means any and all Know-How owned or Controlled by the Initial Licensor and licensed or sublicensed
to Licensor or any Licensor Affiliate as of the Effective Date or at any time during the Term that is necessary or useful for the Development,
Manufacture, use, or Commercialization of any Compound or Licensed Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.43. &ldquo;<B>Inlicensed
Patents</B>&rdquo; means any and all Patent Rights that are owned or Controlled by the Initial Licensor and licensed or sublicensed to
Licensor or any Licensor Affiliate as of the Effective Date or at any time during the Term, that contain one or more Pending Claims and/or
Valid Claims that, but for the license granted under such Patent Rights, would be infringed by the Development or Commercialization of
any Compound or Licensed Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.44. &ldquo;<B>Inlicensed
Technology</B>&rdquo; means the Inlicensed Know-How and Inlicensed Patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.45. &ldquo;<B>Intellectual
Property</B>&rdquo; means any and all intellectual property and similar proprietary rights in any jurisdiction throughout the world, including
any and all of the following: (a) Patent Rights, (b) trademarks, trade names, trade dress, certification marks, domain names, logos, and
service marks, including all registrations and applications for registration of, and all goodwill associated with, any of the foregoing,
(c) copyrights and registrations and applications for registration thereof and (d) Know-How.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.46. &ldquo;<B>Know-How</B>&rdquo;
means any and all: (a) scientific or technical information, results and data of any type whatsoever, in any tangible or intangible form
whatsoever, that is not in the public domain or otherwise publicly known, including discoveries, inventions, trade secrets, devices, databases,
practices, protocols, regulatory filings, methods, processes (including manufacturing processes, specification and techniques), techniques,
concepts, ideas, specifications, formulations, formulae, data (including pharmacological, biological, chemical, toxicological, clinical
and analytical information, quality control, trial and stability data), case reports forms, medical records, data analyses, reports, studies
and procedures, designs for experiments and tests and results of experimentation and testing (including results of Development), summaries
and information contained in submissions to and information from ethical committees, or Regulatory Authorities, and manufacturing process
and development information, results and data, whether or not patentable, all to the extent not claimed or disclosed in a patent or patent
application; and (b) compositions of matter, cells, cell lines, assays, animal models and physical, biological or chemical material, including
drug substance samples, intermediates of drug substance samples, drug product samples and intermediates of drug product samples. The fact
that an item is known to the public shall not be taken to exclude the possibility that a compilation including the item, or a development
relating to the item, is (and remains) not known to the public. &ldquo;Know-How&rdquo; includes any rights including copyright, database
or design rights protecting such Know-How. &ldquo;Know-How&rdquo; excludes Patent Rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.47. &ldquo;<B>Knowledge</B>&rdquo;
means, with respect to a matter that is the subject of a given representation or warranty of Licensor, the actual knowledge, information
or belief of the officers and directors of Licensor listed on <U>Schedule&nbsp;1.47</U> based on such individuals&rsquo; good faith understanding
of the facts and information in their possession or control following reasonable inquiry as to such facts and information. &ldquo;<B>Knowingly</B>&rdquo;
means with Knowledge.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.48. &ldquo;<B>Licensed
Product</B>&rdquo; means any pharmaceutical or biological product, including any form, presentation, dosage form or formulation thereof,
that contains or comprises, in whole or in part, any Compound as an active ingredient (either as the sole active ingredient or in combination
with one or more other active ingredients). For clarity, different forms, presentations, formulations or dosage strengths of a given Licensed
Product shall be considered the same Licensed Product for purposes of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.49. &ldquo;<B>Licensor
Affiliate</B>&rdquo; means any Affiliate of Licensor that is part of Merck KGaA&rsquo;s healthcare sector. In no event shall Licensor
Affiliate be construed to include Merck KGaA&rsquo;s life sciences sector (operating in the United States as EMD Millipore and MilliporeSigma)
or Merck KGaA&rsquo;s electronics sector (formerly referred to as Performance Materials).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.50. &ldquo;<B>Licensor
Exclusive Know-How</B>&rdquo; means any and all Know-How that is owned or Controlled by Licensor or any Licensor Affiliate as of the Effective
Date and at any time during the Term that is necessary or useful in the Development, Manufacture, use, or Commercialization of any Compound
or Licensed Product and specifically related to any Compound and not applicable to other compounds or drugs. The Know-How to be set forth
in the Transfer Plan will, to Licensor&rsquo;s Knowledge, constitute all of such Know-How owned or Controlled by Licensor or any Licensor
Affiliate as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.51. &ldquo;<B>Licensor
Know-How</B>&rdquo; means Licensor Exclusive Know-How and Licensor Non-Exclusive Know-How.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.52. &ldquo;<B>Licensor
Materials</B>&rdquo; means any and all chemical, biological or physical materials that are owned or Controlled by Licensor or any Licensor
Affiliate as of the Effective Date and that are necessary or useful for the Development, Manufacture, use or Commercialization of any
Compound or Licensed Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.53. &ldquo;<B>Licensor
Non-Exclusive Know-How</B>&rdquo; means any and all Know-How that is owned or Controlled by Licensor or any Licensor Affiliate at any
time during the Term and that is necessary or useful in the Development, Manufacture, use, or Commercialization of any Compound or Licensed
Product, excluding Licensor Exclusive Know-How.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.54. &ldquo;<B>Licensor
Non-Exclusive Patents</B>&rdquo; means any and all Patent Rights that are owned or Controlled by Licensor or any Licensor Affiliate during
the Term and that Cover any Licensed Product or Compound or that are necessary for the Development, Manufacture, use, or Commercialization
of any Compound or Licensed Product, excluding Licensor Patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.55. &ldquo;<B>Licensor
Patents</B>&rdquo; means any and all Patent Rights that are owned or Controlled by Licensor or any Licensor Affiliate (a)&nbsp;as of the
Effective Date and that Cover any Licensed Product or Compound or that are necessary for the Development, Manufacture, use, or Commercialization
of any Compound or Licensed Product, including the Patent Rights set forth on <U>Schedule&nbsp;1.55,</U> or (b)&nbsp;during the Term to
the extent that such Patent Rights specifically Cover the composition of matter, formulation, methods of manufacturing or methods of using
any Licensed Product or Compound and do not Cover the composition of matter, formulation, methods of manufacturing or methods of using
any other product or compound.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.56.
&ldquo;<B>Licensor Technology</B>&rdquo; means the Licensor Know-How, the Licensor Patents and the Licensor Materials, collectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.57. &ldquo;<B>Major
Market</B>&rdquo; means each of Japan, Germany, France, Italy, the United Kingdom, Spain and the United States of America.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.58. &ldquo;<B>Manufacture</B>&rdquo;
means all activities associated with the production, manufacture, supply, processing, filling, packaging, labeling, shipping, and storage
of a product, or any components thereof, manufacture of preclinical, clinical and commercial supply, product characterization, quality
assurance and quality control development, testing and release, and interacting with Regulatory Authorities regarding the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.59. &ldquo;<B>Manufacturing
Quality Agreement</B>&rdquo; means the quality assurance agreement mutually agreed upon in writing by the Parties, which shall outline
the Parties&rsquo; respective responsibilities on quality matters, being entered into by the Parties in conjunction herewith prior to
the delivery of Drug Product by Licensor or any of its Affiliates to Licensee, covering all quality assurance agreements being entered
into by the Parties in conjunction with manufacturing of the Drug Product by Licensor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.60. &ldquo;<B>NDA</B>&rdquo;
means a New Drug Application filed pursuant to the requirements of the FDA, as more fully defined in 21 U.S. C.F.R. &sect;&nbsp;314.3
et seq., a Biologics License Application filed pursuant to the requirements of the FDA, as more fully defined in 21 U.S. C.F.R. &sect;&nbsp;601,
and any equivalent application submitted in any country in the Territory, including all additions, deletions or supplements thereto, and
as any and all such requirements may be amended, or supplanted, at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.61. &ldquo;<B>Net
Sales</B>&rdquo; means the gross amounts invoiced by Licensee, its Affiliates and/or its Sublicensees for sales in an arm&rsquo;s length
transaction of a Licensed Product to independent or unaffiliated Third-Party purchasers (other than a Sublicensee for such Licensed Product)
of such Licensed Product, less the following deductions with respect to such sales to the extent that such amounts are either included
in the billing as a line item as part of the gross amount invoiced, or otherwise permitted by Accounting Standards to be specifically
attributable to actual sales of a Licensed Product and where such deductions have actually been taken, have been paid for, or have accrued
in respect of the amount invoiced: [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the event that a Licensed Product
under this Agreement is sold as a Combination Product (&ldquo;<B>Combination Sale</B>&rdquo;), then Net Sales for such Combination Product
shall be calculated separately for each Calendar Quarter and shall be the portion of such Combination Sale allocable to the Licensed Product
included in such Combination Product determined as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Except as provided below, the Net Sales
amount for a Combination Sale shall equal the gross amount invoiced for the Combination Sale, reduced by the deductions permitted under
(a) to (g) above) (the &ldquo;<B>Net Combination Sale Amount</B>&rdquo;), multiplied by the fraction A/(A+B), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>A </B>is the invoice price in that
Calendar Quarter, in the country where such Combination Sale occurs, of the Licensed Product contained in the Combination Product, if
sold as a separate Licensed Product in such country by Licensee or its Affiliates and <B>B</B> is the aggregate of the invoice price or
prices, in that Calendar Quarter and in such country, of such other active ingredients/components, as the case may be, included in the
Combination Product if sold separately in such country by Licensee or its Affiliates, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Where the calculation of Net Sales
resulting from a Combination Sale (including the determination of the invoice price) in a country cannot be determined by the foregoing
method, the calculation of Net Sales for such Combination Sale shall be that portion of the Net Combination Sale Amount reasonably determined
on a country-by-country basis by mutual written agreement of the Parties in good faith taking into account the relevant value of the Licensed
Product and the other ingredient or component included in the Combination Product, as reflected in their respective market prices. In
case no such agreement can be found, an independent expert agreed upon in writing by both Parties, or failing such agreement, the ICC
by way of ad hoc expert proceedings, shall determine such relative value contributions and such determination shall be final and binding
upon the Parties (it being understood that the expert appointed in such ICC ad hoc expert proceedings shall be appointed by the ICC International
Centre for ADR in accordance with the Rules for the Appointment of Experts and Neutrals of the ICC).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In the event a Licensed Product is
&ldquo;bundled&rdquo; for sale together with one or more other products in a country (a &ldquo;<B>Product Bundle</B>&rdquo;), then Net
Sales for such Licensed Product shall be the portion of the gross amount invoiced for the sale of the Product Bundle by Licensee or its
Affiliates or its Sublicensees (less the deductions permitted under (a) to (g) above) allocable to the Licensed Product, which portion
shall be determined based on the list price of the Licensed Product when sold as a separate Licensed Product in such country relative
to the list price of the other product(s) in the Product Bundle or group of products when those other product(s) are sold as separate
product(s) in such country. Where such portion cannot be calculated in a country by the foregoing method because one of the products in
the bundle or group of products is not sold separately in such country or the list price for the Licensed Product and/or other product(s)
cannot be reasonably determined, then the calculation of Net Sales for the Licensed Product in such Product Bundle shall be that portion
of the gross amount invoiced for the sale of the Product Bundle or group of products (less the deductions permitted under (a) to (g) above)
reasonably determined in good faith by mutual written agreement of the Parties, and where no such agreement can be found, an independent
expert agreed upon in writing by both Parties, or failing such agreement, the ICC by way of ad hoc expert proceedings, shall determine
the value of the Licensed Product included in the Product Bundle or group of products, and such determination shall be final and binding
upon the Parties (it being understood that the expert appointed in such ICC ad hoc expert proceedings shall be appointed by the ICC International
Centre for ADR in accordance with the Rules for the Appointment of Experts and Neutrals of the ICC).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For clarification, sale of a Licensed
Product by Licensee, its Affiliates and/or its Sublicensees to another of these entities for resale by such entity to a Third Party (other
than a Sublicensee for such Licensed Product) shall not be deemed a sale for purposes of this definition of &ldquo;Net Sales&rdquo; hereunder
and such sales shall not constitute a &ldquo;First Commercial Sale&rdquo;. Further, transfers or dispositions of a Licensed Product (i)
in connection with patient assistance programs, (ii) for charitable or promotional purposes, (iii) for preclinical, clinical, regulatory
or governmental purposes or under so-called &ldquo;named patient&rdquo; or other limited access programs, or (iv) for use in any tests
or studies reasonably necessary to comply with any Applicable Laws, regulation or request by a Regulatory Authority, shall not, in each
case of clauses (i)-(iv), be deemed sales of such Licensed Product for purposes of this definition of &ldquo;Net Sales&rdquo; and such
sales shall not constitute a First Commercial Sale.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.62.
&ldquo;<B>Out-of-Pocket Costs</B>&rdquo; means, with respect to Licensor, reasonable, documented costs and expenses paid by Licensor to
Third Parties (or payable to Third Parties and accrued in accordance with Accounting Standards), other than employees of Licensor or its
Affiliates. For clarity, all reasonable, documented fees due by Licensor to any contract service provider shall be understood as included
in the definition of Out-of-Pocket Costs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.63. &ldquo;<B>Patent
Right(s)</B>&rdquo; means any and all (a) national, regional and international patents and patent applications, including provisional
patent applications, (b) patent applications filed either from such patents, patent applications or provisional applications or from an
application claiming priority from either of these, including divisionals, continuations, continuations-in-part, provisionals, converted
provisionals and continued prosecution applications, (c) patents that have issued or in the future issue from the foregoing patent applications
((a) and (b)), including utility models, petty patents and design patents and certificates of invention, (d) extensions or restorations
by existing or future extension or restoration mechanisms, including revalidations, renewals, reissues, re-examinations and extensions
(including any supplementary protection certificates and the like) of the foregoing patents or patent applications ((a), (b), and (c))
and (e) rights to claim priority to any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.64. &ldquo;<B>Pending
Claim</B>&rdquo; means a patent claim of a pending patent application which claim (i)&nbsp;has not been cancelled, withdrawn, abandoned
or refused by a court or other Governmental Body of competent jurisdiction in a final decision from which no appeal can be or has been
taken and (ii) has not been pending for more than [***] from the filing date of the first priority application that has been invoked for
such patent application that contains such claim (or if no such priority has been invoked, from the filing date of such patent application).
It is understood that any claim that has been pending for more than the period of [***] referred to in the previous sentence shall not
be considered a Pending Claim for the purposes of this Agreement. Notwithstanding anything to the contrary in this Agreement, it is agreed
between the Parties that a claim of a pending patent application shall not be deemed a Pending Claim for the purposes of this Agreement
if it is directed to obviously unpatentable subject matter (for example, either because of statutory unpatentability or unpatentability
over relevant prior art). Should a dispute arise on the patentability of any subject matter of a claim according to the preceding sentence,
this dispute shall be finally settled by binding expert determination, the expert being a renowned independent patent attorney nominated
by Licensor and acceptable to Licensee, which patent attorney must not be a former employee of either Party and must not have been involved
in any services for either Party before said arbitration. If the Parties fail to agree on an expert, such a dispute shall be finally settled
by the ICC by way of ad hoc expert proceedings, and such resolution shall be final and binding upon the Parties (it being understood that
the expert appointed in such ICC ad hoc expert proceedings shall be appointed by the ICC International Centre for ADR in accordance with
the Rules for the Appointment of Experts and Neutrals of the ICC). Irrespective of the outcome of such expert determination, the cost
of such independent patent attorney shall be shared between the Parties on [***] basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.65. &ldquo;<B>Person</B>&rdquo;
means any natural person, corporation, firm, business trust, joint venture, association, organization, company, partnership or other business
entity, or any government or agency or political subdivision thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.66. &ldquo;<B>Personal
Data</B>&rdquo; means any information relating to an identified or identifiable natural person as defined in the GDPR.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.67. &ldquo;<B>Phase
I Trial</B>&rdquo; means a Clinical Trial in which the Licensed Product is administered to human subjects at multiple dose levels with
the primary purpose of determining safety, metabolism, and pharmacokinetic and pharmacodynamic properties of the Licensed Product, and
which is consistent with 21 U.S. CFR &sect;&nbsp;312.21(a).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.68. &ldquo;<B>Phase
II Trial</B>&rdquo; means a Clinical Trial of the Licensed Product in human patients, the principal purposes of which are to make a preliminary
determination that the Licensed Product is safe for its intended use, to determine its optimal dose, and to obtain sufficient information
about the Licensed Product&rsquo;s efficacy to permit the design of Phase III Trials, and which is consistent with 21 U.S. CFR &sect;&nbsp;312.21(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.69. &ldquo;<B>Phase
III Trial</B>&rdquo; means a pivotal Clinical Trial of any Licensed Product, with a defined dose or a set of defined doses, which trial
is designed to ascertain efficacy and safety of such compound or product for the purpose of enabling the preparation and submission of
an NDA with the FDA or other applicable Regulatory Authority, and which is consistent with 21 U.S. C.F.R. &sect;&nbsp;312.21(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.70. &ldquo;<B>PMDA</B>&rdquo;
means the Japanese Pharmaceutical and Medical Device Agency or its successor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.71. &ldquo;<B>Product
Specifications</B>&rdquo; means the product quality specifications applicable to the Drug Substance and Drug Product, which are substantially
similar to those used by Licensor for Drug Substance and Drug Product prior to the Effective Date. As between the Parties, such specifications
will be set forth in the Manufacturing Quality Agreement. Any change to such specifications must be mutually agreed in writing between
the Parties in accordance with the rules set forth in such Manufacturing Quality Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.72. &ldquo;<B>RCT</B>&rdquo;
means Research Corporation Technologies, Inc. (Delaware).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.73. &ldquo;<B>RCT
Know-How</B>&rdquo; means any and all Know-How owned or Controlled by RCT and licensed or sublicensed to Licensor or any Licensor Affiliate
as of the Effective Date or at any time during the Term that is necessary or useful for the Development, Manufacture, use, or Commercialization
of any Compound or Licensed Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.74. &ldquo;<B>RCT
Patents</B>&rdquo; means any and all Patent Rights that are owned or Controlled by RCT and licensed or sublicensed to Licensor or any
Licensor Affiliate as of the Effective Date or at any time during the Term, that Cover any Licensed Product or Compound or are otherwise
necessary for the Development, Manufacture, use or Commercialization of any Compound or Licensed Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.75.
&ldquo;<B>Regulatory Approval</B>&rdquo; means any and all approvals, licenses, registrations, or authorizations of the relevant Regulatory
Authority necessary for the Development, Manufacture or Commercialization of a Licensed Product in a particular country or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.76. &ldquo;<B>Regulatory
Authority</B>&rdquo; means (a) in the United States, the FDA, (b) in the European Union, the EMA or the European Commission, (c) in Japan,
the PMDA or (d) any Governmental Body with similar regulatory authority over pharmaceutical or biotechnology products in any other jurisdiction
anywhere in the world.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.77. &ldquo;<B>Regulatory
Filing</B>&rdquo; means, with respect to any Licensed Product, the submission of any NDA for such Licensed Product to an applicable Regulatory
Authority in any country by Licensee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.78. &ldquo;<B>Regulatory
Filing Acceptance</B>&rdquo; means, with respect to any NDA and any country, the receipt by Licensee or any of its Affiliates or Sublicensees
of written notice from the relevant Regulatory Authority in such country that such NDA has met all the criteria for filing acceptance
under Applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.79. &ldquo;<B>Sublicensee</B>&rdquo;
means a Person other than an Affiliate of Licensee to which Licensee (or its Affiliate) has, pursuant to <U>Section&nbsp;2.1(c)</U>, granted
sublicense rights under any of the license rights granted under <U>Sections&nbsp;2.1(a)</U> or <U>2.1(b)</U>, but excluding any compulsory
sublicensees or compulsory licensees. &ldquo;<B>Sublicense</B>&rdquo; shall be construed accordingly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.80. &ldquo;<B>Successful
Completion</B>&rdquo; means, with respect to any Clinical Trial of any Licensed Product, the completion of such Clinical Trial where such
Licensed Product achieved the intended primary endpoint established at the beginning of such Clinical Trial with a favourable medical
benefit/risk balance (including considering any serious adverse medical events), allowing further Development or Commercialization, as
applicable, of such Licensed Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.81. &ldquo;<B>Supply
Costs</B>&rdquo; means the actual fully-loaded cost to Licensor or its Affiliates for the Manufacture of Compounds or Licensed Products
(in particular turning Drug Substance to Drug Product), calculated using a methodology consistently applied by Licensor and consistent
with Accounting Standards, plus a mark-up of [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.82.
&ldquo;<B>Tax</B>&rdquo; means any federal, state, local or foreign income, gross receipts, license, payroll, employment, excise, severance,
stamp, occupation, premium, windfall profits, environmental, customs duties, capital stock, franchise, profits, withholding, social security,
unemployment, disability, real property, personal property, sales, use, transfer, registration, value added, alternative or add-on minimum,
estimated, or other tax of any kind whatsoever, including any interest, penalty, or addition thereto, whether disputed or not.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.83. &ldquo;<B>Territory</B>&rdquo;
means all the countries in the world.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.84. &ldquo;<B>Third
Party</B>&rdquo; means any Person that is not a Party or an Affiliate of a Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.85. &ldquo;<B>Third-Party
License Agreement</B>&rdquo; means any agreement entered into by a Party or its Affiliate with a Third Party, or any amendment or supplement
thereto, in each case following the Effective Date, whereby royalties, fees or other payments are to be made by a Party or its Affiliate
to such Third Party in connection with the grant of rights under Intellectual Property rights owned or controlled by such Third Party,
which rights are reasonably necessary or useful to Develop, Manufacture, have made, import, export, use or Commercialize any Compounds
or Licensed Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.86. &ldquo;<B>UK
MHRA</B>&rdquo; means the United Kingdom Medicines and Healthcare products Regulatory Agency.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.87. <B>&ldquo;Underlying
GMP License</B>&rdquo; means that certain license agreement between Licensor and RCT relating to a GMP manufacturing process for using
a strain of <I>Pichia pastoris</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.88. &ldquo;<B>United
Kingdom</B>&rdquo; means the United Kingdom of Great Britain and Northern Ireland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.89. &ldquo;<B>United
States</B>&rdquo; or &ldquo;<B>U.S.</B>&rdquo; means the United States of America and its territories and possessions, including Puerto
Rico.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.90. &ldquo;<B>U.S.
GAAP</B>&rdquo; means generally accepted accounting principles in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.91. &ldquo;<B>Valid
Claim</B>&rdquo; means a claim in an unexpired and issued Patent Right, which claim has not been disclaimed, revoked or held invalid or
unenforceable by a final nonappealable decision of a court or other Governmental Body of competent jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">1.92. <B>Other
Terms</B>. The definition of each of the following terms is set forth in the section or part of this Agreement indicated below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Achieved Commercial Milestone</B>&rdquo;
has the meaning set forth in <U>Section 4.4(c)(iii)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Acquired Competing Biologic
Product&rdquo;</B> has the meaning set forth in <U>Section 1.14</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Action</B>&rdquo; has the
meaning set forth in <U>Section&nbsp;5.4(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Agreement</B>&rdquo; has
the meaning set forth in the first and opening paragraph of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Alliance Manager</B>&rdquo;
has the meaning set forth in <U>Section 11.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Allowed Deductions</B>&rdquo;
has the meaning set forth in <U>Section 4.5(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Auditor</B>&rdquo; has the
meaning set forth in <U>Section 4.7.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Combination Sale</B>&rdquo;
has the meaning set forth in <U>Section 1.61</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Commercial Milestone Event</B>&rdquo;
has the meaning set forth in <U>Section 4.4(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Controlling Party</B>&rdquo;
has the meaning set forth in <U>Section&nbsp;5.5(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Development Plan</B>&rdquo;
has the meaning set forth in <U>Section&nbsp; 3.1(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Diligence Obligations</B>&rdquo;
has the meaning set forth in <U>Section 3.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Dispute</B>&rdquo; has the
meaning set forth in <U>Section 11.11(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Effective Date</B>&rdquo;
has the meaning set forth in the first and opening paragraph of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Excluded Claim</B>&rdquo;
has the meaning set forth in <U>Section 11.11(e)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Extension Payment</B>&rdquo;
has the meaning set forth in <U>Section 3.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>GDPR</B>&rdquo; has the meaning
set forth in <U>Section 1.19</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Licensor&rsquo;s Equity Consideration</B>&rdquo;
has the meaning set forth in <U>Section 4.2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>ICC Rules</B>&rdquo; has
the meaning set forth in <U>Section 11.11(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Improper Conduct</B>&rdquo;
has the meaning set forth in <U>Section&nbsp; 3.8</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Indemnified Party</B>&rdquo;
has the meaning set forth in <U>Section&nbsp;8.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Indemnifying Party</B>&rdquo;
has the meaning set forth in <U>Section&nbsp;8.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Initial Response</B>&rdquo;
has the meaning set forth in <U>Section 3.1(d)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Initial Response Period</B>&rdquo;
has the meaning set forth in <U>Section 3.1(d)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Licensee</B>&rdquo; has the
meaning set forth in the first and opening paragraph of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Licensee Indemnitees</B>&rdquo;
has the meaning set forth in <U>Section&nbsp;8.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Licensee Patents</B>&rdquo;
has the meaning set forth in <U>Section&nbsp;5.2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Licensor</B>&rdquo; has the
meaning set forth in the first and opening paragraph of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Licensor Indemnitees</B>&rdquo;
has the meaning set forth in <U>Section&nbsp;8.2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Losses</B>&rdquo; has the
meaning set forth in <U>Section&nbsp;8.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Manufacturing Technology
Transfer Plan</B>&rdquo; has the meaning set forth in <U>Section 2.2(d)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Milestone Event</B>&rdquo;
has the meaning set forth in <U>Section&nbsp;4.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Milestone Event #1</B>&rdquo;
has the meaning set forth in <U>Section&nbsp; 4.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Milestone Event #2</B>&rdquo;
has the meaning set forth in <U>Section&nbsp;4.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Milestone Event #6</B>&rdquo;
has the meaning set forth in <U>Section&nbsp;4.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Milestone Event #7</B>&rdquo;
has the meaning set forth in <U>Section&nbsp;4.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Milestone Event #8</B>&rdquo;
has the meaning set forth in <U>Section&nbsp;4.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Milestone Payment</B>&rdquo;
has the meaning set forth in <U>Section&nbsp; 4.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Partnering Notice</B>&rdquo;
has the meaning set forth in <U>Section 3.1(d)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Parties</B>&rdquo; has the
meaning set forth in the first and opening paragraph of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Party</B>&rdquo; has the
meaning set forth in the first and opening paragraph of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Patent Challenge</B>&rdquo;
has the meaning set forth in <U>Section 9.6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Product Bundle</B>&rdquo;
has the meaning set forth in <U>Section 1.61</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>ROFN Period</B>&rdquo; has
the meaning set forth in <U>Section 3.1(d)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>ROFN Rights</B>&rdquo; has
the meaning set forth in <U>Section 3.1(d)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Royalty Term</B>&rdquo; has
the meaning set forth in <U>Section&nbsp;4.5(h)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Senior Executives</B>&rdquo;
are defined in <U>Section 10.2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Tax Credit</B>&rdquo; has
the meaning set forth in <U>Section 4.8</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Term</B>&rdquo; has the meaning
set forth in <U>Section&nbsp;9.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Third-Party Action</B>&rdquo;
has the meaning set forth in <U>Section&nbsp;5.5(a)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Transfer Plan</B>&rdquo;
has the meaning set forth in <U>Section 2.2(c)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Transition Committee</B>&rdquo;
has the meaning set forth in <U>Section 2.2(b)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Upfront Payment</B>&rdquo;
has the meaning set forth in <U>Section&nbsp;4.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&ldquo;<B>Withholding Tax</B>&rdquo;
has the meaning set forth in <U>Section 4.8</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
2 - GRANT OF LICENSE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">2.1. <B>Grant
of License</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">(a) <B>Exclusive
License</B>. Subject to the terms and conditions of this Agreement (and expressly conditional upon receipt by Licensor of the (partial)
consideration set forth in <U>Section 4.1)</U>, Licensor hereby grants to Licensee a royalty- and milestone-bearing exclusive (even as
to Licensor), sublicensable (to the extent set forth in <U>Section 2.1(c)</U>), right and license under the Licensor Patents, Licensor
Materials and the Licensor Exclusive Know-How to Develop, have Developed, Manufacture, have Manufactured, use, sell, offer for sale, export
and import and otherwise Commercialize the Compounds and Licensed Products in the Field in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">(b) <B>Non-Exclusive
License</B>. Subject to the terms and conditions of this Agreement (and expressly conditional upon receipt by Licensor of the (partial)
consideration set forth in <U>Section 4.1</U>), Licensor hereby grants to Licensee a royalty- and milestone-bearing non-exclusive, sublicensable
(to the extent set forth in <U>Section 2.1(c)</U>), right and license under the Inlicensed Patents, Licensor Non-Exclusive Patents, Inlicensed
Know-How, the RCT Patents, the RCT Know-How and the Licensor Non-Exclusive Know-How to Develop, have Developed, Manufacture, have Manufactured,
use, sell, offer for sale, export and import and otherwise Commercialize the Compounds and Licensed Products in the Field in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">(c) <B>Sublicenses</B>.
Subject to the terms and conditions of this Agreement, Licensee shall have the right to grant to Third Parties, through one (1) or more
tiers, sublicenses under the licenses and sublicenses granted by Licensor to Licensee under <U>Sections 2.1(a)</U> and 2.1<U>(b)</U>;
<I>provided</I>, that: (i) each Sublicense agreement shall be consistent with the terms and conditions of this Agreement; (ii) Licensee
shall remain responsible for the performance of all of its Sublicensees under such Sublicense agreements to the same extent as if such
activities were conducted by Licensee, and shall remain responsible for any payments due hereunder with respect to activities of any Sublicensees;
and (iii) Licensee shall ensure that its Sublicensees comply with the terms and conditions of this Agreement; <I>provided further</I>
that Licensor shall not terminate this Agreement for any act or omission of any such Sublicensees that constitutes a breach of this Agreement
if Licensee terminates such Sublicensee&rsquo;s applicable sublicense agreement within [***] of becoming aware of such act or omission
or if such breach is cured in accordance with <U>Section 9.4</U>. Licensee shall provide notice to Licensor of any Sublicense entered
into, and, upon request, Licensee shall provide Licensor with a copy of each such executed Sublicense agreement; <I>provided</I>, that
Licensee may redact from each such Sublicense agreement all (x) financial terms and (y) other provisions that are not relevant to Licensee&rsquo;s
performance hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">(d) <B>Obligations</B>.
The rights and sublicenses granted to Licensee under <U>Section 2.1(b)</U> with respect to Inlicensed Patents, and Inlicensed Know-How
are subject to the scope, obligations and limitations of the Initial License Agreement that are binding on Licensor. Inlicensed Technology
is subject to specific restrictions under the Initial License Agreement and those restrictions shall apply accordingly to this Agreement,
<I>mutatis mutandis</I>. For the avoidance of doubt, it is agreed between the Parties that, notwithstanding anything to the contrary in
<U>Section 2.1(b)</U> of this Agreement, the rights and sublicenses granted under <U>Section 2.1(b)</U> are subject to Licensee&rsquo;s
compliance with <U>Sections 23.2</U>, <U>13.3</U>, <U>13.4</U>, <U>14.2</U>, <U>15.2</U>, <U>15.3</U>, <U>15.4</U>, <U>18.2</U> to <U>18.4</U>,
<U>29.10</U>, <U>29.11</U>, <U>29.12</U>, <U>33.1</U>, and <U>37.22(f)</U> and <U>(h)-(l)</U>, and <U>Article 31</U> as set forth under
<U>Section 26.2</U> under the Initial License Agreement. Licensor is required under <U>Section 26.2</U> of the Initial License Agreement
to include the right of Initial Licensor to invoke the following Sections of the Initial License Agreement directly against Licensee:
<U>Sections 11.5</U>, <U>13.3</U>, <U>13.4</U>, <U>14.2</U>, <U>15.2</U> to <U>15.4</U>, <U>18.2</U> to <U>18.4</U>, <U>21.3</U>, <U>37.22(f)</U>,
<U>(h)-(l)</U>, and the last sentence of <U>37.25</U>. Further, Licensor is required to inform Initial Licensor about the identity of
Licensee and allow independent counsel review of this Agreement for Initial Licensor as further set forth below in <U>Section 6.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">2.2. <B>Technology
Transfer</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">(a) <B>Overview.
</B>Subject to the terms of this Agreement, Licensor shall make available to Licensee the Licensor Know-How, Inlicensed Know-How and Licensor
Materials as of the Effective Date, whereby such transfer shall be in accordance with a Transfer Plan in an orderly fashion and in a manner
mutually agreed in writing by the Parties, which shall take into account the value, usefulness and confidentiality of the transferred
Licensor Technology and Inlicensed Know-How. In conjunction with the transfer of Personal Data, as applicable, Licensee and Licensor will
enter into a data transfer agreement to the extent required to comply with Data Protection Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">(b) <B>Transition
Committee.</B> Within [***] following the Effective Date, the Parties will establish a committee to manage the transition of the Compounds
and Licensed Products to Licensee (the &ldquo;<B>Transition Committee</B>&rdquo;), that meets on a regularly scheduled basis to: (i) lead
the generation of a Transfer Plan and Manufacturing Technology Transfer Plan and (ii)&nbsp;oversee and coordinate activities related to
the transfer set forth in the Transfer Plan and the Manufacturing Technology Transfer Plan. Each Party will nominate [***] to the Transition
Committee, who possess a general understanding of research, development, regulatory and manufacturing matters to act as its representatives
and provide written notice thereof to the other Party. The Transition Committee shall remain in existence until the completion of the
technology transfer set forth in the Transfer Plan. Any disputes among the Transition Committee shall be resolved in accordance with <U>ARTICLE
10</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">(c) <B>Transfer
Plan</B>. Within [***] following the Effective Date, the Parties shall mutually agree, under the lead of the Transition Committee, on
a documented transfer plan (the &ldquo;<B>Transfer Plan</B>&rdquo;) to transfer to Licensee the Licensor Know-How, Inlicensed Know-How
and Licensor Materials in the possession and under Control of Licensor, any Licensor Affiliates, or Third Party contractors. An outline
of key building blocks, to be reflected in the Transfer Plan, is attached to this Agreement as <U>Schedule 2.2</U>. With respect to any
Licensor Know-How, Inlicensed Know-How or Licensor Materials which are not in the possession of Licensor but are in the possession of
Third Party contractors, if requested by Licensee, Licensor shall as promptly as reasonably practicable execute one or more letters of
authorization to permit such Third Party contractors to disclose and transfer such Licensor Know-How, Inlicensed Know-How and Licensor
Materials to Licensee as part of the Transfer Plan. The Transfer Plan shall include (i) a detailed listing of the Licensor Know-How, Inlicensed
Know-How and Licensor Materials to be transferred to Licensee, (ii) mutual understanding on a detailed description of the required infrastructure
to facilitate the transfer contemplated in such Transfer Plan, including the transfer of the Licensor Know-How, Inlicensed Know-How and
Licensor Materials (such as information technology platforms, storage facilities, and means of transfer or transport), (iii) a reasonably
detailed timeframe for the transfer of the Licensor Know-How, Inlicensed Know-How and Licensor Material to Licensee, and (iv)&nbsp;estimated
budget for the contemplated technology transfer. For clarity, such activities to be undertaken by Licensor and to be set forth in the
Transfer Plan comprise, but are not limited to: transferring (A) the Licensor Know-How and Inlicensed Know-How and providing support therefor,
(B) all correspondence, submissions, filings or other documentation of communication with any Regulatory Authority and support therefor,
(C) all Licensor Materials, (D) digital copies of the materials in the virtual data room set up by or on behalf of Licensor relating to
the subject matter hereunder, and (E) all clinical and pre-clinical data owned or Controlled by Licensor or any of its Affiliates for
the Compounds or Licensed Products. It is the understanding of both Parties that (1) the transfer shall be completed within a timeframe
of [***] following the approval of the Transfer Plan by the Transition Committee, or such longer timeframe as may be mutually agreed in
writing by the Parties, and (2) if, following the completion of the transfer, Licensee reasonably requests additional materials comprised
in the Licensor Materials (but not yet transferred) that are necessary for Licensee&rsquo;s performance of the Development Plan, Licensor
shall provide such additional materials as promptly as reasonably practicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">(d) <B>Manufacturing
Technology Transfer.</B> Further, within [***] following the Effective Date, a plan describing the transfer of the Manufacturing technology,
including analytical methods, Drug Product Manufacturing processes will be agreed in writing by the Parties (the &ldquo;<B>Manufacturing
Technology Transfer Plan</B>&rdquo;). An outline of key building blocks, to be reflected in the Manufacturing Technology Transfer Plan,
is attached to this Agreement as <U>Schedule 2.2</U>. The transfer process for the Manufacturing technology, including timelines, activities
and the extent of support needed, shall be detailed within the Manufacturing Technology Transfer Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">2.3. <B>Technology
Transfer Cost Reimbursement</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">(a) Licensor
will provide reasonable support and assistance to Licensee during the technology transfer set forth in the Transfer Plan and Manufacturing
Technology Transfer Plan (such amount of support to be specified in the Transfer Plan and Manufacturing Technology Transfer Plan). Such
support to be provided by Licensor will include access to appropriate specified Licensor employees for a maximum of [***] after the Effective
Date or such longer timeframe as may be mutually agreed in writing by the Parties. Licensee will reimburse Licensor for any reasonable
Out-of-Pocket Costs and internal FTE hours based on a rate of [***] per hour for each FTE hour; <I>provided</I> that the first [***] hours
of such support shall be provided at no cost to Licensee. Contemporaneously with the completion of drafting the Transfer Plan and the
Manufacturing Technology Transfer Plan, Licensor shall provide Licensee with a reasonably detailed, good faith estimate of the time and
costs expected to be incurred by Licensor for activities outlined under the Transfer Plan and the Manufacturing Technology Transfer Plan,
and Licensor will periodically, prior to the start of each Calendar Quarter during which the Parties are conducting activities under the
Transfer Plan and the Manufacturing Technology Transfer Plan (as applicable), provide Licensee with updates to such estimate. If Licensor
anticipates that the costs to be incurred by Licensor during any Calendar Quarter will exceed the aggregate estimated cost of such activities
in such good faith estimate by more than [***] of the relevant aggregate Calendar Quarter cost estimate, Licensor will promptly notify
Licensee, provide an updated estimate and discuss the relevant factors leading to such anticipated excess costs in the Transition Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">(b) Licensor
will invoice Licensee within thirty (30) days after the end of each Calendar Quarter for all FTE costs, Supply Costs, and Out-of-Pocket
Costs incurred by Licensor or its Affiliates in such Calendar Quarter for activities outlined under the Transfer Plan. Licensor shall
use Commercially Reasonable Efforts to execute Licensor&rsquo;s activities under the Transfer Plan in a cost-efficient manner, and any
costs incurred by Licensor in excess of the budgets outlined in the Transfer Plan will require unanimous written consent by the Transition
Committee. Subject to <U>Section&nbsp;2.3(a)</U>, Licensee will pay such invoices within thirty (30) days after receipt thereof.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
3 - DEVELOPMENT AND COMMERCIALIZATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">3.1. <B>Development
of Licensed Product by Licensee</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">(a) In
accordance with the terms of this Agreement, as between the Parties, Licensee shall have the exclusive right and responsibility to Develop
Licensed Products and to conduct (either itself or through its Affiliates, agents, subcontractors or Sublicensees) all Clinical Trials
and non-clinical studies Licensee believes appropriate to obtain Regulatory Approval for the Licensed Products in any Indication in the
Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">(b) Subject
to the terms and conditions of this Agreement (including <U>Section 3.5</U>), the Development of each Licensed Product shall be in accordance
with the development plan attached hereto as <U>Schedule 3.1(b)</U> (the &ldquo;<B>Development Plan</B>&rdquo;). The Development Plan
will describe the proposed overall program of Development, the Development assumptions, Development steps and personnel allocation of
Licensee for Licensed Products in the initial target indications of Psoriatic Arthritis, Ankylosing Spondylitis and Hidradenitis Suppurativa,
and shall in particular include a clinical development plan that outlines any contemplated Clinical Trial (including estimated timelines
and milestones, treatment arms, primary and secondary endpoints and estimated number of patients per study) to be undertaken by Licensee
to obtain Regulatory Approval in the Major Markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">(c) Licensee
shall provide Licensor with bi-annual updates to the Development Plan, in the first quarter of each Calendar Year, and such updates shall
take into account the progress and status of Development in any Indication, in particular the completion or cessation of Development activities
or commencement of new Development activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">(d) The
first time that Licensee determines that it intends to grant license rights to a Third Party partner for the Development or Commercialization
of a Licensed Product for the treatment of Multiple Sclerosis (such rights to Develop or Commercialize, the &ldquo;<B>ROFN Rights</B>&rdquo;),
Licensee shall notify Licensor in writing as promptly as reasonably practicable (the &ldquo;<B>Partnering Notice</B>&rdquo;). Within [***]
after receiving the Partnering Notice (the &ldquo;<B>Initial Response Period</B>&rdquo;), Licensor shall notify Licensee in writing as
to whether or not Licensor desires to obtain such ROFN Rights (such notice, the &ldquo;<B>Initial Response</B>&rdquo;). If Licensor provides
an Initial Response to Licensee within the Initial Response Period that indicates that Licensor desires to obtain such ROFN Rights, then
Licensor shall have a one-time right of first negotiation to obtain from Licensee such ROFN Rights for a period of up to [***] after receipt
of the Partnering Notice by Licensor (the &ldquo;<B>ROFN Period</B>&rdquo;). During the ROFN Period, the Parties shall negotiate in good
faith on the terms and conditions under which Licensor may obtain such ROFN Rights; <I>provided</I> that neither Party shall be obligated
to enter into any agreement with regard to such ROFN Rights. During the ROFN Period, Licensee may not enter into an agreement with a Third
Party in relation to such ROFN Rights or solicit new interest from any Third Party regarding such ROFN Rights; <I>provided</I>, <I>however</I>,
that Licensee will not be restricted from negotiation with a Third Party that has expressed or subsequently expresses interest in obtaining
such ROFN Rights without solicitation from Licensee. In the event that (i) Licensor does not provide any Initial Response to Licensee
within the Initial Response Period, (ii) Licensor indicates in the Initial Response that it is not interested in obtaining such ROFN Rights
or (iii) the Parties do not execute an agreement within the ROFN Period (or any mutually agreed upon extension), then Licensee shall be
free to enter into an agreement with any Third Party regarding such ROFN Rights on such terms as Licensee may determine in its sole discretion,
and Licensee shall no longer be subject to the obligations set forth in this <U>Section 3.1(d)</U>. For the avoidance of doubt, (A) the
rights granted to Licensor under this <U>Section 3.1(d)</U> may only be triggered one time during the Term and (B) notwithstanding anything
to the contrary in this Agreement, in no event shall a Change of Control of Licensee or any of its Affiliates trigger the rights granted
to Licensor under this <U>Section 3.1(d)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">3.2. <B>Commercialization</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">(a) Subject
to the terms and conditions of this Agreement (including <U>Section 3.5</U>), as between the Parties, Licensee shall have the exclusive
right and responsibility to Commercialize Licensed Products in the Territory (either itself or through its Affiliates, agents, subcontractors,
Sublicensees or other Third Parties selected by Licensee).</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">(b) The
Commercialization of each Licensed Product shall be governed by a commercialization plan that describes the proposed overall program of
Commercialization, summarizing at a high level of detail the specified Commercialization activities planned for the upcoming year for
each Major Market in the Territory, including (i) information on marketing strategy and sales targets, (ii) an overview on economic and
regulatory conditions, (iii) timelines and key activities (including obtaining and maintaining pricing and reimbursement approval) prior
to and after the First Commercial Sale of a Licensed Product in a given country in the Territory and (iv) personnel resources required
to fulfill such activities in due time (the &ldquo;<B>Commercialization Plan</B>&rdquo;). The Commercialization Plan shall be prepared
by Licensee [***] prior to the expected date of Commercialization of the Licensed Product. Such Commercialization Plan shall thereafter
be updated by Licensee and sent to Licensor at least annually during the Term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">(c)
Licensee shall discuss with Licensor any contemplated material change to the Commercialization Plan and consider in good faith any substantive
comment Licensor may have regarding such change; <I>provided</I> that Licensee shall have the final decision making authority with respect
to any such changes (it being understood that, for the avoidance of doubt, such final decision making authority shall not limit Licensee&rsquo;s
Diligence Obligations).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">3.3. <B>Manufacturing
and Supply</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">(a) Subject
to (i) the terms and conditions of this Agreement and the Underlying GMP License and (ii) Licensor&rsquo;s retained right to Manufacture
Drug Product itself or through one or more Third Parties selected by Licensor on behalf of Licensee pursuant to this <U>Section&nbsp;3.3</U>,
Licensee shall have the exclusive right to Manufacture the Compounds and the Licensed Products itself or through one or more Third Parties
selected by Licensee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">(b) Subject
to the Parties having entered a Manufacturing Quality Agreement, upon Licensee&rsquo;s request (&ldquo;<B>Supply Request</B>&rdquo;),
Licensor agrees to Manufacture and supply Drug Product, Drug Product assembled in [***] and/or placebo, as applicable, to Licensee for
Clinical Trial supply in accordance with this <U>Section 3.3(b).</U> Licensor shall supply such Drug Product and placebo to [***] at Licensor&rsquo;s
Supply Costs, within [***] from the initiation of production, and Drug Product assembled in [***] and such placebo will be delivered within
[***] of the initiation of production of the Drug Product or at such other date mutually agreed upon in writing by the Parties. Licensor
shall initiate production of Drug Product, Drug Product assembled in [***] and/or placebo, as applicable, within [***] from Licensor&rsquo;s
receipt of a Supply Request; <I>provided </I>that the first production period shall begin no later than [***]. Licensor shall provide
an invoice to Licensee upon Licensor&rsquo;s delivery of the Drug Product, Drug Product in [***] and/or placebo, as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">(c) Licensor
shall manufacture the Drug Product, Drug Product in [***] and/or placebo, as applicable, in accordance with this <U>Section 3.3(c)</U>.
The Parties acknowledge and agree that (i) the maximum quantity of Drug Substance from which Licensor is obligated to manufacture Drug
Product hereunder is [***] of Drug Substance, which is expected to produce between [***] to [***] syringes of Drug Product, depending
on strength(s) targeted (as determined by Licensee) and (ii) a maximum of two manufacturing campaigns is foreseen (it being understood
that any manufacturing campaign that results in Drug Product that does not comply with the Manufacturing Quality Agreement shall not count
towards the foregoing maximum of [***] manufacturing campaigns). A first slot, comprising up to [***] presentations (e.g., [***], [***]
and [***]) but excluding assembly of [***] auto-injector devices, has been provisionally reserved for [***]. Licensor shall store the
Drug Substance in a manner compliant with Applicable Laws and the Manufacturing Quality Agreement, and using at least the same standard
of care consistent with Licensor&rsquo;s past practices and shall not destroy, alter or otherwise dispose of any Drug Substance without
the prior written consent of Licensee. The Parties agree that the volumes set forth in this <U>Section 3.3(c)</U> with respect to Drug
Product are estimates and are not binding. Licensor shall not be obliged to Manufacture Drug Product in excess of the amount of Drug Substance
on stock with Licensor as of the Effective Date taking into account the respective yield and batch size. In the event that Drug Product
Manufactured by Licensor is rejected pursuant to the Manufacturing Quality Agreement, Licensor shall replace such non-conforming Drug
Product out of the Drug Substance inventory existing as of the Effective Date. Licensee shall have no claim for any loss of Drug Substance,
nor shall Licensor be obligated to manufacture additional quantities of Drug Substance, and Licensee&rsquo;s sole remedy in case of rejection
of Drug Product shall be the repayment of any amounts paid by Licensee to Licensor for the manufacturing services provided hereunder.
Upon the earlier to occur of (x) Licensee&rsquo;s request or (y) the completion of the second manufacturing campaign hereunder, Licensor
shall promptly transfer to Licensee at Licensee&rsquo;s expense any and all remaining Drug Substance remaining in Licensor&rsquo;s possession
at such time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">(d) Other
than as provided in <U>Section 3.3(b)</U> and <U>Section 3.3(c)</U>, Licensor shall have no further obligation to manufacture or supply
Drug Product hereunder. Notwithstanding the foregoing, Licensor may consider in good faith to Manufacture further volumes of Drug Product
upon timely request by Licensee and upon the supply of Drug Substance by Licensee, which final decision shall be under Licensor&rsquo;s
discretion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">(e) As
soon as reasonably practicable following the Effective Date (and, in any event, within [***] thereafter), the Parties shall agree upon
and execute a Manufacturing Quality Agreement, which shall, at a minimum, contain the Product Specifications. The supply of Drug Product
under this <U>Section 3.3</U> by Licensor shall also be governed by the terms and conditions of the Manufacturing Quality Agreement. To
the extent that there is any conflict between the terms and conditions of this Agreement and the Manufacturing Quality Agreement, the
terms and conditions of this Agreement shall govern and control, except with respect to conflicts or contradictions for matters of quality
or technical nature, in which case the Manufacturing Quality Agreement shall prevail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">3.4. <B>Regulatory
Filings and Pharmacovigilance</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">(a) <B>Regulatory
Filings</B>. As between the Parties, Licensee shall be exclusively responsible for and shall have the exclusive right to own and maintain
all regulatory filings and Regulatory Approvals for the Licensed Products, including all INDs and NDAs, and shall be exclusively responsible
for and exclusively control all communications with Regulatory Authorities with respect to such Licensed Products. Licensor hereby agrees
to transfer the IND held by Licensor in connection with the Licensed Products to Licensee as soon as possible, but at the latest prior
to the start of any Clinical Trial for any Licensed Product sponsored by Licensee, unless agreed by the Transfer Committee that such IND
transfer can be accomplished earlier (it being understood that until such IND can be transferred to Licensee, Licensor (on behalf of itself
and its Affiliates) hereby grants to Licensee an exclusive (even as to Licensor and its Affiliates) fully sublicensable, worldwide license
and right of reference under such IND to Develop, Manufacture, have Manufactured, use and otherwise Commercialize the Compounds and Licensed
Products in the Territory in the Field). To the extent Licensor receives any written or oral communication from any Regulatory Authority
relating to a Licensed Product, or is notified of any such communication to the Initial Licensor, Licensor shall refer such Regulatory
Authority to Licensee and provide Licensee with a copy of any written communication received by Licensor or Initial Licensor or, if applicable,
complete and accurate minutes of such oral communication. Upon Licensee&rsquo;s request, Licensor shall use Commercially Reasonable Efforts
to designate a qualified representative who shall facilitate any assistance by Initial Licensor required by Licensee and, together with
the representatives of Licensee (or where a Sublicensee is the primary point of contact, of the relevant Sublicensee, to the extent provided
for in the relevant Sublicense), participate in and contribute to meetings with the Regulatory Authorities with respect to regulatory
matters relating solely to the Licensed Products. All reasonable and documented costs incurred by Licensor related to the regulatory assistance
provided hereunder shall be reimbursed by Licensee in accordance with <U>Section 2.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">(b) <B>Pharmacovigilance</B>.
The safety teams of the Parties shall, as soon as reasonably practicable following the Effective Date, set up a meeting and agree on the
transfer of the safety data of the global safety database from Licensor to Licensee. The transfer of such global safety database shall
be completed prior to the initial dosing of the first patient in a Clinical Trial conducted by or on behalf of Licensee or any of its
Affiliates in connection with any Compound or Licensed Product. After completion of the transfer of such global safety database, Licensee
will be solely responsible for all safety aspects of the Licensed Products and for ensuring compliance with all Applicable Law pertaining
to safety reporting of the Licensed Products and related activities. If Licensor has or receives any information regarding any adverse
event which may be related to the use of any Licensed Product, then Licensor shall provide Licensee with all such information within such
reasonable timelines which enable Licensee to comply with all Applicable Laws and relevant regulations and requirements to the extent
such information is not otherwise in the possession of Licensee. The adverse event information shall be sent to the following Licensee
e-mail address: info@moonlaketx.com or such other e-mail address as provided in advance by Licensee to Licensor in writing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">(c) <B>Product
Recalls</B>. Licensee shall have the final decision-making authority in its sole discretion to determine whether and how to implement
a recall or other market withdrawal of any Licensed Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">3.5. <B>Diligence
by Licensee</B>. Licensee shall use Commercially Reasonable Efforts to (a) Develop one (1) Licensed Product in at least two (2) Indications,
in accordance with the applicable Development Plan as updated or amended from time to time, (b) launch and Commercialize one (1) Licensed
Product in each of the Major Markets within [***] after having received the required Regulatory Approval (including pricing approval,
if required for Commercialization) in the respective Major Market, (c) secure within [***] after the Effective Date a binding contract
research organization agreement with a qualified vendor for the Development of [***] Licensed Product in at least [***] Indications under
the Development Plan, (d) Initiate the first two Phase II Trials for the Licensed Product within [***] after the Effective Date, taking
into account any regulatory requirements or feedback from the FDA and/or EMA and (e) in the event that Licensee (x)&nbsp;undergoes a Change
of Control, which results in Licensee being controlled by a Competitor or (y) otherwise acquires an Acquired Competing Biologic Product
(other than any Licensed Product), (1) following a Successful Completion of a [***] for a Licensed Product conducted by Licensee or any
of its Affiliates,&nbsp;Initiate in at least [***] [***] a [***] for such Licensed Product and (2) following the Successful Completion
of a [***] for a Licensed Product conducted by Licensee or any of its Affiliates, prepare for and submit at least [***] [***] in a [***]
for such Licensed Product, in each case, taking into account any regulatory requirements or feedback from the FDA and/or EMA (collectively,
the &ldquo;<B>Diligence Obligations</B>&rdquo;). Notwithstanding the foregoing or anything else in this Agreement to the contrary, Licensor
acknowledges and agrees that (i) in no event shall Licensee be deemed to be in breach of this <U>Section 3.5</U> if any failure of Licensee
to comply with its Diligence Obligations results from (A) Licensor&rsquo;s breach of any terms of this Agreement (including Licensor&rsquo;s
failure to timely provide Drug Products in compliance with <U>Section 3.3</U> and the Manufacturing Quality Agreement), (B) any rejection
of Drug Supply by Licensee under <U>Section 3.3</U> or (C) any delay on the part of any Regulatory Authority, and (ii) at Licensee&rsquo;s
election, Licensee may extend the time frame set forth in clause (d) of the Diligence Obligations by providing Licensor written notice
of such election and payment of [***] per each month of such extension (such payment, an &ldquo;<B>Extension Payment</B>&rdquo;) (it being
understood that Licensee shall not be deemed to have breached this <U>Section 3.5</U> during any period of time for which Licensee has
paid Licensor an Extension Payment).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">3.6. <B>Reporting
Obligations and Information Rights</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">(a) Licensee
shall by [***] of each Calendar Year provide Licensor with a written report or presentation summarizing in reasonable detail its Development
and, as applicable, Commercialization activities conducted during the preceding Calendar Year, along with a copy of the then current Development
Plan. Further, Licensee shall provide an oral update via phone or in person to Licensor each Calendar Year during normal business hours
at a time mutually agreed upon by the Parties by [***] of each Calendar Year. Further, Licensee shall notify Licensor of the Initiation
of any Phase III Trial for a Licensed Product promptly, but no later than [***] after such Initiation of such Phase III Trial.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">(b) <B>Data
Protection Law Reporting</B>. To the extent required by Data Protection Law, Licensee shall, at no cost to Licensor, make available on
request in a timely manner such information as is reasonably required by Licensor to determine whether or not Personal Data obtained,
processed or stored in connection with the Development, Manufacture or Commercialization of a Compound or a Licensed Product under this
Agreement is or has been processed by Licensee or its Affiliates in compliance with Data Protection Law and Licensee&rsquo;s covenants
in <U>Section&nbsp;7.4</U>. To the extent required by Data Protection Law, (i) Licensee shall inform Licensor of any rectification or
erasure of Personal Data or restriction of processing under Data Protection Law; <I>provided</I> such Personal Data was disclosed to Licensor
in the course of the performance of this Agreement and (ii) Licensee shall promptly notify Licensor in writing after becoming aware of
any breach of security leading to the accidental or unlawful destruction, loss, alteration, unauthorized disclosure of, or access to,
Personal Data provided hereunder to Licensee by Licensor. In such case, Licensor may request further reasonable information about the
incident, including a reasonably detailed description of the incident and the categories of Personal Data affected by the incident. The
Parties acknowledge and agree that any information provided by Licensee to Licensor under this <U>Section 3.6(b)</U> shall be considered
Confidential Information of Licensee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">3.7. <B>Trademarks</B>.
As between the Parties, Licensee shall have the sole authority to select trademarks for the Licensed Products and shall exclusively own
all such trademarks.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">3.8. <B>Compliance
Obligations</B>. Licensor intends to conduct its business in accordance with environmental, labor and social standards and to abide by
the standards set forth in the Licensor Code of Conduct and the Licensor Human Rights Charter (available at http://www.merckgroup.com).
Licensee shall comply, and shall ensure that its Affiliates or subcontractors comply, with all Applicable Laws relating to environmental,
labor and social standards. Licensee further acknowledges and ensures that Licensee and its Affiliates (and Licensee shall use Commercially
Reasonable Efforts to ensure that its subcontractors) are familiar with the provisions of the United States Foreign Corrupt Practices
Act, the UK Bribery Act and applicable local bribery and corruption laws, and shall not take or permit any action that will either constitute
a violation under, or cause Licensor to be in violation of, the provisions of the United States Foreign Corrupt Practices Act, the UK
Bribery Act or applicable local bribery and corruption law, environmental, labor and social standards and the Licensor Code of Conduct
and Licensor Human Rights Charter (collectively, &ldquo;<B>Improper Conduct</B>&rdquo;). In addition to any other rights Licensor may
have under this Agreement, if Licensee notifies Licensor of, or if Licensor otherwise has a reasonable suspicion of, the occurrence of
Improper Conduct, Licensor may, upon reasonable prior written notice to Licensee, have an independent auditor who is selected by Licensor
and approved by Licensee (and whose fee is not contingent upon the outcome of the audit and who has executed a confidentiality agreement
reasonably acceptable to Licensee) inspect the premises, books and records of Licensee relevant to Improper Conduct during normal business
hours for the purpose of ensuring compliance by Licensee of its obligations under this <U>Section&nbsp;3.8</U>. The auditor shall promptly
notify Licensor in writing of its conclusions and, provide any evidence of non-compliance by Licensee (it being understood that (a) the
information shared with Licensor shall be limited to information relating thereto and (b) any analysis or reports prepared by the auditor
in connection with such audit shall be considered Confidential Information of Licensee).</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-transform: uppercase; text-align: center; text-indent: 0in">ARTICLE
4 - FINANCIAL TERMS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">4.1. <B>Upfront
Payment</B>. In partial consideration for the grant of the rights hereunder, Licensee shall pay to Licensor a one-time, non-refundable,
non-creditable sum of twenty-five million U.S. Dollars ($25,000,000.00) (the &ldquo;<B>Upfront Payment</B>&rdquo;) within thirty (30)
days after the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">4.2. <B>Equity
Consideration</B>. As further partial consideration for the grant of the rights and licenses hereunder, no later than the Effective Date,
Licensee shall transfer to Licensor, against the payment of one U.S. Dollar ($1.00), such number of Licensee&rsquo;s Series A Preferred
Stock representing 9.9% of Licensee&rsquo;s equity on an undiluted basis, as referenced, among others, in the Equity Documentation (&ldquo;<B>Licensor&rsquo;s
Equity Consideration</B>&rdquo;). In this context, the Parties shall, together with other investors, sign the Equity Documentation on
or prior to the Effective Date. Licensor&rsquo;s Equity Consideration shall be transferred to Licensor by Licensee in accordance with
the terms of the Equity Documentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">4.3. <B>Milestone
Payments</B>. With respect to each milestone event set forth in the table below (a &ldquo;<B>Milestone Event</B>&rdquo;), Licensee shall
notify Licensor within [***] after the first achievement by Licensee or any of its Affiliates or Sublicensees of such Milestone Event
with a Licensed Product. Following such notice, Licensor shall issue an invoice to Licensee for the milestone payment applicable to such
Milestone Event. Subject to the terms and conditions herein, as further consideration for the grant of the rights hereunder, Licensee
shall, within [***] after Licensee&rsquo;s receipt of such invoice, pay to Licensor the one-time milestone payment applicable to such
Milestone Event set forth below (each such payment, a &ldquo;<B>Milestone Payment</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Milestone Payment (in Euro)</B></P></TD>
    <TD STYLE="vertical-align: bottom; width: 70%; text-align: left"><FONT STYLE="font-size: 10pt"><B>Milestone Event </B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">[***]</TD>
    <TD STYLE="text-align: justify">[***] (such Milestone Event, &ldquo;<B>Milestone Event #1</B>&rdquo;) <B>&nbsp;</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">[***]</TD>
    <TD STYLE="text-align: justify">[***] (other than the Indication of Milestone Event #1) (such Milestone Event, &ldquo;<B>Milestone Event #2</B>&rdquo;)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">[***]</TD>
    <TD STYLE="text-align: justify">[***]</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">[***]</TD>
    <TD STYLE="text-align: justify">[***]</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">[***]</TD>
    <TD STYLE="text-align: justify">[***]</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">[***]([***])</TD>
    <TD STYLE="text-align: justify">[***](such Milestone Event, &ldquo;<B>Milestone Event #6</B>&rdquo;)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">[***] ([***])</TD>
    <TD STYLE="text-align: justify">[***](&ldquo;<B>Milestone Event #7</B>&rdquo;)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">[***] ([***])</TD>
    <TD STYLE="text-align: justify">[***](&ldquo;<B>Milestone Event #8</B>&rdquo;)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">[***]</TD>
    <TD STYLE="text-align: justify">[***]</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">[***]</TD>
    <TD STYLE="text-align: justify">[***]</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">[***]</TD>
    <TD STYLE="text-align: justify">[***]</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: justify">Notwithstanding anything in this Agreement
to the contrary, the Parties acknowledge and agree that, for purposes of this <U>Section 4.3<B>.</B></U>
the following shall apply:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">(a) If,
prior to the achievement of Milestone Event #1 or Milestone Event #2 by Licensee or any of its Affiliates or Sublicensees, Licensor is
obligated to pay to Initial Licensor under the Initial License Agreement (i) the [***] milestone payment for the &ldquo;[***]&rdquo; milestone
event and (ii)&nbsp;the [***] milestone payment for the &ldquo;[***]&rdquo; milestone event, Licensee shall pay such [***] and [***],
as applicable, to Licensor within [***] after Licensee&rsquo;s receipt of an applicable invoice; <I>provided</I> that (x) Licensor shall
provide Licensee written notice of such milestone payments becoming due as soon as reasonably practicable, (y) upon payment of such [***]
to Licensor, Licensee shall no longer be obligated to pay Licensor any milestone payment in connection with the achievement of Milestone
Event #1 by Licensee or any of its Affiliates or Sublicensees and (z) upon payment of such [***] to Licensor, Licensee shall no longer
be obligated to pay Licensor any milestone payment in connection with the achievement of Milestone Event #2 by Licensee or any of its
Affiliates or Sublicensees.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">(b) A
Milestone Event that occurs in or with respect to the &ldquo;EU&rdquo; shall mean any such event in or with respect to (i) in the case
of a Milestone Event relating to the [***], any country of the European Union or the United Kingdom, or (ii) in the case of a Milestone
Event related to [***], the UK MHRA, EMA or the European Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">(c) Licensee&rsquo;s
obligation to pay the Milestone Payments pursuant to this <U>Section&nbsp;4.3</U> shall apply accordingly, if one or more of the Milestone
Events set forth above is achieved with respect to a Licensed Product containing or comprising, in whole or in part, a Compound as an
active ingredient in combination with one or more other active ingredients.</P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">(d) Except
with respect to Milestone Event #6, Milestone Event #7, and Milestone Event #8, each of which may be achieved and paid no more than [***]
times, in no event shall any Milestone Payment set forth in this <U>Section 4.3</U> be paid more than once, even if the same Milestone
Event is achieved by more than one Licensed Product or achieved multiple times by the same Licensed Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">(e) The
maximum aggregate amount payable by Licensee (i) under this <U>Section&nbsp;4.3</U> is [***], (ii) under Milestone Event #6 is [***],
(iii) under Milestone Event #7 is [***] and (iv) under Milestone Event #8 is [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">4.4. <B>Commercial
Event Milestones</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">(a) Subject
to the terms and conditions of this Agreement, as further partial consideration for Licensor&rsquo;s grant of rights and licenses to Licensee
hereunder, Licensee shall pay Licensor the following one-time amounts upon the achievement of the following commercial event milestones
(each, a &ldquo;<B>Commercial Milestone Event</B>&rdquo;) by Licensee or any of its Affiliates or Sublicensees on a Licensed Product-by-Licensed
Product basis:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">[***] for the first Calendar Year in which the aggregate annual Net Sales in all Indications of such Licensed
Product in the Territory equals or exceeds [***];</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">[***] for the first Calendar Year in which the aggregate annual Net Sales in all Indications of such Licensed
Product in the Territory equals or exceeds [***];</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">[***] for the first Calendar Year in which the aggregate annual Net Sales in all Indications of such Licensed
Product in the Territory equals or exceeds [***];</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">[***] for the first Calendar Year in which the aggregate annual Net Sales in all Indications of such Licensed
Product in the Territory equals or exceeds [***]; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 2in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 1.5in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">[***] for the first Calendar Year in which the aggregate annual Net Sales in all Indications of such Licensed
Product in the Territory equals or exceeds [***].</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(b) Licensee
shall deliver written notice to Licensor of the achievement of a Commercial Milestone Event by Licensee or any of its Affiliates or Sublicensees
with respect to a Licensed Product within [***] following the end of the Calendar Year in which such Commercial Milestone Event is achieved.
Licensee shall deliver the corresponding Commercial Milestone Event payment for such Commercial Milestone Event to Licensor within [***]
of Licensee&rsquo;s receipt of a corresponding invoice from Licensor for such Commercial Milestone Event payment set forth in the aforementioned
written notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(c)
Notwithstanding anything in this Agreement to the contrary, the Parties acknowledge and agree that, for purposes of this <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>4.4</U>
the following shall apply:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(i) Each
payment corresponding to a Commercial Milestone Event shall be payable by Licensee to Licensor upon the first achievement of each Commercial
Milestone Event by Licensee or any of its Affiliates or Sublicensees with respect to the first Licensed Product to achieve such Commercial
Milestone Event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(ii) In
no event shall any payment set forth in this <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>4.4</U> be paid more than once, regardless
of the number of Calendar Years in which such Licensed Product achieves such Commercial Milestone Event and regardless of the number of
Licensed Products to achieve such Commercial Milestone Event. By way of example only, if for a Calendar Year, aggregate annual Net Sales
for all Indications of a Licensed Product in the Territory are [***], the total Commercial Milestone Event payments earned shall be [***],
and such commercial event payment shall no longer be payable in any subsequent Calendar Year. The maximum aggregate amount payable by
Licensee under this <U>Section&nbsp;<FONT STYLE="font-size: 10pt">&lrm;</FONT>4.4</U> with respect to a Licensed Product is [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">(iii) If
any Commercial Milestone Event (&ldquo;<B>Achieved Commercial Milestone</B>&rdquo;) is achieved by a Licensed Product in any Calendar
Year and any preceding Milestone Event with respect to such Licensed Product has not achieved in such Calendar Year or any preceding Calendar
Year by any Licensed Product, such preceding Commercial Milestone Event shall be deemed to have been achieved upon the achievement of
such Achieved Commercial Milestone. By way of example only, if in the first Calendar Year following the First Commercial Sale of a Licensed
Product, annual Net Sales for all Indications of such Licensed Product in the Territory are [***], and the Commercial Milestone Event
in <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>4.4(a)(i)</U> above has not previously been achieved by any Licensed Product in
any Calendar Year, the Commercial Milestone Events in <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>4.4(a)(i)</U> and <U>Section&nbsp;<FONT STYLE="font-size: 10pt">&lrm;</FONT>4.4(a)(ii)</U>
shall both be deemed to have been achieved.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">4.5. <B>Royalty</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(a) <B>Royalty
Rate</B>. Subject to the terms and conditions of this Agreement, as further consideration for Licensor&rsquo;s grant of the rights
and licenses to Licensee hereunder, Licensee shall pay to Licensor on a Licensed Product-by-Licensed Product and country-by-country
basis, a royalty on aggregate Net Sales of such Licensed Product in such country during the Royalty Term for such Licensed Product
at the rate of [***]. Except as expressly set forth in this Agreement, such royalty shall not be subject to offset or reduction for
any reason, including any royalties, milestone payments or other consideration that Licensee pays under any Third-Party
licenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(b) <B>Underlying
GMP License</B>. Licensee shall reimburse Licensor for all payments due under the Underlying GMP License solely to the extent such
payments relate to the Compounds and Licensed Products and are accrued on or following the Effective Date. In addition to the
Royalty Rate under <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>4.5(a)</U>, Licensee shall pay to Licensor the royalties due
to RCT to the extent such royalties relate to the Compounds and Licensed Products at the same time when the royalty payments under
this <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>4.5</U> become due. For the remaining payments due under the Underlying
GMP License, Licensor will send an invoice to Licensee, and Licensee will repay those amounts within thirty (30) days of receipt of
such invoice. Further, Licensee shall use Commercially Reasonable Efforts to support Licensor in providing reports and data required
under the Underlying GMP License. Notwithstanding anything in this Agreement to the contrary, at such time as Licensee enters into a
direct license agreement with RCT pursuant to <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>7.4(e)</U>, Licensee shall have
no further obligation to reimburse Licensor for any payments due under the Underlying GMP License with respect to any Compounds or
Licensed Products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(c)   <B>Allowed
Deductions. </B>The obligation of Licensee to pay royalties to Licensor under <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>4.5(a)</U>
shall be reduced upon the occurrence of the following events (such reductions, &ldquo;<B>Allowed Deductions</B>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">(i)   In
the event that (A) no Valid Claim or Pending Claim of any Licensor Patent or Inlicensed Patents Covering a Licensed Product exists in
a country or (B) no Valid Claim of any Licensor Patent or Inlicensed Patents Covering a Licensed Product exists in a country, but a Pending
Claim of a Licensor Patent or an Inlicensed Patent Covering a Licensed Product exists in such country and a Competing Product enters the
market in such country, then in each case of clauses (A) and (B), Licensee&rsquo;s obligation to pay royalties on Net Sales of such Licensed
Product in such country shall be reduced by [***]; <I>provided</I> that, in the case of (B), such reduction shall only apply until either
(1) a Valid Claim of a Licensor Patent or Inlicensed Patent in said country is granted or (2) in the case of clause (B), the applicable
Competing Product is withdrawn from the market in such country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)   In
the event that it is reasonably necessary for Licensee to enter into a Third-Party License Agreement in order to Develop, Manufacture
or Commercialize any Licensed Product and Licensee subsequently pays such Third Party royalties, milestone payments or any other payments
under such Third-Party License Agreement, Licensee may offset [***] of any such royalty, milestone or other payments made under such Third-Party
License Agreements against Licensee&rsquo;s obligation to pay Licensor royalties under <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>4.5(a)</U>.
For clarity, no deductions can be taken for payments with respect to the Underlying GMP License or such direct license agreement between
Licensee and RCT pursuant to <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>7.4(e)</U>, if applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">(iii)   In
the event that the total Euro amount of the royalty reductions permitted pursuant to paragraphs (i) and (ii) of this <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>4.5(c)</U>
for a particular Calendar Quarter equals an amount greater than [***] of the Euro amount of royalties with respect to the Licensed Products
that would otherwise be due from Licensee to Licensor for such Calendar Quarter, the total Euro amount of the royalty reductions for such
Calendar Quarter shall be limited to the amount equal to [***] of the Euro amount of royalties that would otherwise be due.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">(iv)   Subject
to the terms and conditions of this Agreement, during the term of the Initial License Agreement, in no event shall the Euro amount of
royalties after aforementioned royalty reductions (if applicable) payable from Licensee to Licensor be [***] than the royalties due from
Licensor to [***] in any given Calendar Quarter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">(v)   Should
Licensor determine after receipt of the royalty report described in <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>4.6(b)</U>, that
its royalty obligations under the [***] [***] the royalty obligations due by Licensee under <U>Section&nbsp;<FONT STYLE="font-size: 10pt">&lrm;</FONT>4.5(a)</U>
after taking into account the Allowed Deductions under Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>4.5(c)(i)-(iii), Licensor shall
promptly notify Licensee in writing thereof with a detailed explanation of the basis for such determination, including an accounting of
its calculations of royalty obligations owed under the [***], and send an invoice to Licensee for the differential amount. Licensee shall
repay any such undisputed amounts within thirty (30) days of Licensee&rsquo;s receipt of such invoice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(d)   <B>Attribution
to Multiple Products</B>. If the rights to any Intellectual Property that is the subject of any Third-Party License Agreement are also
attributable to products other than the Compounds or Licensed Products, then only an equitable portion of any amounts payable under it
shall be allocated to such Compounds and Licensed Products, as determined from time to time by the Parties in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(e)   <B>Royalty
Deduction Carry Forward</B>. In the event that Licensee is not able to make the full amount of its Allowed Deductions against royalties,
Licensee shall be entitled to deduct any undeducted amounts against any royalties due to Licensor in any subsequent Calendar Quarters
until fully deducted; <I>provided</I> that <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>4.5(c)(iii)</U> and <U>(iv)</U> shall
continue to apply to such subsequent Calendar Quarters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(f)   <B>Compulsory
License</B>. In the event that Licensor or Licensee receives a request for a compulsory license for any Licensed Product anywhere in the
world, it shall promptly notify the other Party in writing. If any Third Party obtains a compulsory license in the Territory, then Licensor
or Licensee (whoever has first notice) shall promptly notify the other Party. If either Party receives any payments from a Third Party
pursuant to such a compulsory license, [***] of such payments shall be distributed to Initial Licensor and the remainder of such payments
shall be considered Net Sales under this Agreement and shall be subject to the royalty obligations set forth in <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>4.5</U>
(it being understood that, notwithstanding anything in this Agreement to the contrary, any sales of any Licensed Product by a compulsory
licensee shall not be deemed a Net Sale of such Licensed Product for purposes of <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>4.4</U>
or <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>4.5</U>).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(g)   <B>Royalties
Generally</B>. Nothing herein contained shall obligate Licensee to pay or cause to be paid to Licensor more than one royalty on any unit
of a Licensed Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(h)   <B>Royalty
Term</B>. Licensee&rsquo;s obligation to pay royalties under <U>Section&nbsp;<FONT STYLE="font-size: 10pt">&lrm;</FONT>4.5</U> shall be
on a Licensed Product-by-Licensed Product and country-by-country basis from the date of First Commercial Sale of a Licensed Product in
a country until the later of (i) ten (10) years from such First Commercial Sale of such Licensed Product in such country or (ii) the expiration
or invalidation of the last remaining Valid Claim of a Licensor Patent or Inlicensed Patent Covering such Licensed Product in such country
(&ldquo;<B>Royalty Term</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(i)   <B>Payment
of Royalties</B>. Simultaneous with the delivery of the report described in <U>Section&nbsp;<FONT STYLE="font-size: 10pt">&lrm;</FONT>4.6(b)</U>
hereof, Licensee shall pay, or cause to be paid, to Licensor at such place as Licensor may from time to time designate in writing, all
royalties earned pursuant to this <U>Section&nbsp;<FONT STYLE="font-size: 10pt">&lrm;</FONT>4.5</U> in the preceding Calendar Quarter,
taking into account all Allowed Deductions. All such payments shall be made in Euros.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">4.6.   <B>Royalty
Reports; Currency Conversion; Disputes Regarding Reports</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(a)   Net
Sales shall be calculated and reported in Euros. With respect to Net Sales denominated in a currency other than Euros, Licensee shall
convert each applicable monthly net sales into Euros by using the then-current and reasonable standard exchange rates applied to and derived
from its external reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(b)   Commencing
with the Calendar Quarter in which the First Commercial Sale of a Licensed Product is made by Licensee or its Affiliate or Sublicensee,
Licensee shall submit to Licensor with each royalty payment a detailed, written report detailing its computation of royalties due on Net
Sales on a Licensed Product-by-Licensed Product and a country-by-country basis during each Calendar Quarter within [***] after the end
of each Calendar Quarter, and the report shall indicate: (i) the amount of Net Sales of each Licensed Product sold by Licensee or its
Affiliates or Sublicensees during the reporting period; (ii) the royalties due thereon; (iii) the exchange rates used in determining the
amount of Euros; (iv) the number of units and average selling price for each Licensed Product included in Net Sales for such Calendar
Quarter, (v) the computation of the Allowed Deductions (if any) under <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>4.5(c)</U>,
and (vi) any other information reasonably requested by Licensor and necessary to assess the calculation of the royalty payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(c)   All
payments to Licensor hereunder shall be made by deposit of Euros in the requisite amount to such bank account as Licensor may from time
to time designate by written notice to Licensee. Royalties shall be calculated and reported in Euros based upon the Net Sales in Euros.
For accounting and documentation purposes, Licensor shall provide to Licensee an invoice for the Upfront Payment, milestone payments and
royalty payments that are payable hereunder. The Parties may vary the method of payment set forth herein at any time upon mutual agreement,
and any change shall be consistent with the Applicable Laws at the place of payment or remittance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">4.7.   <B>Record
Retention, Inspection</B>. Licensee shall keep or cause its Affiliates to keep complete and accurate records in accordance with Licensee&rsquo;s
then-normal accounting principles of Net Sales of Licensed Products and royalties payable under <U>Section&nbsp;<FONT STYLE="font-size: 10pt">&lrm;</FONT>4.5</U>
for a period of [***] after the end of each Calendar Year in which such Net Sales occur. At the request of Licensor an independent chartered
or certified public accountant (&ldquo;<B>Auditor</B>&rdquo;) chosen by Licensor but approved in writing by Licensee (which approval shall
not be unreasonably withheld or delayed) shall be allowed access during ordinary business hours to such records pertaining to the preceding
[***] solely to verify the accuracy of any royalty payments made to Licensor under <U>Section&nbsp;<FONT STYLE="font-size: 10pt">&lrm;</FONT>4.5</U>;
<I>provided</I> that (x) such Auditor shall in no event be entitled to any contingency fee (or otherwise have any portion of its compensation
be directly or indirectly determined based on the outcome of such inspection), (y) such Auditor shall execute a confidentiality agreement
that is reasonably acceptable to Licensee and such records or information examined by such Auditor shall be the Confidential Information
of Licensee and be subject to <U>ARTICLE 6</U> and (z) Licensor shall not be permitted to exercise such inspection right more often than
[***] each Calendar Year and no such records may be audited more than [***]. The accountant shall not disclose to Licensor any information
other than that which should properly be contained in a report of matters relevant to Net Sales and royalty calculation and payment arising
under <U>Section&nbsp;<FONT STYLE="font-size: 10pt">&lrm;</FONT>4.5</U> above. Any inspection conducted under this <U>Section&nbsp;<FONT STYLE="font-size: 10pt">&lrm;</FONT>4.7</U>
shall be at the expense of Licensor, unless such inspection reveals any underpayment of the payments due hereunder for the audited period
by at least [***], in which case the full costs of such inspection for such period shall be borne by Licensee. Any underpayment shall
be paid by Licensee to Licensor within thirty (30) days of written notice of the results of such inspection with interest on the underpayment
at the rate specified in <U>Section&nbsp;<FONT STYLE="font-size: 10pt">&lrm;</FONT>4.10</U> from the date such payment was originally
due. Any overpayment shall be credited against future amounts due by Licensee to Licensor; <I>provided</I> that to the extent no future
amounts are due by Licensee to Licensor hereunder, Licensor shall pay to Licensee such overpayment within thirty (30) days of written
notice of the results of such inspection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">4.8.   <B>Withholding
Tax</B>. Licensor shall be responsible for the payment of any and all Taxes levied on account of the royalties and other payments paid
to Licensor by Licensee or its Affiliates and received by Licensor under this Agreement. If Applicable Laws require that Taxes shall be
deducted and withheld from royalties or other payments paid under this Agreement (the &ldquo;<B>Withholding Tax</B>&rdquo;), Licensee shall,
and shall procure that its Affiliates proceed accordingly, (a) increase the amount of the payment due from Licensee to Licensor to an
amount which (after making any Withholding Tax deduction) leaves an amount equal to the payment which would have been due if no Withholding
Tax deduction had been required ([***]), (b) deduct those Withholding Taxes assessed thereon from the payment owed hereunder; (c) pay
the Withholding Taxes to the proper Governmental Body; (d) send evidence of the obligation together with proof of Withholding Tax payment
to Licensor within [***] following such payment; and (e) remit the net amount including the Tax gross-up, after Withholding Tax. Licensor
shall take all necessary steps and the Parties shall cooperate in any way reasonably requested by a Party to obtain available reductions
of, credits against, relief or remissions for, rebate or repayment of or refunds of such Withholding Taxes (the &ldquo;<B>Tax Credit</B>&rdquo;)
to the ultimate benefit of the Licensee. Assuming that Licensor is the beneficial owner of Licensor Technology, the cooperation referred
to in the foregoing sentence shall include Licensor providing Licensee with a written confirmation from the competent Tax authority on
the Tax application form that Licensor has its residence for Tax purposes in Germany. If the Licensor determines that it has obtained
or utilized a Tax Credit either on a standalone or an affiliated basis, Licensor shall pay an amount to the Licensee which the Licensor
determines and not in excess of the Tax Credit actually obtained or utilized, providing such evidence to the Licensee in respect of such
amounts as the Licensee may reasonably request in writing, will leave it (after that payment) in the same after-Tax position as it would
have been in had the Withholding Tax deduction not been made by the Licensee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">4.9.   <B>Indirect
Tax</B>. All royalties and other payments to be paid by Licensee to Licensor shall be understood as net amounts for indirect Tax (VAT,
GST, Sales Tax and similar) purposes. It is the common understanding of the Parties that the transactions under this Agreement are not
subject to indirect Tax in the country of the Licensor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">4.10.   <B>Late
Payments</B>. All payments under this Agreement shall earn interest from the date due until paid at a per annum rate equal to the lesser
of (a) the maximum rate permissible under Applicable Laws and (b) [***] above the monthly Reuters (01 EURIBOR), measured at 2 p.m. Frankfurt/Germany
time on the date payment is due. Interest will be calculated on an actual/360 basis. An example of the interest rate calculation follows,
assuming that the Reuters interest rate is 0.25% and a payment of 10,000,000 EUR is thirty (30) days overdue:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Step 1: applicable annual interest rate
on a 365/360 basis = [***]% + 0.25% = [***]%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Step 2: applicable interest rate for
the period of delay = 30/360 x [***]% = [***]%</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Step 3: total interest due = 10,000,000
EUR x [***]% = [***] EUR</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">4.11.   <B>No
Obligation to Achieve Milestone Events or Commercial Milestone Events</B>. Licensor hereby acknowledges and agrees that (a) there is no
assurance that the Licensor will receive any Milestone Payments or Commercial Milestone Event payments and it is possible that no Milestone
Events or Commercial Milestone Events will be achieved without any breach of this Agreement by Licensee or its Affiliates, (b) Licensee
has not promised or projected any amounts to be received by Licensor in respect of any Milestone Payments or Commercial Milestone Event
payments, and Licensor has not relied on any statements or information provided by or on behalf of Licensee with respect to the likelihood
of development or potential sales of any Licensed Product and (c) Licensee shall have no obligation to use Commercially Reasonable Efforts
other than as set forth in <U>Section&nbsp;<FONT STYLE="font-size: 10pt">&lrm;</FONT>3.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">ARTICLE
5 - IP Ownership, INVENTIONS AND<BR>
PATENT Prosecution and Maintenance</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 4.5pt; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">5.1.   <B>Intellectual
Property Ownership</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(a)   Subject
to the licenses and rights granted in this Agreement, as between the Parties, Licensor shall own or Control and retain all right, title
and interest in the Licensor Technology and in any and all other Patent Rights, Know-How and other Intellectual Property rights that are
(i) in existence and Controlled by Licensor as of the Effective Date or (ii) developed by, for or on behalf of Licensor after the Effective
Date other than in the course of performance of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(b)   Subject
to the licenses and rights granted in this Agreement, as between the Parties, Licensee shall own or Control and retain all right, title
and interest in any and all other Patent Rights, Know-How and other Intellectual Property rights that are (i) in existence and Controlled
by Licensee as of the Effective Date or (ii) developed by, for or on behalf of Licensee after the Effective Date other than in the course
of performance of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(c)   All
right, title and interest in any and all other Patent Rights, Know-How and Intellectual Property rights that are developed in the course
of performance of this Agreement shall be owned, as between the Parties, (i) solely by Licensor, if developed solely by employees, agents
or independent contractors of Licensor, or (ii) solely by Licensee, if developed solely by employees, agents or independent contractors
of Licensee and its Affiliates and (iii) jointly and equally by both Parties, if developed jointly by employees, agents or independent
contractors of both Parties; <I>provided</I> that any such Patent rights jointly owned by the Parties shall be included in the Licensor
Patents and subject to the terms and conditions herein. Determination of &lsquo;joint&rsquo; or &rsquo;sole&rsquo; inventorship will be
made in accordance with U.S. patent laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">5.2.   <B>Patent
Prosecution, Maintenance and Enforcement of Licensee Patents</B>. For the avoidance of doubt, as between the Parties, Licensee shall have
the sole right, but not the obligation, to file, prosecute, maintain and enforce the Patent Rights owned by Licensee pursuant to <U>Section&nbsp;<FONT STYLE="font-size: 10pt">&lrm;</FONT>5.1</U>
(such Patent Rights, the &ldquo;<B>Licensee Patents</B>&rdquo;). Licensee shall bear all costs and expenses of filing, prosecuting and
maintaining Licensee Patents in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">5.3.   <B>Patent
Prosecution and Maintenance of Licensor Patents</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(a)   <B>US
Drug Product Listing</B>. As between the Parties, Licensee shall have the sole right to determine which of the Licensor Patents, if any,
shall be (i) listed for inclusion in the Approved Drug Products with Therapeutic Equivalence Evaluations pursuant to 21 U.S. C.F.R. &sect;&nbsp;355,
or (ii) provided to any biosimilar applicant pursuant to 42 U.S.C. &sect; 262(l), in each case of clauses (i) or (ii), or any successor
Law in the United States, together with any comparable laws in any other country in the Territory. Licensor shall provide, consistent
with its obligations under Applicable Law, reasonable cooperation to Licensee in filing and maintaining such registrar (and foreign equivalent)
listings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(b)   <B>Responsibility
and Costs</B>. As between the Parties, Licensee shall have the first right, but not the obligation, to file, prosecute and maintain Licensor
Patents, including any related proceedings (e.g., interferences, oppositions, reexaminations, reissues, revocations, nullifications, post-grant
review, <I>inter partes</I> review, etc.). Licensee shall bear all costs and expenses of filing, prosecuting and maintaining Licensor
Patents. Licensee shall keep Licensor informed of the status of the filing and prosecution of Licensor Patents or related proceedings
(e.g., interferences, oppositions, reexaminations, reissues, revocations, nullifications, post-grant review, <I>inter partes</I> review,
etc.) in a timely manner, and will take into consideration the advice and recommendations of Licensor. At Licensee&rsquo;s request, Licensor
will provide Licensee with reasonable free-of-charge assistance in prosecuting and defending Licensor Patents to the extent possible,
including providing such data in Licensor&rsquo;s possession and control that is, in Licensee&rsquo;s reasonable judgment, needed to support
the prosecution of a Licensor Patent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(c)   <B>Election
Not to File and Prosecute Licensor Patents</B>. If Licensee elects not to file or to continue to prosecute or maintain a Licensor Patent
in Licensor&rsquo;s name, then it shall notify Licensor in writing at least [***] before any deadline applicable to the filing, prosecution
or maintenance of such Licensor Patent, as the case may be, or any other date by which an action must be taken to establish or preserve
such Licensor Patent in such country of possession. In such case, Licensor shall have the right to pursue the filing or support the continued
prosecution or maintenance of such Licensor Patent. If Licensor fails to continue prosecution or maintenance of any of the Licensor Patents
then such abandoned Licensor Patents shall not extend the Royalty Term (i.e., no royalty payments shall be due under this Agreement on
account of such abandoned Licensor Patents).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(d)   <B>Patent
Term Extension</B>. As between the Parties, Licensee shall have the first right and decision-making authority regarding obtaining patent
term extensions for Licensor Patents. Licensor shall provide Licensee with all relevant information, documentation and assistance in this
respect as may reasonably be requested by Licensee. Any such assistance, supply of information and consultation shall be provided promptly
and in a manner that will ensure that all patent term extensions for Licensor Patents are obtained wherever legally permissible, and to
the maximum extent available. In the event that any election with respect to obtaining patent term extensions is to be made, Licensee
shall have the first right to make such elections, and Licensor shall abide by all such elections. If Licensee elects not to file for
a patent term extension for any Licensor Patent Covering a Licensed Product which has received Regulatory Approval where legally permissible,
Licensor shall have the right to file for any patent term extensions or restorations or supplemental protection certificates or their
equivalents with respect to such Licensor Patent in any country or jurisdiction in the Territory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">5.4.   <B>Enforcement
of Patent Rights</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(a)   <B>Notice</B>.
If either Party believes that an infringement, unauthorized use, misappropriation or ownership claim or threatened infringement or other
such activity by a Third Party exists with respect to any Licensor Technology or Inlicensed Technology, or if a Third Party claims that
any Licensor Patent or Inlicensed Patent is invalid or unenforceable (collectively, &ldquo;<B>Third Party Infringement</B>&rdquo;), the
Party possessing such knowledge or belief shall notify the other Party and provide it with details of such infringement or claim that
are known by such Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(b)   <B>Right
to Bring an Action</B>. As between the Parties, Licensee shall have the first right, but not the obligation, to attempt to resolve any
Third-Party Infringement, including by filing an infringement suit, defending against such claim or taking other similar action, with
respect to a Licensor Patent (each, an &ldquo;<B>Action</B>&rdquo;) and to compromise or settle any such Third-Party Infringement or claim.
At Licensee&rsquo;s request, Licensor shall immediately provide Licensee with all relevant documentation (as may be requested by Licensee)
evidencing that Licensee is validly empowered by Licensor to take such an Action. Licensor shall be obligated to join Licensee in any
such Action if Licensee determines that Licensor is a necessary and/or indispensable party to such Action, and Licensor hereby consents
to being joined in, such Action. Licensor further covenants to facilitate the joinder of the Initial Licensor in any such Action if Licensee
determines that Initial Licensor is a necessary and/or indispensable party to such Action. If Licensee does not intend to prosecute or
defend an Action, Licensee shall promptly inform Licensor, and Licensor shall then have the right, but not the obligation, to attempt
to resolve any Third-Party Infringement or claim, including by filing an Action with respect to a Licensor Patent and to compromise or
settle any such infringement or claim. Licensor shall cooperate and assist Licensee in all reasonable respects in connection with an Action
brought under this <U>Section <FONT STYLE="font-size: 10pt"><I>&lrm;</I></FONT>5.4(b)</U> and shall facilitate any necessary cooperation
and assistance from the Initial Licensor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(c)   <B>Costs
of an Action</B>. Subject to the respective indemnity obligations of the Parties set forth in <U>ARTICLE 8</U>, the respective Party taking
such Action shall pay all costs associated with such Action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(d)   <B>Settlement</B>.
Neither Party shall settle or otherwise compromise any Action without the prior written consent of the other Party that would (i) give
rise to liability (economic or otherwise) to the other Party or any of their respective Affiliates (or, in the case of Licensee, Sublicensees)
or (ii) in any manner alter, diminish or be in derogation of the other Party&rsquo;s rights under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(e)   <B>Reasonable
Assistance</B>. The Party not enforcing or defending Licensor Patents shall provide reasonable assistance to the other Party, including
providing access to relevant documents and other evidence and making its employees available, subject to the other Party&rsquo;s reimbursement
of any Out-of-Pocket Costs incurred by the non-enforcing or non-defending Party in providing such assistance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(f)   <B>Distribution
of Amounts Recovered</B>. Any amounts recovered by the Party taking an Action pursuant to this <U>Section&nbsp;<FONT STYLE="font-size: 10pt"><I>&lrm;</I></FONT>5.4</U>,
whether by settlement or judgment, shall be allocated in the following order: (i) to reimburse the Party taking such Action for any costs
incurred, (ii) to reimburse the Party not taking such Action for its costs incurred in such Action, if it joins such Action; and (iii)
the remaining amount of such recovery shall be paid to or kept by Licensee; <I>provided</I> that such remaining amount be deemed to be
Net Sales and Licensee shall pay to Licensor a royalty on such remaining amount based on the royalty rates set forth in <U>Section <FONT STYLE="font-size: 10pt"><I>&lrm;</I></FONT>4.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 35; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">5.5.   <B>Third-Party
Actions Claiming Infringement</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(a)   <B>Notice</B>.
If a Party becomes aware of any claim or action by a Third Party against either Party that claims that a Licensed Product, or its use,
Development, Manufacture or Commercialization infringes, misappropriates or otherwise violates such Third Party&rsquo;s Intellectual Property
rights (each, a &ldquo;<B>Third-Party Action</B>&rdquo;), such Party shall promptly notify the other Party in writing of all details regarding
such Third-Party Action that is reasonably available to such Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(b)   <B>Right
to Defend.</B> As between the Parties, Licensee shall have the first right, at its sole expense, but not the obligation, to defend a Third-Party
Action through counsel of its choosing. If Licensee declines or fails to assert its intention to defend such Third-Party Action to Licensor
within [***] of Licensee&rsquo;s receipt or sending, applicable, of written notice under <U>Section&nbsp;<FONT STYLE="font-size: 10pt"><I>&lrm;</I></FONT>5.5(a)</U>,
then Licensor shall have the right to defend such Third-Party Action. The Party defending such Third-Party Action shall have the sole
and exclusive right to select counsel for such Third-Party Action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(c)   <B>Consultation</B>.
The Party defending a Third-Party Action pursuant to <U>Section&nbsp;<FONT STYLE="font-size: 10pt"><I>&lrm;</I></FONT>5.5(b)</U> shall
be the &ldquo;<B>Controlling Party</B>&rdquo;. The Controlling Party shall consult in good faith with the non-Controlling Party on all
material aspects of the defense. The non-Controlling Party shall have a reasonable opportunity for meaningful participation in decision-making
and formulation of defense strategy; <I>provided</I> that, subject to <U>ARTICLE 6</U> and <U>Section <FONT STYLE="font-size: 10pt"><I>&lrm;</I></FONT>5.5(f)</U>,
the Controlling Party shall have all final decision making authority with respect to such Third-Party Action. The Parties shall reasonably
cooperate with each other in all such Third-Party Actions. The non-Controlling Party will be entitled to be represented by independent
counsel of its own choice at its own expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(d)   <B>Appeal</B>.
In the event that a judgment in a Third-Party Action is entered against the Controlling Party and an appeal is available, the Controlling
Party shall have the first right, but not the obligation, to file such appeal. In the event the Controlling Party does not desire to file
such an appeal, it will promptly, in a reasonable time period (i.e., with sufficient time for the non-Controlling Party to take whatever
action may be necessary) prior to the date on which such right to appeal will lapse or otherwise diminish, permit the non-Controlling
Party to pursue such appeal at such non-Controlling Party&rsquo;s own cost and expense. If Applicable Laws requires the other Party&rsquo;s
involvement in an appeal, the other Party shall be a nominal party of the appeal and shall provide reasonable cooperation to such Party
at such Party&rsquo;s expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(e)   <B>Costs
of an Action</B>. Subject to the respective indemnity obligations of the Parties set forth in <U>ARTICLE 8</U> and the last sentence of
<U>Section <FONT STYLE="font-size: 10pt"><B><I>&lrm;</I></B></FONT>5.5(c)</U> and this <U>Section <FONT STYLE="font-size: 10pt"><B><I>&lrm;</I></B></FONT>5.5(e)</U>,
the Controlling Party shall pay all costs associated with such Third-Party Action other than the expenses of the other Party if the other
Party elects to join such Third-Party Action. Each Party shall have the right to join a Third-Party Action defended by the other Party,
at its own expense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 36; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(f)   <B>No
Settlement Without Consent</B>. Neither Party shall settle or otherwise compromise any Third-Party Action without the prior written consent
of the other Party that would (i) give rise to liability (economic or otherwise) to the other Party or any of their respective Affiliates
(or, in the case of Licensee, Sublicensees) or (ii) in any manner alter, diminish or be in derogation of the other Party&rsquo;s rights
under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">5.6.   <B>Certification
Under Drug Price Competition and Patent Restoration Act</B>. Licensor shall immediately give written notice to Licensee of any certification
of which it becomes aware filed pursuant to 21 U.S. C.F.R. &sect;&nbsp;355(b)(2)(A) (or any amendment or successor statute thereto) claiming
that any Licensor Patents or Inlicensed Patents Covering a Compound or a Licensed Product, or the Manufacture or use of each of the foregoing,
are invalid or unenforceable, or that infringement will not arise from the Manufacture, use or sale of a product by a Third Party or any
other any allegations of alleged patent invalidity, unenforceability or non-infringement of any Licensor Patents or Inlicensed Patents
pursuant to a bioequivalent or biosimilar application.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">ARTICLE
6 - CONFIDENTIALITY</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-transform: uppercase; text-align: center; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">6.1.   <B>Confidentiality
Obligations</B>. Each Party agrees that, for the Term and for [***] thereafter, such Party shall, and shall ensure that its officers,
directors, employees and agents shall, keep completely confidential and not publish or otherwise disclose and not use for any purpose
except as expressly permitted hereunder any Confidential Information disclosed to it by the other Party pursuant to this Agreement. For
clarity, <U>Section 31.15</U> of the Initial Licensor Agreement shall apply to such Confidential Information that is attributable to the
Initial Licensor and for the confidentiality term of the Initial License Agreement such confidential information shall be subject to confidentiality
obligations as set forth therein. The foregoing obligations shall not apply to any Confidential Information disclosed by a Party hereunder
to the extent that the receiving Party can demonstrate that such Confidential Information:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(a)   was
already known to the receiving Party or its Affiliates, other than under an obligation of confidentiality, at the time of disclosure;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(b)   was
generally available to the public or otherwise part of the public domain at the time of its disclosure to the receiving Party;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(c)   became
generally available to the public or otherwise part of the public domain after its disclosure to the receiving Party and other than through
any act or omission of the receiving Party in breach of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(d)   was
subsequently lawfully disclosed to the receiving Party or its Affiliates by a Third Party without an obligation of confidentiality other
than in contravention of a confidentiality obligation of such Third Party to the disclosing Party; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(e)   was
developed or discovered by employees or agents of the receiving Party or its Affiliates without use of or reference to the Confidential
Information of the disclosing Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 37; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify; text-indent: 0in">Notwithstanding the above obligations
of confidentiality and non-use, a receiving Party may disclose Confidential Information of the disclosing Party to the extent that such
disclosure is reasonably necessary in connection with:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0.5in">(i)   in
the case of Licensee as the receiving Party, (A) the filing or prosecuting patent applications included in the Licensee Patents or Licensor
Patents, subject to the terms of <U>Section&nbsp;<FONT STYLE="font-size: 10pt">&lrm;</FONT>5.2</U> or <U>Section&nbsp;<FONT STYLE="font-size: 10pt">&lrm;</FONT>5.3</U>,
(B) prosecuting or defending litigations regarding the Licensor Patents or any Licensed Products, (C) conducting pre-clinical studies
or Clinical Trials for any Licensed Product or Compound and (D) seeking Regulatory Approval of any Licensed Product;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0.5in">(ii)   complying
with Applicable Laws (including securities law and the rules of any securities exchange or market on which a Party&rsquo;s securities
are or may in the future be listed or traded) or court order, if in the reasonable opinion of such receiving Party&rsquo;s counsel, such
disclosure is necessary for such compliance; <I>provided, however</I>, that except where impracticable, such receiving Party shall give
the disclosing Party reasonable advance written notice of such disclosure requirement (which shall include a copy of any applicable subpoena
or order) and shall afford such disclosing Party a reasonable opportunity to oppose, limit or secure confidential treatment for such required
disclosure, and in the event of any such required disclosure, (A) such receiving Party shall disclose only that portion of the Confidential
Information of such disclosing Party that such receiving Party is legally required to disclose, (B) such Confidential Information may
only be used for the purposes for which the order was issued or such disclosure was required by Applicable Law, and (C)&nbsp;such receiving
Party shall endeavour to obtain confidential treatment of economic, trade secret information and such other information as may be requested
by the disclosing Party, and shall provide the disclosing Party with the proposed confidential treatment request with reasonable time
for such disclosing Party to provide comments, and shall include in such confidential treatment request all reasonable comments of the
disclosing Party;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0.5in">(iii)   disclosure,
in connection with the performance of this Agreement and solely on a &ldquo;need to know basis&rdquo;, to Affiliates, existing or potential
collaborators (including existing or potential co-marketing and co-promotion contractors), research collaborators, employees, consultants,
or agents, each of whom prior to disclosure must be bound by written obligations of confidentiality and non-use no less restrictive than
the obligations set forth in this <U>ARTICLE 6</U> ; <I>provided, however</I>, that such receiving Party shall remain responsible for
any failure by any Person who receives Confidential Information pursuant to this <U>ARTICLE 6</U> to treat such Confidential Information
as required under this <U>ARTICLE 6</U>; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0.5in">(iv)   disclosure
made by such receiving Party to existing or potential acquirers, merger candidates, Sublicensees, investment bankers, public and private
sources of funding, existing or potential investors, venture capital firms or other financial institutions or investors for purposes of
obtaining financing or in connection with an acquisition, merger, Sublicense or similar transaction, <I>provided</I> that such receiving
Party has secured an agreement from any such Third Party to be bound by obligations of confidentiality and restrictions on use of Confidential
Information that are no less restrictive than the obligations set forth in this <U>ARTICLE 6</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.75in; text-align: justify; text-indent: 0in">For clarity, Licensor is entitled to
share this Agreement with independent legal counsel selected by Initial Licensor to have such counsel review compliance of this Agreement
with the Initial License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 38; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">6.2.   <B>Publications.
</B>Licensor shall not publish any information relating to any Compound or Licensed Product without the prior written consent of Licensee
(which consent may not be unreasonably withheld), unless such information has already been publicly disclosed either prior to the Effective
Date or after the Effective Date through no fault of Licensor or otherwise not in violation of this Agreement. Licensee shall have the
right to make such publications as it chooses, in its sole discretion, without the approval of Licensor, unless Licensor&rsquo;s company
name shall be used. Licensor shall submit to Licensee for Licensee&rsquo;s written approval any publication or presentation (including
in any seminars, symposia or otherwise) of information related directly or indirectly to the Licensed Product for review and approval
at least [***] prior to submission for the proposed date of publication or presentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">6.3.   <B>Press
Releases and Disclosure</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(a)   The
proposed public announcement by Licensor of the execution of this Agreement is set forth in <U>Schedule&nbsp;<FONT STYLE="font-size: 10pt"><I>&lrm;</I></FONT>6.3</U>
hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(b)   Licensor
may not make any subsequent press release or public announcements regarding this Agreement without the prior written consent of Licensee
unless the Licensor believes it is required to issue a press release or make another public announcement to comply with Applicable Laws
as a publicly traded company (in which case, such press release or public announcements shall comply with the terms of <U>Section&nbsp;<FONT STYLE="font-size: 10pt"><I>&lrm;</I></FONT>6.1(e)(ii)</U>.
Licensor will provide the text of such planned disclosure to Licensee no less than [***] prior to disclosure and make reasonable efforts
to incorporate all reasonable comments of Licensee regarding such disclosure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(c)   Licensee
shall have the right to make such press releases as it chooses, in its sole discretion, without the approval of Licensor, unless Licensor&rsquo;s
company name shall be used. In such case, Licensee will inform Licensor no less than [***] prior to the planned publication of such press
release and request approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">ARTICLE
7 - REPRESENTATIONS AND WARRANTIES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-transform: uppercase; text-align: center; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">7.1.   <B>Mutual
Representations and Warranties</B>. Each Party represents and warrants to the other Party that, as of the Effective Date:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(a)   it
is duly organized, validly existing and in good standing under the Applicable Laws of the jurisdiction of its incorporation and has full
power, authority and right to enter into this Agreement and to perform its obligations hereunder in accordance with the terms and conditions
hereof;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(b)   all
requisite corporate action has been taken to authorize its execution, delivery and performance of this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(c)   this
Agreement has been duly executed and delivered on behalf of such Party, and is legally binding and enforceable on each Party in accordance
with its terms;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(d)   the
execution, delivery and performance of this Agreement by such Party does not breach, violate, contravene or constitute a default under
any contract, arrangement or commitment to which such Party is a party or by which it is bound, or violate any statute, law or regulation
or any court or Governmental Body having jurisdiction over such Party; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 39; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(e)   no
government authorization, consent, approval, license, exemption of or filing or registration with any court or Governmental Body, domestic
or foreign, under any Applicable Laws currently in effect, is or will be necessary for, or in connection with, the transaction contemplated
by this Agreement or any other agreement or instrument executed in connection herewith, or for the performance by it of its obligations
under this Agreement and such other agreements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">7.2.   <B>Licensor
Representations and Warranties</B>. Licensor represents and warrants to Licensee that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(a)   As
of the Effective Date, subject to the limitations contained in the Initial License Agreement and the Underlying GMP License, (i) Licensor
has all right, title and interest in and to the Licensor Technology and (ii) the Licensor Technology is free and clear of any liens, charges,
encumbrances or rights of others to possession or use.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(b)   As
of the Effective Date, Initial Licensor has opted out in full from the Initial Project pursuant to <U>Section 9.5</U> of the Initial License
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(c)   As
of the Effective Date, neither Licensor nor any of its Affiliates are Developing, Manufacturing or Commercializing, or have plans to Develop,
Manufacture or Commercialize, either directly or indirectly, any inhibitor of IL-17 or inhibitor of any receptor of IL-17, other than
in performance of Licensor&rsquo;s obligations under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(d)   As
of the Effective Date, the Patent Rights set forth on <U>Schedule&nbsp;<FONT STYLE="font-size: 10pt">&lrm;</FONT>1.55</U> constitute all
Licensor Patents owned or Controlled by Licensor as of the Effective Date. As of the time the Transfer Plan is agreed upon in writing
by the Parties, the Know-How and Licensor Materials to be set forth in such Transfer Plan constitute all Licensor Know-How, Inlicensed
Know-How and Licensor Materials owned or Controlled by Licensor as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(e)   As
of the Effective Date, to Licensor&rsquo;s Knowledge, no Affiliate of Licensor owns or Controls any Patent Rights that are necessary for
the Development, Manufacture or Commercialization of any Compound or Licensed Product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(f)   As
of the Effective Date, Licensor does not have the right to grant a license or sublicense under any Patent Rights or Know-How Controlled
by any of Licensor&rsquo;s Affiliates other than Licensor Affiliates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(g)   As
of the Effective Date, no claims have been asserted, or, to Licensor&rsquo;s Knowledge, threatened by any Person, nor are there any valid
grounds for any claim of any such kind (i) challenging the validity, enforceability, effectiveness, or ownership of any Licensor Patents
or Inlicensed Patents (including, by way of example, through the institution of or written threat of institution of interference, <I>inter
partes</I> review, reexamination, protest, opposition, nullity or similar invalidity proceeding before the United States Patent and Trademark
Office or any foreign patent authority or court), or (ii) to the effect that the Development, Manufacture, Commercialization or use of
any Compound or Licensed Product infringes, misappropriates or otherwise violates or will infringe, misappropriate or otherwise violate
any Intellectual Property right of any Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(h)   As
of the Effective Date, Licensor is not aware of any facts or circumstances that are reasonably likely to provide a basis for a finding
of invalidity or unenforceability of any of the Licensor Patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(i)   As
of the Effective Date, Licensor has the right to grant to Licensee all of the rights and licenses granted by Licensor to Licensee under
this Agreement (including pursuant to <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>2.1</U> hereof).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(j)   As
of the Effective Date, to Licensor&rsquo;s Knowledge, the Licensor Materials were manufactured, tested, stored and handled in accordance
with all Applicable Laws and specifications (including, to the extent applicable, any release specifications as provided by Licensor to
Licensee in writing prior to the Effective Date) and the Licensor Materials are not adulterated or misbranded within the meaning of any
Applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(k)   As
of the Effective Date, to Licensor&rsquo;s Knowledge, no Third Party is infringing, misappropriating or otherwise violating any of the
Licensor Patents or Inlicensed Patents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(l)   As
of the Effective Date, the Initial License Agreement is a valid and binding agreement between Licensor and the Initial Licensor and neither
Licensor nor, to Licensor&rsquo;s Knowledge, the Initial Licensor is or has been in default or breach in any material respect under the
terms of the Initial License Agreement and, to Licensor&rsquo;s Knowledge, no event or circumstance has occurred that, with notice or
lapse of time or both, would constitute any event of default or breach in any material respect thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(m)   As
of the Effective Date, a copy of the Initial License Agreement and Underlying GMP License have been delivered to Licensee which, except
for appropriate redactions, are true and complete.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(n)   As
of the Effective Date, to Licensor&rsquo;s Knowledge, neither Licensor, nor any of its employees, officers, subcontractors, or consultants
who have rendered services relating to the Compounds or Licensed Products: (i) has ever been debarred or is subject to debarment or convicted
of a crime for which a Person could be debarred by the FDA under 21 U.S.C. Section&nbsp;335a or (ii) has ever been under indictment for
a crime for which a Person could be so debarred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(o)
With respect to Drug Product and placebo Manufactured and supplied to Licensee pursuant to <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>3.3</U>,
such Drug Product and placebo shall have been Manufactured in accordance with GMP (if applicable), Applicable Laws and the Manufacturing
Quality Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">7.3.   <B>Licensor
Covenant</B>. Licensor (a) shall comply with the terms and conditions of, and perform all relevant obligations under, the Initial License
Agreement and the Underlying GMP License, (b) shall not modify, amend or terminate the Initial License Agreement or the Underlying GMP
License or agree to do any of the foregoing such that Licensee&rsquo;s rights under this Agreement would be impacted without Licensee&rsquo;s
prior written consent and (c) shall enforce all of its rights and Initial Licensor&rsquo;s obligations under the Initial License Agreement
(including <U>Section 4</U> of the Initial License Agreement) and its rights and RCT&rsquo;s obligations under the Underlying GMP License,
in each case upon the request of Licensee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt"></P>

<!-- Field: Page; Sequence: 41; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">7.4.   <B>Licensee
Representations, Warranties and Covenants</B>. Licensee represents, warrants and covenants to Licensor as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(a)   As
of the Effective Date, all written declarations made, directly or indirectly, by Licensee to Licensor related to Licensee&rsquo;s qualifications,
ability and competence to Develop and Commercialize the Licensed Products in the Territory are true and correct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(b)   As
of the Effective Date and at any time during the Term, Licensee (i) shall have and maintain facilities, personnel, experience and expertise
sufficient in quality and quantity to perform its obligations hereunder (including through subcontractors or Sublicensees), (ii) shall
perform its obligations hereunder with reasonable due care and in conformity with current generally accepted industry standards and procedures
and (iii) shall procure that its management establishes and maintains appropriate quality assurance, quality controls and review procedures
to secure good standard performance of its obligations hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(c)   As
of the Effective Date and at any time during the Term, Licensee will procure that all data related to human samples and other Personal
Data obtained in course of the Development, Manufacturing or Commercialization of a Compound or a Licensed Product will be obtained, processed
and stored in compliance with Applicable Laws, including applicable Data Protection Law, in all material respects. In particular, to the
extent applicable to the activities contemplated to be conducted by this Agreement and required by Applicable Law, the signature of the
informed consent from the donor will be obtained, the confidentiality and anonymization of the human samples will be procured and the
personnel involved in such activities will be authorized and will have the capacity to perform such activities, in each case, in all material
respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(d)   As
of the Effective Date and at any time during the Term, Licensee will comply with all Applicable Laws for the care, welfare and ethical
treatment of animals in the country where the Development is being performed. In order to ensure proper treatment and use of animals,
Licensee will adhere at a minimum to (i) Licensor&rsquo;s policy on the use, care and welfare of laboratory animals, (ii) Licensor Standard
on &ldquo;Housing and Husbandry Practices for Common Laboratory Animals&rdquo;, (iii) the principle of &ldquo;3Rs&rdquo; &ndash; reduction,
refinement and replacement of animal studies; (iv) the principle to offer state of the art housing and husbandry conditions in the care
and use of animals which means access to species appropriate food and water; access to species specific housing, including species appropriate
temperature and humidity levels; access to humane care and a program of veterinary care; animal housing that minimizes the development
of abnormal behaviors; review of study design and purpose by institutional ethical review panel; commitment to minimizing pain and distress
during the studies conducted under the research plan and work is performed by demonstrable trained staff; <I>provided</I> that in each
case of clauses (i)&ndash;(iv) such policies, standards and principles have been provided to Licensee in writing prior to the Effective
Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(e)   Prior
to First Commercial Sale of a Licensed Product, Licensee shall use Commercially Reasonable Efforts to request a direct license agreement
from RCT such that Licensee no longer requires a sublicense under the Underlying GMP License and shall use Commercially Reasonable Efforts
to negotiate in good faith with RCT the terms and conditions of such license agreement. Notwithstanding the foregoing, Licensor acknowledges
and agrees that in no event shall Licensee be deemed to be in breach of this <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>7.4(e)</U>
if Licensee is unable to enter into any such direct license agreement with RCT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 42; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">7.5.   <B>Disclaimer</B>.
EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, EACH PARTY HEREBY DISCLAIMS ALL OTHER REPRESENTATIONS AND WARRANTIES EXPRESS OR IMPLIED,
INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS OF A COMPOUND OR LICENSED PRODUCT FOR A PARTICULAR PURPOSE.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">7.6.   <B>Limitation
of Liability</B>. NOTWITHSTANDING ANYTHING IN THIS AGREEMENT OR OTHERWISE, NEITHER PARTY SHALL BE LIABLE TO THE OTHER WITH RESPECT TO
ANY SUBJECT MATTER OF THIS AGREEMENT, WHETHER UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY, FOR
ANY INCIDENTAL, INDIRECT, SPECIAL, EXEMPLARY, PUNITIVE, MULTIPLE, OR CONSEQUENTIAL DAMAGES (INCLUDING, WITHOUT LIMITATION, LOST PROFITS,
LOSS OF USE, DAMAGE TO GOODWILL, OR LOSS OF BUSINESS); <I>PROVIDED</I>, <I>HOWEVER</I>, THAT THE FOREGOING SHALL NOT APPLY TO (a) ANY
BREACH BY A PARTY OF <U>ARTICLE 6</U> HEREOF, (b) THE WILLFUL MISCONDUCT, OR GROSS NEGLIGENCE BY A PARTY, OR (c) FOR AMOUNTS THAT ARE
SUBJECT TO THE PARTIES&rsquo; RESPECTIVE INDEMNITY OBLIGATIONS UNDER <U>ARTICLE 8</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">ARTICLE
8 - INDEMNIFICATION and Insurance</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-transform: uppercase; text-align: center; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">8.1.   <B>Indemnification
by Licensor</B>. Licensor shall defend, indemnify and hold harmless Licensee and its Affiliates, and their respective officers, directors,
employees and agents (the &ldquo;<B>Licensee Indemnitees</B>&rdquo;) from and against any and all liability, damage, loss, cost and expense
(including reasonable attorney&rsquo;s fees and expenses of litigation) (&ldquo;<B>Losses</B>&rdquo;) arising or resulting from any claims
made or suits brought by Third Parties to the extent such Losses arise or result from (a)&nbsp;a breach of any of Licensor&rsquo;s representations,
warranties or covenants set forth in <U>Section&nbsp;<FONT STYLE="font-size: 10pt"><I>&lrm;</I></FONT>7.1</U> or <U>Section <FONT STYLE="font-size: 10pt"><I>&lrm;</I></FONT>7.2</U>,
(b) the failure of any Licensor Indemnitee to comply with Applicable Law in connection with Licensor&rsquo;s performance of its obligations
or exercise of its rights under this Agreement; (c) the gross negligence, willful misconduct or fraud of any Licensor Indemnitee; (d)
any Development or Manufacture of any Compound or Licensed Products performed by or for Licensor or any of its Affiliates on or prior
to the Effective Date, including any product liability claims in the Territory or any personal injury or property damage in the Territory
arising therefrom; and/or (e) any personal injury that is caused by any Drug Product Manufactured pursuant to <U>Section <FONT STYLE="font-size: 10pt"><I>&lrm;</I></FONT>3.3</U>
which fails to conform to the Manufacturing Quality Agreement; <I>except</I> in the case of clauses (a)-(e) for Losses to the extent arising
out of any matter for which Licensee has an indemnification obligation to Licensor pursuant to <U>Section&nbsp;<FONT STYLE="font-size: 10pt"><I>&lrm;</I></FONT>8.2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">8.2.   <B>Indemnification
by Licensee</B>. Licensee shall defend, indemnify and hold harmless Licensor, its Affiliates, and their respective officers, directors,
employees and agents (the &ldquo;<B>Licensor Indemnitees</B>&rdquo;) from and against any and all Losses arising or resulting from any
claims made or suits brought by Third Parties to the extent such Losses arise or result from (a) the negligence or willful misconduct
of Licensee or its Affiliates and its or their respective directors, officers, employees and agents, in connection with the performance
of Licensee&rsquo;s obligations or exercise of Licensee&rsquo;s rights under this Agreement; (b) a breach of any of Licensee representations,
warranties or covenants set forth in <U>Section&nbsp;<FONT STYLE="font-size: 10pt"><I>&lrm;</I></FONT>7.4</U>; (c) the activities that
are actually conducted by or on behalf of Licensee or its Affiliates under this Agreement on or after the Effective Date, including the
Development, Manufacture and Commercialization of the Compounds and/or Licensed Products, in particular the handling and storage by or
on behalf of Licensee or its Affiliates of any chemical agents or other compounds for the purpose of conducting Development by or on behalf
of Licensee or its Affiliates, including any product liability, personal injury, property damage or other damage caused thereby; or (d)
any infringement of Patent Rights of any Third Party, on or after the Effective Date, by Licensee or its Affiliates with respect to any
Development or Commercialization on any Licensed Product anywhere in the world or with respect to any other activity performed under this
Agreement; <I>except</I> in the case of clauses (a)-(d) for Losses to the extent arising out of any matter for which Licensor has an indemnification
obligation to Licensee pursuant to <U>Section&nbsp;<FONT STYLE="font-size: 10pt"><I>&lrm;</I></FONT>8.1</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt"></P>

<!-- Field: Page; Sequence: 43; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">8.3.   <B>Procedure</B>.
A Party seeking indemnification under this <U>ARTICLE 8</U> (&ldquo;<B>Indemnified Party</B>&rdquo;) shall give prompt written notification
to the other Party (&ldquo;<B>Indemnifying Party</B>&rdquo;) of the claim for which indemnification may be sought (it being understood
and agreed, however, that the failure by a Party to give notice of such claim as provided in this <U>Section&nbsp;<FONT STYLE="font-size: 10pt"><I>&lrm;</I></FONT>8.3</U>
shall not relieve the Indemnifying Party of its indemnification obligation under this Agreement except and only to the extent that such
Indemnifying Party is actually prejudiced as a result of such failure to give notice). Within ninety (90) days after delivery of such
notification, the Indemnifying Party may, upon written notice thereof to the other Party, assume control of the defense of such claim
with counsel reasonably satisfactory to the Indemnified Party. If the Indemnifying Party does not assume control of such defense, the
Indemnified Party shall control such defense and, without limiting the Indemnifying Party&rsquo;s indemnification obligations, the Indemnifying
Party shall reimburse the Indemnified Party for all costs and expenses, including reasonable attorneys&rsquo; fees and disbursements,
incurred by the Indemnified Party in defending itself within sixty (60) days after receipt of any invoice therefor from the Indemnified
Party. The Party not controlling such defense may participate therein at its own expense; <I>provided</I> that, if the Indemnifying Party
assumes control of such defense and the Indemnified Party in good faith concludes, based on written advice from outside counsel, that
the Indemnifying Party and the Indemnified Party have conflicting interests with respect to such claim sufficiently adverse to make unadvisable
the representation by the same counsel of both Parties under Applicable Laws, ethical rules or equitable principles, the Indemnifying
Party shall be responsible for the reasonable fees and expenses of a single counsel to the Indemnified Party in connection therewith.
The Party controlling such defense shall keep the other Party advised of the status of such claim and the defense thereof and shall consider
recommendations made by the other Party with respect thereto. The Indemnifying Party shall not agree to any settlement of such claim or
consent to any judgment in respect thereof that does not include a complete and unconditional release of the Indemnified Party from all
liability with respect thereto, that imposes any liability or obligation on the Indemnified Party, that would have an adverse effect on
the Indemnified Party&rsquo;s interests (including any rights under this Agreement or the scope or enforceability of the Licensor Technology
or Inlicensed Technology) or that acknowledges fault by the Indemnified Party, without the prior written consent of the Indemnified Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">8.4.   <B>Insurance</B>.
Each Party shall maintain, at its cost, insurance against liability and other risks associated with its activities and obligations under
this Agreement, in such amounts and on such terms as are customary for a company such as the respective Party for the activities to be
conducted by it under this Agreement. Each Party shall furnish to the other Party evidence of such insurance upon request. It is understood
that such insurance shall not be construed to create a limit of either Party&rsquo;s liability with respect to its indemnification obligations
under this <U>ARTICLE 8</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt"></P>

<!-- Field: Page; Sequence: 44; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">ARTICLE
9 - TERM AND TERMINATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">9.1.   <B>Term
of Agreement</B>. The term of this Agreement (the &ldquo;<B>Term</B>&rdquo;) shall commence on the Effective Date and, unless earlier
terminated as provided in this <U>ARTICLE 9</U>, shall continue in full force and effect, on a Licensed Product-by-Licensed Product and
country-by-country basis, until the date on which the Royalty Term in such country with respect to such Licensed Product expires. Upon
expiration of the Term with respect to any Licensed Product in any country, the licenses granted under this Agreement (including the licenses
granted under <U>Section <FONT STYLE="font-size: 10pt"><I>&lrm;</I></FONT>2.1</U>) with respect to such Licensed Product in such country
shall become fully paid up, royalty free, perpetual and irrevocable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">9.2.   <B>Termination
of this Agreement by Licensee for Convenience / for Safety Reasons</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(a)   Following
receipt by Licensor of the Upfront Payment set forth in <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>4.1</U> above, Licensee may,
at its convenience, terminate this Agreement in its entirety upon ninety (90) days&rsquo; prior written notice to Licensor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(b)   At
any time during the Term, Licensee may terminate this Agreement in its entirety upon ninety (90) days&rsquo; prior written notice to Licensor,
if, based upon an analysis of the existing information at any time, Licensee has the reasonable belief that the medical risk/benefit of
any Licensed Product is unfavorable in light of the welfare of patients and not suitable for further Development or Commercialization.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">9.3.   <B>Termination
for Non-Payment</B>. If Licensee has not paid a milestone payment by the required respective payment dates set forth in <U>Sections&nbsp;
<FONT STYLE="font-size: 10pt">&lrm;</FONT>4.3</U> and <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>4.4</U> and/or Licensee fails
to grant Licensor&rsquo;s Equity Consideration as agreed in <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>4.2</U> and the Equity
Documentation, Licensor shall have the right to terminate this Agreement if such breach is not cured within [***] after written notice
thereof is given to Licensee by Licensor; <I>provided</I> that in the case of a bona fide dispute over whether or to what extent a payment
by Licensee to Licensor is due, Licensor&rsquo;s right to terminate this Agreement under this <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>9.3</U>
shall be tolled during the pendency of such dispute.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">9.4.   <B>Termination
for Breach and Other Causes</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(a)   Subject
to <U>Sections <FONT STYLE="font-size: 10pt"><I>&lrm;</I></FONT>9.4(b)</U> and <FONT STYLE="font-size: 10pt"><I><U>&lrm;</U></I></FONT><U>9.4(c)</U>,
if either Party materially breaches this Agreement or the Initial License Agreement, the non-breaching Party may deliver written notice
of such breach to the other Party. The breaching Party shall have [***] from the date of such Party&rsquo;s receipt of such written notice
to cure such breach; <I>provided</I>, that if such breach is capable of being cured but cannot be cured within the applicable cure period,
the breaching Party may cure such breach during an additional period as is reasonable in the circumstances by initiating actions to cure
such breach during such applicable cure period and using reasonable efforts to pursue such cure. If the allegedly breaching Party fails
to cure such breach within the applicable cure period set forth above, then subject to <U>Sections <FONT STYLE="font-size: 10pt"><I>&lrm;</I></FONT>9.4(b)</U>
and <FONT STYLE="font-size: 10pt"><I><U>&lrm;</U></I></FONT><U>9.4(c)</U>, the Party originally delivering the written notice of breach
may terminate this Agreement immediately by providing written notice of termination to the other Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 45; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(b)   Notwithstanding
anything in this Agreement to the contrary, in the event that Licensor believes that Licensee has materially breached its Diligence Obligations
with regard to Development or Commercialization under <U>Section <FONT STYLE="font-size: 10pt"><I>&lrm;</I></FONT>3.5</U>, Licensor shall
notify Licensee thereof in writing, specifying the basis for its belief, and the Parties shall discuss in good faith such concerns. If,
after the expiry of [***] following the commencement of such good faith discussions and in the reasonable opinion of Licensor, Licensor
reasonably believes that Licensee remains in breach of its Diligence Obligations or has not undertaken reasonable efforts to cure such
breach, the matter shall be referred to the dispute resolution procedures set forth in <U>ARTICLE 10</U> and <U>Section <FONT STYLE="font-size: 10pt"><I>&lrm;</I></FONT>9.4(c)</U>
shall apply.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(c)   Any
right to terminate this Agreement under <U>Section <FONT STYLE="font-size: 10pt"><I>&lrm;</I></FONT>9.4(a)</U> or <U>Section <FONT STYLE="font-size: 10pt"><I>&lrm;</I></FONT>9.4(b)</U>,
shall be stayed and the applicable cure period tolled if, during such cure period, the Party alleged to have been in breach has initiated
dispute resolution in accordance with <U>ARTICLE 10</U> with respect to the alleged breach, which stay and tolling shall continue until
such dispute has been resolved in accordance with <U>ARTICLE 10</U>. If a Party is determined to be in material breach of this Agreement
or of the Initial License Agreement by the dispute resolution procedures set forth in <U>ARTICLE 10</U>, the non-breaching Party may terminate
this Agreement if the breaching Party fails to cure such breach within [***] after the conclusion of the dispute resolution procedure
(and such termination shall then be effective upon written notification from the notifying Party to the breaching Party); <I>provided</I>
that if Licensee is determined to have breached its Diligence Obligations with respect to any Licensed Product in any country by the dispute
resolution procedures set forth in <U>ARTICLE 10</U> and does not cure such breach within [***] after the conclusion of the dispute resolution
procedure, Licensor may only terminate this Agreement with respect to such Licensed Product and country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(d)   If
Initial Licensor alleges a breach by Licensor of the Initial License Agreement based on the material breach by Licensee of its obligations
under this Agreement, Licensor shall inform Licensee of such allegation in writing as soon as is reasonably possible. The Parties shall
work together to cure such material breach in accordance with the Initial License Agreement. If following such efforts the Parties are
unable to cure a material breach of the Initial License Agreement due to the Licensee&rsquo;s uncured material breach of this Agreement,
and the Initial Licensor terminates the Initial License Agreement as a result, then, Licensee will be considered to be in breach of this
Agreement with no further cure possible and Licensor shall be entitled to terminate this Agreement with immediate effect; <I>provided</I>
that if Licensee disputes in good faith such alleged breach of the Initial License Agreement, Licensor shall assist and cooperate with
Licensee to submit such dispute to the respective dispute resolution mechanisms of the Initial License Agreement and for so long as there
is no final determination as to whether Licensor, as a result of Licensee acts or omissions hereunder, has breached the Initial License
Agreement&nbsp;(and the Initial License Agreement is not in fact terminated), Licensor shall have no right to terminate this Agreement
pursuant to this <U>Section <FONT STYLE="font-size: 10pt"><I>&lrm;</I></FONT>9.4(d)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 46; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(e)   If
Initial Licensor alleges a breach by Licensor of the Initial License Agreement, where termination of such Initial License Agreement or
any diminishment of the scope or exclusivity of the Sublicenses granted to Licensee under the Inlicensed Technology is being or could
reasonably be sought by the Initial Licensor, then Licensor will promptly, but in no event more than [***]&nbsp;thereafter, provide written
notice thereof to Licensee and grant Licensee the right (but not the obligation) to cure such alleged breach. However, if Licensor disputes
the material breach of the Initial License Agreement, the respective dispute resolution mechanisms of the Initial License Agreement shall
have priority and for as long as there is no final determination as to whether the Licensor has breached the Initial License Agreement&nbsp;(and
the Initial License Agreement is not in fact terminated), the Licensee shall have no right to make any claims with respect to such alleged
breach of the Initial License Agreement towards the Licensor. In the event that a breach is undisputed or finally determined
to have occurred, and such breach is not timely cured or not capable of being timely cured by Licensor, then&nbsp;in accordance with <U>Section
37.25</U> of the Initial License Agreement, Licensee shall&nbsp;have the right to enter into a direct license with Initial Licensor, including
without limitation by way of Licensor assigning this Agreement to the Initial Licensor. Licensee may offset the costs of curing
the alleged breach&nbsp;of the Licensor&nbsp;against any amounts due to Licensor under this Agreement, to the extent that the breach of
the Initial License Agreement did not arise from Licensee&rsquo;s breach of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">9.5.   <B>No
Termination on Bankruptcy</B>. To the extent permitted by Applicable Laws, all rights and licenses granted pursuant to this Agreement
by a Party to the other Party shall not be terminated on the insolvency or bankruptcy of such Party or its Affiliates, and each Party
hereby claims the benefit of any Applicable Laws which may enable it to prevent such termination. All rights and licenses granted under
or pursuant to this Agreement by Licensor are, and shall otherwise be deemed to be, licenses of rights to &ldquo;intellectual property&rdquo;
as defined under any Applicable Law governing bankruptcy. The Parties agree that Licensee, as the recipient of such rights under this
Agreement, shall retain and may exercise all of its rights and elections to the fullest extent permitted under any Applicable Law governing
bankruptcy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">9.6.   <B>No
Challenge</B>. In the event that Licensee or any of its Affiliates or Sublicensees, anywhere in the world, institutes, prosecutes or otherwise
participates in (or in any way aids any Third Party in instituting, prosecuting or participating in), at law or in equity or before any
administrative or regulatory body, including the U.S. Patent and Trademark Office or its foreign counterparts, any claim, demand, action
or cause of action for declaratory relief, damages or any other remedy, or for an enjoinment, injunction or any other equitable remedy,
including any interference, re-examination, opposition or any similar proceeding, alleging that any claim in a Licensor Patent is invalid,
unenforceable or otherwise not patentable, except in the case where asserted as a defense or counterclaim to an action brought by Licensor
against Licensee or any of its Affiliates or Sublicensees (&ldquo;<B>Patent Challenge</B>&rdquo;), Licensor shall have the right to terminate
with immediate effect (i) this Agreement or, in its sole discretion, (ii) the license granted to Licensee or Sublicensee under such challenged
Licensor Patent, on a patent-by-patent basis, upon written notice to Licensee, and, as necessary, its Affiliates or Sublicensees; <I>provided</I>,
<I>however</I>, that Licensor shall have no right to terminate this Agreement if such Patent Challenge is brought by a Sublicensee of
Licensee and Licensee as soon as reasonably practicable terminates the applicable Sublicense or such Sublicensee terminates or otherwise
withdraws such Patent Challenge within [***] following notice of Licensee&rsquo;s intent to terminate such applicable Sublicense.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt"></P>

<!-- Field: Page; Sequence: 47; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">9.7.   <B>Effects
of Termination or Expiration</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(a)   <B>Accrued
Rights and Obligations</B>. Termination or expiration of this Agreement shall not release either Party from its obligations accrued prior
to the effective date of such termination or expiration nor deprive either Party from any rights that this Agreement has conferred on
such Party prior to such effective date. Such obligations and rights shall survive termination or expiration of this Agreement. Termination
of this Agreement by either Party shall be in addition to and not in lieu of any other remedies available to such Party, at law and in
equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(b)   <B>Surviving
Terms</B>. Notwithstanding anything in this Agreement to the contrary, the following provisions shall expressly survive any expiration
or termination of this Agreement in accordance with their terms: <U>ARTICLES 1</U> (Definitions), <U>6</U> (Confidentiality), <U>10</U>
(Dispute Resolution), <U>11</U> (Miscellaneous) and <U>Sections&nbsp;<FONT STYLE="font-size: 10pt">&lrm;</FONT>4.4</U> (Sales Milestone
Payments (to the extent sales milestone payment obligations are not fully fulfilled upon expiration of the Royalty Term)), <FONT STYLE="font-size: 10pt"><I>&lrm;</I></FONT>4.8
(Withholding Tax (to the extent sales milestone payment obligations are not fully fulfilled upon expiration of the Royalty Term)), <FONT STYLE="font-size: 10pt"><I>&lrm;</I></FONT>5.1
(Intellectual Property Ownership), <FONT STYLE="font-size: 10pt"><I><U>&lrm;</U></I></FONT><U>5.4</U> (Enforcement of Patent Rights (but
only in respect of Third Party Infringements and Actions arising during the Term and pending at the time of such expiration or termination),
<FONT STYLE="font-size: 10pt">&lrm;</FONT>7.5 (Disclaimer), <FONT STYLE="font-size: 10pt">&lrm;</FONT>7.6 (Limitation of Liability), <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>8.1</U>
(Indemnification by Licensor), <FONT STYLE="font-size: 10pt">&lrm;</FONT>8.2 (Indemnification by Licensee), <FONT STYLE="font-size: 10pt"><U>&lrm;</U></FONT><U>8.3</U>
(Procedure)<FONT STYLE="font-size: 10pt">&lrm;</FONT>9.5 (No Termination on Bankruptcy) and <FONT STYLE="font-size: 10pt"><I><U>&lrm;</U></I></FONT><U>9.7</U>
(Effects of Termination or Expiration).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(c)   <B>Consequences
of Termination by Licensee pursuant to <U>Section <FONT STYLE="font-size: 10pt"><I>&lrm;</I></FONT>9.2</U> or by Licensor pursuant
to <U>Sections <FONT STYLE="font-size: 10pt"><I>&lrm;</I></FONT>9.3</U> or <FONT STYLE="font-size: 10pt"><I><U>&lrm;</U></I></FONT><U>9.4</U></B>.
Upon any termination of this Agreement pursuant to <U>Section&nbsp;<FONT STYLE="font-size: 10pt"><I>&lrm;</I></FONT>9.2</U> or by Licensor
pursuant to <U>Section&nbsp;<FONT STYLE="font-size: 10pt"><I>&lrm;</I></FONT>9.3</U> or <U>Section&nbsp;<FONT STYLE="font-size: 10pt"><I>&lrm;</I></FONT>9.4</U>
in whole:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">(i)   all
licenses granted by Licensor to Licensee under <U>Section&nbsp;<FONT STYLE="font-size: 10pt">&lrm;</FONT>2.1</U> shall terminate;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">(ii)   Licensee
shall if Licensor at its sole discretion decides to take over and then-pending Clinical Trials being conducted by Licensee or any of its
Affiliates for any Licensed Products, upon written request by Licensor and subject to Licensor assuming legal responsibility for such
Clinical Trials, transfer to Licensor, at Licensor&rsquo;s cost and expense, except in the case of termination of this Agreement for material
breach by Licensee in which case Licensee shall bear the cost and expense, all regulatory documentation, regulatory dossiers and Regulatory
Approvals prepared or obtained by or on behalf of Licensee prior to the date of such termination, to the extent transferable. If Licensor
does not want to continue Clinical Trials, Licensee shall wind such Clinical Trials down in line with Applicable Laws and at Licensee&rsquo;s
sole cost and expense;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">(iii)   each
receiving Party shall return to the disclosing Party (or at the disclosing Party&rsquo;s request, destroy) all Confidential Information
of the disclosing Party then-in the possession and control of the receiving Party; <I>provided</I> that the receiving Party may retain
a copy of computer records or files containing such Confidential Information of the Disclosing Party that have been created pursuant to
automatic archiving or back-up procedures that cannot reasonably be deleted; <I>provided</I>, <I>however</I>, that such copy will be kept
confidential by the receiving Party in accordance with the terms and provisions of this Agreement for as long as the receiving Party is
in possession of such copy;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">(iv)   to
the extent permitted under Applicable Law, Licensee shall, at Licensor&rsquo;s option, transfer to Licensor, at cost except in the case
of termination of this Agreement for material breach by Licensee in which case Licensee shall transfer to Licensor free of charge, any
and all chemical, biological or physical materials exclusively relating to or comprising Licensed Products, including clinical supplies
of Licensed Products, that are then-owned or Controlled by Licensee;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 48; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">(v)   Licensee
or its Affiliates shall cease all Commercialization of Licensed Products in the Territory in a prompt manner and in accordance with Applicable
Laws; <I>provided</I>, however, that Licensee or its Affiliates shall be entitled, during the [***]&rsquo; period following the effective
date of such termination, to sell any commercial inventory of Licensed Products which remains on hand as of the effective date of the
termination, so long as Licensee pays to Licensor the royalties and, if applicable, sales milestones applicable to said subsequent sales
in accordance with the terms and conditions set forth in this Agreement. Any commercial inventory remaining following such [***]&rsquo;
period shall be offered for sale to Licensor, at a price equal to fully loaded cost of goods plus [***]% surcharge; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 1in; text-align: justify; text-indent: 0.5in">(vi)   Licensee
shall reasonably cooperate with Licensor and its designees to facilitate an orderly and prompt transition of the Development and Commercialization
activities with respect to the Licensed Products and shall provide all transition services reasonably requested by Licensor to the extent
necessary for this purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(d)   <B>Consequences
of Termination by Licensee pursuant to <U>Sections <FONT STYLE="font-size: 10pt"><I>&lrm;</I></FONT>9.4</U></B>. Upon any termination
of this Agreement by Licensee pursuant to <U>Sections&nbsp;<FONT STYLE="font-size: 10pt"><I>&lrm;</I></FONT>9.4</U>, Licensee or its Affiliates
shall be entitled to sell any commercial inventory of Licensed Products which remains on hand as of the date of the termination, so long
as Licensee pays to Licensor the royalties and, if applicable, sales milestones applicable to said subsequent sales in accordance with
the terms and conditions set forth in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(e)   <B>Consequences
of Termination in Part</B>. Upon any termination of this Agreement by Licensor pursuant to <U>Section&nbsp;<FONT STYLE="font-size: 10pt"><I>&lrm;</I></FONT>9.4</U>
not in whole, but in part with view to one or more Licensed Products or one or more countries of the Territory, <U>Section&nbsp;<FONT STYLE="font-size: 10pt"><I>&lrm;</I></FONT>9.7(c)</U>
shall apply accordingly, but solely with view to the terminated Licensed Product or, as the case may be, the terminated country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">ARTICLE
10 - DISPUTE RESOLUTION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-transform: uppercase; text-align: center; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">10.1.   <B>Disputes</B>.
The Parties recognize that disputes as to certain matters may from time to time arise during the Term which relate to either Party&rsquo;s
rights and/or obligations hereunder. It is the objective of the Parties to establish under this <U>ARTICLE 10</U> procedures to facilitate
the resolution of disputes arising under this Agreement in an expedient manner by mutual cooperation and without resort to litigation.
Any disputes shall be brought to the attention of the Alliance Managers for resolution. The Alliance Managers will endeavor to propose
and define mutually acceptable solutions and facilitate communications in an attempt to bring the dispute to a mutually agreeable resolution.
In the event that the Parties are unable to resolve such dispute through diligent review and deliberation by the Alliance Managers within
[***] from the day that one Party had designated the issue as a dispute in written notice to the other Party, then either Party shall
have the right to escalate such matter to the Senior Executives (as defined below) as set forth in <U>Section <FONT STYLE="font-size: 10pt"><I>&lrm;</I></FONT>10.2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt"></P>

<!-- Field: Page; Sequence: 49; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">10.2.   <B>Escalation
to Senior Executives</B>. Either Party may, by written notice to the other Party, request that a dispute that remains unresolved by the
Alliance Managers for the [***] period set forth in <U>Section <FONT STYLE="font-size: 10pt"><I>&lrm;</I></FONT>10.1</U> be resolved by
the Senior Executives, within [***] after referral of such dispute to them. The Senior Executive for Licensor shall be Licensor&rsquo;s
Senior Vice President of Global Business Development and for Licensee shall be Licensee&rsquo;s Chief Executive Officer (collectively,
the &ldquo;<B>Senior Executives</B>&rdquo;)<I>. </I>If the Senior Executives cannot resolve such dispute within [***] after referral of
such dispute to them, then, at any time after such [***] period, either Party may proceed to enforce any and all of its rights with respect
to such dispute in accordance with <U>Section <FONT STYLE="font-size: 10pt"><I>&lrm;</I></FONT>11.11</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">10.3.   <B>Injunctive
Relief</B>. No provision herein shall be construed as precluding a Party from bringing an action for (preliminary or permanent) injunctive
relief prior to the initiation or completion of the above procedure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">ARTICLE
11 - MISCELLANEOUS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-transform: uppercase; text-align: center; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">11.1.   <B>Relationship
of the Parties</B>. Each Party is an independent contractor under this Agreement. Nothing in this Agreement is intended or shall be deemed
to constitute a partnership, agency, joint venture or employer-employee relationship between the Parties. Neither Party shall have any
express or implied right or authority to assume or create any obligations on behalf of or in the name of the other Party or to bind the
other Party to any contract, agreement or undertaking with any Third Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">11.2.   <B>Performance
by Affiliates</B>. Each Party recognizes that the other Party may perform some or all of its obligations under this Agreement through
Affiliates; <I>provided</I>, <I>however</I>, that such other Party shall remain responsible for the performance by its Affiliates as if
such obligations were performed by such other Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">11.3.   <B>Alliance
Managers</B>. Each Party will appoint a representative of such Party to act as its Alliance Manager under this Agreement (the &ldquo;<B>Alliance
Manager</B>&rdquo;). The Alliance Managers will serve as the primary contact point between the Parties. Each Party may replace its Alliance
Manager at any time upon notice to the other Party. The initial Alliance Managers will be: [***], for Licensor and [***] for Licensee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">11.4.   <B>Assignment</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(a)   Except
as expressly provided herein, neither this Agreement nor any interest hereunder shall be assignable, nor any other obligation delegable,
by Licensee without the prior written consent of Licensor (not to be unreasonably withheld or delayed). Notwithstanding the foregoing,
Licensee may assign this Agreement in whole without the consent of Licensor to (i) any Affiliate or (ii) a successor to substantially
all of the business of Licensee to which this Agreement relates, in connection with any merger, sale of stock, sale of assets or other
similar transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(b)   Except
as expressly provided herein, neither this Agreement nor any interest hereunder shall be assignable, nor any other obligation delegable,
by Licensor without the prior written consent of Licensee (not to be unreasonably withheld or delayed). Notwithstanding the foregoing,
Licensor may assign this Agreement in whole without the consent of Licensee to (i)&nbsp;any Affiliate or (ii)&nbsp;a successor to all
of the Licensor Technology and Licensor&rsquo;s entire right, title and interest under the Initial License Agreement. Licensor shall not,
directly or indirectly, assign or otherwise transfer to any Third Party any of its right, title or interest in or to, or obligations under,
the Initial License Agreement or any Licensor Technology separate and apart from its rights, title and interests in or to, and obligations
under, this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 50; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(c)   No
assignment under this <U>Section&nbsp;<FONT STYLE="font-size: 10pt"><I>&lrm;</I></FONT>11.4</U> shall relieve the assigning Party of any
of its responsibilities or obligations hereunder and <I>provided</I>, <I>further</I>, that as a condition of such assignment, the assignee
shall agree to be bound by all obligations of the assigning Party hereunder. Any assignment in contravention of this <U>Section <FONT STYLE="font-size: 10pt"><I>&lrm;</I></FONT>11.4</U>
shall be null and void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(d)   This
Agreement shall be binding upon the successors and permitted assigns of the Parties. In the event that Licensor assigns, delegates or
otherwise transfers this Agreement, in whole or in part, to an Affiliate of Licensor, Licensor hereby agrees to be jointly and severally
liable with any such Affiliates for the actions of such Affiliates and for any and all amounts that become due and payable hereunder to
Licensee. In the event that Licensee assigns or otherwise transfers or assigns this Agreement to an Affiliate of Licensee, Licensee hereby
agrees to be jointly and severally liable with any such Affiliates for the actions of such Affiliates and for any and all amounts that
become due and payable hereunder to Licensor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(e)   Any
assignment not in accordance with this <U>Section&nbsp;<FONT STYLE="font-size: 10pt"><I>&lrm;</I></FONT>11.4</U> shall be void.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">11.5.   <B>Further
Actions</B>. Each Party agrees to execute, acknowledge and deliver such further instruments and to do all such other acts as may be necessary
or appropriate in order to carry out the purposes and intent of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">11.6.   <B>Accounting
Procedures</B>. Each Party shall calculate all amounts, and perform other accounting procedures required, under this Agreement and applicable
to it in accordance with Accounting Standards.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">11.7.   <B>Force
Majeure</B>. Neither Party shall be liable to the other for failure or delay in the performance of any of its obligations under this Agreement
for the time and to the extent such failure or delay is caused by acts of God, earthquake, riot, civil commotion, terrorism, war, strikes
or other labour disputes, fire, flood, pandemic or disease outbreaks (including with respect to COVID-19), failure or delay of transportation,
default by suppliers or unavailability of raw materials, governmental acts or restrictions or any other reason which is beyond the control
of the respective Party. The Party affected by force majeure shall provide the other Party with full particulars thereof as promptly as
reasonably practicable (including its best estimate of the likely extent and duration of the interference with its activities), and will
use Commercially Reasonable Efforts to overcome the difficulties created thereby and to resume performance of its obligations hereunder
as soon as reasonably practicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">11.8.   <B>No
Implied License; No Trademark Rights</B>. Except as expressly provided herein, no right or license is granted to Licensee hereunder by
implication, estoppel, or otherwise to any Know-How, Patent Right or other Intellectual Property right owned or Controlled by Licensor
or its Affiliates. No right, express or implied, is granted by this Agreement to a Party to use in any manner the name or any other trade
name or trademark of the other Party in connection with the performance of this Agreement or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">11.9.   <B>Entire
Agreement; Amendments</B>. This Agreement constitutes and contains the entire understanding and agreement of the Parties respecting the
subject matter hereof and cancels and supersedes any and all prior negotiations, correspondence, understandings and agreements between
the Parties, whether oral or written, regarding such subject matter. No waiver, modification or amendment of any provision of this Agreement
shall be valid or effective unless made in a writing referencing this Agreement and signed by a duly authorized officer of each Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt"></P>

<!-- Field: Page; Sequence: 51; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">11.10.   <B>Governing
Law</B>. This Agreement shall be governed by and interpreted in accordance with the laws of Switzerland, excluding the United Nations
Convention on Contracts for the International Sale of Goods (CISG) and the application of any conflict of laws principles that would require
application of the laws of a jurisdiction outside of Switzerland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">11.11.   <B>Arbitration</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(a)   Except
as expressly permitted in <U>Section <FONT STYLE="font-size: 10pt">&lrm;</FONT>11.11(f)</U>, if a dispute arises between the Parties in
connection with or relating to this Agreement (each, a &ldquo;<B>Dispute</B>&rdquo;) that the Parties are unable to resolve in accordance
with <U>ARTICLE 10</U> and that is not an Excluded Claim, and a Party wishes to pursue the Dispute, such Dispute shall be finally resolved
by binding arbitration administered in accordance with the Rules of Arbitration of the ICC then in effect (the &ldquo;<B>ICC Rules</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(b)   The
arbitration shall be conducted by a panel of three (3) neutral arbitrators, each of whom shall have significant legal or business experience
in the pharmaceutical industry, and none of whom shall be a current or former employee or director, or a current significant shareholder,
of either Party or any of their respective Affiliates or Sublicensees. Each Party shall select in the request for arbitration and in the
answer to the request, respectively, one (1) person to act as arbitrator and the two (2) Party-selected arbitrators shall select a third
(3<SUP>rd</SUP>) arbitrator, who will act as president of the arbitral tribunal, within thirty (30) days of their appointment. If the
arbitrators selected by the Parties are unable or fail to agree upon the third (3<SUP>rd</SUP>) arbitrator, the third (3<SUP>rd</SUP>)
arbitrator shall be appointed by the ICC. The place of arbitration shall be Zurich, Switzerland, and all proceedings and communications
shall be in English. The award rendered by the arbitral tribunal shall be final, binding and judgment may be entered upon it in any court
of competent jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(c)   Either
Party may apply to the arbitral tribunal for preliminary injunctive relief until the arbitration award is rendered or the controversy
is otherwise resolved. Each Party shall bear its own costs and expenses and attorneys&rsquo; fees and an equal share of the arbitrators&rsquo;
fees and any administrative fees of arbitration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(d)   Except
to the extent necessary to confirm or enforce an award or as may be required by Applicable Law, neither Party nor an arbitrator may disclose
the existence, content, or results of an arbitration without the prior written consent of the other Party or both Parties, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(e)   As
used in this <U>Section&nbsp;<FONT STYLE="font-size: 10pt">&lrm;</FONT>11.11</U>, the term &ldquo;<B>Excluded Claim</B>&rdquo; means a
dispute, controversy or claim that concerns (i)&nbsp;the construction, scope, validity, enforceability, inventorship or infringement,
misappropriation or other violation of any Intellectual Property; or (ii)&nbsp;any antitrust, anti-monopoly or competition law or regulation,
whether or not statutory.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">(f)   Nothing
contained in this Agreement shall deny either Party the right to seek preliminary injunctive relief from a court of competent jurisdiction
in the context of a <I>bona fide</I> emergency or prospective irreparable harm, and such an action may be filed and maintained notwithstanding
any ongoing discussions between the Parties or any ongoing arbitration proceeding. In addition, either Party may bring an action in any
court of competent jurisdiction to resolve disputes pertaining to any Excluded Claim and no such Excluded Claim shall be subject to arbitration.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 52; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 20.15pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 76.5pt">11.12.   <B>Notices
and Deliveries</B>. Any notice, request, approval or consent required or permitted to be given under this Agreement shall be in writing
and shall be deemed to have been sufficiently given if delivered in person, transmitted by facsimile (receipt verified) or by express
courier service (signature required) to the Party to which it is directed at its address or facsimile number shown below or such other
address or facsimile number as such Party shall have last given by notice to the other Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><U>If to Licensor,
addressed to</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">Merck Healthcare KGaA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">[***]</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">Attention:</TD><TD STYLE="padding-left: 0.25in; text-align: justify">Head of Alliance Management</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">With a copy, which shall
not constitute notice, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">Merck Healthcare KGaA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">Frankfurter Stra&szlig;e 250</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">64293 Darmstadt</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">Germany</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">Attention:</TD><TD STYLE="padding-left: 0.25in; text-align: justify">Healthcare Legal Department / LE-H</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">Facsimile:</TD><TD STYLE="padding-left: 0.25in; text-align: justify">[***]</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in"><U>If to Licensee,
addressed to</U>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">Unterm&uuml;li 7</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">Postfach 7444</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">6302 Zug</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">Schweiz/Switzerland</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">Attention:</TD><TD STYLE="padding-left: 0.25in; text-align: justify">Chief Operating Officer</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Any such notice shall
be deemed delivered on the date received.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">11.13.   <B>Language</B>.
This Agreement shall be written and executed in, and all other communications under or in connection with this Agreement shall be in,
the English language. Any translation into any other language shall not be an official version thereof, and in the event of any conflict
in interpretation between the English version and such translation, the English version shall control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">11.14.   <B>Waiver</B>.
A waiver by either Party of any of the terms and conditions of this Agreement in any instance shall not be deemed or construed to be a
waiver of such term or condition for the future, or of any other term or condition hereof. All rights, remedies, undertakings, obligations
and agreements contained in this Agreement shall be cumulative and none of them shall be in limitation of any other remedy, right, undertaking,
obligation or agreement of either Party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt"></P>

<!-- Field: Page; Sequence: 53; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">11.15.   <B>Severability</B>.
When possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under Applicable Laws,
but if any provision of this Agreement is held to be prohibited by or invalid under Applicable Laws, such provision will be ineffective
only to the extent of such prohibition or invalidity, without invalidating the remainder of this Agreement. The Parties shall make a good
faith effort to replace the invalid or unenforceable provision with a valid one which in its economic effect is most consistent with the
invalid or unenforceable provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">11.16.   <B>Counterparts</B>.
This Agreement may be executed in one or more counterparts, each of which will be deemed an original, and all of which together will be
deemed to be one and the same instrument. A facsimile or a portable document format (PDF) copy of this Agreement, including the signature
pages with signatures (in form of handwritten, non-certified electronic or certified electronic signatures), will be deemed an original.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">11.17.   <B>Remedies</B>.
Notwithstanding anything to the contrary herein, the Parties shall be entitled to seek any relief available under Applicable Law, including
(preliminary or permanent) injunctive relief and specific performance, as a remedy for any breach of this Agreement. Such remedies shall
not be deemed to be the exclusive remedies for a breach of this Agreement but shall be in addition to all other remedies available at
law. No remedy referred to in this Agreement is intended to be exclusive, but each shall be cumulative and in addition to any other remedy
referred to in this Agreement or otherwise available under Applicable Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 76.5pt">11.18.   <B>Headings;
Construction; Interpretation</B>. Headings used herein are for convenience only and shall not in any way affect the construction of or
be taken into consideration in interpreting this Agreement. The terms of this Agreement represent the results of negotiations between
the Parties and their representatives, each of which has been represented by counsel of its own choosing, and neither of which has acted
under duress or compulsion, whether legal, economic or otherwise. Accordingly, the terms of this Agreement shall be interpreted and construed
in accordance with the definitions for such terms provided herein or, if no such definitions are provided, with their usual and customary
meanings, and each of the Parties hereto hereby waives the application in connection with the interpretation and construction of this
Agreement of any rule of Applicable Laws to the effect that ambiguous or conflicting terms or provisions contained in this Agreement shall
be interpreted or construed against the Party whose attorney prepared the executed draft or any earlier draft of this Agreement. Any reference
in this Agreement to an Article, Section, subsection, paragraph, clause, Schedule or Exhibit shall be deemed to be a reference to any
Article, Section, subsection, paragraph, clause, Schedule or Exhibit, of or to, as the case may be, this Agreement. All Schedules and
Exhibits to this Agreement shall form an integral part of this Agreement. Except where the context otherwise requires, (a) any definition
of or reference to any agreement, instrument or other document refers to such agreement, instrument other document as from time to time
amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein
or therein), (b) any reference to any Applicable Laws refers to such Applicable Laws as from time to time enacted, repealed or amended,
(c) the words &ldquo;herein&rdquo;, &ldquo;hereof&rdquo; and &ldquo;hereunder&rdquo;, and words of similar import, refer to this Agreement
in its entirety and not to any particular provision hereof, (d) the words &ldquo;include&rdquo;, &ldquo;includes&rdquo; and &ldquo;including&rdquo;
shall be deemed to be followed by the phrase &ldquo;but not limited to&rdquo;, &ldquo;without limitation&rdquo; or words of similar import,
(e) the word &ldquo;or&rdquo; is used in the inclusive sense (and/or), unless otherwise indicated by the term &ldquo;either/or&rdquo;
and (f) the singular shall include the plural, the plural the singular, the use of any gender shall be applicable to all genders. Any
reference in this Agreement to &ldquo;royalty&rdquo; or &ldquo;royalties&rdquo; (whether used in capitalized letters or not) shall include
royalties and other recurring or deferred payments payable by a Party to the other Party for compensation or consideration of rights granted
hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>[Signature Pages follow]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>


<!-- Field: Page; Sequence: 54; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>,
the Parties hereto have caused this Agreement to be executed and delivered in duplicate by their duly authorized representatives with
legal and binding effect as of the date first above written.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>M<FONT STYLE="font-variant: small-caps">oonLake Immunotherapeutics A</FONT>G</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-variant: small-caps"><B>Merck
Healthcare KGaA</B></FONT>&nbsp;</P>

</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Arnout Ploos van Amstel</FONT></TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Arnout Ploos van Amstel MSc. Econ&nbsp;</P></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Operating Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Kristian Reich</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Kristian Reich MD, PhD</P></TD>
    <TD>&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Name:&nbsp;</P></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Scientific Officer</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">55</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>3
<FILENAME>ea156790ex10-10_helixacq.htm
<DESCRIPTION>SIDE LETTER TO LICENSE AGREEMENT, DATED APRIL 29, 2021, BY AND BETWEEN MOONLAKE IMMUNOTHERAPEUTICS AG AND MERCK HEALTHCARE KGAA
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit 10.10</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Certain personally identifiable information contained in this document,
marked by brackets as [***], has been omitted from this exhibit pursuant to Item 601(a)(6) under Regulation S-K.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">April 29, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Merck Healthcare KGaA Frankfurter Stra&szlig;e 250</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">64293 Darmstadt</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Germany</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Attention: Head of Alliance Management</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Merck Healthcare KGaA Frankfurter Stra&szlig;e 250</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">64293 Darmstadt Germany</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Attention: Healthcare Legal Department / LE-H</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">Re:</TD><TD STYLE="text-align: justify">Effect of Assignment of the License Agreement upon a Termination
of Initial License Agreement</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Dear Madams and Sirs:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">Reference is made to that certain License
Agreement by and between <B>MERCK Healthcare KGaA</B>, a corporation with general partners organized under German law, having a place
of business at Frankfurter Strasse 250, 64293 Darmstadt, Germany(&ldquo;<B>Licensor</B>&rdquo;), and <B>MoonLake Immunotherapeutics AG</B>,
a corporation organized under the laws of Switzerland, having a place of business at Unterm&uuml;li 7 / Postfach 7444, 6302 Zug, Switzerland
(&ldquo;<B>Licensee</B>&rdquo;) effective as of April 29, 2021 (the &ldquo;<B>License Agreement</B>&rdquo;), a copy of which is attached
hereto as <U>Exhibit A</U>.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">Pursuant
to the License Agreement, Licensor sublicenses to Licensee certain intellectual property licensed to Licensor by Ablynx N.V.,
Belgium (&ldquo;<B>Initial Licensor</B>&rdquo;) pursuant to that certain Agreement for Joint Discovery and Development by and
between Initial Licensor and Licensor, dated September 3, 2008 (such agreement, the &ldquo;<B>Initial License Agreement</B>&rdquo;).
Pursuant to <U>Section 37.25</U> of the Initial License Agreement, in the event of termination of the Initial License Agreement for
any reason, the License Agreement is automatically assigned to Initial Licensor. In the event of any such termination of the Initial
License Agreement and assignment of the License Agreement to the Initial Licensor, the Parties desire for Licensor to continue to be
bound by the terms of the License Agreement with respect to certain patents, materials and know-how owned or controlled by Licensor
and Licensor Affiliates.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">In consideration of the covenants
and conditions set forth herein, the Parties hereby agree as follows:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">1. <B>Definitions</B>
.. Capitalized terms used but not otherwise defined herein shall have the meanings set forth in the License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Execution Copy</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">2. <B>Effect
of Assignment of the License Agreement upon a Termination of Initial License Agreement</B>. The Parties hereby agree that in the event
the License Agreement is assigned or otherwise transferred by Licensor (or any of its successors-in- interest under the License Agreement)
to the Initial Licensor pursuant to <U>Section 37.25</U> of the Initial License Agreement, whether in whole or in part, and notwithstanding
any such assignment or transfer, Licensor hereby agrees that the license granted by Licensor to Licensee under the License Agreement shall
continue in full force and effect and Licensor shall be bound by any and all of Licensor&rsquo;s obligations and liabilities under the
License Agreement; <I>provided </I>that, with respect to obligations and liabilities relating to Intellectual Property rights, such obligations
and liabilities shall be limited to those Patent Rights, materials and Know-How that remain owned or Controlled by Licensor or any Licensor
Affiliate following the termination of the Initial License Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">3. <B>No
Changes </B>. The Parties acknowledge and agree that the terms and conditions of the License Agreement shall remain in full force and
effect to the full extent provided therein and shall not be limited, modified, altered, expanded or superseded by this letter agreement
except as set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.5in"></TD><TD STYLE="text-align: justify; width: 0.25in"><FONT STYLE="font-weight: normal">4.</FONT></TD><TD STYLE="text-align: justify">Assignment<FONT STYLE="font-weight: normal">.</FONT></TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in">(a) This
letter agreement shall not be assignable by either Party without the prior written consent of the other Party (not to be unreasonably
withheld or delayed). Following any such permissible assignment, this letter agreement shall be binding upon the successors and permitted
assigns of the Parties. Notwithstanding the foregoing, (i) Licensee may assign this letter agreement in whole without the consent of Licensor
to (A) any Affiliate or (B) a successor to substantially all of the business of Licensee to which this letter agreement relates, in connection
with any merger, sale of stock, sale of assets or other similar transaction or (ii) Licensor may assign this letter agreement in whole
without the consent of Licensee to (A) any Affiliate or (B) a successor to all (but not less than all) of the Licensor Technology. In
the event that either Party assigns or otherwise transfers the License Agreement in accordance with <U>Section 11.4</U> of the License
Agreement, such assigning Party shall assign all of its rights and obligations under this letter agreement to such assignee and such assignee
shall agree to be bound by all obligations of the assigning Party hereunder.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in">(b) The
Parties acknowledge and agree that this letter agreement runs with the Licensor Technology. In the event that Licensor or any of its Affiliates
sells, conveys, assigns or otherwise transfers to any other Person any Licensor Technology, Licensor shall cause the acquiring Person
to agree in writing to be bound by the terms and conditions of this letter agreement. Any sale, conveyance, assignment or transfer in
contravention of the foregoing shall be null and void <I>ab initio</I>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 72.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 72.1pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 72.1pt">&nbsp;</P>

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt">Execution Copy</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 72.1pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-weight: normal">5.</FONT></TD><TD>Miscellaneous<FONT STYLE="font-weight: normal">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in">(a) <B>Further
Actions</B>. Each Party agrees to execute, acknowledge and deliver such further instruments and to do all such other acts as may be necessary
or appropriate in order to carry out the purposes and intent of this letter agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 72.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in">(b) <B>Entire
Agreement; Amendment</B>. This letter agreement and the License Agreement constitute and contain the entire understanding and agreement
of the Parties respecting the subject matter hereof and cancel and supersede any and all prior negotiations, correspondence, understandings
and agreements between the Parties, whether oral or written, regarding such subject matter. No waiver, modification or amendment of any
provision of this letter agreement shall be valid or effective unless made in a writing referencing this letter agreement and signed by
a duly authorized officer of each Party.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in">(c) <B>Governing
Law; Jurisdiction</B>. This letter agreement shall be governed by and interpreted in accordance with the laws of Switzerland, excluding
the United Nations Convention on Contracts for the International Sale of Goods (CISG) and the application of any conflict of laws principles
that would require application of the laws of a jurisdiction outside of Switzerland. This letter agreement will be subject to the exclusive
jurisdiction of the courts of competent jurisdiction located in the City of Zug, Switzerland.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 72.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt; text-indent: 1in">(d) <B>General
Provisions.</B> The Parties hereby acknowledge and agree that <U>Sections 7.5</U> (<I>Disclaimer</I>), <U>7.6</U> (<I>Limitation of
Liability</I>), <U>11.1</U> (<I>Relationship of the Parties</I>), <U>11.11</U> (<I>Notices and Deliveries</I>), <U>11.12</U>
(<I>Language</I>), <U>11.13 </U>(<I>Waiver</I>), <U>11.14</U> (<I>Severability</I>), <U>11.15</U> (<I>Counterparts</I>), <U>11.16</U>
(<I>Equitable Relief</I>) and <U>11.17</U> (<I>Headings; Construction; Interpretation</I>) and <U>Articles 6</U>
(<I>Confidentiality</I>) and <U>10</U> (<I>Dispute Resolution</I>) of the License Agreement are incorporated herein by reference and
shall apply in full force and effect to this letter agreement <I>mutatis mutandis</I> as if contained in the body of this letter
agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">By signing where indicated below and returning it to
the undersigned, you acknowledge and agree to be bound by the terms and conditions of this letter agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>[Signature Pages Follow]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>MoonLake Immunotherapeutics AG</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Arnout Ploos van Amstel</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Arnout Ploos van Amstel MSc. Econ</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Operating Officer</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Kristian Reich</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Kristian Reich MD, PhD</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Scientific Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Acknowledged and agreed:</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>Merck Healthcare KGaA</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">4</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>4
<FILENAME>ea156790ex10-11_helixacq.htm
<DESCRIPTION>CONTRACT MANUFACTURING AGREEMENT, DATED OCTOBER 15, 2018, BY AND BETWEEN MOONLAKE IMMUNOTHERAPEUTICS AG, AS ASSIGNEE OF MERCK HEALTHCARE KGAA, AND RICHTER-HELM BIOLOGICS GMBH & CO
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.11</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><B>Certain confidential information contained in this document, marked
by brackets as [***], has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
In addition, certain personally identifiable information contained in this document, marked by brackets as [***], has been omitted from
this exhibit pursuant to Item 601(a)(6) under Regulation S-K.</B></P>

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CLINICAL AND COMMERCIAL MANUFACTURING AGREEMENT
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">dated October 15<SUP>th</SUP>, 2018</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">by and between</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Richter-Helm BioLogics GmbH &amp; Co. KG </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Merck KGaA</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TABLE OF CONTENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 90%; text-align: left; font-weight: bold"></TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 9%; text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; font-weight: bold"></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font-weight: bold"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article 1 DEFINITIONS</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">1</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article 2 MANUFACTURER&rsquo;S OBLIGATIONS</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">8</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article 3 INTELLECTUAL PROPERTY</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">11</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article 4 FORECASTS AND ORDERS</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">12</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article 5 DELIVERY OF PRODUCT</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">14</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article 6 PRICE</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">17</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article 7 INVOICES AND PAYMENT</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">20</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article 8 QUALITY ASSURANCE</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT>20</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article 9 DEFECTIVE PRODUCTS AND DEFECTIVE SERVICES</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">21</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article 10 PRODUCT LICENSES</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">24</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article 11 TRIAL AUTHORIZATION</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT>24</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article 12 CHANGES TO PRODUCT SPECIFICATIONS</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT>24</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article 13 QUALITY &amp; REGULATORY COMPLIANCE</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center">25</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article 14 OPERATIONAL MANAGEMENT; STEERING COMMITTEE</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">28</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article 15 PRODUCT COMPLAINTS AND ADVERSE EVENTS</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center">28</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article 16 CONFIDENTIALITY AND DATA PROTECTION</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">29</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article 17 WARRANTIES</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">30</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article 18 INDEMNITY</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">32</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article 19 TERM AND TERMINATION</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">33</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article 20 EFFECTS OF TERMINATION</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">35</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article 21 DISASTER RECOVERY AND BUSINESS CONTINUITY</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">36</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article 22 DISPUTE RESOLUTION</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">36</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Article 23 MISCELLANEOUS PROVISIONS</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">37</FONT></TD></TR>
  </TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">CLINICAL AND COMMERCIAL MANUFACTURING AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This CLINICAL AND COMMERCIAL MANUFACTURING AGREEMENT
(the &ldquo;Agreement&rdquo;) is made as of October 15<SUP>th</SUP>, 2018 (the &ldquo;<B>Effective Date</B>&rdquo;) by and between Richter
Helm Biologics GmbH &amp; Co. KG, a corporation organized under the laws of Germany having a place of business at [***] (&ldquo;Manufacturer&rdquo;),
and Merck KGaA, a corporation organized under the laws of Germany having a place of business at Frankfurter Stra&szlig;e 250, 64293 Darmstadt,
Germany (&ldquo;<B>Merck</B>&rdquo;). Manufacturer and Merck may be referred to herein as a &ldquo;<B>Party</B>&rdquo; or, collectively,
as &ldquo;<B>Parties</B>.&rdquo;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>RECITALS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">WHEREAS, Merck, its Affiliates
or a Merck&rsquo;s designated third party are engaged in the discovery, development, manufacture and sale of pharmaceuticals products
and intend to conduct clinical trials of the Products (as defined below);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">WHEREAS, in order to ensure
a continuous manufacturing and a reliable supply of the Product for the development of Merck&rsquo;s Anti IL-17 A/F Nanobody&reg;, an
investigational therapy for the potential treatment of inflammatory deseases, in a phase III study in plaque psoriasis, and to secure
enough manufacturing capacity after the potential launch of the Product Merck is interested in entering in an agreement with Manufacturer
for clinical and commercial manufacturing services;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">WHEREAS, Manufacturer has the
requisite infrastructure, licenses, permits and capabilities, including trained and experienced personnel and technical skills, to manufacture
and supply the Product (as defined below) to Merck for the aforesaid purposes and in accordance with this Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">NOW, THEREFORE, in consideration
of the mutual promises, covenants and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, and intending to be legally bound, the Parties hereby agree as follows:</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">Article
1<BR>
DEFINITIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Definitions contained in this
Agreement are applicable to the singular as well as the plural forms of such terms. Unless otherwise specifically provided herein, the
following terms shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">1.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Adverse Event</B>&rdquo; means any of: an &ldquo;adverse drug
experience,&rdquo; a &ldquo;life-threatening adverse drug experience,&rdquo; a &ldquo;serious adverse drug experience,&rdquo; or an &ldquo;unexpected
adverse drug experience,&rdquo; as those terms are defined at either 21 C.F.R. &sect; 312.32 or 21 C.F.R. &sect; 314.80 or other applicable
or other regulations and laws&rdquo;.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.2</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Affiliate</B>&rdquo; means a person or entity that Controls, is
Controlled by or is under common Control with a Party, but only for so long as such control exists. &ldquo;<B>Control</B>&rdquo; means
the ownership of more than fifty (50%) percent of the voting stock of any organization or the legal power to direct or cause the direction
of the general management of the organization as appropriate, and &ldquo;<B>Controlled</B>&rdquo; shall be construed accordingly.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.3</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Agreed Hourly Rate</B>&rdquo; means the hourly rate which has
been agreed between both Parties as per <B>Schedule 1</B>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">1.4</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Applicable Laws</B>&rdquo; means the applicable provisions of
constitutions, statutes, laws, rules, treaties, regulations, orders and decrees of all applicable Regulatory Authorities.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.5</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Batch</B>&rdquo; means a batch of the Product manufactured by
Manufacturer on a [***] litre scale under cGMP, in accordance with the Services Related Requirements of the Specifications and Quality
Agreement and using the Manufacturing Process.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.6</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Batch Documentation</B>&rdquo; means all documentation relating
to a Batch, including the executed Batch record and additional documents relating to the Batch such as the analytical testing records,
the release for the Materials, deviations, and all documents relating to a Batch that Manufacturer is required to maintain according to
cGMP, the Services Related Requirements of the Specifications, the Quality Agreement, the relevant Purchase Order or Work Order, and all
Applicable Laws.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.7</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Change of Control</B>&rdquo; means with respect to Manufacturer,
the consummation of any transaction (or series of related transactions) of the following events: (a) any Third Party (or group of Third
Parties acting in concert) becomes the beneficial owner, directly or indirectly, of more than fifty percent (50%) of the total voting
power of the stock or other ownership interests (as applicable) then outstanding of Manufacturer normally entitled to vote in elections
of directors or equivalent governing body, (b) Manufacturer consolidates with or merges into another entity, or any entity consolidates
with or merges into Manufacturer, in either event pursuant to a transaction in which more than fifty percent (50%) of the total voting
power of the stock or other ownership interests (as applicable) outstanding of the surviving entity normally entitled to vote in elections
of directors or equivalent governing body is not held by the parties holding at least fifty percent (50%) of the outstanding stock or
other ownership interests (as applicable) of Manufacturer immediately preceding such consolidation or merger, (c) any other arrangement
whereby a Third Party controls or has the right to control the board of directors or equivalent governing body that has the ability to
cause the direction of the management or policies of Manufacturer or (d) Manufacturer shall dissolve, transfer, sell, assign, mortgage,
encumber, pledge, or otherwise dispose of (i) all or substantially all of its assets, or (ii) any controlling interest in its business
(whether in the form of stock or otherwise) or the Manufacturing Site.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.8</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Commercial Manufacturing Services</B>&rdquo; means the tasks and
activities to be performed by Manufacturer hereunder, except for the Development Services, as further set out in the Agreement and in
the Purchase Orders, in case all conditions under Section 2.2 are met and satisfied, which shall include, (i) the manufacture of (Batches
of) the Product using the Manufacturing Process, (ii) all activities and services (be it under cGMP, research laboratory or non-cGMP conditions)
related thereto, such as, without limitation, performance of assays and other analytical work, quality control of the Product, storage
of the Product, and (iii), storage activities, and (iv) all further services and activities (be it under cGMP, research laboratory or
non-cGMP conditions) as may be mutually agreed in writing between the Parties from time to time; all as performed by the Manufacturer
011 behalf of Merck pursuant to the terms and conditions of this Agreement. For the avoidance of doubt, Manufacturing Services do not
include tasks and activities to be performed by Merck (such as sample analysis) and Manufacturer shall not be liable hereunder for any
failure of Merck in performing such tasks and activities.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.9</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Commercially Reasonable Efforts</B>&rdquo; means, with respect
to the efforts to be expended by either Party with respect to any objective, such reasonable, diligent, and good faith efforts as such
Party would normally use to accomplish a similar objective under similar circumstances as expeditiously as possible, which in no event
shall be less than the standard of care generally adhered to in the industry of such Party for the providing of such efforts. &ldquo;<B>Confidential
Information</B>&rdquo; means any and all information (in whatever form, tangible or intangible) relating to either Party&rsquo;s, their
Affiliates&rsquo; and/or their business partners&rsquo; business and/or technologies and/or any business, employee or customer information
or data which is disclosed, or otherwise comes into possession of the other Party, directly or indirectly as a result of this Agreement
and which is of a confidential nature (including, without limitation, any information relating to business affairs, operations, products,
processes, methodologies, formulae, plans, intentions, projections, know-how, Intellectual Property, trade secrets, market opportunities,
suppliers, customers, marketing activities, sales, software, computer and telecommunications systems, costs and prices, wage rates, records,
finances and personnel).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">1.10</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Confidentiality Agreement (CDA)</B>&rdquo; means the confidentiality
agreement entered into between the Parties effective as of [***].</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.11</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Current Good Manufacturing Practice</B>&rdquo; or &ldquo;<B>cGMP</B>&rdquo;
means the Current Good Manufacturing Practices officially published and interpreted by EMA, FDA and other applicable Regulatory Authorities
that may be in effect from time to time and are applicable to the Manufacture of the Product(s) in the Territory, as required:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 36pt"></TD><TD STYLE="text-align: justify; width: 36pt">(A)</TD><TD STYLE="text-align: justify">if the Manufacturing Site is within the European Union or if the Product(s) is/are to be supplied to a
country within the European Union, by the standards, rules, principles and guidelines set out in the provisions of Chapter II of EC Commission
Directive 2003/94/EC, together with Volume 4 of the Rules Governing Medicinal Products in the European Union entitled &ldquo;EU Guidelines
to Good Manufacturing Practice Medicinal Products for Human and Veterinary Use&rdquo;;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 36pt"></TD><TD STYLE="text-align: justify; width: 36pt">(B)</TD><TD STYLE="text-align: justify">if the Manufacturing Site is within the United States of America, or if the Product(s) is/are to be supplied
to the Unites States of America, by the provisions of 21 C.F.R., parts 210 and 211 and all applicable rules, regulations, orders and guidance
published by the FDA (as defined below);</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 36pt"></TD><TD STYLE="text-align: justify; width: 36pt">(C)</TD><TD STYLE="text-align: justify">if the Manufacturing Site is in, or if the Product(s) is/are to be supplied to, any other part of the
Territory, such standards as the Parties may agree in writing to reflect the requirements of Regulatory Authorities in the country of
manufacture or supply; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 36pt"></TD><TD STYLE="text-align: justify; width: 36pt">(D)</TD><TD STYLE="text-align: justify">such other requirements as agreed between the Parties and set out in the Quality Agreement, in each case,
as amended and updated from time to time.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.12</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Defect</B>&rdquo; means, in respect of a Product, a failure to
comply with the applicable Specification and/or to have been manufactured in accordance with cGMP, and &ldquo;<B>Defective</B>&rdquo;
shall be construed accordingly.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.13</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Defective Product</B>&rdquo; means a Product with a Defect.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.14</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Delivery Date</B>&rdquo; means the date agreed by Merck and Manufacturer
for the delivery of Products in a Work Order or in a Purchase Order according to ARTICLE 4.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.15</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Delivery Terms</B>&rdquo; means EXW [***] Incoterms 2010 or such
other terms as may be agreed in writing between the Parties and terms such as &ldquo;delivery&rdquo; and &ldquo;delivered&rdquo; shall
be construed accordingly. Accordingly, Merck shall be responsible for the transport of the Product and shall engage a carrier. However,
Manufacturer shall coordinate in advance with Merck&rsquo;s carrier each shipment of the Products.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">1.16</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Development Services</B>&rdquo; means all the tasks and activities
to be performed by Manufacturer pursuant to <B>Schedule 5</B> for the supply of the Product in the context of the phase III clinical trial
described in the recitals above including but not limited to the Technical Transfer, the manufacture and supply of Engineering Batche(s),
the GMP Batches (Phase III) and the PPQ Batches, as described in <B>Schedule 5</B>. In the event Merck reasonably requires further tasks
and activities for the manufacture of the Product to be used by Merck for development purposes in a phase III clinical trial and Manufacturer
is able to provide such further tasks and actives, Manufacturer shall upon request of Merck provide them against Merck&rsquo;s payment
of a reasonable additional price.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.17</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Engineering Batch</B>&rdquo; means a Batch that is produced to
test production equipment, to finalize process control strategy and/or to train operations staff and is not released by Manufacturer for
human use. Engineering Batches to test the production equipment will be produced at the Manufacturing Site. Engineering Batch will be
at the cause scale as [***].</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.18</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Executive Officers</B>&rdquo; means, together, a member of the
senior management of the pharmaceutical division of Merck /executive management board of the pharmaceutical division reporting to the
executive board of Merck and the Chief Executive Officer of Manufacturer.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.19</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Finished Medicinal Product</B>&rdquo; means any pharmaceutical
product(s) comprising the Product.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.20</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Force Majeure Event</B>&rdquo; means in relation to either Party,
any circumstances beyond the reasonable control (including the taking of reasonable precautions) of that Party (including without limitation
any acts or restraints of governments or public authorities, war, terrorism, revolution, riot or civil commotion disruption at suppliers,
fire, explosion, accident, flood, sabotage, lack of adequate fuel, power, Materials, transportation, labour dispute and/or general strike
of a national or industry-wide nature).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.21</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Governmental Authority</B>&rdquo; means any court, tribunal, arbitrator,
agency, legislative body, commission, official or other instrumentality of (i) any government of any country, (ii) a federal, state, province,
county, city or other political subdivision thereof or (iii) any supranational body, including any Regulatory Authority.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.22</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Hazardous Materials</B>&rdquo; means any material or substance
that, whether by its nature or use, is now or hereafter defined or regulated as a hazardous waste, hazardous substance, pollutant, or
contaminant under any Applicable Law relating to or addressing public and employee health and safety and protection of the environment,
or which is toxic, explosive, corrosive, flammable, radioactive, carcinogenic, mutagenic or otherwise hazardous or which is or contains
petroleum, gasoline, diesel, fuel, another petroleum hydrocarbon product, or polychlorinated biphenyls. Hazardous Materials specifically
include asbestos-containing materials (ACM), mold and lead-based paints.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.23</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Independent Expert</B>&rdquo; means a laboratory or expert mutually
agreed upon by the Parties who shall act as an expert in accordance with the ICC Rules for Expertise, and if no agreement can be reached
then the Parties will accept a laboratory or expert appointed by the International Chamber of Commerce of Switzerland according to the
ICC Rules for Expertise.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.24</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Intellectual Property</B>&rdquo; means patents, trademarks, service
marks, design rights (whether registerable or otherwise), including applications for any of the foregoing, copyright, all rights in know-how,
trade or business secrets and/or trade or business names and other rights or forms of protection of a similar nature or having equivalent
or similar effect to any of these which may subsist anywhere in the Territory whether registerable or not.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt"></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">1.25</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Latent Defect</B>&rdquo; means a Defect existing at the time of
delivery of the Product in question to Merck, but which could not reasonably be discovered by a visual inspection of its outer packaging
or any accompanying documentation.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.26</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Losses</B>&rdquo; means all losses, claims, liabilities, costs,
awards, fines, penalties, expenses (including reasonable attorney&rsquo;s fees, court fees and other reasonable professional expenses)
and damages of any nature whatsoever reasonably foreseeable and unavoidable, however, always excluding any loss of profit or anticipated
profit, loss of production, losses caused by business interruptions, loss of revenue and loss of goodwill or reputation.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.27</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Manufacturing License</B>&rdquo; means any consent, permit, authorization
or approval required for or in connection with the Manufacture of the Product at the Manufacturing Site(s)and the export/import of the
Product to Merck in accordance with the Delivery Terms, including any license required pursuant to Article 13.1 of the Directive 2001/20/EC,
Article&nbsp;61 of Regulation 536/2004, Article 40 of Directive 2001/83/EC and, as applicable, a current drug establishment registration
with the FDA (as defined below) as set forth in 21 C.F.R. &sect;207.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.28</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Manufacturing Process</B>&rdquo; means the anti IL-17 A/F Nanobody
manufacturing process proprietary to Merck and transferred to Manufacturer as set out in the master batch records of the Product.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.29</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Manufacturing Run</B>&rdquo; means a manufacturing run for the
Product on a [***] scale under cGMP, in accordance with the Services Related Requirements of the Specifications and Quality Agreement
and using the Manufacturing Process.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.30</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Manufacturing Site</B>&rdquo; means the manufacturing facility
located at [***] or such other manufacturing facility of Manufacturer as agreed to by the Parties pursuant to the change control procedures
set out in the Quality Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.31</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Materials</B>&rdquo; means the active ingredients, raw materials,
excipients, packaging materials and components used in the manufacture of the Products.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.32</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Price</B>&rdquo; means for Development Services the amounts set
out in <B>Schedule 1</B> and for Commercial Manufacturing Services, the price set out in Section 6.2.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.33</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Product License</B>&rdquo; means the product license, marketing
authorization or any other authorization(s) (as the case may be) required for the marketing, sale and/or distribution or clinical investigation
of Finished Medicinal Products by Merck in the jurisdictions in which the foregoing activities take place, or extension or renewal of
any of the foregoing.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.34</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Product(s)</B>&rdquo; means each of the products set out in the
Specifications as included in the Quality Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.35</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Qualified Person</B>&rdquo; means the person named in the Quality
Agreement (or any replacement notified in writing by Manufacturer, from time to time), who is suitably qualified to enable Manufacturer
to perform and discharge its quality management obligations as required by Current Good Manufacturing Practice or other Applicable Laws.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">1.36</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Quality Agreement</B>&rdquo; means the future document outlining
the Parties&rsquo; respective responsibilities on quality matters, as the same may be amended by written agreement between the Parties.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.37</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Quality Control Procedure</B>&rdquo; means the analytical testing
of a Batch according to written testing instruction including in-process-control testing and analytical testing of the Product.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.38</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Regulatory Authority</B>&rdquo; means any multinational, federal,
state, local, municipal or other Governmental Authority in the Territory having jurisdiction over any aspect of the activities contemplated
by this Agreement, including to the extent applicable, in the United States, the United States Food and Drug Administration (&ldquo;<B>FDA</B>&rdquo;),
and in the European Union, the European Medicines Agency.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.39</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Services</B>&rdquo; means Development Services and Commercial
Manufacturing Services.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.40</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Services Related Requirements</B>&rdquo; means all provisions
of the Specifications which describe or require a certain minimum conduct and/or level of performance of Manufacturer when performing
a Service as further described in this Agreement and the Quality Agreement as opposed to &ldquo;<B>Product Related Requirements</B>&rdquo;
which describe a certain measurable property of a deliverable (such as impurities allowed in the Product) resulting from Manufacturer&rsquo;s
performance of a Service.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.41</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Specifications</B>&rdquo; means with respect to each Product the
technical specifications for the required quality and characteristics of the Product agreed between the Parties in writing in the Quality
Agreement (as the same may be amended from time to time in accordance with this Agreement).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.42</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Steering Committee</B>&rdquo; means within thirty (30) days alter
the Effective Date, the Parties will establish a joint steering committee to oversee and manage the Parties activities under this Agreement.
The Steering Committee will continue to be in effect throughout the Term of the Agreement and will disband following termination of the
Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.43</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Territory</B>&rdquo; means as of the Effective Date any country
of the European Union and the United States of America. Merck shall be entitled to include further countries into the Territory including,
without limitation, China and Japan by written notice to Manufacturer provided (a) Manufacturer, acting reasonably, is able to fulfil
any additional regulatory or other requirements of any such further country, and (b) Merck agrees to bear all additional costs of Manufacturer
arising from the inclusion of any such further country.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.44</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Third Party</B>&rdquo; means any person or entity other than a
Merck or Manufacturer or their Affiliates or [***] or any other third party having signed an agreement with Merck in relation to the Trial.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.45</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Trial</B>&rdquo; means the Phase III clinical trial of the Product
conducted or sponsored by Merck or a Merck&rsquo;s designated third party described in the recitals above.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.46</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Trial Authorizations</B>&rdquo; means all regulatory and ethical
authorizations and approvals required for the lawful conduct of the Trial by Merck or by a Merck&rsquo;s designated third party.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.47</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Trial Subject</B>&rdquo; means an individual enrolled into the
Trial in accordance with the Protocol.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">1.48</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Work Order</B>&rdquo; means Merck&rsquo;s order for Manufacturing
Runs which are part of the Development Services.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt"></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">1.49</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Working Day</B>&rdquo; means a day other than Saturday or Sunday
or a day that is a public holiday in the jurisdiction in which the Manufacturing Site is located.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">1.50</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Other Terms</B>. The definition of each of the following terms is set
forth in the section of the Agreement indicated below:</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border: Black 1pt solid; width: 63%">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Defined Term</P></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 37%; text-align: left"><FONT STYLE="font-size: 10pt">Section</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>Acceptance</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>9.3</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>Average Yield</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>5.11</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>Background IP</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>3.1</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>BCP</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>21</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>Consequential damages</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>18.3</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>Designated Vendors</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>2.10(a)</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>Effective Date</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>Preamble</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>FDA</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>1.38</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>Firm Zone</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>4.2</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>Green Zone</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>4.2</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>Initial Term</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>19.1</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>KPIs</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>5.9</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>Manufacturer Background IP</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>3.1</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>Manufacturer Confidential Information</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>16.8</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>Manufacturing Problem</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>5.7</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>Manufacturing Problem Notice</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>5.8</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>Merck Arising IP</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>3.2</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>Merck Background IP</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>3.1</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>Non-Escalable Dispute</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>22.1</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>Payee</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>6.19</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>Payer</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>6.19</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>Payments</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>6.19</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>Product Event</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>15.1</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>Purchase Order</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>4.5</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>Punitive Damages</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>18.3</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>REACH</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>13.11</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>Renewal Term</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>19.1</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>Required Manufacturing Change</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>12.3</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>Rolling Forecast</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>4.1</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>Taxes</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>6.18</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>Technical Change</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>12.1</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>Term</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>19.1</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>Third Party Claims</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>18.1</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>Yearly Capacity Reservation</B></FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>2.6</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">Article
2<BR>
MANUFACTURER&rsquo;S OBLIGATIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">2.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Scope of the Agreement</B>. Manufacturer agrees to provide Merck with
both Development Services and Commercial Manufacturing Services including the manufacture and sale to Merck of Products ordered by Merck
in accordance with ARTICLE 4 in consideration of Merck paying the Price for the Services.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">2.2</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Notwithstanding the execution of this Agreement, the commencement of certain
Services described herein below is subject to and conditional an satisfaction or waiver by Merck of the following conditions:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 72pt"></TD><TD STYLE="text-align: justify; width: 36pt">i</TD><TD STYLE="text-align: justify">For the start and continuation of GMP manufacturing of at least [***] [***] Batches : (i) the Manufacturer
has transferred the process from Merck to his relevant site(s) without any major deviation from the agreed timelines under<B>Project Timelines</B>
and the Product Specifications, and (ii) the Parties have signed the Quality Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 72pt"></TD><TD STYLE="text-align: justify; width: 36pt">ii</TD><TD STYLE="text-align: justify">For the start of the manufacturing of at least [***] [***] Batches: the Manufacturer has successfully
supplied Merck with at least [***] [***] Batches without any major deviation from the Project Timelines and according to the Product Specifications</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 108pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 72pt"></TD><TD STYLE="text-align: justify; width: 36pt">iii</TD><TD STYLE="text-align: justify">For the start of the Commercial Manufacturing Services: (i) Manufacturer shall have successfully manufactured
and supplied to Merck at least [***] [***] Batches without any major deviation from the Project Timelines and according to the Product
Specifications, (ii) Merck Phase III Clinical Trials data package can support a successful BLA registration and (iii)&nbsp;Merck has decided
to go on with the commercial manufacturing of the Products.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">For the purpose of this Section 2.2 a
major deviation from the Project Timelines herein consists of a delay from such Project Timelines equal to or longer than [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">2.3</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">In case one of the conditions under Section 2.2 is not met, Merck shall
have the right to terminate the Agreement in accordance with Section 19.2.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">2.4</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>No General Terms and Conditions</B>. The supply of the Product shall
be exclusively governed by the terms and conditions of this Agreement. General terms and conditions of the Parties shall not apply even
if mentioned by routine in a Work Order or Purchase Order of Merck or in any of Manufacturer&rsquo;s order confirmations.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">2.5</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Project Timelines</B>. Manufacturer will provide Merck with the Services
within the Project Timelines indicated in <B>Schedule 5 </B>(&ldquo;<B>Project Timelines</B>&rdquo;). Table 1 of <B>Schedule 5 </B>indicates
some binding timelines to be complied with by Manufacturer and Table 2 of <B>Schedule 5 </B>indicates some indicative timelines, which
will be further discussed and agreed upon by the Parties. In case Manufacturer does not comply with a binding Project Timeline or does
not use Commercially Reasonable Efforts to comply with an agreed indicative timeline, Merck, without prejudice to Sections 9.8 and 9.9
as applicable, may either request the payment of a late performance penalty in accordance with Section 5.6 (where applicable) and/or terminate
this Agreement in accordance with ARTICLE 19.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">2.6</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Capacity Reservation of Products in the performance of Commercial Manufacturing
Services</B>. Following Manufacturer&rsquo;s letters to Merck dated [***] and [***] about capacity expansions (attached in <B>Schedule
7</B>), in view of performing the Commercial Manufacturing Services Manufacturer hereby commits on a yearly capacity reservation (&ldquo;<B>Yearly
Capacity Reservation</B>&rdquo;) as shown in the table below. Such reservation shall terminate automatically in case Merck does not place
Purchase Orders with the Manufacturer, observing the agreed lead time. Unless otherwise agreed, the Yearly Capacity Reservation from [***]
onwards shall be of [***] Manufacturing Runs. In case Manufacturer foresees that it will not be able to fulfil the below Yearly Capacity
Reservation, Manufacturer shall send to Merck a written notice at least [***] in advance. In this event, Manufacturer shall bear the technology
transfer costs of the transfer of the Manufacturing of the Products to another manufacturer.</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: #B2B2B2">
    <TD STYLE="border: Black 1pt solid; text-align: center; padding-top: 2.9pt; width: 32%; vertical-align: bottom">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Year</P></TD>
    <TD STYLE="border-top: Black 1pt solid; vertical-align: bottom; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 17%; text-align: center"><FONT STYLE="font-size: 10pt">2022</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; vertical-align: bottom; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 17%; text-align: center"><FONT STYLE="font-size: 10pt">2023</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; vertical-align: bottom; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 17%; text-align: center"><FONT STYLE="font-size: 10pt">2024</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; vertical-align: bottom; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 17%; text-align: center"><FONT STYLE="font-size: 10pt">2025</FONT></TD></TR>
  <TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; text-align: left"><FONT STYLE="font-size: 10pt">Yearly Capacity Reservation ([***])</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">[***]*</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">[***]*</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">[***]*</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt">[***]*</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">The specific number of reserved Manufacturing Runs at [***] scale will be defined according to the
                                                                                Rolling Forecasts provided by Merck.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt"></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">2.7</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Expansion of the Manufacturing Capacities</B>. In order to meet a potential
increase of Product demand by Merck from [***] Manufacturing Run in [***] to the [***] Manufacturing Runs from [***] onwards as shown
in the table under Section 2.6, Manufacturer undertakes to expand at its own cost its manufacturing capacity accordingly in [***]. In
the event Merck requires more than [***] and up to [***] Manufacturing Runs, Manufacturer shall set up a fully dedicated line for Merck.
In such case, Merck shall inform Manufacturer at least [***] in advance of its additional Product requirements to allow Manufacturer to
plan the investment and discuss necessary changes to this Agreement which may then include annual minimum order quantities in order to
ensure utilization of the dedicated line.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">2.8</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Restrictions on Competing Products</B>. During the Term, Manufacturer
shall not manufacture on its own or for any Third Party or engage in the performance of services for a product which competes with the
Product in the [***].</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">2.9</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Standards Applicable to the Manufacture of the Product</B>. Manufacturer
shall manufacture the Products at the Manufacturing Site in accordance with Current Good Manufacturing Practice, the Specifications, the
Manufacturing License, the Quality Agreement, Merck&rsquo;s Labelling and all Applicable Laws relevant to the Manufacture of the Products
and with personnel that are knowledgeable, qualified and trained to perform the activities required to Manufacture the Products in accordance
with the terms and conditions of this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">2.10</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Designated Vendors</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 36pt"></TD><TD STYLE="text-align: justify; width: 36pt">(a)</TD><TD STYLE="text-align: justify"><U>Approval of Designated Vendors</U>. If Merck elects, at its sole discretion, to require Manufacturer
to procure Materials from Third Parties designated and approved by Merck in writing (&ldquo;<B>Designated Vendors</B>&rdquo;) which are
not then under contract with Manufacturer, Merck shall so advise Manufacturer in writing, and Manufacturer shall establish supply arrangements
with such Designated Vendors (which supply arrangements shall comply with the terms of this Agreement, the Quality Agreement and any other
related agreements) and the terms and conditions of such supply shall be subject to the approval of Merck. If Merck elects that Materials
need to be purchased by vendors which are not qualified vendors of Manufacturer, Merck shall bear the cost for contracting, qualification
and auditing of those vendors. Manufacturer shall allow Merck to agree with Designated Vendors an indemnification of Merck and Manufacturer
by such Designated Vendors with respect to risks or liabilities created by such Designated Vendors, and include Merck as a Third Party
beneficiary of these provisions. Manufacturer has to qualify such Designated Vendors according to cGMP requirements and establish the
related contractual framework (including a Quality Agreement) also to support the terms of this Agreement and ancillary agreements hereto.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 36pt"></TD><TD STYLE="text-align: justify; width: 36pt">(b)</TD><TD STYLE="text-align: justify"><U>Notification</U>. Manufacturer shall immediately advise Merck if it encounters supply problems, including
delays and/or delivery of non-conforming Materials from Designated Vendors and (except to the extent Materials are provided by Merck)
Manufacturer shall use Commercially Reasonable Efforts to reduce and eliminate any supply problems from such Designated Vendors (and Merck
shall provide Manufacturer with reasonable assistance in connection therewith).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 36pt"></TD><TD STYLE="text-align: justify; width: 36pt">(c)</TD><TD STYLE="text-align: justify"><U>Audits and Assessment</U>. Manufacturer shall maintain an adequate system, which functions as a risk-based
assessment of Designated Vendors that provide Materials to ensure compliance with the terms of this Agreement and any ancillary agreements
hereto, cGMPs and Applicable Laws. Furthermore, Merck may, at its option, independently conduct audits or participate in Manufacturer
audits (including, but not limited to, quality, safety, social responsibility and environment) of such Designated Vendors, on a routine
or for-cause basis. As a result of such audits, if necessary, Merck shall have the right to direct Manufacturer to disqualify a Designated
Vendor as a source of Materials. Manufacturer shall use Commercially Reasonable Efforts to identify a new supplier as a source of Materials
and replace the disqualified supplier with such new supplier, pursuant to the provisions set forth in Section 2.10 (a) above at Merck&rsquo;s
expense.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">2.11</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Use of Affiliates and Subcontractors</B>. Manufacturer may not, without
the prior written consent of Merck, use Affiliates or Third Party sub-contractors to perform the Services. For any subcontract authorized
by Merck, Manufacturer shall ensure that the subcontractor complies with the obligations and restrictions applicable to Manufacturer under
this Agreement and shall further ensure that its subcontractor protects Merck&rsquo;s interests in Confidential Information, Merck Background
IP and Merck Arising IP. Manufacturer (a)&nbsp;shall manage the performance of the subcontractor at its sole cost and expense and (b)&nbsp;shall
remain responsible to Merck for all acts and omissions of any subcontractor and the performance of those subcontracted activities just
as though Manufacturer had performed them itself and for purposes of this Agreement such acts or omissions and the performance of those
subcontracted Services shall be deemed to be Manufacturer&rsquo;s. Manufacturer shall be Merck&rsquo;s sole point of contact regarding
the Services, including with respect to payment. Merck hereby agrees that the external [***] services will be provided by the service
providers listed in the Quality Agreement, being Manufacturer&rsquo;s sole subcontractor as of the Effective Date. For the avoidance of
doubt, the costs for any external [***] services are not included in the Price for the Product and will be passed on to Merck plus a [***]
handling fee.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">2.12</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Responsibility</B>. Unless otherwise specified herein or expressly consented
to in writing by Merck, as between the Parties, Manufacturer shall be solely responsible for performance of all Services necessary for
Merck to be supplied with Products as agreed hereunder including the ordering and purchasing all of the Materials to enable Manufacturer
to meet its manufacturing and delivery obligations under this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">2.13</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Safety Stock</B>. During the Term, Manufacturer shall maintain at all
times a safety stock of Materials (list of Materials to be agreed in writing between the Parties) sufficient to meet the Manufacturing
Runs set out in the Firm Zone, unless mutually agreed to in writing by Merck Manufacturer shall notify Merck immediately whenever the
inventories of Materials become insufficient to Manufacture enough Product to meet the Manufacturing Runs set out in the Firm Zone. Manufacturer
will pay the Materials. However, all Materials will then be invoiced by Manufacturer to Merck upon their receipt. Manufacturer shall send
to Merck an invoice with a copy of the invoice paid by Manufacturer for the Materials. Merck shall pay this invoice within [***] after
its receipt.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">2.14</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Development Services</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 36pt"></TD><TD STYLE="text-align: justify; width: 36pt">(a)</TD><TD STYLE="text-align: justify"><B>Performance</B>. Manufacturer shall perform the Development Services set out in <B>Schedule 5 </B>to
this Agreement pursuant to and consistent with the terms of this Agreement, any applicable Specifications and <B>Schedule 5, </B>all reasonable
written directions and instructions from Merck, generally accepted professional standards of care and all Applicable Laws of each country
where Development Services shall be conducted, including without limitation cGMPs. Manufacturer shall perform all Development Services
in a competent, professional and in a timely manner. Manufacturer shall perform all quality reviews, quality controls and process checks
necessary in their performance of Development Services and as outlined in <B>Schedule 5 </B>in accordance with the quality standards agreed
upon by Merck and Manufacturer in <B>Schedule 5 </B>and the Quality Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt"><B></B></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt">(b)</TD><TD STYLE="text-align: justify"><B>Purchaser Obligations</B>. Merck shall provide to Manufacturer (in a timely manner) such assistance,
information and co-operation as reasonably requested by Manufacturer in connection with the performance of the Development Services.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 36pt"></TD><TD STYLE="text-align: justify; width: 36pt">(c)</TD><TD STYLE="text-align: justify"><B>Change Orders</B>. Merck may, from time to time, submit to Manufacturer a request for changes to <B>Schedule
5</B>. Unless, in Manufacturer&rsquo;s reasonable judgment, Manufacturer can implement the requested changes without requiring additional
Manufacturer time or resources and without affecting Manufacturer&rsquo;s ability to maintain the Project Timeline, Manufacturer will
implement the change at Merck&rsquo;s expense. Manufacturer will provide Merck with a written change order proposal for the additional
work, including: (i) price change, (ii) impact an Project Timelines, and (iii) revised <B>Schedule 5</B>, including additional requirements
of Merck, if any. Merck may, at its discretion, accept or reject Manufacturer&rsquo;s change order proposal. Each Party will use Commercially
Reasonable Efforts to respond as expeditiously as possible to change order proposals.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 36pt"></TD><TD STYLE="text-align: justify; width: 36pt">(d)</TD><TD STYLE="text-align: justify"><B>Work Location</B>. Manufacturer shall perform the Development Services to be provided under this Agreement
at the location indicated in <B>Schedule 5</B>, or, if no such location is indicated, at the Manufacturing Site unless mutual agreement
to the contrary has been made and stipulated by the Parties.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 36pt"></TD><TD STYLE="text-align: justify; width: 36pt">(e)</TD><TD STYLE="text-align: justify"><B>Project Staffing</B>. Manufacturer shall perform the Development Services with highly qualified, trained
and educated personnel knowledgeable and trained as appropriate for a particular Development Service in cGMPs, applicable regulatory requirements,
fraudulent practices, project management, and pharmaceutical drug development and related services. Manufacturer is responsible for the
training of its staff in order to maintain their knowledge to the standards of the industry and to perform their obligations under this
Agreement and <B>Schedule 5</B>. All costs and expenses for such training will be fully paid by Manufacturer.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">Article
3<BR>
INTELLECTUAL PROPERTY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">3.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Background IP</B>. Each Party shall, at all times throughout and after
the Term, remain the owner of any and all Intellectual Property that it owned (or was licensed to use) by the effective date of the signed
CDA, and which Intellectual Property shall, for the purposes of this Agreement, be defined as &ldquo;<B>Background IP</B>&rdquo;. Manufacturer
acknowledges that Intellectual Property relating to the Products shall remain vested solely and exclusively in Merck or its relevant Affiliate.
Merck acknowledges that Intellectual Property relating to manufacturing processes, including testing and packaging, which are generally
used at the Manufacturing Site (to the extent existing prior to the Effective Date, or developed independently of this Agreement without
the use of Merck&rsquo;s Confidential Information), shall remain vested in Manufacturer or its relevant Affiliate. For the purposes of
this Section, Background IP vested in Merck (or its Affiliates) shall be defined as &ldquo;<B>Merck Background IP</B>&rdquo; and Background
IP vested in Manufacturer (or its Affiliates) shall be defined as &ldquo;<B>Manufacturer Background IP</B>&rdquo;.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">3.2</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Merck Arising IP</B>. Neither Manufacturer, its Affiliates, nor any of
their respective subcontractors shall acquire any rights of any kind whatsoever with respect to the Products by conducting Manufacturing
activities hereunder. All rights to any Intellectual Property (whether or not patentable) conceived (whether or not reduced to practice)
in the performance of work conducted under this Agreement by Manufacturer&rsquo;s or its Affiliates&rsquo; employees, or independent contractors,
either solely or jointly with employees, agents, consultants or other representatives of Merck exclusively or primarily relating to the
Products or the manufacturing, processing, testing, packaging, storing thereto, will be owned solely and exclusively by Merck (&ldquo;<B>Merck
Arising IP</B>&rdquo;).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">3.3</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Use of Intellectual Property</B>. Manufacturer will not use, or allow
others to use, any Merck Background IP or Merck Arising IP for any other purpose than the Manufacture of the Products for Merck. Merck
hereby grants Manufacturer and any Affiliates and subcontractors approved by Merck a non-exclusive and royalty free license for the Term
to use the Merck Background IP and Merck Arising IP to the extent necessary to Manufacture the Products under this Agreement. Manufacturer
hereby grants Merck and its Affiliates an irrevocable, worldwide, non-exclusive, and royalty free license to use the Manufacturer Background
IP to the extent necessary for Merck or its Affiliates to further manufacture, commercialize, distribute, market, export, sell and otherwise
exploit the Products.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">3.4</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Assistance</B>. Manufacturer shall fully cooperate in the preparation,
filing, prosecution and maintenance of all trademarks, copyrights, patents or other intellectual Property of any Merck Arising IP at Merck&rsquo;s
cost and expense. Such cooperation shall include execution of all papers and instruments appropriate so as to enable Merck to prepare,
file, prosecute and maintain such rights in any country.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">Article
4<BR>
FORECASTS AND ORDERS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">4.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Forecast</B>. Provided that all conditions under Section 2.2 have been
met, in view of the performance by Manufacturer of the Commercial Manufacturing Services Merck shall provide a rolling forecast for [***]
(the &ldquo;<B>Rolling Forecast</B>&rdquo; or &ldquo;<B>RF</B>&rdquo;). The RF shall be updated on a [***] basis and shall be delivered
by Merck to Manufacturer by [***] of each [***]. The minimum order size will be [***] Batches per campaign and the maximum order size
will be [***] Batches per [***], i.e. a Purchase Order for one (1) campaign consisting of [***] needs to be spread over [***].</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">4.2</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The first [***] of the RF (e.g. [***] to [***] of the following [***] in
a RF provided on [***]) shall be broken down on a [***] basis. The first [***] thereof shall be firm and cannot be changed (&ldquo;<B>Firm
Zone</B>&rdquo;). The [***] of the RF shall constitute a non-binding forecast (&ldquo;<B>Green Zone</B>&rdquo;), however, the first [***]
of the Green Zone may only be changed [***], i.e. the number of Manufacturing Runs forecasted for the first [***] of the Green Zone cannot
be [***] without prior agreement between the parties.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">4.3</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">On or before [***] after receipt of the RF by Manufacturer, Manufacturer
shall inform Merck in writing if it is able to fulfil such RF, whether related to the Firm Zone or Green Zone as depicted. If no notification
is received by Merck within that [***] period then the RF shall be deemed to have been accepted by Manufacturer, unless such RF exceeds
the Yearly Capacity Reservation. Upon agreement of a RF Manufacturer shall submit to Merck on or before [***] a plan for Product delivery
and tentative production schedule for the [***] of the RF. During the RF negotiations, the Parties shall also discuss any implications
with regard to the residual shelf life of Product to be delivered under such RF.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">4.4</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">In the event the Manufacturer cannot fulfil any part of a RF relating to
the Green Zone, then the Parties shall discuss and agree on quantities and delivery dates of Product which are mutually acceptable. Manufacturer
shall be obliged to supply Merck with commercial supply of the Product in accordance with the agreed upon RF.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">4.5</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Orders of Manufacturing Runs for commercial purposes - Purchase Orders</B>.
Provided that all the conditions precedents under Section 2.2 are met and the Commercial Manufacturing Services start, Merck shall throughout
the Term, order Manufacturing Runs by delivering purchase orders to Manufacturer (each such order being referred to as a &ldquo;<B>Purchase
Order</B>&rdquo;). Each Purchase Order shall, unless otherwise agreed between the Parties, specify the number of Manufacturing Runs ordered
and the required Delivery Date which shall be at least [***] after the date of receipt of the Purchase Order by Manufacturer. Unless otherwise
agreed, Merck&rsquo;s Purchase Order must allow for a Manufacturing in maximum [***] campaigns per calendar year.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">4.6</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Manufacturer&rsquo;s Response to Purchase Orders</B>. Purchase Orders
under Section 4.5 above shall be issued by Merck either electronically or by such other means, and to such location or contact person
or system, as Manufacturer shall specify in writing. Manufacturer shall respond to each such Purchase Order received from Merck within
[***] from receipt. Provided that (i) the number of Manufacturing Runs ordered by Merck does not exceed the number of Manufacturing Runs
forecasted for the respective [***] in accordance with Sections 4.1 and 4.2 above, (ii) the Purchase Order allows for a Manufacturing
in maximum [***] per [***], (iii) Merck complies with the above lead time of [***] under Section 4.5 and (iv) Merck&rsquo;s Purchase Order
otherwise complies with this Agreement, Manufacturer shall accept the Purchase Order and its response shall include confirmation of the
number of Manufacturing Runs and the Delivery Date. Deliveries confirmed by Manufacturer shall not occur later than [***] from the date
indicated in the relevant Purchase Order. A failure of Merck to issue a Purchase Order shall not affect Merck&rsquo;s obligations to purchase
the quantities set forth in the Firm Zone and, accordingly, in the event of any such failure, the missing Purchase Order shall be deemed
issued by Merck. For the avoidance of doubts, in the event Merck cancels a Purchase Order issued or deemed issued within the Firm Zone,
Merck shall pay [***] of the Price of each cancelled Purchase Order.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">4.7</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Orders of Manufacturing Runs during the development phase - Cancellation
of Work Orders</B>. In the context of the Development Services Merck shall order the Manufacturing Runs by issuing specific Work Orders
to Manufacturer. Each Work Order shall, unless otherwise agreed between the Parties, specify the number of Manufacturing Runs ordered
and the required Delivery Date reflecting the timeline under <B>Schedule 5</B>. Each Work Order shall be issued and sent to Manufacturer
at least [***] prior the Delivery Date of the Manufacturing Runs indicated in such Work Order except for the Work Order for the first
[***] Batch for which the Work Order shall be issued and sent to the Manufacturer at least [***] prior to Delivery Date. Provided that
Work Orders are in line with the number of Batches agreed under Section 2.2 (i) and (ii) the timelines set forth in <B>Schedule 5</B>,
Work Orders issued by Merck under this Section 4.7 at least [***] prior the Delivery Date of the Manufacturing Runs indicated in such
Work Order shall be accepted the Manufacturer within [***] from the receipt of the Work Order.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">4.8</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Merck may cancel a Work Order without any obligation or incurring any liability
to manufacture at the latest [***] prior to the Delivery Date. If notice of the cancellation or reduction is given by Merck less than
[***] prior to the Delivery Date, Merck shall be obliged to make the following payment to Manufacturer:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt">(a)</TD><TD STYLE="text-align: justify">If notice is given by Merck between [***] and [***] prior to the Delivery Date, Merck shall pay [***]
of the Price for each cancelled Manufacturing Run except if these can be used for further campaigns (if the shelf life allows it).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt">(b)</TD><TD STYLE="text-align: justify">If notice is given by Merck between [***] to [***] prior to the Delivery Date, Merck shall pay [***] of
the Price of each cancelled Manufacturing Run.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt">(c)</TD><TD STYLE="text-align: justify">If notice is given by Merck less than [***] prior to the Delivery Date, Merck shall pay [***] of the Price
for each cancelled Manufacturing Run.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">4.9</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Reallocation of Manufacturing Runs in case of cancellation of Purchase
Orders and Work Orders</B>. Manufacturer shall use Commercially Reasonable Efforts to re-allocate the manufacturing slot for any such
cancelled Manufacturing Run (whether set out in a Work Order or Purchase Order) to customers of Manufacturer for non GMP or GMP Batches,
and/or shall consider in good faith a proposal of an alternative project or use for the manufacturing slot by Merck and/or its Affiliates;
and if Manufacturer successfully re-allocates the manufacturing slot, Merck shall not be required to make any of the payments above but
only for Materials purchased for the cancelled Manufacturing Run which cannot be used for a later Manufacturing Run as well as for any
other non-cancellable costs of Manufacturer.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">4.10</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Addressees for Correspondence</B>. All Forecast Schedules, Purchase or
Work Orders, written confirmation of Purchase or Work Orders and other notices contemplated under this ARTICLE 4 shall be sent to the
attention of such Party as set forth in Section 23.10, or such persons as each Party may identify to the other in writing from time to
time.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">4.11</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Affiliates of Merck</B>. Affiliates of Merck may order Products directly
from Manufacturer. Manufacturer shall manufacture and supply to such Affiliates the ordered Products in accordance with the terms and
conditions of this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">Article
5<BR>
DELIVERY OF PRODUCT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">5.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Delivery</B>. Manufacturer shall provide Merck with authorized electronic
copies of the [***] records, the [***], the [***], and when applicable, the [***] at each time point and the invoice for each Manufacturing
Run in accordance with the Delivery Terms on the Delivery Date specified in the relevant Work Order or Purchase Order confirmed by Manufacturer
pursuant to ARTICLE 4 above. For the avoidance of doubt, punctual &ldquo;delivery&rdquo; in terms of this Agreement by Manufacturer does
not require the pick-up of the stored Product by Merck but shall occur upon Manufacturer providing the above mentioned documents to Merck.
As defined in Section 7.2, in case Manufacturer will store Product [***] at Merck&rsquo;s demand at Manufacturer&rsquo;s premises, payment
process will be triggered at the reception of the Batch Documentation.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">5.2</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Sample Analysis by Merck</B>. Delivery dates set out in a Work Order
or Purchase Order include [***] for the results (starting from samples arrival at the site in [***] designated by Merck for the performance
of the samples analysis) of the sample analysis performed by Merck in accordance with the Manufacturing Process. Any delay of Merck may
lead to a potentially much longer delay of the delivery of the respective Batch, in particular if Merck misses the slot reserved at Manufacturer
for the final review of the Batch Documentation. Manufacturer shall not be responsible for any delay caused by Merck failure to perform
sample analysis within [***]. Upon Merck&rsquo;s notice that sample analysis may be delayed by a certain number of days or weeks, Manufacturer
shall inform Merck whether and, if so, to what delay of the delivery of the respective Batch this will lead. If a slot for the final review
of the Batch Documentation at Manufacturer is missed due to Merck&rsquo;s delay, Manufacturer shall use the next free slot.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">5.3</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Title; Risk of Loss</B>. Risk and title in the Products shall remain
with Manufacturer until delivered in accordance with the Delivery Terms at which point it shall pass to Merck.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt"></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">5.4</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Accompanying Documentation</B>. With each shipment of Product, Manufacturer
shall provide Merck with the documentation set forth in the Quality Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">5.5</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Retention of Samples</B>. Provisions covering Manufacturer&rsquo;s obligation
to store and retain appropriate samples (identified by Batch number) of Products that it supplies to Merck and access by Merck to the
same are set forth in the Quality Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">5.6</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Late Delivery</B>. Without prejudice to the Merck&rsquo;s rights and
Manufacturer&rsquo;s obligations under this Agreement, in the event that the Manufacturer is unable to fulfil the Services, regardless
of whether such Services are Development Services or Commercial Manufacturing Services, within the timelines defined under this Agreement,
it shall notify Merck as soon as possible and the Parties will work together to agree a mutually acceptable resolution. If conforming
Product is not received by Merck within [***] from the Delivery Date, except where Manufacturer can reasonably demonstrate that the delay
is not due to its fault (e.g. unavailability of Materials), then Merck shall have the right to claim from Manufacturer payment of a late
performance penalty equal to [***] of the Price of such delayed Manufacturing Run per each calendar day beyond the above [***] grace period,
up to a total amount of [***] of the Price of such delayed Manufacturing Run in total. The foregoing amounts may be deducted by Merck
from any amounts invoiced to Merck. The rights and remedies contained in this Section 5.6 are non-exclusive and without prejudice to Merck&rsquo;s
right to terminate this Agreement pursuant to Section 19.8 or any other remedy under this Agreement, however, the above late delivery
penalty shall be deducted from any claim of Merck for damages arising from late delivery of a Batch by Manufacturer.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">5.7</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Manufacturing Problem</B>. In the event that Manufacturer or Merck becomes
aware of any matter, circumstance or event which (i) would reasonably be expected to give rise to a material delay in the shipment of
Product; (ii) reasonably indicate that the quality standards set forth herein and in the Quality Agreement have been materially compromised
or (iii) may reasonably give rise to a material breach hereunder or the right of Merck to terminate this Agreement under ARTICLE 19 (each
a &ldquo;<B>Manufacturing Problem</B>&rdquo;)<B>, </B>Manufacturer shall promptly give written notice to Merck of such Manufacturing Problem,
the cause thereof, the anticipated length of such Manufacturing Problem, and the action to be taken to reduce, minimize or remove the
adverse effects of any such Manufacturing Problem. Within [***] of receipt of the notice given pursuant to this ARTICLE 5, Merck and Manufacturer
shall meet with a view to agreeing to any actions necessary to ensure that no interruption to supply or shortfall in quantities of any
Product occurs. For purposes of clarity, a Manufacturing Problem which shall give rise to the remedies set forth in this ARTICLE 5 includes,
but is not limited to, (i) receipt by Manufacturer of a warning letter from a Regulatory Authority or a FDA Form 483 affecting a Product,
(ii) continuous errors or inadequacies in batch processing or documentation as determined by Merck in its sole discretion, (iii) circumstances
which could in the reasonable opinion of Merck likely lead to a warning letter from a Regulatory Authority and (iv) delivery of one or
more Batches which do not meet quality standards for the Product as set forth under this Agreement, the Quality Agreement, cGMPs, the
Specifications or Applicable Laws.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">5.8</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Manufacturing Problem Remediation</B>. In the event that Merck or the
Manufacturer becomes aware of a Manufacturing Problem, the knowledge Party shall give written notice to the other Party of such Manufacturing
Problem (the &ldquo;<B>Manufacturing Problem Notice</B>&rdquo;).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 36pt"></TD><TD STYLE="text-align: justify; width: 36pt">(a)</TD><TD STYLE="text-align: justify">In addition to the actions contemplated in the Quality Agreement, Merck shall have the right to physically
inspect such areas of the Manufacturing Sites that relate to the Manufacturing Problem and Manufacturer shall provide Merck with reasonable
access to all relevant equipment, process, records, appropriate quality system documents and personnel (wherever located) of Manufacturer
associated with the Manufacturing Problem.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt"></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt">(b)</TD><TD STYLE="text-align: justify">Within [***] of receipt of the Manufacturing Problem Notice, the Steering Committee shall meet with a
view to agreeing on remedial actions in good faith discussions.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 36pt"></TD><TD STYLE="text-align: justify; width: 36pt">(c)</TD><TD STYLE="text-align: justify">In the event that the Steering Committee cannot agree on remedial actions for the Manufacturing Problem
within [***] of receipt of the Manufacturing Problem Notice, each Party shall have the right to request that an independent expert examines
the root cause for the Manufacturing Problem and renders a respective expert opinion. As soon as possible, the Parties shall agree on
an appropriate independent expert to be engaged by Merck.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 36pt"></TD><TD STYLE="text-align: justify; width: 36pt">(d)</TD><TD STYLE="text-align: justify">The fees of the independent expert shall be paid by the Party against whom the independent expert&rsquo;s
decision is made.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 36pt"></TD><TD STYLE="text-align: justify; width: 36pt">(e)</TD><TD STYLE="text-align: justify">If the Parties or the independent expert (as the case may be) acknowledges that the Manufacturing Problem
cannot be cured within a period of [***] following the Manufacturing Problem Notice and results in a supply shortage in the Territory,
Merck shall have the right to initiate the technology transfer with regard to the Product(s) affected by the Manufacturing Problem and
this Agreement shall terminate upon successful completion of the technology transfer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 36pt"></TD><TD STYLE="text-align: justify; width: 36pt">(f)</TD><TD STYLE="text-align: justify">Any and all reasonable costs in fulfilling the technology transfer contemplated by this Section 5.8 shall
be borne by Manufacturer except where Manufacturer can reasonably demonstrate that the Manufacturing Problem is not due to its fault (e.g.
unavailability of Materials or equipment). Nothing contained in this Section 5.8 shall limit any rights or remedies that may be available
to Merck on account of any failure of Manufacturer to supply the Product hereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">5.9</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Key Performance Indicators</B>. The Parties agree to measure Manufacturer&rsquo;s
performance of its Development (when applicable) &amp; Commercial Manufacturing Services through the establishment of Key Performance
Indicators (&ldquo;<B>KPIs</B>&rdquo;). As long as Manufacturer only delivers up to [***] commercial Batches per year, Manufacturer shall
provide Merck with [***] reports out of its performance based on the KPIs. From [***] Batches per year, the reports should occur [***].
The Parties are currently negotiating these KPIs which will be integrated to this Agreement by way of written amendment signed by both
Parties. If the Parties do not manage to agree on reasonable KPIs within six (6) months from the Effective Date, either Party shall have
the right to terminate this Agreement with immediate effect upon written notice sent in accordance with Section 23.10 to the other Party.
The Parties may agree on additional KPIs by means of further amendments to this Agreement. The Parties shall agree upon the relative importance
of the KPIs by classifying each KPI with a designation of &ldquo;[***]&rdquo;, &ldquo;[***]&rdquo; or &ldquo;[***]&rdquo;. The Parties
shall agree in good faith by [***] of each [***], (beginning with the [***] of the Agreement), the performance level objectives of Manufacturer
for the following [***]. The performance level objectives shall be established for individual KPIs and for overall performance and on
the basis of actual, past performance, and shall be expressed in measurable values. In addition, minimum acceptance levels shall be agreed
upon for all critical KPIs and for overall performance. Manufacturer shall use all Commercially Reasonable Efforts to ensure that its
performance does not fall below these minimum acceptance levels. Notwithstanding Manufacturer&rsquo;s use of all Commercially Reasonable
Efforts, if at any time Manufacturer&rsquo;s overall performance or performance for critical KPIs falls below the established minimum
acceptance levels, Manufacturer shall promptly take corrective action to cure such under-performance.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">5.10</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Process Improvements and Sharing of Costs Efficiencies</B>. Manufacturer
shall monitor potential cost and quality improvements, including by seeking productivity improvements, by minimizing waste and improving
yields, by purchasing quality materials at lower cost, by improving manufacturing processes, by streamlining organizational processes
and by reducing cycle times and lead times. [***] per [***] during the Term, the Parties shall meet to discuss potential improvements
identified by Manufacturer. Merck shall decide whether or not to implement at Merck&rsquo;s costs necessary changes to achieve the potential
improvements. The Parties shall share [***] of any cost savings so achieved.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 36pt">5.11</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Average Yield</B>. After the Manufacture of the first [***] successful
Manufacturing Runs for validation and commercial purposes, the Parties shall calculate the average yield (&ldquo;<B>Average Yield</B>&rdquo;)
of such [***] Manufacturing Runs, disregarding [***]. As from the [***] Manufacturing Run, the price per Manufacturing Run set out in
Section 6.2 below shall be adjusted as follows: if the average yield of all Manufacturing Runs in a campaign is more than [***] higher
or lower than the Average Yield, the price for all Manufacturing Runs of such campaign shall be increased or reduced by applying a surcharge
or discount, as the case may be, of [***] the percentage points beyond such [***] range, e.g. if the average yield of all Manufacturing
Runs of a campaign is [***] below the Average Yield, a discount of [***] shall apply for Manufacturing Runs of such campaign. For the
avoidance of doubt, in case the investigation of the low yield shows a technical failure due to Manufacturer&rsquo;s fault, then the price
for all Manufacturing Runs of such campaign will be reduced by the difference below the [***], i.e, if the average yield of all Manufacturing
Runs of such campaign is [***] below the Average Yield, a discount of [***] shall apply for all Manufacturing Runs of such campaign. Price
[***] will be discussed and implemented once sufficient data are available.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-transform: uppercase; text-align: center">Article
6<BR>
PRICE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">6.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Development Services</B>. In consideration of the performance by Manufacturer
of the Development Services, Merck shall pay Manufacturer the amounts specified in <B>Schedule&nbsp;1</B>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">6.2</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Manufacturing Runs for commercial purposes</B>. In consideration of each
Manufacturing Run, Merck agrees to pay to Manufacturer, in addition to the further costs and charges as set out in this Agreement, an
amount of</FONT></TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 30pt">&nbsp;</TD>
    <TD STYLE="width: 36pt; padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">for each of the first [***] Manufacturing Runs in a [***] (based on the agreed Delivery Date),</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">for each of the [***] to [***] Manufacturing Runs in a [***] (based on the agreed Delivery Date),</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">for each of the following [***] to [***] Manufacturing Runs in a [***] (based on the agreed Delivery Date), and</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: justify"><FONT STYLE="font-size: 10pt">for each further Manufacturing Run in a [***] (based on the agreed Delivery Date),</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">All the above mentioned prices include
production costs, Batch Documentation and IPC testings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">6.3</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Raw Materials and Consumables</B>. Costs of Materials and consumables
to be used by the Manufacturer in the performance of the Services are not included in the fees under Sections 6.1 and 6.2 and shall be
passed on to Merck at cost plus [***] handling fee. Costs of [***] shall be passed on to Merck at a cost plus [***]. Merck is aware that
the consumption and prices of Materials and consumables vary from Manufacturing Run to Manufacturing Run. If an increase of total costs
of Materials or consumables by more than [***] occurs, Manufacturer will give Merck sufficient and detailed information about the increase
in costs for such Materials or consumables to reasonably demonstrate that the increase of the costs is justified. Upon request of Merck,
Manufacturer will share the specific supplier invoices of such Materials or consumables.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt"></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">6.4</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Packing and Qualification of Columns</B>. Manufacturer shall be entitled
to charge for the packing and qualification of each column a lump-sum amount of [***]. Costs for spare parts for the columns are not included
and shall be passed on to Merck at cost plus a [***] handling fee.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">6.5</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Filling of Stability Samples</B>. Manufacturer shall be entitled to invoice
for the filling of stability samples required for the performance and testing of stability studies performed at Merck an amount [***]
for up to [***] bags. The costs for external testing ([***]) and transport of analytical samples and stability samples are not included
and shall be passed on to Merck at cost plus [***] handling fee.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">6.6</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Annual Product Review</B>. Manufacturer shall be entitled to charge for
the annual product review an amount [***] per review.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">6.7</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Project Management</B>. Manufacturer shall be entitled to charge for
overall project management services [***] per [***].</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">6.8</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Regulatory Support</B>. Manufacturer shall be entitled to charge for
regulatory support as set out in Section 13.9.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">6.9</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>External Analytical Testing</B>. Costs of external analytical testing
for [***], [***] and [***] are not included and shall be passed on to Merck at cost plus a [***] handling fee.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">6.10</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Transport of the Samples</B>. In the event Manufacturer organizes the
transport of the samples to Merck or any third party including Manufacturer&rsquo;s subcontractors, transport costs shall be passed on
to Merck at cost. Manufacturer shall bear the risk of loss during the transport of samples to/from its subcontractors. Merck shall bear
the risk of loss during any other transport of samples starting from the moment Manufacturer hands over a sample to the courier service,
including but not limited to the transport from Manufacturer to Merck.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">6.11</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Storage of Columns</B>. Manufacturer shall be entitled to charge Merck
for storage for columns that are not used during [***] consecutive [***] [***] per [***] per column for each [***] following the [***]
period.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">6.12</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Potential Extra Costs</B>. In addition to the above, Manufacturer shall
be entitled to charge Merck costs and expenses of (i) changes to documentation, e.g. due to a request of a Regulatory Authority, (ii)
the potential requirement of an [***] before production of the Drug Substance, (iii) reporting in the context of the continuous process
verification (iv) concurrent lifetime and hold time studies (reports) for [***], and (v) any stability study.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">6.13</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Costs of Process-Dedicated Equipment</B>. Where the performance of the
Services requires Manufacturer to purchase any process-dedicated equipment (such as [***]) and when Merck consents in writing to it in
advance, such consent not to unreasonably withheld, delayed or conditioned, Manufacturer shall be responsible for purchasing such process-dedicated
equipment, for the implementation of such process-dedicated equipment at its facilities as required for the purposes of the Services,
and for qualifying and maintaining such process-dedicated equipment. Manufacturer shall only purchase such process-dedicated equipment
upon prior approval by Merck, for which Manufacturer shall provide Merck with a quotation from its supplier. Merck shall be responsible
for any delay in the performance of the Services caused by a failure on the part of Merck to approve the purchase of such process-dedicated
equipment within a reasonable time from being requested to do so by Manufacturer. Manufacturer shall also include the costs of such process-dedicated
equipment as a separate item plus a [***] handling fee in its invoices for the Services. It is understood and agreed that, upon Merck
paying the invoice that itemizes such process-dedicated equipment, Merck shall become the owner of such process-dedicated equipment, but
shall allow Manufacturer to use such process-dedicated equipment for the purposes of the Services. Any process-dedicated equipment shall
be used only for the purposes of the Services, and shall promptly be returned to Merck upon termination of this Agreement for any reason.
Notwithstanding the above, Manufacturer shall purchase the first set of [***] at its own expense. In the event Merck does not order any
commercial Batches under this Agreement, Manufacturer shall be entitled to invoice to Merck such first set of [***] at [***].</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">6.14</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Storage</B>. Manufacturer shall be entitled to charge Merck for the storage
of Products in accordance with the Storage Agreement, however, only alter the first [***] of storage of Products.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">6.15</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Travelling Costs</B>. Merck shall reimburse travelling expenses as may
be reasonably incurred by Manufacturer in the course of the direct performance of the Services provided that (i) such expenses have been
previously agreed upon in writing by Merck; (ii) such expenses will be based on 2nd class/economy class travel for all travels within
Europe, unless agreed to otherwise in advance and in writing by Merck (with expenses for travel outside Europe to be agreed in advance
and in writing); and (iii) that the reimbursement requests are accompanied with appropriate supporting evidence of such expenses.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">6.16</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Agreed Hourly Rate</B>. The initial Agreed Hourly Rate shall be [***].
The hourly rate for formal validation support shall be [***].</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">6.17</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Indexation</B>. Except for pass-through costs, all amounts payable to
Manufacturer under this Agreement as well as the Agreed Hourly Rate shall be revised upwards or downwards each year in accordance with
the increase or decrease, as the case may be, of the harmonized German consumer price index published by the German Federal Statistical
Office (<I>Statistisches Bundesamt</I>) on their official website (https://www.destatis.de) from January of the previous year to January
of the then current year and invoices from Manufacturer to Merck from April onwards shall take such increase or decrease into account,
e.g., if such index increases by zero point nine percent (0.9%) between January 2018 and January 2019, all amounts payable to Manufacturer
which are invoiced on or after 1 April 2019 shall also increase by zero point nine percent (0.9%). However, just yearly increase or decrease
cannot exceed [***] For the avoidance of doubt, the value of such index in December 2017 was 110.6 (on basis 2010 = 100). Manufacturer
shall not be entitled to delay an invoice in order to charge the new increased amount instead of the applicable old amount. This clause
shall apply for the first time as per [***], taking into account change of the German consumer price index from [***] to [***] and thereafter
on a yearly basis.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">6.18</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Taxes</B>. All payments under the Agreement are deemed exclusive of VAT
or any other indirect taxes; The invoicing Party shall, if required under applicable laws &amp; regulations, add VAT or any other indirect
taxes to the Price at the prevailing rate under applicable laws &amp; regulations; the invoicing Party shall also fulfill all material
and formal conditions required from the invoicing Party under applicable laws &amp; regulations to ensure a refund of the VAT or any other
indirect taxes charged to the invoiced Party provided a refund is available to the invoiced Party under applicable laws &amp; regulations.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">6.19</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Tax Withholding</B>. The amounts payable by one Party (the &ldquo;<B>Payer</B>&rdquo;)
to another Party (the &ldquo;<B>Payee</B>&rdquo;) pursuant to this Agreement (&ldquo;<B>Payments</B>&rdquo;) shall not be reduced on account
of any Taxes unless required by law. The Payee alone shall be responsible for paying any and all Taxes (other than withholding Taxes required
to be paid by the Payer) levied on account of, or measured in whole or in part by reference to, any Payments it receives. The Payer shall
deduct or withhold from the Payments any Taxes that it is required by law to deduct or withhold. Notwithstanding the foregoing, if the
Payee is entitled under any applicable Tax treaty to a reduction of rate of, or the elimination of, or recovery of, applicable withholding
Tax, it shall promptly deliver to the Payer or the appropriate Governmental Authority (with the assistance of the Payer to the extent
that this is reasonably required and is expressly requested in writing) the prescribed forms necessary to reduce the applicable rate of
withholding or to relieve the Payer of its obligation to withhold Tax, and the Payer shall apply the reduced rate of withholding, or dispense
with the withholding, as the case may be. If, in accordance with the foregoing, the Payer withholds any amount, it shall make timely payment
to the proper Governmental Authority of the withheld amount, and send to the Payee reasonable proof of such payment within sixty (60)
days following that payment. If Taxes are paid to a tax authority, each Party will provide the other such assistance as is reasonably
required to obtain a refund of Taxes withheld, or obtain a credit with respect to Taxes paid.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">Article
7<BR>
INVOICES AND PAYMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">7.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Invoices</B>. Manufacturer shall invoice Merck in accordance with ARTICLE
6. Each invoice shall specify the Price in respect of the Products delivered, the quantity of Batches of the Products delivered and the
amount of sales, use, value added, excise or equivalent indirect tax due in respect of the Products delivered and the Purchase Order reference
number. Manufacturer&rsquo;s invoices shall comply with all Applicable Laws.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">7.2</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Payment of Invoices</B>. Merck shall pay the invoices issued by Manufacturer
in Euro within [***] from the date of receipt of the invoice by electronic transfer to the account nominated in writing by Manufacturer,
except in case of any Product rejected in accordance with ARTICLE 9. In case of rejection, the term of payment will start once the delivery
is accepted by Merck. In case Manufacturer will store Product free of charge at Merck&rsquo;s demand at Manufacturer&rsquo;s premises,
payment process will be triggered at reception of the Batch Documentation.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">Article
8<BR>
QUALITY ASSURANCE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">8.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Validation Studies</B>. Manufacturer shall perform validation studies
as agreed between the Parties in writing, or to the extent required by the Specifications, cGMP or Applicable Laws to manufacture the
Products at the Manufacturing Site.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">8.2</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Analytical Reference Standards</B>. Merck shall provide, without charge
to Manufacturer, analytical reference standards for the Products. The reference standards shall be provided in quantities reasonably required
for Manufacturer to perform its obligations relating to the manufacture, stability testing or any other testing of the Products under
this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">8.3</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Technical and Quality Matters</B>. The respective responsibilities of
each Party in relation to technical and quality matters connected to the performance of the Services are further set out in the Quality
Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">8.4</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Release Testing</B>. Prior to release of the Products to finished goods
inventory, Manufacturer shall test the Products in accordance with the testing procedures for bioburden (external lab), content by[***]
described in the Specifications. All other release testing procedures will be performed by Merck.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">8.5</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Man-in-Plant</B>. Manufacturer agrees that, at Merck&rsquo;s option,
Merck representatives may be present at the Manufacturing Site (including adequate temporary desk space and other reasonable resources
available to these representatives during the periods they are at the Manufacturing Site) during the performance of certain Services and
manufacturing of Product(s) for the purposes of inspecting, sampling, check weighing, and documenting the manufacturing of the Product(s)
and all associated records in connection therewith. Any Merck employees who are present at the Manufacturing Site shall comply with Manufacturer&rsquo;s
site regulations and rules. The Merck representative, if present, does not have responsibility for the supervision of Manufacturer&rsquo;s
personnel or the manufacturing of the Product(s). However, if at any time the Merck representative thinks that Manufacturer is operating
in a manner not compliant with the know-how or which could adversely affect the manufacturing of Product(s), he/she may recommend that
Manufacturer cease operations until such condition is remedied.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">Article
9<BR>
DEFECTIVE PRODUCTS AND DEFECTIVE SERVICES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">9.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Warranty</B>. Subject to Section 18.3, Manufacturer warrants to Merck
that at the time of delivery of any Batch of the Product: (i) as far as Services performed by Manufacturer, its Affiliates and/or subcontractors
are concerned, the Batch will have been manufactured in accordance with the relevant conditions applicable hereunder as specified in the
relevant Work Order or Purchase Order; (ii) each Batch will only be released by Manufacturer if it has passed the Quality Control Procedure
conducted by Manufacturer and Merck whereby Manufacturer may, in the process of its Quality Control Procedure, unconditionally rely on
all data provided by Merck; (iii) as far as Services performed by Manufacturer, its Affiliates and/or subcontractors are concerned the
Batch will be manufactured using and in accordance with the Manufacturing Process and in accordance with cGMP, the Services Related Requirements
of the Specifications, the provisions of the Quality Agreement and Applicable Laws. Further, Manufacturer warrants and represents to Merck
(i) that, during the Term of this Agreement, Manufacturer will have obtained and maintained such approvals and licenses as may be required
under applicable laws, rules, regulations and requirements to operate its manufacturing facilities for the purposes contemplated by this
Agreement, and (ii) as far as Services performed by Manufacturer, its Affiliates and/or subcontractors are concerned that Batch Documentation
shall be generated and stored in accordance with cGMP, the Services Related Requirements of the Specifications, the provisions of the
Quality Agreement and Applicable Laws.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">9.2</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Non-conforming Batch</B>. Where Manufacturer or Merck, through own sample
analysis before delivery of a Batch, finds that any Batch fails or will fall to comply with any Product Related Requirements of the Specifications,
including but not limited to the release specifications (i) Manufacturer or Merck, as the case may be, shall notify the other Party thereof
within [***], (ii) Manufacturer shall not deliver the Batch, (iii)&nbsp;Manufacturer shall, upon request by Merck in case Manufacturer
had not already provided samples, promptly provide Merck with samples of the Batch in order to allow Merck to perform its own analysis
of the failed Batch; (iv) at the latest within [***] of the first notification, Manufacturer shall provide Merck with a written report
summarizing results of Manufacturer&rsquo;s investigation of the cause of such failure, and (v) the Parties shall thereafter discuss in
good faith said failure and consider which optimization or correction shall be implemented by Manufacturer in order to perform another
Batch, which additional Manufacturing Run, if mutually decided, shall be subject to the execution of a written amendment to the respective
Work Order or Purchase Order which shall set forth the new terms and conditions or such additional Manufacturing Run. In case the non-compliance
of said Product is determined to have arisen from Manufacturer&rsquo;s breach of the warranties set out in Section 9.1, Sections from
9.6 to 9.9 shall apply. In case the non-compliance of said Product is determined not to have arisen from Manufacturer&rsquo;s breach of
the warranties set out in Section 9.1, Merck may request Manufacturer to perform, at Merck&rsquo;s sole cost, an additional Manufacturing
Run and produce a new cGMP Batch replacing the rejected cGMP Batch as soon as reasonably possible. Notwithstanding the foregoing, Merck
shall have the unfettered right to discretionary decide not to perform an additional production Service. For clarity: Merck shall pay
Manufacturer the applicable Price for a Manufacturing Run despite the fact that a non-conforming Product was generated unless such non-compliance
was caused by Manufacturer&rsquo;s breach of the warranties set out in Section 9.1 and rejected by Merck in accordance with Section 9.6.
In case the non-compliance of said Product is determined to have arisen from Manufacturer&rsquo;s failure to perform the Services in accordance
with the warranties set out in Section 9.1, Section 9.6 shall apply. In case the reason for the non-compliance cannot be determined, Merck
shall pay Manufacturer [***] of the applicable Price for the respective Manufacturing Run.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">9.3</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Acceptance, Rejection of Product</B>. Merck will notify Manufacturer
in writing of its acceptance or rejection of any shipment of Product hereunder within [***] of the [***] receipt of any [***], including
but not limited to the [***], and within [***] of the [***] receipt of [***] to Merck or to the third party designated by Merck or, in
the case of any defects not reasonably susceptible to discovery upon receipt, within [***] after discovery by Merck or third party designated
by Merck. For clarity: the aforementioned notice periods shall in any case not start during storage of the containers containing the Product
at Manufacturer as the containers containing the Product need to be physically received by Merck or a third party designated by Merck.
Merck has no obligation to accept such Products if they do not comply with any warranty set out in Section 9.1. In the absence of any
such written notification of Merck to Manufacturer within the applicable time period set out above, containing in reasonable detail the
reasons of the non-conformance, the applicable Product shall be deemed to comply with and accepted by Merck (&ldquo;<B>Acceptance</B>&rdquo;).
Upon receipt of a Product, Merck shall retain full control and title to the relevant Product and shall transport and store (or shall ensure
that the third party designated by Merck shall transport and store) such Product under appropriate and controlled conditions compliant
with cGMP requirements. Any other use or processing of such Product by or on behalf of Merck [***] shall be at the sole risk, responsibility
and expense of Merck and shall constitute an unconditional Acceptance of such Product. This Section 9.3 shall apply to both (i) the shipment
of the Batch Documentation to Merck as well as (ii) the shipment of the Product itself. In the former event, the Acceptance relates to
the Batch Documentation, i.e. the compliance of the Product with any warranty as set out in Section 9.1, while in the latter event the
Acceptance relates to the primary packaging of the Product.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">9.4</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Resolution of Dispute as to Whether a Product is Non-Conforming</B>.
The Parties shall cooperate in good faith to determine whether a rejection of Product is appropriate. If the Parties disagree, a sample
of the rejected Product and a sample retained by Manufacturer shall be exchanged between Merck (or a third party designated by Merck reasonably
acceptable to Manufacturer) and Manufacturer for a counter-check. If such counter-check does not resolve the dispute, a sample of the
rejected Product and a sample retained by Manufacturer shall be submitted to an independent, qualified Independent Expert that is mutually
acceptable and selected by Manufacturer and Merck promptly in good faith. Such Independent Expert shall determine whether the rejected
deliverable met the warranties set out in Section 9.1 at the time of delivery by Manufacturer to Merck or to the third party designated
by Merck, as applicable and such Independent Expert&rsquo;s determinations shall be final, binding upon the Parties and determinative
for purposes of this Agreement. The Party against whom the Independent Expert rules, shall bear all costs of the Independent Expert.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">9.5</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Conforming Product</B>. If the Parties have agreed, or if the Independent
Expert determines that the Product was conforming in all respect with the warranties set out in Section 9.1 at the time of delivery by
Manufacturer then such Product shall be deemed to have been accepted by Merck, and Merck shall make the final payment therefor in accordance
with ARTICLE 6.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">9.6</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Non-Conforming Product</B>. If the Parties have agreed or if the Independent
Expert determines that the Product was not conforming to the warranties set out in Section 9.1 at the time of delivery by Manufacturer
then such Product shall be deemed to have been rejected by Merck, and Manufacturer shall refund to Merck all payments made by Merck therefore
in accordance with ARTICLE 6.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">9.7</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Responsibility of Manufacturer</B>. For the avoidance of doubt, Manufacturer
shall not be responsible for (and Merck shall pay the Price for such Manufacturing Run in full) if the reason for the non-compliance of
the Product is for any other reason but for a breach of the warranties set out in Section 9.1, such other reason being for example [***].
Accordingly, Manufacturer shall also not be responsible for any delay or non-performance of Services of Manufacturer caused by reasons
outside of Manufacturer&rsquo;s responsibility (e.g. [***]), if Manufacturer took all reasonable actions to prevent such delay or non-performance
of the Services.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">9.8</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Sole Remedy</B>. It is specifically agreed that, in addition and without
prejudice to what is set out in Sections 5.6, 18.1 and ARTICLE 19, the actions described in this ARTICLE 9 shall be the sole remedy of
Merck in the event any Product supplied by Manufacturer in the context of Commercial Manufacturing Services fails to conform to the warranties
set out in Section 9.1. The limitation of remedies set out herein shall not apply in case of failure by the Manufacturer to perform its
obligations hereunder due to the Manufacturer&rsquo;s wilfull misconduct or gross negligence unless Manufacturer&rsquo;s gross negligence
in the performance of its obligations hereunder has resulted into a Defect in a Batch ordered by Merck and Manufacturer, at Merck&rsquo;s
request, offers and successfully performs at its own costs a new Manufacturing Run under the terms and conditions of Section 9.9.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">9.9</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Defective Services</B>. In the event that Manufacturer is not properly
performing Development Services pursuant to this Agreement, except where Manufacturer can reasonably demonstrate that such malperformance
is not due to its fault (e.g. [***]), Manufacturer shall, at Merck&rsquo;s option, either re-perform as set out below at its own costs
the defective Development Services in accordance with the Specifications and this Agreement or refund to Merck the price and/or any advance
payments paid for such defective Development Services. For the avoidance of doubt, in the event that Merck opts for the re-performance
of defective Development Services consisting in the re-performance of Manufacturing Runs, Manufacturer shall use its best efforts to schedule
the start of such new Manufacturing Runs as early as possible and anyway not later than a maximum of [***] from Merck&rsquo;s request
for the reperformance of the defective Development Service or, as the case may be, not later than a maximum of [***] after the root cause
identification of the Defect affecting the Batch to be replaced. In order to secure a quicker slot, Merck shall also have the option to
reserve one or several back-up Manufacturing Runs by issuing one or more Work Orders at least [***] prior the Delivery Date. In case such
back-up Manufacturing Run(s) is/are needed due to a failure by the Manufacturer to perform its obligations hereunder, no cost will be
charged by the Manufacturer to Merck for such back-up Manufacturing Run(s). If the ordered back-up Manufacturing Run(s) is/are not needed
and the relevant Work Order is cancelled by Merck, Merck shall pay in derogation of Section 4.8 a lump-sum of [***] as cancellation fee
independently of the time when the cancellation of the Work Order occurred unless the reallocation of such back-up Manufacturing Run(s)
is possible under Section 4.9 excluding Merck&rsquo;s obligation to pay a cancellation fee. In addition and without prejudice to what
is set out in Sections 5.6, 18.1 (for the case of death and bodily injuries) and ARTICLE 19, the remedies set out in this Section 9.9
shall be Merck&rsquo;s sole and exclusive remedies under this Agreement with respect to any defective Development Services and any delay
caused by defective Development Services. The limitation of remedies set out herein shall not apply in case of failure by the Manufacturer
to perform a Development Service due to the Manufacturer&rsquo;s wilfull misconduct or gross negligence unless Manufacturer&rsquo;s gross
negligence in the performance of its obligations hereunder has resulted into a Defect in a Batch ordered by Merck and Manufacturer, at
Merck&rsquo;s request, offers and successfully performs at its own costs a new Manufacturing Run under the terms and conditions of this
Section 9.9.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">Article
10<BR>
PRODUCT LICENSES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Merck shall, at its expense, obtain and maintain
all necessary Product Licenses. Merck shall be responsible for responding to all requests for information related to such Product Licenses
made by, and for making all legally required filings relating to such Product Licenses with, any Regulatory Authority having jurisdiction
to make such requests or require such filings. If any Product License held by Merck relating directly to the Products is hereafter suspended
or revoked, Merck shall promptly notify Manufacturer of the event and shall promptly inform Manufacturer of the Impact an Merck&rsquo;s
purchases of the affected Products and Merck&rsquo;s general intentions with respect to the affected Product.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">Article
11<BR>
TRIAL AUTHORIZATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Merck or a Merck&rsquo;s designated third party
shall, at its expense, obtain and maintain all necessary Trial Authorizations. Merck or a Merck&rsquo;s designated third party shall be
responsible for responding to all requests for information related to such Trial Authorizations made by, and for making all legally required
filings relating to such Trial Authorizations with, any Regulatory Authority having jurisdiction to make such requests or require such
filings. If any Trial Authorization held by Merck or a Merck&rsquo;s designated third party relating directly to the Products is hereafter
suspended or revoked, Merck shall promptly notify Manufacturer of the event and shall promptly inform Manufacturer of the impact on Merck&rsquo;s
purchases of the Product and Merck&rsquo;s general intentions with respect to the Trial.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">Article
12<BR>
CHANGES TO PRODUCT SPECIFICATIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">12.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Changes Requested by Manufacturer</B>. Notwithstanding anything herein
to the contrary, Manufacturer shall not amend, change or supplement any of the following except in accordance with the change control
provisions set forth in the Quality Agreement: (a) the Specifications, (b) the Materials, (c) the source of Materials, (d) the specifications
for Materials, (e) the Manufacturing Site or the equipment used in manufacturing the Product, (f) the test methods used to test the Products
or Materials, or (g) the process for manufacturing the Products (each of the foregoing a &ldquo;<B>Technical Change</B>&rdquo;).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">12.2</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Changes Requested by Merck</B>. Merck may request a Technical Change
by written notice to Manufacturer, and except as prohibited by Applicable Law, Manufacturer shall use Commercially Reasonable Efforts
to implement such change within a reasonable period of time.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">12.3</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Required Manufacturing Changes</B>. Each Party shall notify the other
Party of any Technical Change which is required by cGMPs or Applicable Laws (a &ldquo;<B>Required Manufacturing Change</B>&rdquo;). Manufacturer
shall use Commercially Reasonable Efforts to implement Required Manufacturing Changes within a reasonable period of time.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">12.4</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Cost of Technical Changes</B> All reasonable out-of-pocket costs associated
with Required Manufacturing Changes that relate to the Product or to the performance of any Services (including the cost of any Regulatory
Authority filings and any write offs and other similar costs due to such changes associated with obsolete Materials, work-in-process and
finished Product inventories, and printed materials, including packaging and labelling materials) shall be borne by Merck, except with
respect to Materials purchased by Manufacturer in excess of the amounts needed to fulfil Manufacturing Runs set out in the Firm Zone,
unless otherwise procured by Manufacturer in advance with Merck&rsquo;s consent (provided that Manufacturer will use Commercially Reasonable
Efforts to minimize the costs associated therewith).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">12.5</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Technical Change Implementation</B>. All Technical Changes (including
Required Manufacturing Changes) shall be implemented in accordance with Applicable Laws, cGMP and the Quality Agreement. Prior to implementation
of any Technical Change, the Parties shall ensure that any implications on the quality of the Products have been considered and recorded,
and the change is approved by the relevant Regulatory Authorities. Manufacturer shall provide Merck with technical assistance at the Agreed
Hourly Rate, including through the provision of supporting documentation in order to permit Merck to amend and file any relevant document
required to be filed with a Regulatory Authority.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">Article
13<BR>
QUALITY &amp; REGULATORY COMPLIANCE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">13.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Maintenance of Permits</B>. Manufacturer shall maintain all Manufacturing
Licenses and other regulatory and governmental permits, licenses and approvals that may be necessary to Manufacture Product.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">13.2</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Notification of Adverse Manufacturing Activities</B>. Manufacturer shall
advise Merck of any information arising out of its Services that has adverse regulatory compliance and/or reporting consequences concerning
the Product.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">13.3</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Activities at the Manufacturing Site and Machinery Used to Manufacture
Products</B>. Manufacturer shall not carry out any other activities at the Manufacturing Site that may prejudice the quality, safety or
efficacy of the Products.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">13.4</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Storage</B>. Manufacturer shall at all times store and warehouse all
Materials and Products in premises that are secure, clean, compliant with the Specifications, Manufacturing Licenses and the Quality Agreement
and otherwise reasonably acceptable to Merck and shall be physically separated from all other materials and products in Manufacturer&rsquo;s
possession. Manufacturer shall be responsible for the safe storage and handling of the Products until delivery to Merck in accordance
with the Delivery Terms. The Manufacturer shall keep records of the storage conditions in relation to each Batch of Products in accordance
with the requirements set forth in the Quality Agreement. Manufacturer agrees to disclose to Merck from time to time or upon Merck&rsquo;s
request, subject to Manufacturer&rsquo;s confidentiality obligations to its other customers, the nature of any relevant products manufactured
or packaged by Manufacturer for itself or third parties which use the same machinery as that used by Manufacturer for the Manufacture
of Products under this Agreement or that are stored in the same location where the Products or Materials are stored in order that Manufacturer
and Merck may identify any potential effects on quality, safety or efficacy of the Products which may result.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">13.5</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Requests from and Inspections by Regulatory Authorities</B>. Provisions
covering correspondence, interaction with and provision of information to Regulatory Authorities, including inspections, are set forth
in the Quality Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">13.6</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Audits by Merck</B>. Representatives of Merck may, upon reasonable notice,
at times reasonably acceptable to Manufacturer and in accordance with the further terms and conditions agreed in the Quality Agreement,
(i) visit, inspect and audit the Manufacturer&rsquo;s facilities where the Services are being performed, and (ii) consult informally,
during such visits and by telephone, with personnel of Manufacturer performing work on the Services; provided, however, that Manufacturer
shall accompany each on Merck&rsquo;s initial visit to Manufacturer&rsquo;s facilities. Any such visits will be coordinated with a representative
of Manufacturer to be designated in writing following execution of this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">In addition, Merck shall also be entitled,
upon prior written notice to Manufacturer, to conduct audits &ldquo;for cause&rdquo; which shall include, without limitation, manufacturing
or facility issues affecting the Manufacture of the Product or quality of the Product (including cGMP), at times reasonable acceptable
to Manufacturer, but in any case no later than [***] from receipt by Manufacturer of said prior written notice. Merck shall not be charged
by Manufacturer for any audit made &ldquo;for cause&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">Any information and data disclosed to
Merck pursuant to this Section 13.6 shall be deemed Confidential Information subject to the obligations of confidentiality and non-use
as provided in ARTICLE 16.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">13.7</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Audit and Inspection Fees</B>. Manufacturer shall be entitled to charge
for the costs of audit and inspections at the agreed hourly rate except for [***] audit every [***] which shall be [***]. In addition,
Manufacturer shall not be entitled to charge any amounts to Merck where an audit or inspection is &ldquo;for cause&rdquo;.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">13.8</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Handling of Materials; Wastes</B>. Manufacturer shall inform its employees,
contractors and other personnel of any known or reasonably ascertainable chemical hazards associated with the Products or any wastes (including,
Hazardous Materials) generated through performance of the Services, and to provide such persons with reasonable training in the proper
methods of handling and disposing of such items. In addition, Manufacturer shall handle, accumulate, label, package, ship and dispose
of all wastes (including, Hazardous Materials) generated through performance of the Services in accordance with all Applicable Laws.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">13.9</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Documentation for Regulatory Authority Requirements</B>. Manufacturer
shall maintain in accordance with and for the period specified in the Quality Agreement (unless cGMP or Applicable Laws require a longer
period), complete and accurate records relating to the manufacture of Products and to the performance of Services as it may be required
to hold under such Applicable Law. Manufacturer shall provide Merck with such documentation promptly upon Merck&rsquo;s request.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">13.10</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Assistance with Regulatory Filing</B>. Manufacturer shall prepare and
provide to Merck, at no additional cost (unless otherwise agreed to in writing by the Parties), the reports agreed and described in <B>Schedule
5</B> supporting manufacturing operations for the Products (including, without limitation, [***]) for Merck&rsquo;s use in updating the
[***] of the applicable IND/CTA and/or NDA/BLA. The above-mentioned reports might be used as is in regulatory submission or in the framework
of response to questions. Assistance to provide response to questions received from authorities should be provided within the due evaluation
timelines as appropriate and at Merck&rsquo;s expense as described in <B>Schedule 5</B>, except in case of deficiency of Manufacturer&rsquo;s
Services in which case Merck shall not pay for such Services. Manufacturer shall provide at the Agreed Hourly Rate mentioned in Section
6.16 further regulatory assistance as may reasonably be required by Merck.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">13.11</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Debarment and Exclusion</B>. Manufacturer represents and warrants that
neither it, its subcontractors, nor any individual, corporation, partnership or association engaged in connection with the performance
of services under this Agreement, has ever been, are currently, nor during the performance of any services hereunder, shall become:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt">(i)</TD><TD STYLE="text-align: justify">disqualified or debarred by the FDA or other competent Regulatory Authorities for any purpose pursuant
to Applicable Laws (including but not limited to United States law, including but not limited to the statutory debarment provisions at
21 U.S.C. &sect; 335a(a) or (b));</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt">(ii)</TD><TD STYLE="text-align: justify">charged or convicted for conduct relating to the development or approval of, or otherwise relating to
the regulation of, any drug product under any Applicable Laws; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt">(iii)</TD><TD STYLE="text-align: justify">excluded or threatened with exclusion under state or federal laws, including under 42 U.S.C. &sect; 1320a-7
or relevant regulations in 42 C.F.R. Part 1001, or assessed or threatened with assessment of civil money penalties pursuant to 42 U.S.C.
Part 1003.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">Manufacturer agrees to notify Merck immediately,
in the event that Manufacturer or any of its officers, directors, employees, agents, or parties under contract to perform and work under
this Agreement (i) becomes debarred, excluded or convicted, or (ii) receives notice of action with respect to its debarment, exclusion
or conviction during the Term. Manufacturer hereby certifies that it has not utilized, and shall not utilize, in any capacity the services
of any individual, corporation, partnership or association in the performance of work for Merck under this Agreement that has been (X)
debarred, or to its knowledge has received notice of action with respect to debarment, under the Generic Drug Enforcement Act of 1992,
21 United States Code &sect;335a(a) and (b), as amended or any foreign equivalent thereof, (Y) excluded pursuant to 42 U.S.C. &sect; 1320a-7
or relevant regulations in 42 C.F.R. Part 1001 or to its knowledge has received notice of exclusion or any foreign equivalent thereof
or (Z) otherwise convicted pursuant to (ii) above, or to its knowledge has received notice of conviction or any foreign equivalent thereof.
In the event that Manufacturer receives any notice of actions set forth in this Section 13.110 (with regard to Manufacturer only but not
including an individual employee, officer, director, agent or subcontractor), without limiting any other rights or remedies of Merck,
Merck shall have the right to terminate this Agreement immediately pursuant to the provisions of this Agreement. Any termination by Merck
pursuant to this Section 13.11 shall be deemed to be a termination by Merck for material breach of this Agreement by Manufacturer pursuant
to Section 19.7.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">13.12</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Compliance with REACH</B>. Merck Manufacturer shall ensure compliance
with the Registration requirements stipulated in Regulation (EC) No. 1907/2006 (&ldquo;<B>REACH</B>&rdquo;) with respect to Products manufactured
and Raw Materials required by Manufacturer. Merck shall, at its expense, be responsible for responding to regulatory developments with
impact on the manufacturing process, such as the inclusion of Raw Materials in Annex XIV to the Reach regulation (&ldquo;Authorization&rdquo;),
and to decide on the approach chosen, such as technical changes to substitute substances of concern, or regulatory action to satisfy the
requirements.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">Article
14<BR>
OPERATIONAL MANAGEMENT; STEERING COMMITTEE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">14.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">During the Term, the operational management of the relationship between
the Parties shall lie with the Steering Committee established by the Parties in accordance with this ARTICLE 14.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">14.2</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Steering Committee shall be composed of [***] representatives of each
Party but of at least one member of the management of each Party and one additional representative of each Party. It shall have the general
responsibility for the implementation of the Clinical and Commercial Supply Agreement. The Steering Committee&rsquo;s resolutions shall
be adopted unanimously, with an escalation to the Parties&rsquo; senior management in the event of a blockage or tie.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">14.3</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The tasks of the Steering Committee shall include, without limitation:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt">(a)</TD><TD STYLE="text-align: justify">periodically review the KPIs outlined in <B>Schedule 2</B>, and update such KPIs as may be required;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt">(b)</TD><TD STYLE="text-align: justify">consider and, when appropriate, approve amendments to the Material Specifications;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt">(c)</TD><TD STYLE="text-align: justify">periodically review the level of the Manufacturer&rsquo;s Safety Stocks and adjust their level as deemed
necessary, as contemplated in Section 2.13;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt">(d)</TD><TD STYLE="text-align: justify">work on a mutually acceptable resolution to minimize the consequences of a late delivery, as contemplated
in Section 5.6; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt">(e)</TD><TD STYLE="text-align: justify">agree on remedial actions to address Manufacturing Problems, as contemplated in Section 5.8.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">14.4</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Steering Committee shall pass its resolutions:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt">(a)</TD><TD STYLE="text-align: justify">in meetings on the occasion of which all members are present (either in person or through voice or video
conferencing systems); or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt">(b)</TD><TD STYLE="text-align: justify">by written consent to a proposal submitted by one of their members.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">Article
15<BR>
PRODUCT COMPLAINTS AND ADVERSE EVENTS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">15.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Product Complaints, Adverse Events and Product Events</B>. Provisions
covering complaints or Adverse Events are set forth in the Quality Agreement. Provisions covering voluntary and involuntary recalls, product
withdrawals, field corrections, field alerts, or other related actions (&ldquo;<B>Product Event</B>&rdquo;) of Finished Medicinal Products
are set forth in the Quality Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">15.2</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Expenses Resulting from a Product Event</B>. In the event that a Regulatory
Authority requires, or Merck decides to, initiate a Product Event with respect to a Finished Medicinal Product using Product manufactured
by Manufacturer under this Agreement, Merck shall promptly notify Manufacturer. Manufacturer shall fully cooperate with Merck in implementing
the foregoing as Merck or the Regulatory Authority may require. If the Product Event is due to a breach of this Agreement by Manufacturer
or Manufacturer&rsquo;s negligence or wilful misconduct, Manufacturer shall replace all Products used for manufacturing recalled Finished
Medicinal Products, at Manufacturer&rsquo;s cost.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">Article
16<BR>
CONFIDENTIALITY AND DATA PROTECTION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">16.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Non-Use, Non-Disclosure</B>. Manufacturer shall use the Confidential
Information only for the purpose of providing Development and Commercial Manufacturing Services hereunder. Except as otherwise provided
for herein, Manufacturer shall not, at any time (whether during this Agreement or alter its termination) use, for Manufacturer&rsquo;s
own or any Third Party&rsquo;s benefit or purposes or disclose, publish or make available all or any portion of the Confidential Information
to any other Third Party, without the Prior written consent of Merck. Merck Background IP and Merck Arising IP shall be considered the
Confidential Information of Merck.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">16.2</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Standard of Care</B>. Manufacturer shall maintain and protect the confidentiality
of Confidential Information and shall use at least the same degree of care to safeguard and to prevent disclosing of Confidential Information
as it employs to avoid unauthorized disclosure, publication, dissemination, destruction, lass, or alteration of its own confidential information
(or information of its customers of a similar nature), but at all times shall use at least reasonable care. Manufacturer shall implement
and maintain appropriate security measures to prevent unauthorized access to, or disclosure of Confidential Information. Manufacturer
personnel and approved subcontractors shall have access to Confidential Information Only to the extent necessary for such person to perform
his or her obligations under or with respect to this Agreement or as otherwise naturally occurs in such person&rsquo;s scope of responsibility,
provided that such access is not in violation of Applicable Law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">16.3</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Required Disclosures</B>. The obligations of confidentiality, non-disclosure
and non-use hereunder shall continue until the relevant Confidential Information falls within the exceptions provided for in Section 16.4
hereof. Notwithstanding the foregoing, Manufacturer shall be entitled to disclose the Confidential Information to the extent required
by Applicable Law or court order on the condition that Manufacturer provides Merck with written notice that the Confidential Information
is required to be disclosed sufficiently in advance of the disclosure so as to provide Merck with reasonable opportunity to seek to prevent
the disclosure of or to obtain a protective order for the Confidential Information; and provided further that Manufacturer shall reasonably
assist Merck in obtaining a protective order, shall make any required disclosures in consultation with Merck and shall clarify the confidential
nature of the disclosed Confidential Information.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">16.4</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Exclusions to Confidentiality</B>. Manufacturer shall not have any obligation
hereunder with respect to any Confidential Information if such Confidential Information (a) is, at the time of disclosure or becomes alter
disclosure, general or public knowledge through no breach of the Agreement by Manufacturer; (b) was, at the time of disclosure by Merck,
already known by Manufacturer, as established by written record; or (c) is received by Manufacturer from a Third Party having the right
to disclose same and who is not bound by a confidentiality agreement in favour of Merck or its Affiliates.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">16.5</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Notification</B>. In the event Manufacturer becomes aware or has knowledge
of any unauthorized use or disclosure of Confidential Information under Manufacturer&rsquo;s control, Manufacturer shall promptly notify
Merck of such unauthorized use or disclosure and, thereafter, shall take all reasonable steps to assist Merck in attempting to minimize
any potential or actual damages or losses resulting from such unauthorized use or disclosure.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">16.6</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Return</B>. Upon receipt of a written request from Merck, or upon termination
of this Agreement, Manufacturer shall promptly return to Merck all Confidential Information, including all reproductions and copies thereof
together with all internal material and documents generated by Manufacturer containing Confidential Information or references thereto
and Manufacturer shall delete all such Confidential Information and references thereto stored electronically. Notwithstanding the above,
Manufacturer may retain a single copy of any Confidential Information as is reasonably necessary for regulatory or insurance purposes,
subject to Manufacturer&rsquo;s obligations of confidentiality under this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">16.7</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Public Announcements</B>. Neither Party shall make any press nor other
public announcement concerning any aspect of this Agreement, unless the text of such announcement is first approved in writing by the
Parties to this Agreement. Provisions covering inspections and audits of Manufacturer, including with respect to the Manufacturing Site,
whether by Merck or a Regulatory Authority, are set forth in the Quality Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">16.8</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Manufacturer Confidential Information</B>. Merck acknowledges it may
receive confidential and proprietary information from Manufacturer including but not limited regarding its methodology, testing processes,
packaging and manufacturing techniques, data collection and/or data management techniques, commercial information, prices and contractual
terms (&ldquo;<B>Manufacturer Confidential Information</B>&rdquo;). Merck shall treat any Manufacturer Confidential Information in the
same confidential manner as Manufacturer is obliged to treat Confidential Information as set forth in this Agreement, except that Merck
may disclose such information as is requested by Regulatory Authorities or as is necessary to be included in regulatory filings or Product
Licenses (e.g. Drug Master Files).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">16.9</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Data Processing Agreement</B>. If and to the extent Personal Data is
processed on behalf of Merck by Manufacturer so that Manufacturer is acting as a &ldquo;<B>Processor</B>&rdquo;, the Data Processing Agreement
attached as <B>Schedule 6</B> shall apply.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">16.10</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Audit And Inspection Rights</B>. Additional provisions covering inspections
and audits of Manufacturer, including with respect to the Manufacturing Site, whether by Merck or a Regulatory Authority, are set forth
in the Quality Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">Article
17<BR>
WARRANTIES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">17.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Mutual Representations and Warranties</B>. Merck and Manufacturer each
represent and warrant to the other that:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt">(a)</TD><TD STYLE="text-align: justify"><B>Organization and Authority</B>. It has full corporate right, power and authority to enter into this
Agreement and to perform its respective obligations under this Agreement;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt">(b)</TD><TD STYLE="text-align: justify"><B>No Conflicts or Violations</B>. The execution and delivery of this Agreement by such Party and the
performance of such Party&rsquo;s obligations hereunder (a) do not conflict with or violate any requirement of Applicable Laws existing
as of the Effective Date and applicable to such Party and (b) do not conflict with, violate, breach or constitute a default under, and
are not prohibited or materially restricted by, any contractual obligations of such Party or any of its Affiliates existing as of the
Effective Date; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt">(c)</TD><TD STYLE="text-align: justify"><B>Valid Execution</B>. Such Party is duly authorized, by all requisite corporate action, to execute and
deliver this Agreement and the execution, delivery and performance of this Agreement by such Party does not require any shareholder action
or approval or the approval or consent of any Third Party, and the person executing this Agreement on behalf of such Party is duly authorized
to do so by all requisite corporate action.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">17.2</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Manufacturer Representations and Warranties for Manufacturing the Products</B>.
In addition to the warranty pursuant to Section 9.1, Manufacturer represents and warrants to Merck that:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt">(a)</TD><TD STYLE="text-align: justify"><B>Good Title, No Encumbrances</B>. It will convey good title to the Products supplied under this Agreement,
free from any lawful security, interest, lien or encumbrances;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt">(b)</TD><TD STYLE="text-align: justify"><B>Right to Manufacturer Background IP</B>. It has the title and/or right to any and all Manufacturer
Background IP used to Manufacture the Products in accordance with this Agreement; and the Manufacture of the Products by Manufacturer
or its. Affiliates or by Merck or its Affiliates will not infringe the Intellectual Property or any other rights of any Third Party;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt">(c)</TD><TD STYLE="text-align: justify"><B>Compliance Obligations</B>. Merck intends to conduct its business in accordance with environmental,
labor and social standards and to abide by the standards set forth in the <I>Human Rights Charter and Code of Conduct</I> (including Merck
values) referred to under <B>Schedule 3</B>. Manufacturer shall comply, and shall ensure that its subcontractors comply, with reasonably
comparable environmental, labor and social standards. Manufacturer acknowledges that it is aware of the <I>OECD Convention an Combating
Bribery of Foreign Public Officials in International Business Transactions</I> and shall comply, and shall ensure that its subcontractors
comply, with its principles. Manufacturer shall not offer, promise, give, authorize or consent to the giving of money or anything of material
value to any person (i) with the purpose or effect of securing any improper advantage in order to obtain or retain business or (ii) to
induce or prevent the performance of an individual&rsquo;s duties in violation of Applicable Law. Should Merck discover that Manufacturer
or its subcontractors are in breach of the foregoing, Merck may terminate this Agreement without notice.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt">(d)</TD><TD STYLE="text-align: justify"><B>Compliance with Merck&rsquo;s Responsible Sourcing Principles and Customs and Foreign Trade</B>. It
will, and it will endeavour to ensure that its subcontractors, comply with internationally recognized fundamental environmental, labour
and social standards, as described in Merck&rsquo;s Responsible Sourcing Principles referred to under <B>Schedule 3</B>. Upon request
of Merck, Manufacturer shall provide Merck with a supplier declaration as per <B>Schedule 4</B>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt">(e)</TD><TD STYLE="text-align: justify"><B>Bribery</B>. It will neither offer to give nor give money or gifts to Merck employees or members of
their families in exchange for business from Merck; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt">(f)</TD><TD STYLE="text-align: justify"><B>Change of Control</B>. It will provide prompt written notice to Merck in the event of any Change of
Control.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">17.3</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Manufacturer Representations and Warranties for the Development Services</B>.
Manufacturer represents and warrants to Merck that:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt">(a)</TD><TD STYLE="text-align: justify"><B>Performance</B>. The Services shall be performed in accordance with cGMP and Applicable Laws with respect
to the performance of Services;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt">(b)</TD><TD STYLE="text-align: justify"><B>Right to Manufacturer Background IP</B>. It has the title and/or right to any and all Manufacturer
Background IP used to perform the Services in accordance with this Agreement; and the use by Manufacturer or its Affiliates of Manufacturer
Background IP will not infringe the Intellectual Property or any other rights of any Third Party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">17.4</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Merck Representations and Warranties</B>. Merck represents and warrants
to Manufacturer that it holds all necessary Product Licenses with respect to the Products and that:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt">(a)</TD><TD STYLE="text-align: justify"><B>Trial Authorizations</B>. It holds all necessary Trial Authorizations to conduct the Trial.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt">(b)</TD><TD STYLE="text-align: justify"><B>Right to Merck Background IP</B>. It has the title and/or right to any and all Merck Background IP
supplied to Manufacturer in accordance with this Agreement for the Manufacture, labelling and packaging of the Products, and further that
it has the title and/or right to grant Manufacturer the right to use such Intellectual Property in accordance with the terms of this Agreement
and the use by Manufacturer or its Affiliates of Merck Background IP will not infringe the Intellectual Property or any other rights of
any third party.</TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">Article
18<BR>
INDEMNITY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">18.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Indemnification by Manufacturer</B>. Manufacturer shall indemnify, hold
harmless and, upon request of Merck, defend Merck, its Affiliates and its and their directors, officers, representatives, shareholders,
employees and agents, and their respective successors and permitted assigns, from any and all Losses from any Third Party claims, proceedings,
actions or causes of actions (&ldquo;<B>Third Party Claims</B>&rdquo;) which arise out of (a) the faire of Products to meet the warranties
set forth in Section 9.1 and (b) any other breach by Manufacturer of any of its representations, warranties, covenants, agreements or
obligations under this Agreement, or the negligence, recklessness or wilful misconduct of Manufacturer (or its Affiliates or subcontractors)
in the performance the Services and any of its obligations hereunder; in each case except to the extent such Third Party Claim arises
out of matters contemplated in Section 18.2 (a) or (b) below. In the event a Third Party Claim is caused by both Party&rsquo;s behaviour,
the amount of indemnification shall depend on the circumstances, in particular to what extend the Third Party Claim is caused mainly by
one or the other Party.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">18.2</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Indemnification by Merck</B>. Merck shall indemnify, hold harmless and,
upon request of Manufacturer, defend Manufacturer, its Affiliates and its and their directors, officers, representatives, shareholders,
employees and agents, and their respective successors and permitted assigns, from any and all Losses from any Third Party Claims which
arise out of (a) a breach by Merck of any of its representations, warranties, covenants, agreements or obligations under this Agreement
and (b) the negligence, recklessness or wilful misconduct of Merck (or its Affiliates or subcontractors) in the performance of its obligations
hereunder; in each case except to the extent such Third Party Claim arises out of result from matters contemplated in Section 18.1(a)
or (b) above. In the event a Third Party Claim is caused by both Party&rsquo;s behaviour, the amount of Indemnification shall depend on
the circumstances, in particular to what extend the Third Party Claim is caused mainly by one or the other Party.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">18.3</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>No Consequential Damages</B>. EXCEPT WITH RESPECT TO EACH PARTY&rsquo;S
INDEMNIFICATION OBLIGATIONS UNDER SECTION 18.1 OR SECTION 18.2, AS APPLICABLE, AND/OR EXCEPT IN THE EVENT OF WILFUL MISCONDUCT AND GROSS
NEGLIGENCE, IN NO EVENT SHALL EITHER PARTY OR ANY OF ITS AFFILIATES FOR BREACH OF ITS OBLIGATIONS UNDER THIS AGREEMENT BE LIABLE TO THE
OTHER PARTY OR ANY OF ITS AFFILIATES FOR (I) ANY CONSEQUENTIAL, INCIDENTAL, INDIRECT, SPECIAL OR PUNITIVE DAMAGES, OR CLAIMS BROUGHT BY
[***] OR ANY OTHER THIRD PARTY HAVING SIGNED AN AGREEMENT WITH MERCK IN RELATION TO THE TRIAL, WHETHER IN CONTRACT, WARRANTY, TORT, NEGLIGENCE,
STRICT LIABILITY OR OTHERWISE ARISING OUT OF OR RELATING TO THIS AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREIN OR ANY BREACH HEREOF.
FOR THE PURPOSES OF THIS CLAUSE &ldquo;<B>CONSEQUENTIAL DAMAGES</B>&rdquo; SHALL BE DEFINED AS LOSS OF PROFIT OR ANTICIPATED PROFIT, LOSS
OF PRODUCTION, LOSSES CAUSED BY BUSINESS INTERRUPTIONS, LOSS OF REVENUE AND LOSS OF GOODWILL OR REPUTATION AS WELL AS DAMAGES RESULTING
FROM REMOTE EVENTS THAT ARE VERY UNLIKELY TO HAPPEN, &ldquo;<B>PUNITIVE DAMAGES</B>&rdquo; SHALL BE DEFINED AS COMPENSATION CLAIMS THAT
EXCEED THE DAMAGE ACTUALLY INCURRED. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS AGREEMENT SHALL LIMIT EITHER PARTY FROM SEEKING OR
OBTAINING ANY REMEDY AVAILABLE UNDER APPLICABLE LAW, INCLUDING EQUITABLE REMEDIES, FOR ANY BREACH OF ITS CONFIDENTIALITY AND NON-USE OBLIGATIONS
UNDER ARTICLE 16.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">18.4</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Notification of Claims; Conditions to Indemnification Obligations</B>.
As a condition to a Party&rsquo;s right to receive indemnification under this ARTICLE 18, it shall: (a) promptly notify the other Party
as soon as it becomes aware of a claim or suit for which indemnification may be sought pursuant hereto; (b) cooperate, and cause the individual
indemnitees to cooperate, with the indemnifying Party in the defence, settlement or compromise of such claim or suit; and (c) permit the
indemnifying Party to control the defense, settlement or compromise of such claim or suit, including the right to select defence counsel.
In no event, however, may the indemnifying Party compromise or settle any Claim or suit in a manner which admits fault or negligence on
the part of the indemnified Party or any indemnitee without the prior written consent of the indemnified Party. Each Party shall reasonably
cooperate with the other Party and its counsel in the course of the defence of any such suit, claim or demand, such cooperation to include
without limitation using Commercially Reasonable Efforts to provide or make available documents, information and witnesses. The indemnifying
Party shall have no liability under this ARTICLE 18 with respect to Claims or suits settled or compromised without its prior written consent.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">18.5</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Insurance</B>. During the Term, each Party shall obtain and maintain,
at its sole cost and expense, insurance (including any self-insured arrangements) in types and amounts that are reasonable and customary
in the pharmaceutical and biotechnology industry for companies engaged in comparable activities in the jurisdiction where such activities
are being performed. Manufacturer shall add Merck as an additional insured on any product liability and comprehensive general liability
policy carried by Manufacturer. Without prejudice to the foregoing, Manufacturer shall maintain a minimum product liability insurance
coverage of [***] per occurrence, with a deductible of a maximum of [***]. It is understood and agreed that this insurance shall not be
construed to limit either Party&rsquo;s liability with respect to its indemnification obligations hereunder. Each Party will, except to
the extent self-insured, provide to the other Party upon request a certificate evidencing the insurance such Party is required to obtain
and keep in force under this Section 18.5.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">Article
19<BR>
TERM AND TERMINATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">19.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Term</B>. This Agreement shall commence on the Effective Date and continue
for an initial period of [***] (the &ldquo;<B>Initial Term</B>&rdquo;), and thereafter shall automatically renew for further successive
periods of [***] each (the &ldquo;<B>Renewal Term</B>&rdquo; and together with the Initial Term, the &ldquo;<B>Term</B>&rdquo;), unless
terminated earlier as provided for elsewhere in this Agreement. Either Party shall have the right to terminate this Agreement at the end
of the Initial Term or at the end of a Renewal Term by providing the other Party with no less than [***] prior written notice.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">19.2</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Termination On Failure of a Condition Precedent under Section 2.2</B>.
In case one of the events described in Section 2.2 is not met, Merck shall have the right to terminate this Agreement with immediate effect
by sending a written notice to Manufacturer in accordance to Section 23.10.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">19.3</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Termination for Convenience</B>. Merck shall have the right to terminate
this Agreement at any time in its sole discretion by giving [***] advance written notice to Manufacturer.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">19.4</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Patient Safety</B>. Merck may terminate the Agreement (a) at any time
if termination is reasonably considered necessary by Merck by giving written notice to the Manufacturer in the interest of the health
and well-being of the Trial Subjects, in which case notice of termination shall have immediate effect and (b) on a Product-by-Product
basis by giving [***] advance written notice to Manufacturer if Merck decides to withdraw the Product from the market.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">19.5</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Change of Control Term</B>. Manufacturer shall provide notice to Merck
as soon as possible after a Change of Control with a company developing or commercializing [***] and upon receipt of such notification
Merck shall have the right to terminate this Agreement with immediate effect.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">19.6</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Regulatory Authority Warning Letter</B>. Merck may terminate the Agreement
immediately upon written notice to Manufacturer if Manufacturer is subject to any Regulatory Authority warning letter or sanction.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">19.7</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Termination for Breach</B>. If either Party to this Agreement shall have
materially breached or defaulted in the performance of any of its obligations and does not remedy the breach within [***] of notice from
the other Party to do so (if capable of remedy) the non-breaching Party may terminate this Agreement immediately by written notice to
the Party in breach. It is understood and agreed by the Parties that the non-respect by Manufacturer of its Yearly Capacity Reservation
obligation as provided for in Section 2.6, is considered a material breach under this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">19.8</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Termination for Late Delivery</B>. If Manufacturer becomes more than
[***] liable under Section in any calendar year, Merck shall have the right to terminate this Agreement upon written notice to Manufacturer.
The provisions of this Section 19.8 are non-exclusive and without prejudice to the payment of penalties pursuant to Section 5.6 above
or any other remedy under this Agreement or Applicable Law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">19.9</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Termination for Force Majeure Event</B>. Notwithstanding anything to
the contrary contained in this Agreement, in the event a Force Majeure Event shall have occurred and be continuing for [***], the Party
not suffering such Force Majeure Event shall be entitled to terminate this Agreement effective immediately upon written notice to the
Party suffering such Force Majeure Event.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">19.10</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Termination for Reasons of Insolvency or Termination of Business Activities</B>.
Either Party shall be entitled to terminate this Agreement if the other Party becomes insolvent or is the subject of a petition in bankruptcy
whether voluntary or involuntary or of any other proceeding under bankruptcy, insolvency or similar laws, makes an assignment for the
benefit of creditors, is named in such a petition, or its property is subject to a suit for the appointment of a receiver, or is dissolved
or liquidated. Such termination right may be exercised without the need for written notice within [***] following the date as of which
the Party entitled to terminate receives knowledge of such insolvency or termination of business activities by the other Party.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">Article
20<BR>
EFFECTS OF TERMINATION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">20.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Termination Due to Reasons other than Manufacturer Default or Insolvency</B>.
Upon expiration or termination of this Agreement other than in case of termination by Merck pursuant to Sections 19.5, 19.6, 19.7, 19.8
or 19.10, Merck shall, by written notice to Manufacturer: (i) request Manufacturer to execute outstanding Work Orders or Purchase Orders,
and, unless the Products delivered to Merck do not comply with the terms of this Agreement due to Manufacturer&rsquo;s breach of the warranties
set out in Section 9.1, Merck shall pay Manufacturer in accordance with the terms of this Agreement, or (ii) cancel any outstanding Work
Order or Purchase Order, pay the Price for the cancelled Manufacturing Runs and reimburse Manufacturer for any actual costs in executing
such Work Order or Purchase Order, provided that Manufacturer shall use Commercially Reasonable Efforts to mitigate such actual costs.
For the avoidance of doubt, Section 4.8 shall apply, i.e. Merck shall only be obliged to pay part of the Price for a Manufacturing Run
set out in a Work Order depending on the time of receipt of Merck&rsquo;s termination notice.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">20.2</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Termination Due to Manufacturer Default or Insolvenc</B>y. Upon termination
of this Agreement by Merck pursuant to Sections 19.5 19.6, 19.7, 19.8 or 19.10, Merck shall, by written notice to Manufacturer: (i) request
Manufacturer to execute outstanding Work Orders or Purchase Orders, and provided that the Products delivered to Merck comply with the
terms of this Agreement, Merck shall pay Manufacturer in accordance with the terms of this Agreement, or (ii) cancel outstanding Work
Orders or Purchase Orders without any liability to Merck.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">20.3</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Termination for any Reason</B>. Upon expiration or termination of this
Agreement for any reason, each Party shall return or destroy all of the other Party&rsquo;s Confidential Information which it has in its
possession or under its control, unless and to the extent the Party is under a statutory obligation to keep such Confidential Information.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">20.4</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Termination On Failure of a Condition Precedent under Section 2.2 or
for Convenience</B>. Termination of this Agreement by Merck pursuant to Section 19.2 or Section 19.3 shall not give rise to any claim
for Losses by Manufacturer against Merck. For the avoidance of doubt, termination pursuant Section 19.2, unless due to a Manufacturer&rsquo;s
failure to perform its obligations under this Agreement, and Section 19.3 shall not affect Merck&rsquo;s obligation to fully pay for Manufacturing
Runs set out in the Firm Zone or Merck&rsquo;s obligations under any open Work Order or Purchase Order in accordance to Sections 4.6 and
4.8.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">20.5</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Ongoing Supply Obligations</B>. In the event of expiration or termination
of this Agreement pursuant to ARTICLE 19 hereabove, except if this Agreement is terminated by Merck pursuant to Section 19.1 or by Manufacturer
for any reason, Manufacturer shall continue to supply Merck with Merck&rsquo;s new Work Orders or Purchase Orders after the expiration
date or termination date of this Agreement, if Merck has not identified and fully registered with the competent Regulatory Authorities
a new Manufacturer of a replacement product. Such obligation of Manufacturer shall continue until the earlier of (i) successful completion
of the technical transfer pursuant to Section 20.8, and (ii) notification by Merck to the Manufacturer that it has identified and duly
registered with the competent Regulatory Authorities a new manufacturer of the Products.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">20.6</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Accrued Rights and Surviving Obligations</B>. Termination or expiration
of this Agreement for any reason shall be without prejudice to any rights that have accrued to the benefit of any Party prior to such
termination or expiration. Such termination or expiration shall not relieve any Party from obligations which are expressly or by implication
intended to survive termination or expiration of this Agreement and shall not affect or prejudice any provision of this Agreement which
is expressly or by implication provided to come into effect on, or continue in effect after, such termination or expiration.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">20.7</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Regulatory Assistance</B>. After expiration or termination of this Agreement,
Manufacturer agrees to provide Merck with reasonable support in relation to any investigation required by any Regulatory Authority with
respect to Manufacture of the Products carried out at the Manufacturing Site during the Term, provided that Merck shall reimburse Manufacturer
for its reasonable costs in providing such assistance (other than in case of Merck&rsquo;s termination under Sections 19.6, 19.7 or 19.10).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">20.8</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Technical Transfer Assistance</B>. For a period of [***] following expiration
or termination of this Agreement for any reason, Manufacturer will provide, upon the request of Merck, its reasonable support and cooperation
in transferring the then-current manufacturing process of the Product to an alternative site, designated by Merck. Manufacturer shall
be entitled to charge Merck for its reasonable costs in supporting the technical transfer of the Products, at the Agreed Hourly Rate based
on a written and accepted quotation, provided, however, if the technical transfer is requested by Merck following its termination of this
Agreement under Sections 19.6, 19.7 or 19.10 then the Manufacturer shall provide the above technical transfer services free-of-charge.
Additionally, in connection with the technical transfer assistance provided pursuant to this Section 20.8, Manufacturer shall grant to
Merck and its Affiliates and designees a perpetual, fully-paid, non-exclusive, royalty-free license, with the right to sublicense, under
any Manufacturer intellectual Property which is reasonably necessary for the manufacture of each Product. Manufacturer&rsquo;s obligations
to support a technical transfer shall continue until such time as Merck, or its designee, successfully manufactures a validated Batch
of each Product.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">Article
21<BR>
DISASTER RECOVERY AND BUSINESS CONTINUITY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Manufacturer shall provide
Merck prior to the commencement of the first Manufacturing Run under a Purchase Order with a true, correct and complete copy of Manufacturer&rsquo;s
business continuity plan (the &ldquo;<B>BCP</B>&rdquo;) which provides for, among other things, the high level design and processes for
disaster recovery and business continuity for Manufacturer. The BCP shall be revised and updated by Manufacturer from time to time, but
in no event less than every [***]. The Parties shall meet periodically, as specified by Merck, to discuss and analysis the status of the
BCP. Manufacturer shall provide a written report to Merck for such discussions and analysis which shall analysis the effectiveness of
the applicable BCP, propose necessary changes, suggest improvements, and provide an updated risk assessment for the activities to which
the BCP relates.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">Article
22<BR>
DISPUTE RESOLUTION</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">22.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Disputes</B>. The Parties recognize that disputes as to certain matters
may from time to time arise during the Term which relate to either Party&rsquo;s rights and/or obligations hereunder. It is the objective
of the Parties to establish under this ARTICLE 22 procedures to facilitate the resolution of disputes arising under this Agreement (other
than any disputes relating to matters which under this Agreement Merck has sole decision-making authority and/or discretion (each, a &ldquo;<B>Non-Escalable
Dispute</B>&rdquo;), in which case, such matter shall be determined by Merck and shall not be part of the dispute resolution procedure
set forth in this ARTICLE 22) in an expedient manner by mutual cooperation and without resort to litigation. In the event that the Parties
are unable to resolve such dispute through diligent review and deliberation within [***] from the day that one Party had designated the
issue as a dispute in written notice to the other Party, then either Party shall have the right to escalate such matter to the Executive
Officers as set forth in Section 22.2.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">22.2</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Escalation to Executive Officers</B>. Either Party may, by written notice
to the other Party, request that a dispute (other than a Non-Escalable Dispute) that remains unresolved for a period of [***] as set forth
in Section 22.1 arising between the Parties in connection with this Agreement be resolved by the Executive Officers, within [***] alter
referral of such dispute to them. If the Executive Officers cannot resolve such dispute within [***] after referral of such dispute to
them, then, at any time after such [***] period, either Party may proceed to enforce any and all of its rights with respect to such dispute
in accordance with this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">22.3</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Injunctive Relief</B>. No provision herein shall be construed as precluding
a Party from bringing an action for injunctive relief or other equitable relief prior to the initiation or completion of the above procedure.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center; text-indent: 0cm">Article
23<BR>
MISCELLANEOUS PROVISIONS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">23.1</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Relationship of the Parties</B>. Nothing in this Agreement is intended
or shall be deemed, for financial, tax, legal or other purposes, to constitute a partnership, agency, joint venture or employer-employee
relationship between the Parties.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">23.2</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Assignment</B>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt">(a)</TD><TD STYLE="text-align: justify"><B>Assignment Generally</B>. Except as expressly provided herein, neither this Agreement nor any interest
hereunder shall be assignable, nor any other obligation delegable, by Manufacturer without the prior written consent of Merck (not to
be unreasonably withheld or delayed).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt">(b)</TD><TD STYLE="text-align: justify"><B>Assignment by Merck</B>. Merck may assign this Agreement, in whole or in part, to any Affiliate or
Third Party without the consent of Manufacturer. Merck shall give written notice to Manufacturer promptly following any such assignment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt">(c)</TD><TD STYLE="text-align: justify"><B>Continuing Obligations</B>. No assignment under this Section 23.2 shall relieve the assigning Party
of any of its responsibilities or obligations hereunder and, as a condition of such assignment, the assignee shall agree in writing to
be bound by all obligations of the assigning Party hereunder. This Agreement shall be binding upon the successors and permitted assigns
of the Parties.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 36pt"></TD><TD STYLE="width: 36pt">(d)</TD><TD STYLE="text-align: justify"><B>Void Assignments</B>. Any assignment not in accordance with this Section 23.2 shall be void.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">23.3</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Performance and Exercise by Affiliates</B>. Merck shall have the right
to have any of its obligations hereunder performed, or its rights hereunder exercised, by, any of its Affiliates and the performance of
such obligations by any such Affiliate(s) shall be deemed to be performance by Merck; provided, however, that Merck shall be responsible
for ensuring the performance of its obligations under this Agreement and that any failure of any Affiliate performing obligations of Merck
hereunder shall be deemed to be a failure by Merck to perform such obligations.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">23.4</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Technical Managers</B>. Each Party will notify the other in writing with
the name of a technical manager who will be responsible for dealing with all matters relevant to this Agreement. The appointment of Manufacturer&rsquo;s
technical manager shall be subject to approval of Merck, not to be unreasonably withheld or delayed. Manufacturer shall replace its technical
manager upon Merck&rsquo;s request for reasonable cause within [***]. Unless otherwise mutually agreed, the technical managers and other
appropriate representatives from each Party shall endeavor to meet no less than once every [***] to discuss matters relevant to the Manufacture
and supply of Products hereunder.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">23.5</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Occurrence of Force Majeure Event</B>. If any Force Majeure Event occurs
in relation to either Party which affects or may affect the performance of any of its obligations under this Agreement, it shall use all
Commercially Reasonable Efforts to mitigate the effects of such delay or prevention upon the performance of its obligations under this
Agreement, promptly notify the other Party as to the nature and extent of such Farce Majeure event; and resume performance of its obligations
as soon as reasonably possible alter the removal of the cause of the delay or prevention. Neither Party shall be deemed to be in breach
of this Agreement, or shall be otherwise liable to the other Party, by reason only of any delay in performance, or the non-performance
of any of its obligations hereunder, to the extent that the delay or non-performance is due to any Force Majeure Event of which it has
duly notified the other Party, and the time for performance of that obligation shall be extended accordingly. Without limiting Merck&rsquo;s
right to terminate this Agreement pursuant to Section 19.9, if the performance by either Party of any of its obligations under this Agreement
is prevented or delayed by a Force Majeure Event for a continuous period in excess of [***], the Parties shall enter into bona fide discussions
with a view to alleviating its effects, or to agreeing upon such alternative arrangements as may be fair and reasonable in the circumstances.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">23.6</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>No Trademark Rights</B>. No right, express or implied, is granted by
this Agreement to a Party to use in any manner the name or any other trade name or trademark of the other Party in connection with the
performance of this Agreement or otherwise.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">23.7</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Entire Agreement of the Parties; Amendments</B>. This Agreement and the
Schedules hereto constitute and contain the entire understanding and agreement of the Parties in respect of the subject matter hereof
and cancel and supersede any and all prior negotiations, correspondence, understandings and agreements between the Parties, whether oral
or written, regarding such subject matter. In the event of any conflict or contradiction between this Agreement and a Schedule, the provisions
of this Agreement shall prevail, except with respect to conflicts or contradiction for matters of quality or technical nature, in which
case the applicable Quality Agreement shall prevail. No waiver, modification or amendment of any provision of this Agreement shall be
valid or effective unless made in a writing referencing this Agreement and signed by a duly authorized officer of each Party.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">23.8</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Captions</B>. The captions to this Agreement are for convenience only,
and are to be of no forte or effect in construing or interpreting any of the provisions of this Agreement.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">23.9</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Governing Law and Arbitration</B>. This Agreement shall be governed by
and interpreted in accordance with the laws of Germany, excluding application of any conflict of laws principles that would require application
of the Law of a jurisdiction outside of Germany and further excluding the UN Convention an Contracts for the International Safe of Goods
(CISG). All disputes arising out of or in connection with this Agreement or its validity shall be submitted to the International Court
of Arbitration and shall be finally settled in accordance with the Arbitration Rules of the International Chamber of Commerce. The place
of arbitration shall be Geneva, Switzerland. The number of arbitrators shall be three (3). The language of the arbitral proceedings shall
be English.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">23.10</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Notice</B>. Any notice to be given by either Party under or in connection
with this Agreement to the other Party must be in writing in English and shall be delivered by hand or by courier. A copy by fax or by
email shall be sent to the addresses set out below (or such other address or number as may be notified to the other Party from time to
time):</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">Manufacturer:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">Address: Richter-Helm BioLogics GmbH
&amp;Co.KG., [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">Fax: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">Email: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">Attention: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">Merck:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">Address: Merck Serono S.A.&mdash;[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">Phone: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">Email: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">Attention: [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">With copy to: Legal Department</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify">Unless there is evidence that it was
received earlier, notices sent in accordance with this Section 23.10 are to be deemed to have been received: if delivered by hand or by
courier, when left at the address referred to above; or if sent by fax or email, when transmitted, provided that if deemed receipt occurs
before 9am on a Working Day the notice shall be deemed to have been received at 9am on that day, and if deemed receipt occurs alter 5pm
on a Working Day, or on a day which is not a Working Day, the notice shall be deemed to have been received at 9am on the next Working
Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">23.11</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Waiver</B>. A waiver by either Party of any of the terms and conditions
of this Agreement in any instance shall not be deemed or construed to be a waiver of such term or condition for the future, or of any
other term or condition hereof All rights, remedies, undertakings, obligations and agreements contained in this Agreement shall be cumulative
and none of them shall be in limitation of any other remedy, right, undertaking, obligation or agreement of either Party.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">23.12</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Severability</B>. When possible, each provision of this Agreement will
be interpreted in such manner as to be effective and valid under Applicable Law, but if any provision of this Agreement is held to be
prohibited by or invalid under Applicable Law, such provision will be ineffective only to the extent of such prohibition or invalidity,
without invalidating the remainder of this Agreement. The Parties shall make a good faith effort to replace the invalid or unenforceable
provision with a valid one which in its economic effect is most consistent with the invalid or unenforceable provision.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">23.13</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>No Implied License</B>. Except as set forth in Section 3.3, no right
or license is granted to Manufacturer hereunder by implication, estoppel, or otherwise to any know-how, patent or other Intellectual Property
owned or controlled by Merck or its Affiliates.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">23.14</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Interpretation</B>. The words &ldquo;include,&rdquo; &ldquo;includes&rdquo;
and &ldquo;including&rdquo; shall be deemed to be followed by the phrase &ldquo;without limitation.&rdquo; All references herein to Articles,
Sections, and Schedules shall be deemed references to Articles and Sections of, and Schedules to, this Agreement unless the context shall
otherwise require. Unless the context otherwise requires, countries shall include territories.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 36pt; text-align: justify; text-indent: -36pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 36pt">23.15</TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Counterparts</B>. This Agreement may be executed in counterparts, each
of which will be deemed an original, and all of which together will be deemed to be one and the same instrument. A facsimile or a portable
document format (PDF) copy of this Agreement, including the signature pages, will be deemed an original.</FONT></TD></TR></TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[SIGNATURE PAGE FOLLOWS]</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">IN WITNESS WHEREOF, the Parties
have caused this Agreement to be executed, by duly authorized representatives, as of the Effective Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B></B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Merck KGaA</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Richter-Helm
    Biologics GmbH &amp; Co. KG</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: justify; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="width: 20%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="text-align: justify; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">[***]</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">40</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 0pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>5
<FILENAME>ea156790ex10-12_helixacq.htm
<DESCRIPTION>AMENDMENT NO. 2 TO CONTRACT MANUFACTURING AGREEMENT, BY AND BETWEEN MOONLAKE IMMUNOTHERAPEUTICS AG, AS ASSIGNEE OF MERCK HEALTHCARE KGAA, AND RICHTER-HELM BIOLOGICS GMBH & CO.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit 10.12</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Certain confidential information contained in this document, marked
by brackets as [***], has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
In addition, certain personally identifiable information contained in this document, marked by brackets as [***], has been omitted from
this exhibit pursuant to Item 601(a)(6) under Regulation S-K.</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>AMENDMENT NO.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TO THE CLINICAL AND COMMERCIAL MANUFACTURING
AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">This Amendment No.2 (the &ldquo;Amendment No.2&rdquo;),
is made and entered into, as of November 20<SUP>th</SUP>, 2020 (&ldquo;Effective Date&rdquo;), by and between:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Richter Helm Biologics GmbH &amp; Co.KG, a corporation organized
under the laws of Germany having a place of business at [***] (&ldquo;<B>Manufacturer</B>&rdquo;), and</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Merck Healthcare KGaA, a corporation organized under the
laws of Germany and having a place of business at Frankfurter Strasse 250, 64293 Darmstadt, (&ldquo;<B>Merck</B>&rdquo;).</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Manufacturer and Merck may be referred to herein individually
as a &ldquo;<B>Party</B>&rdquo; or, collectively, as &ldquo;<B>Parties</B>.&rdquo;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>WITNESSETH</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>WHEREAS</B>, Merck, and Manufacturer have entered into
a Clinical and Commercial Manufacturing Agreement dated as of October 15<SUP>th</SUP>, 2018 and amended by Amendment No.1 dated as of
December 6, 2019 (hereinafter referred to as the &ldquo;Agreement&rdquo;);</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>WHEREAS</B>, the Agreement was transferred from Merck
KGaA to Merck Healthcare KGaA an 1st April 2019 as part of a business restructuring of Merck KGaA;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>WHEREAS</B>, the Parties wish to amend the Agreement
in accordance with the terms set forth in this Amendment;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>NOW, THEREFORE</B>, in consideration of the premises
and the mutual covenants herein contained and eventual addenda, the Parties agree to amend the existing Agreement, with effect from the
Effective Date, as follows:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>ARTICLE 1&mdash; DEFINITIONS</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Capitalized terms not otherwise defined herein shall have
the meanings given in the Agreement.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>ARTICLE 2 &mdash; AMENDMENTS</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">As of the Effective Date of this Amendment No.2, the Agreement
shall be amended as follows:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2.1 The Parties hereby
acknowledge and agree to delete Article 5.9 (Key Performance Indicators) in its entirety and replace it by the following Article 5.9
(Key Performance Indicators):</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>5.9 Key Performance Indicators.</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The Parties agree to measure Manufacturer&rsquo;s
performance of its Development (when applicable) &amp; Commercial Manufacturing Services through the establishment of Key
Performance Indicators (&ldquo;<B>KPIs</B>&rdquo;) set forth in Schedule 2. As long as Manufacturer only delivers up to [***]
commercial Batches per year, Manufacturer shall provide Merck with [***] reports out of its performance based on the KPIs. From
[***] Batches per year, the reports should occur [***]. The Parties may agree on additional KPIs by means of further amendments to
this Agreement. The Parties shall agree upon the relative importance of the KPIs by classifying each KPI with a designation of
&ldquo;minor&rdquo;, &ldquo;major&rdquo; or &ldquo;critical&rdquo;. The Parties shall agree in good faith by [***] of each [***],
(beginning with the [***] of the Agreement), the performance level objectives of Manufacturer for the following year. The
performance level objectives shall be established for individual KPIs and for overall performance and on the basis of actual, past
performance, and shall be expressed in measurable values. In addition, minimum acceptance levels shall be agreed upon for all
critical KPIs and for overall performance. Manufacturer shall use all Commercially Reasonable Efforts to ensure that its performance
does not fall below these minimum acceptance levels. Notwithstanding Manufacturer&rsquo;s use of all Commercially Reasonable
Efforts, if at any time Manufacturer&rsquo;s overall performance or performance for critical KPIs falls below the established
minimum acceptance levels, Manufacturer shall promptly take corrective action to cure such under-performance.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">2.2 The Parties hereby
acknowledge and agree to delete in its entirety Schedule 2 (KPIs) and replace it by a new Schedule 2 (KPIs) attached to this
Amendment No.2.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2.3 The Parties hereby
acknowledge and agree to add to Schedule 5 &mdash; DEVELOPMENT SERVICES, DELIVERABLES &amp; TIMELINES an additional sub-section
entitled &ldquo;<B>Performance of the HSA binding Assay (ELISA)</B> &rdquo; as follows:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>[***]</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>ARTICLE 3 &mdash; NO OTHER AMENDMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Except as expressly amended hereby,
all of the terms and conditions of the Agreement shall remain unchanged and in full force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>IN WITNESS WHEREOF, </B>the Parties
have caused this Amendment No.2 to be executed by their respective duly authorized officers or representatives in two (2) copies, each
an original. This Amendment No.2 may be executed via facsimile or &ldquo;.pdf&rsquo; file and in counterparts, each of which shall be
signed by each of the contracting parties and deemed an original, but all of which together shall constitute one and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MERCK HEALTHCARE
    KGAA</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Richter
    Helm Biologics GmbH &amp; Co.KG</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***] </FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***] </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="text-align: justify; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD STYLE="width: 20%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="text-align: justify; width: 35%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***] </FONT></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***] </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>6
<FILENAME>ea156790ex10-13_helixacq.htm
<DESCRIPTION>ASSIGNMENT OF CONTRACT MANUFACTURING AGREEMENT, DATED JULY 1, 2021, BY AND AMONG MOONLAKE IMMUNOTHERAPEUTICS AG, MERCK HEALTHCARE KGAA, AND RICHTER-HELM BIOLOGICS GMBH & CO.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 10.13</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Certain personally identifiable information contained in this document,
marked by brackets as [***], has been omitted from this exhibit pursuant to Item 601(a)(6) under Regulation S-K.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: center"><B>ASSIGNMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify">This ASSIGNMENT AGREEMENT (the &ldquo;<B>Assignment</B>&rdquo;)
is entered into as of 1 July 2021, (&ldquo;<B>Assignment Effective Date</B>&rdquo;) by and among Merck Healthcare KGaA, Frankfurter StraBe
250, 64293 Darmstadt, Germany (&ldquo;<B>Merck</B>&rdquo;), Richter-Helm BioLogics GmbH &amp; Co. KG, [***] (&ldquo;<B>Richter Helm</B>&rdquo;),
and MoonLake Immunotherapeutics AG, c/o KD Zug-Treuhand AG, Untermuli 7, 6302 Zug, Switzerland (CHE-433.093.536) (&ldquo;<B>MoonLake</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: center"><B>WITNESSETH:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>,
Merck and the Richter Helm entered into a contract manufacturing agreement dated 15 October 2018, as amended by Amendment No. 1 effective
6 December 2019, by Amendment No. 2 effective 20 November 2020, Amendment No. 3 effective I January 2021 and Amendment No. 4 effective
30 June 2021 (together the &ldquo;<B>CMO Agreement</B>&rdquo;), with respect to the manufacture of Merck&rsquo;s proprietary ILl7 nanobody named
sonelokimab (also known as M1095);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>,
MoonLake and Merck informed Richter Helm that they have entered into a certain License Agreement on 29 April 2021 (the &ldquo;<B>License
Agreement</B>&rdquo;), pursuant to which Merck agreed to transfer and license, among other things, certain assets and rights related to
its Ml095 compound; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify; text-indent: 0.5in"><B>WHEREAS</B>,
in connection with the License Agreement, and subject to the terms and conditions of this Assignment, Merck desires to assign to MoonLake,
and MoonLake desires to accept and assume, all of Merck&rsquo;s rights, obligations, title and interest in and to the CMO Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify; text-indent: 0.5in"><B>NOW, THEREFORE</B>,
in consideration of the promises and mutual agreements set forth in this Assignment, the receipt and sufficiency of which are hereby acknowledged,
the parties agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify; text-indent: 0.5in">1. Effective
as of the Assignment Effective Date, (i) Merck hereby assigns to MoonLake, and MoonLake hereby accepts and assumes from Merck all of Merck&rsquo;s
rights, obligations, title and interest in and to the CMO Agreement and all purchase orders placed by Merck under the CMO Agreement (&ldquo;<B>Purchase
Orders</B>&rdquo;), and MoonLake and Richter Helm undertake to observe, perform under, and to be bound by the terms of, the CMO Agreement
and the Purchase Orders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify; text-indent: 0.5in">2. Effective
as of the Assignment Effective Date, Richter Helm hereby releases and discharges Merck from all obligations and liabilities of Merck under
the CMO Agreement (provided that Merck shall remain responsible for any obligations under the CMO Agreement that survive such agreement
and have occurred or been triggered prior to the Assignment Effective Date), and accepts the performance thereof by MoonLake in place
of performance by Merck.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify; text-indent: 0.5in">3. The
CMO Agreement shall remain in full force and effect, subject to the terms set forth in this Assignment and the Amendment No. 5, which
is currently being negotiated by Richter Helm and MoonLake.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify; text-indent: 0.5in">4. Representations
and Warranties. Merck hereby represents and warrants to MoonLake the following: (i) the CMO Agreement is currently in force, valid and
enforceable; and (ii) to its knowledge, Merck and Richter Helm each fulfilled and performed their obligations under the CMO Agreement
and neither Merck nor Richter Helm are in a material breach of the CMO Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify; text-indent: 0.5in">5. Each
Party will keep confidential and will not disclose to any third party (other than its advisors who are under a duty of confidence) the
terms of this Agreement. For the avoidance of doubt, Merck undertakes to continue to be bound by the obligations of confidentiality contained
in the CMO Agreement, unless Richter Helm and MoonLake agree otherwise in writing. As of the Assignment Effective Date, confidential information
disclosed by Merck to Richter Helm under the CMO Agreement shall be deemed to have been disclosed by MoonLake to Richter Helm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify; text-indent: 0.5in">6. Richter
Helm and MoonLake are currently negotiating the Amendment No. 5 to the CMO Agreement and will, in addition, negotiate in good faith a
Quality Agreement (as defined in the CMO Agreement) within ninety (90) days of the Assignment Effective Date (but in no event later than
ninety (90) days prior to the anticipated start of the first GMP manufacturing campaign) which shall essentially correspond to the existing
Quality Agreement between Merck and Richter Helm.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify; text-indent: 0.5in">7. Each
party hereto covenants and agrees to execute and deliver such other documents, certificates, agreements and other writings and to take
such other actions as may be reasonably necessary or desirable in order to consummate or implement expeditiously the transactions contemplated
by this Assignment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify; text-indent: 0.5in">8. This
Assignment shall be binding upon and inure to the benefit of the parties hereto and their respective successors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify; text-indent: 0.5in">9. For
the convenience of the parties hereto this Assignment may be executed in three or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same agreement. A facsimile or a portable document format (PDF) copy
of this Agreement, including the signature pages with signatures (in form of handwritten, non-certified electronic or certified electronic
signatures), will be deemed an original.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify; text-indent: 0.5in">10. An
amendment of any of the provisions of this Assignment is only valid if it is in writing and signed by each Party or authorized representatives.
Any provision contained in this Agreement may only be waived by a document signed by the Party waiving such provision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify; text-indent: 0.5in">11. This
Assignment shall be governed by and interpreted in accordance with the laws of Germany, excluding application of any conflict of laws
principles that would require application of the Law of a jurisdiction outside of Germany and further excluding the UN Convention on Contracts
for the International Sale of Goods (CISG).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify; text-indent: 0.5in">12. All
disputes arising out of or in connection with this Assignment or its validity shall be submitted to the International Court of Arbitration
and shall be finally settled in accordance with the Arbitration Rules of the International Chamber of Commerce. The place of arbitration
shall be Geneva, Switzerland. The number of arbitrators shall be three (3). The language of the arbitral proceedings shall be English.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify; text-indent: 0.5in">13. Should
one or several provisions of this Assignment be or become invalid, then the Parties hereto shall substitute valid provisions for such
invalid ones. The substituted provision(s) shall in their economic effect come so close to the invalid provision(s) that it can be reasonably
assumed that the Parties would have contracted on the basis of the new provision(s). If such provision(s) cannot be found, the invalidity
of one or several provisions of this Assignment shall not affect the validity of the Assignment as a whole, unless the invalid provision(s)
is of such essential importance for this Assignment that it is reasonably assumed that the Parties would not have entered this Assignment
without the invalid provision(s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify; text-indent: 0.5in">14. The
validity of this Assignment is subject to the execution of the Amendment No. 5 to the CMO Agreement which is currently being negotiated
by Richter Helm and MoonLake. For the avoidance of doubt, the assignment of the CMO Agreement to MoonLake shall only become effective
if and when the Amendment No. 5 has been executed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: center">[SIGNATURE PAGE FOLLOWS]</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 1.5pt 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the parties hereto have executed
this Agreement as of the date first set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Merck Healthcare KGaA</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name: </FONT></TD>
    <TD STYLE="width: 31%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Merck Healthcare KGaA</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Richter-Helm BioLogics GmbH &amp; Co. KG</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title: </FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Richter-Helm BioLogics GmbH &amp; Co. KG</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid">[***]</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;[***]</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="3"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MoonLake Immunotherapeutics AG</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ A. Ploos van Amstel</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A. Ploos van Amstel</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Operating Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>hlxa-20211231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.12b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +a8pw7xRiXhun8uCa3NMOaOB6cOdypp0CZkxsGd+fYk6nyosLF32xy6MH0KmMawA -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:HLXA="http://helixacquisitioncorp.com/20211231" elementFormDefault="qualified" targetNamespace="http://helixacquisitioncorp.com/20211231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://helixacquisitioncorp.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="hlxa-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="hlxa-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>hlxa-20211231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.12b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>hlxa-20211231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoXBRL; Version: 5.12b -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://helixacquisitioncorp.com/role/Cover" xlink:href="hlxa-20211231.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://helixacquisitioncorp.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140619400756920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">S-1/A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">This registration statement
registers the resale of up to 11,500,000 Class&#160;A Ordinary Shares (the &#8220;PIPE Shares&#8221;), par value $0.0001
per share, of Helix Acquisition Corp., a Cayman Islands exempted company (&#8220;Helix&#8221;), by the selling shareholders
named in this prospectus (or their permitted transferees) (the &#8220;Selling Shareholders&#8221;). The Selling Shareholders
are expected to be issued the PIPE Shares in private placements immediately prior to or substantially concurrently with the consummation
of the proposed business combination (the &#8220;Business Combination&#8221;) by and among Helix, MoonLake Immunotherapeutics
AG, a Swiss stock corporation (&#8220;MoonLake&#8221;), the existing securityholders of MoonLake (collectively, the &#8220;ML
Parties&#8221;), Helix Holdings LLC, a Cayman Islands limited liability company and the sponsor of Helix, and the representative
of the ML Parties.

&#160;

The PIPE Shares will
not be issued and outstanding at the time of the extraordinary general meeting of Helix&#8217;s shareholders relating to the Business
Combination and, accordingly, will not be entitled to vote at the extraordinary general meeting and will not have redemption rights in
connection therewith. Further, the holders of the PIPE Shares will not receive any proceeds from the trust account established in connection
with Helix&#8217;s initial public offering in the event Helix does not consummate an initial business combination by the October&#160;22,
2022 deadline set forth in its amended and restated memorandum and articles of association. In the event the Business Combination is not
approved by Helix shareholders or the other conditions precedent to the consummation of the Business Combination are not met or waived,
the PIPE Shares will not be issued and Helix will seek to withdraw this registration statement prior to its effectiveness.

&#160;

Helix is filing this
Amendment No. 2 to the registration statement as an exhibits-only filing to file the exhibits attached hereto. Accordingly, this amendment
consists only of the facing page, this explanatory note, Part II of the registration statement, the signature pages to the registration
statement, and the filed exhibits.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Helix Acquisition Corp<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001821586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">E9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>ea156790-s1a2_helixacq_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="hlxa-20211231.xsd" xlink:type="simple"/>
    <context id="From2021-01-01to2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001821586</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-01-01to2021-12-31">0001821586</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-01-01to2021-12-31">true</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0010">S-1/A</dei:DocumentType>
    <dei:EntityRegistrantName contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0012">Helix Acquisition Corp</dei:EntityRegistrantName>
    <dei:EntityFilerCategory contextRef="From2021-01-01to2021-12-31" id="xdx2ixbrl0015">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-01-01to2021-12-31">E9</dei:EntityIncorporationStateCountryCode>
    <dei:EntitySmallBusiness contextRef="From2021-01-01to2021-12-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-01-01to2021-12-31">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2021-01-01to2021-12-31">false</dei:EntityExTransitionPeriod>
    <dei:AmendmentDescription contextRef="From2021-01-01to2021-12-31">This registration statement
registers the resale of up to 11,500,000 Class&#160;A Ordinary Shares (the &#x201c;PIPE Shares&#x201d;), par value $0.0001
per share, of Helix Acquisition Corp., a Cayman Islands exempted company (&#x201c;Helix&#x201d;), by the selling shareholders
named in this prospectus (or their permitted transferees) (the &#x201c;Selling Shareholders&#x201d;). The Selling Shareholders
are expected to be issued the PIPE Shares in private placements immediately prior to or substantially concurrently with the consummation
of the proposed business combination (the &#x201c;Business Combination&#x201d;) by and among Helix, MoonLake Immunotherapeutics
AG, a Swiss stock corporation (&#x201c;MoonLake&#x201d;), the existing securityholders of MoonLake (collectively, the &#x201c;ML
Parties&#x201d;), Helix Holdings LLC, a Cayman Islands limited liability company and the sponsor of Helix, and the representative
of the ML Parties.

&#160;

The PIPE Shares will
not be issued and outstanding at the time of the extraordinary general meeting of Helix&#x2019;s shareholders relating to the Business
Combination and, accordingly, will not be entitled to vote at the extraordinary general meeting and will not have redemption rights in
connection therewith. Further, the holders of the PIPE Shares will not receive any proceeds from the trust account established in connection
with Helix&#x2019;s initial public offering in the event Helix does not consummate an initial business combination by the October&#160;22,
2022 deadline set forth in its amended and restated memorandum and articles of association. In the event the Business Combination is not
approved by Helix shareholders or the other conditions precedent to the consummation of the Business Combination are not met or waived,
the PIPE Shares will not be issued and Helix will seek to withdraw this registration statement prior to its effectiveness.

&#160;

Helix is filing this
Amendment No. 2 to the registration statement as an exhibits-only filing to file the exhibits attached hereto. Accordingly, this amendment
consists only of the facing page, this explanatory note, Part II of the registration statement, the signature pages to the registration
statement, and the filed exhibits.</dei:AmendmentDescription>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M+1[/X<XU]91=9>:+]"J[+',-@>R.7<NG3HR Q$Z!^E^_JB/9J9>:*CDQA<U
MWW"$-1YZKT;^9265%-U+(\0S::>@QIIORA'1/3SW[9>\*Q!DUVV(7*N:2W"
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M#%=$77ZE*!^LRMV7@;FR5J7NYPJS6FC:@/<+A;9:/9""YEO1]7]02P,$%
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M$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XUA]) 1-MC0[!:+#Y
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M4')O<',O8V]R92YX;6Q02P$"% ,4    " #Q@6Y4F5R<(Q &  "<)P  $P
M            @ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    (
M /&!;E2WD8L0IP8  #<2   8              " @0T(  !X;"]W;W)K<VAE
M971S+W-H965T,2YX;6Q02P$"% ,4    " #Q@6Y4GZ ;\+$"  #B#   #0
M            @ 'J#@  >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( /&!;E27
MBKL<P    !,"   +              "  <81  !?<F5L<R\N<F5L<U!+ 0(4
M Q0    ( /&!;E2JQ"(6,P$  "("   /              "  :\2  !X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    " #Q@6Y4)!Z;HJT   #X 0  &@
M        @ $/%   >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    " #Q@6Y499!YDAD!  #/ P  $P              @ 'T%   6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"   ^%@     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>123</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea156790-s1a2_helixacq.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://helixacquisitioncorp.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="S-1/A" original="ea156790-s1a2_helixacq.htm">ea156790-s1a2_helixacq.htm</File>
    <File>ea156790ex10-10_helixacq.htm</File>
    <File>ea156790ex10-11_helixacq.htm</File>
    <File>ea156790ex10-12_helixacq.htm</File>
    <File>ea156790ex10-13_helixacq.htm</File>
    <File>ea156790ex10-9_helixacq.htm</File>
    <File>hlxa-20211231.xsd</File>
    <File>hlxa-20211231_lab.xml</File>
    <File>hlxa-20211231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="10">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ea156790-s1a2_helixacq.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "ea156790-s1a2_helixacq.htm"
     ]
    },
    "labelLink": {
     "local": [
      "hlxa-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "hlxa-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "hlxa-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 5
   },
   "keyCustom": 0,
   "keyStandard": 123,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "HLXA",
   "nsuri": "http://helixacquisitioncorp.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea156790-s1a2_helixacq.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AmendmentDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://helixacquisitioncorp.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "ea156790-s1a2_helixacq.htm",
      "contextRef": "From2021-01-01to2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AmendmentDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://helixacquisitioncorp.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001213900-22-012161-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-22-012161-xbrl.zip
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M$<)RH?JJC( TMO.68PR8YP\L\6Z]#92XQ\JEGL^NS"XT.1-]=NETN9V7#_(
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MHV][>^ @O=+>UX?0AWY$P;PM2)N>_.F$MX5>581*^9>"_O+X0Z-Y=5F_ C'
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MG1NUGXEQ[>$@]D1(U_</^0 0PAJ>Q6W#&XYF1^3>BO_I&Z/KFEHU)-4"DJ7
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M*."-LCI%;[BW%$!"WQ*+?SONC[P$Y>QO^0B83RLM!90;6EE3YOI.>;>P SY
M"->OAG)F=SL7("FRD*"L)A](I<\^@$MN8Q[K7!=A_+"FWN$@AOYT.O:\Z7/"
M7,E"1'OKD%M&[%SCL!?%<R42#YQ;L !W\^S+-49#V4<G\ 3"F'\((#^X$CZ,
MQSX48H:COS!51:NM_4]_EPOE<JE*L"3P!:_(\JW6%+_L5H%?2EM;SYM?+@>
MJ+JBE-/ ?3"..4"Z$#8[#*E4N _'.1_,ED<>4&#;"5W(#MW US'N.7]5.!:6
M6JW&3E4":AB4"=VVTKRUR%@HFD &[V%)=-/3G3P[K(=,4"[5'@J&C6HY9+[*
M;F5463W-H.#*5WLROMIBQOTG\'RS/9B2,MCKN<ZMV<7=%X.V8,#PU9UN%P_
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M>1^#H'?N0]#WH>(EH=R=QY&^IQP<LU^0O1FE&Q[0E'T,PMQ]882YNP0B]<_
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M*T%1!V 1N-#>L@;L"VKGDXOG+98J+X>(%GI+18*&1FZI(!/."@QYQW5HL=7
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M]+3C],%==],/48O%RLAV$A8<PT D@CEV%0!=B?4EA6C&BS?9RHP[#[/Q6/(
M#OGP"HGC#^:8ME+H\P:P;UH6AKU *SLHA4.JE@8XEWJ?]JOCO6L,Y**'Z+B1
MN1PM&)!&T!,NK!SY_UW' .XCAHG'E)XZ+'R(F@G6==;,^OS.N,?Q$<YX";J
M<!.:6H.AJ811')K26@[FM%(/3U@]U!:B'H8H#RV4+(W!LA1&'( CFSGMS8[8
M.#+DD[W-EMA>4SP/K,.1GKMX!B]EUR<C:).Z3*JM"?LN&&6\YJYA@3Q.]=C'
M46AW1_@=QY!"''D+"&_8? O]^EB5FB,F'NX7A9X+;B*A11>R:HS2E"T9FXIM
MQ[*</H&C.W@L4QTDFXQ5E(G2TT*@Y=V.*3A)OX6M0#)ZH(-<.4T"E0#%^0YY
M4R1DTY"O]J^60+0L>/^J3IM68$VA_^&F-K#2VFV4,^-@:89S'T>DPVTP:85-
ML3]7.UM/F>3N0'-M5PBFY'%ZUW0,'0&1@EV%5 ?R%%T$<-(%6/KM*3H#FI*8
MA[_)9 U)<3#AHQ45/FDJG#74CVI39F1&JIG\SFFT2:HR19SH@7!IAV7N&/ 6
M5C^>3*68)IVP+7K*?633R3TIB%<[54^=?&]F%Z*27%/68^1?AP&9T**/0]SD
M>$Z4?R-&Y<K+7 :2NB=%;<U&4 W;<]K<Q:"7.53: EW/T+^4?@]EFHS?1PHS
M$'KHGE)".U!45!(C'U7!D(=%,'P#SA!)6WB82) ?Z_LE,CNDI/3(<Z* %7%%
MW_141D*B#Z!EF6;/#?@BS,L(&:0' CSV<C$10NVVII&!O'4-PM[S54H]*!'X
M<X"($[>8X>"A2%:]#N&%@H_2PW,IJSH/2!2H*71!1Q=90Z4DW$31*,YTBYM=
M6H5A8$)("-+D$FT0%G _BZOD(2ZOJU",G]0];81;V!ZE;0"XRIWM<9.T#X]6
M+EHX?#VZ;!FK)K&PE@/X=$ ,'D4PP JS9?P"52ZGS#@,S9EA0 U39J#7UX1J
MP*:K0HXR!#8C+# R/+5EXAU%#&6>W80=FA%ZD0'(P*9 PBB9H,;600R!.ZUR
M5GR,!T=4Y@G?MR3H"0#7<CU,KC(H4.$%+6 0"L-@5RI"W0,D]%R,  )[ J\9
MIJYDNV _ TS_P2EU!(G_3"*%(66T>ARIKN4B6F7C236,(USC:6];3H68#YQ%
M"[CHG\ (1PSW9TW/"Q88E5R*DR5;JY,E\<F2Z@L^6;+P<R#A DXZ!M)L?#BK
M7WVY/&Z^Y ,?%T/V@8H[T68C)6;-EF2=83$86 "?CN,9DZ+.*L"EC&G40+X7
M^FQ2;*HXO&RA;(  -\]H!![X'<<U_\572B(?JG ^8$S"^+?C_@!T^6H;:.BY
MTA#EJH\[10-9GL7%Q%RLK5!<%LJ(S?*D&3YLIM\9Q(35#;!( :QCKF[/ PD3
M_FM]AN(B,]<0&5.6 \;"VA/OUK7UR=\OO$3'Q^.3QC=6/_S\I=%L7#7.S]CA
M^>7%?0JN/#9.$IW>'V)%(ENE7[NEN?9X]U,?#/8FUI29;GBH.53&3V*>\&YZ
MF^S [ 2<'7:$'>+VP:GO<;F0+"8UZR4$+UZ?%[<R5R8X:),YZK'J:W5,T6;'
M4=W0<^7L4J&U#C?=/G8SI<C18VOZ)VH#Q@?M\M+@2QTB:48&7^SH2YNO)?#
M3N@BA]O[44PKC(7H',T>&4BSC=!J,Z@FAZFJ<Q@K:VTF:TUR9880FJX(%?C)
MB&VE_&HHXER::\&T%JD"Z:5-%SD2LJPB<2'R,J"=)&3OA9-J]56V2[I0/)%@
M?EJ(TBJ/@:@C$!;#>)I%=8]EG.3,[H*SJ6MQW\YF0>E3 "RY*K]*<MFKN4A2
MFUS*<BJ.9P4X$_>NTQ_C.V8B(]Y66P@F9K/,V,:%:]IXRYTUVO9U-C*GS',F
MQ&9.?E:*GKI!N7B11@$K98S).]:T<:+M;G-)4=S$7>:YSB?;N7I@!KHOT\PL
MO>:&^%\2Y,N-HV67\!BJ.7*+K&X;+GST9Y%==$S+,GO>:-AFI0#8>]/F(-]!
MO(<*("'QXY>H%>HZ[A)3-ME* ;PT!0 L)6<3\97\&3+72BVLU,(RJX7'-/SO
M(Z$>@J55"M)\,;,2W$LJN,] E0_0M;.OGPHO+$IT+HA&5[IEM:0K5;A2A2M5
MN)RJ\"NF 9^(OOG$O96EI<R5 EPMZ4H!KA3@2@$NIP+\T^G8K*EWNJ;Q5%C@
MF8G+>>:T/?/4IS!QY_&RE'^?7YKRUH.E*6?O?4V^P?-N^>3SR,MY"EFU]\#D
M"GL1]NHPFFN+ 8C$ I;XGQ_>YB!#IUS)-FIES"\G^&D-W6@4:HM-X;WC[;+I
MH@2/<7OL@B:_V7*, 1+U9L?O6OMI=#2%'YY8O35NW[#&$?WC>VGGX#OT*FRJ
M&R!AI>_$G[?O__E2^M3_I_ZY\V7S\WG_]G_FX._+LW*9^XW.7[V#R]L/?Y2<
M_M7_KOZ\^6!?;G[Z6K:O.J=']9V*??/OX=7QY3DO^]?]@?V_OZQZYVOE6[=Q
M\+G:^?*_RN>O'R]/6O_K_7.D'W<WOQ[\^W=P^:=UY1X.NLW>SL</G\\NMK;?
MGW_6:W;3^Z-T\/.OJT_B0_]XQ[[X=Z=CM/XN!5_/SNOZU1>]>_13^U#_MU*M
MMC_=G%J76JE=/S:LEFYVG9^7__I'FMD[._^WQ__:/C;ZN^]__&W].#;URW/C
M_)\_M&-Q8=5/?O9;K6OQ[>.6_<?52?GD]K+IO).H^/]02P,$%     @ \8%N
M5*@(#2!*$   =5X  !P   !E83$U-C<Y,&5X,3 M,3!?:&5L:7AA8W$N:'1M
M[5Q;4QNY$GYWE?^##E6;@BUC[N0L)JXRF! VA%#@9&O/UC[(,[*M93R:E69P
MO+_^=+?F[C&0C0'GDH=@SVBDOO?7+8T/W_3>G;?KM<,W)YTN_&7X[[!WUCL_
M:1]NV+]P=R.^?7CTOOL[N^[]?G[R:F6@_/" ;6T&(>O)L3#L0DS8E1ISOV$O
M--BUT'*P @_"HY?)<Z'X%*YS3P[] Z;E<!2VV$.G:K$QUT/IKX<J.& P/+W0
M5V&HQG1MI7UXU#[Y-))]&<*<S:W-PXTCX.:R1,>"%WWA]TW0FETFS^Y?D0GE
M8/H8#!\+'7+ILT!HHWSN>5,F7>'#<I+W/<&D/U!ZS$.I?.; ZC!6N'"5A2-I
MF*N<: RC&_4:S'\#=_I3UM?<N1&A8=RP/W[^^><_&VP$'_M"^$R-91C"L(%6
M8SN%B"4>1-I$W ]9J-A9*,9L?W-KE:^M[J^QR'>%9E=B&'F6D.OUM\UG5<Z"
ME^D$6GIL^Y<&V][<WOI6N'HGM'/#W@CNA2.':\'>GO(.>ZVY?S.(= @JO0XU
M?V'^ 2-O";:]M_GH).WO;O^RP[I<CTW(W?#1USL5X#O^]/$-")S*1]<X0'F[
M3 U8Q_,D]QW!WG&?#P5ZZ0_#>BK#8L^C^$0>YV+(/=85 =<A*IYML/.3]3=/
MK?]>Y^C\A!V?G)]?=KK=LXO35RN;*_3]^K)SG'POD-)7GKLH>EIL(MUPA/QM
M_@3)KG>5K'4+24\ZW$OR*\S28A4)%R'(8:^;/!9/MRG]%40YW7;%O>;VGO2+
MDWEB +*Y$@?E9RI7/!D,A!.2!QL#MTA_\"T<@5ZE(WPC6&>H!7DTBP)(AYSU
MP-RD3\FQ7H/!9[X,)9C S -$ B*SWA6R@ IZ7), B)%8Q1/DZZ[@&@*>R\>
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M(!=_F%=2'-%F'*["_I]  $_2+ZA>.EWT/^OK[+44GGL 5CL4+9CY[PC!,Q#
MUM?CYO9A]^QC0EU^S:WMBD7W\5I?:?"B]-H1@,(;MM7< YZ,\J0+)%P69YRQ
MTL,-6+6"@#YDE)OUO@"5 I4!49TG:K^")B3T<Y?,B68#96/%L20VLH#M %J5
M;=+_6RB'DT_"B2CN'0,,7BJ7>*X8M4TQRC8EJ$[[=UT)=G=3XJC=9+UY>8,0
M:1Z* ;Z>"Z42\ 39/0N34$+Z!FIB740#;)4P*=4[,C2(HQPHUY0V((5U0N
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M]%:"!0(P@6MK -N)I4%0H-#["5B08+H66"UP#94J(J$ S]MHJBBPI:H)*RO
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M:W/;1K8V^IU5_ \X.353TBZ:MN1+XB0[58PD.WK'%VU)SISL4^=#DVR*B$&
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M7++!AB<V PUZE2YUJA+N8[W."G@Z?!;M7*$=ZSUNUW1 M68%=I$+FI9>D[\
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M(M,;P68MLC35">>.L.?V^S2[2O3T0G,*'T&?\"J":"AS1?XG5BKR/N?<&'8
MXE,K-R1%F"E:-^O!W#*VY&,@6)TZV!9UL+>AWK<W]_KZ3'+P_7XG!\V%_7A1
MH!YHMY&$=[^ 9LNS2[",8>.WK?L[].H,#A*T'BB4@?%_B@ST(=KFN>8\-F@A
MT4BU<X%KK2<5?0%ZAZH<R$ESUDW,1:5F!*1Z:7!>$(PZ<><Q&5P>ZJ%=8"W6
M@<T?4+<,W2*_@/T^+#;$LX3U<PA(\/V@(D,G)ZYC =QHN%*OQ0L#>Q%4>US,
M#5I6Y3FZ+N0*B3(FYZOY#@BZPH&W_%!N[J/+G$9?4]+;./9XBE/IF=[OP:'&
M,V\N*'8C4Y^X[JR@H<L +:C"*P"F\\H3,78YZQ+%YZ&5#%@FS6?:F"HQ"#Y"
M0G I,V-7E&QH=VJ:[VLPW7 Q+?R!?'>TE(T8T$+*W=B<X--;55.6.9I:K N1
M!PW;EER<6U-,2M/):]2RQ@I=U*E>I/:1#G9<%ZE^#Z9@G;#0 W*-D6^:^3PN
MWA=4/1*K,?BQM+\P_E+R5*ZY#PNR\9IE'#!,WPU!<'>J8;PQNN)L[Q2:0]8$
MEJI-"Q7>9C*QZ]\@"+-/L.XW"!O@N-QN(B//2*Q9/_3P9[E:Z"N$=>\X*@;5
ME'Z0[02V-3S*%%==LX-DJTSB),%7=CN$L%IE]EFKH[I3<4.GXOC6IR)V=#'[
MD<_ EGT>+Q9Z&H, HG*6TX$/*8R#@:,^R:J40(>B()?<+Z88.)*0?H]*P0J#
MIH6_D Z!=E6:I0^PHD" A+6#LU673*,=_0&[HAO="^]'$4;[6]29C=S2KN\O
MV?>[)<09W(]JPNPF,'@#$$Q7];?VRMW:SCI2=DQ\PH^W(/D0/D]:SHY#%5A5
M1TXC%]FE$LG%(TWCU;O=WMR&O3FYO<6*AS$+^Z@H=%$PS<^:3;H %QJ92PA]
M/\6J2I#.8E64>B%U!=&L2B6@1P<='IP/QFAQ(,+>/*#=/F;#Q4FJV668*N 8
M,I='N*C&S8?,JO6@Z??XI!G0R2BO'T8EAM$++HS !((Q>19J9>WU;,EF.@KE
M4I-D(J08##J, 2J>5U!"2[3&)_%2<6 F-$'D,G>X#J)Q59(=AKN_),--K*@2
MGEVHF:;_9H1_1@L%2V'))%FQUD@OXSQ+^5 V-F6;94) :"G?ZO<X1/I@HE!/
MP7K%, $C6D!=5$EI[\0#'J!6MOF#T"!LUDI.P>J8E/4$!?HZQHA1W@C[/1XB
MRT^1@<6JV005>6B5S%NJ5VZ^1T],88]+3?OZ9['%FFM"7W/.PHP:+63[>^=Y
M^+<=H+U=5%YHRUEUE%'"<<U1*ES*;.\1:.]=A,Y?$C Y"*;U>_K#$F-O7Z>
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MO A((\X,TB1@:>\:LT!;/!E2Z%N<9'Q!.O_@<,2JDVMKVA\HKV:\F_48PT%
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MZ<4#RL7]&#T=/O$_3?3,??@)LD>VA+]&C<%\WN=;WO06MVZ=H\'?[@0Y8&D
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M=W/J]7Z5\A^4\\+> 2WF%:<47"%1C@2;].^U+'+X&1AT2*'Z%SSRI<9S3VJ
MX"68\0XE[0/XWH:J6HKBY.(7&LE>$@0QEW%!"]SOO<62*AWM_'S\B_F\()_Z
M5YR=0BW*GQ\>_[(K,; 8PRA8@P6WN=+C(H;IV)F7Y;+X\>'#JZNKX129LN$6
M\(]=#F;]'YAQQ6WCF9R-#UN>&CB$Y'M+>40T;B:G01?Q@62B3&NSV_S5"&8"
MXY6\"-)3"9FWZ8QIFW)LO9"9[BZ#?@^31,3L)K_ *36_H]JUOW2>,8%?E,:I
MI?6+=AX-G_]C%Q:LO *[PK[X_J.]'^@=O ^>KY/0&@T41TGQ6)4)( ,##0AB
MMMR3U\4[UL)__&HWCG8(DBTF/>Y%FG VQQKS9!MX84L@;5!)0OT7M3'_X>=$
M?F_/>#.;T:&>Z,487@&&_CTR]49[>X^&SZ(=>#WFW8<O'D7_C40ZN^ULPM)+
MS'=Y.,I+98D<V(E3B1PY?P@'E8*B=$2/@@K&AGC(NBMRZ+JH1)A+XXOP\(*Q
M@3U7X834>?B<*\2)N,*EQ <HA9SM<](FJ4KSR.LV]<PU)[&@?<+A8\Z&I %V
M$$:4905I$KO3[VN??AL"IIZK#P;--6+2-R;C-B>8]@\PI,O$?V-F?))4!<(T
M0,)^'YT38:D#+V%C#'*D2KS]3V*8X<ZA;EW*-G0A=6CS4/Q0;W\DZJJ03D."
M?<5ZZ0%F^O&I4>M#X0S$I[H6>M3.K[2'A(K);R2+[Y9/_,E+'M3>@/6B-$PC
MW6NHOFW2;$'%RY(<]--NN>V1&=[XEJ/RFFE@OF=6I5;'U"<'<5[^DHC.LB O
M>PCP *R/:^^+U>"&FG/-CVXYZKNO.NYLI'OOOD>ZGW>1[NZX:SWN-@2FA^,N
MPJ;VB&*R /ISC]C4&,Q@WV:I:6J\@]K.<:J?J)7.0RYUM+Q2KS-8VT^T_Q/,
M8Q:52LN6IFP[P>_H/ Y^&EBIAEC:]9$DAP<U/YWM)NIG3QUX,U#,I@L"# L.
M+7S5]2 5M3+09-,SE.^\(TAE)-NX<I,JWYH'&C*5L%<TS. N-C>*@Z'#\37
M<TMZ%7*X$&Y+[@+\FX 2U-W"L&>7V8!&9B8*L3S4ROU2%^X=+>YOJJEP+\OM
M@-TI;&_AYDY@ GCZU>:/G8+ZS9JMJ)BK#(X_\),N#*TW]M+#B8?;6B=#3L]T
MY9^@**[8]J-<&6"AAP D T8FC-+;"-RV:?<!T\Q/,B*'PK^]^WJKU>_!0P;X
MDK7\OG11M&843:/QR;S(ZTM\0DIPI,0A'"5<3!<7X#"4?BR=[R4WQJJ5E AF
MR$:+"YYM&\"W$Z_8#)%F:/(-XUB\J+(Q\XI)'H\9V[3PFX40#PMNF;HO)M,)
MKK$GREG./TAL5Q&9!^[[F(T30SD/EUF1HAD5'\J7/W'H.,[-VU:>ZJ\(K=PT
M+BAHS<.AGP27-(,Y2)PS6)=Q\T30C<G<D"6>-: G"0L,;J"[B0@MWANTEWF"
M,W1 UZR]++-!R=E;$XI$IU-?IK2/5(+;PF\MGH8?ZK6-1+EZ]@CT[52MB@#Q
M#;(CEQ.!$&]?)F6(I[QYP/"-E$/@4AB-E34E6@P\C' ]I-@$2VBE5]5$$POR
M1#8QF3)&(%Q@B?,H'%@0^^F9JR;PL[@T/;^1HH>. OX)#OI;),#?W+!&AOS^
M>R:_/W[S^]OC@Z.S:/3F,#H9_?'ZZ,UYQ^[VA>RW[S?%A7\LP=JU2 43GA,*
MLZ8R')V>'Q^\.NKWG@VC(T6!0_Z%-((BJBS385L"?69[FM/+H!ODA-32&^8_
M:,Z)^C/XL;4_,<>#1T<>%2K!U:HP6,_1336=XMWUATG,(5/4-_ 5]ZMU#CV5
M'MQFI.Y4,C"ZMQ3%M 95OY=6&#X=MA?=V6BY-"$"6T'@T&07CMQQ^@J<_[OO
MZM_S;;>ILALYB$&L:CNPUB_"BPKA65E43=P%D>8A4L <ZU*]9:SPJ1A$9,0O
MK2B;;0IWTPF(>)ZE\81K$V?.EC1N1)IQ2^@&DL'O*]#O:4[UF3Y"XC:=6'8/
M9&D0#$.[&HF><[\#^37_@@J"*.&D\P5^[.P8U# E@;U3,4!E9X(M@1$VZOLJ
M<T9UE?;N+?Q^)18%F<'.J.WTS.0B&CWSIGI!SEO9OJ_!8%[$!2']S6@%1&Q1
M*&4>7URP#F$7:^F7(K70J78&S$8,F!_8@/F?=Z-7Q^=_1*.SLW>GHS==)Y\O
MID9_V)3U\KO#E)QQ[=Q:.T8 : $,A7\"!H.%<)F$,/M2W!W0*;R!>*_.R0Z"
M& 1J$V90DU>9O'Q]@K^JG>-XEX77YY!#&,:XD-1*R.1Z%I<="\37EML-'?\>
M\<BI#;R=880+H1 ME@![T@,Z*I&9QC0U;'3V\8A*7$BO,'>VF6\+]:6 7MN5
MCNS!9*Y@'XA!'NO6>!*7<#4J#67CA=$=O &FK[A<D'@7W.\&7H&KI<_S$Y,>
MIUY@E5/(#P-??O3W[F^:.YL>V[_GZ;']1UUZK%/T;8I^0P7=Y[8[JN7<+=%I
M*D&N"Y<KDR@#HC]LKLB4%6, W8NL4DPBL1'R,GB UQL='X 8B90]+A-EOH%?
MWW3-"!J^:3/P?F^+E.H]%] -%2J=@N^/WG# ?W9"U>"<IO'I\^TY"U_-XI2!
MJQ=9-L7V]"G6@F;YJK68$P_L\!9KTBKF9"=?>5KE4A<QCK-Q!8=(&NU83K9$
MC7<'3,618@Y3"&JF-E$EPAN:Y(S*8C/"O%[+0XV/[@AZ;02AD_RO*_D;*HX"
M*85Y?'"2J%;N4=-!DVK?&\&?C$(UV"6"K/1<8WZ4PS27NI#\820?KO?GHAU'
M%J:F8'U0]PJ]6&8Y9E9!E-\C$[K4$!FAM<D]N'U6Y1-R86M0LD(W!N7QK3&)
M$R4\5UP)M&Z$N[6?^:?'!-94$4>F.4%2\ $6P3U<6>&.T-G4R^+CE,\^=*^)
M6HW^-9EKI)30\<6<L[/81$1B868XC2=Y"@:>QFA!2A(713:)*7J)^7MT;ZC/
M"!V.,</E<XTZB*O]>5%A&9)LA4)P-<\X\WGC>C:#^&W!P7Z/T/@^\!"'FE>)
M@5BTB15A'>2#@2NWI^JXP&IP .>B6N+:%!)6;!\+7%+@5"0&BW##O'HX=!@0
MLH\AS6 L! YM(T<00OI>P!]AR2!N)6IKB[@)2N/"TY$" E^-YC%6DK"FV[]/
MLZL'\^PJLKPDDZS"A/@4!E1@8EW-9I3#:7L1]Q*#:*X?%G-.]:-0+!:41J?.
M/,$0)WP"+J7Y+CJ999Q81ALAR*(T-AP3V%*FB])N(DK[G*.TAT<OC@[.CW\_
MBDY.WQZ^.SCGA+/[^.SH]'?,0W?1VR]T C_?5/3VWRH'02E7?/J>5>,_!;)A
M29?!#ZOWF>+?.)Y3@3F)2B8UA%4MIH>?9* XF1*JLA^IU%@AAU.._W'UR('-
M%S;.AB>/9C/0LG":D-9^2'VJ?'92.'=RXH2#\S$UJ6P> %F5MIS9#WFUYL08
MUI3H2U2!'M[=PUCAP25 MUH/>0HIVU__.\O?2V8:!ASFJJ54FIQ,;YS$&S#6
MQDINJ?=&R!:\3F$(83U7$9O$E7F6,),9VM3(!I/BO+?<"4\_(9'"%ZI_#3IZ
M8 FA)(DF>+&UC\/B;#ME<"BCED]6Q%F+1_14E<J%-H.B\<\B%%$@$[PXWER/
M=2@,56'XP-:(16A["%W<NA]@$F(0.ONG&$. !YTZAL3"UO75DQ@R[VQ(6 B&
MF7JOG 4>7P<L1"\XI+!N'Y/A8ZP%?UOO2!'[P+= SR4!?"U_D-MEC T3D(9A
M5H,_&8<F;&<\!ABT3WK @F_BVJV%& ,VV 9-.\Z;4\*QD>V@24Y"D\1CCVN8
MQN38@OVC2I-=B@LO #,PM?Y?1%I!O;;DHTU5'<S5A4[I)87J'#/I?T<4HX^1
MQ'[O=J+8.>Y?UVS84/+L398^ -E$^<8]1'+IDV+6:-,-DZ&I.D<>,Z;P1@=1
M)2NL8!5"V,!LX#L/,-(U-3S+UI1 OL&"@>JP 684X\I"])8'?/D($;\%?[@)
M6Q7!+\F:6?/N;87JMN;!H//\8@MRB UTVT"*F&.W+;R'@[3H=F/M"'LNRWCS
M1\(H:)A]+2M*W(+/Z??F:DI/44FNU=2KIQ,B]X&#V;>P4AJV]P!:XQ<<"X&@
M88L,<I97:63DQ)Z0,^YF2C?ZB>E]Q0+%A2[*$(IE?D3EQC3CLFCM?'QMK)J(
M0"AU*E3$H'BK!6S<^"]FGRRJQ#3@;8<88H#S0OGP(B+/M,!PH<]T+,,^ $)"
MN+9Z&:'TDZHHB.(5P[_X<YKE>&J).$W7VAAGF#UU#)HMXK]D&$COFN=BZ=MS
MQ#*QMO,+V04S*R0U0F),#>1)AK=:)<UVN!2U6%1E14;A%+80(4+M" KGAS#.
M@^C3>>+<.B@,%]!)8S>E2>'T>]<9VS)" <=JHL40FPY+W1'A9EO^&GO?M,*]
M[K4<L(UN13J2HR<3IA"CU3$**4;\&K-*LEXA<PD$"JRP)F^#E21,?#H_2FPX
M$I%FQQQP$P>1;<B,]P2??O@,'_9\^-POW[ANZ-'U(Q<JX8\</7-ZW&+XO 4Y
M1,1J:@VZH25$7&"1%5*<#*B=V9JEZ_>P;3.W?LZHB$:1'!!NB/44;/E$38P%
M;#&4WA7H^F58\Q7 ,L",I)*S&TNHQ.#F%:&IQ NJ=*8QBXA!T_AB3O.,&S_7
M]!ZYV3MF#=R.]%_6HU@7@V](/!231&'1R(]UP&LM^%:K*&( .;%RM32_GL(6
MC$OA,544 Z1VW&EH,!A)0B8+9[9*41_ML_KNP2L=V? F=H;X";*4_ME7-YC=
MCYX-^[U/WBBWWB1&?WLK&ECKP1#]6JI;*P-\E?7;GP78ND.UEQ1:D['VWJTF
MP(B:#F0H.(-;A2G4WRVZ]<Y[#G<60?3XOB.(]CH$4>?MMGF[&T(0C:B"@;LH
MG)IJ""^7Y8-%R1<5CZY1(6**-B1PJNQ]N:S9NS-U&)D+N[E[DA=K;O-N^ ^O
MR 1O(WZC=6G[O34^K=?DY%8WM_1*MMF9::[E]3L#@P!F6P5';(8AL)0M0+]&
M9:HQ;<@I5<^(*JJ"ZC(DLXX&$-=_B_-* QJ$8W9.$E_J/7O-\&!:;'U*8!W1
MD85*@O+>F9B\>&Z9%+ZITJ.7H!?"-^":& F<>A2_]-;_?WO?VMRVD6W[G57\
M#ZBINE/2*5CQ(W;B^-RIHB7:9HTLZ5!2?#*G[@>0!"7$(, #D)(UO_[N5S_1
MI&B'EA0%'R8C2R30:'3OWH^UURHY#<KX,*4U815&NAV_3*OR![=]$UQ7?J4(
M?KB$B'DLF7>B#W#> K8/KW]5>PI=@16&HO1:PWG]LK]F0$53AC1,2E,_MM(Q
MXJ/<K/!0-*U],JH5W2G1V---5.1GQ^^.Q(27@Z8%X;D<5)[B-Z?'(,3\UH02
MQ$^#/,#1 9=,E7/PUSJ/83FV;" :'@Z_%1W;"M=4(U,U:39*V9P9Q@;9K!GP
M?LZM3<#QL=S2U7>H4L*)3)>$C>!"#;5-(E&#G=6B4I4:M5%(,()Y.KD<[90J
M7\*$39KNX'83L/*BN\YR,O1+FIE!XG)\ $S_6"&ZABJ(2TS1F5T(8&0)Y]B6
MW'HJI2PE#F_?&LE2*J3Q&*4PV*E99VQA] N5)Z98$]4/8P\)PA@8H>LU5S%3
MBRD:> U+>CBW9!;UK"/"'9]PZYF]\\*E8P # $\:<0DGU8>)3I\%:@F6%JIA
M]=S)O"MX)5P\R=)\JC<NU3PJEJ7@W6 ] \%FB<6,K7]@$' T[$& RK;.CJSL
M>S;-25@RF&*>Z\LL3U7M,B=8KJAFT(8.#D^J'-D,@^PY>+K)11.(\_!CDD?N
MWVT-@ N;5R<8#[)Z3GN1UL&GRY3L16(']5C^V-?9#'+_F'?93=>.2UUV+"(K
M24LL.Q(Z8[5=;E %7$NBJ#/6CVA [+PP>#B$DHRU**K>X#JU81MS+9W*YT$@
MPVO$$;XPW:;IR)-#:1/'P2$4$3\W0-G*6F;._3FS1!W/$&T2!I&>6L!>UJ\-
M_@Y!F+GDS";\^LR$Z KE'YV0>CF:H?_!S"L%,8V"49^0H6,),<1]#,ROHSY8
M_4J28/ F5<K;F1+FC\G36U 9NK;BK"7$[,"\!.[)PVZN,WMI(%*;*D8TD%FZ
MV#1SM@+IXX]^X]C .-]4*+/\)YJ=\"-:;>"6.)/5-C>%7^5Q-,HXY<HR3M;F
M(4"K^>Z5"*"Y@E%.&UND-CEJ'R1(@8O 5$[/!=Z!@!,L!68V"[4I/3:_]?!/
ME0>;Z?KQL6>ZGK>9KM83"GE"6VK(V&^4:$2'V/4ZN(Q![?K4CY\U;%FW(R90
M'T "WW"\^(22&.J.F$"A2)7I?C8O:ZPYCYJUK,*-\@)QN0&'-B+RV#J0;3ZY
M2SEL-"L*5>JG916LU2B>E5</W]0_\FVS)>D6-Q[8=.O\P9W#V35]4_&OMN:\
M48#^-9NE44J-F\Z]RD41EZ#)-M@<[;-DDIHP0NVCE#M35A 6M1OIOC?2EF1K
MAFX/E8>FX@VU3D)CC?"%3P"\XUMR1?5E:M*T]IL8!TFC[JK-N[Y<KJ N5D"O
MQ&+M9D("&G+L^]4('QJG>S&21,;+I5\XO%7J4#W:0O#7/-PE3,3_*Z;,*$.7
M%3VFUXRH 0K>>[. &Y(][W:4O-HJP)S73;>#,C.B?T[H,2_.+#^+[Z!S]LE8
MRPF@/@*I!.,\K7H @[Q7JL.M3;E?F[(E,9!33,P/\;R2+B?6V=;(W=P(&7*O
M0V;04[H86J+0-:RCWY<344"^EIQ.<U/6T<N]5S%V3C'&2)U2*&-$ADL^Y77)
M8Z)!$?"9D]:4%N@)R)QHH!*!(Z\8:V^0SB+UOD8<LL"9Q*VW;\2AO4Y:M949
M9$W5JH*12+Z? 79V12D/DR548]:%.NG/-+.&QWNFL*<$+J;JA45>J,!00NZU
MAMH(=K#%;60JY4@C*J,.FIKK+*>RV RKQ85B/[^HRAHIMB_@DA1D"SHM> G_
MP^2M+)KMVCX!DQGD)0$'$41,ZX&XG0^H'D[K477/86+"3K/Z'E83!,E\SBEB
M(,OI%.O&DE+#NA<^]XT:9&W+C'.2BH&0S2/0".F$P;)3:R&\;@WI/1O2+<E,
M\')$=)ZR#F)/;4,4["_'C<WDZIC[EN6&:^D OI277%8TC5,K122(-!@A!]?-
M+I-Q4MB@D4DZP[(J55]H3'3XSY+<.?)E;&(A<.U/$]B"GKL1:IQ814<1I9DX
M8D\T&M>8NU&*/0[^-F,'<:*G-S@KJU2GW0849D)VA#<(6N0&7%+<9$Z+'\2S
MTXJV.A0CEGGM"*\?WWJ_/&LN$:X+S!>U!?]L^&.WS DU-S!OC-S!O8;K78KQ
MJH-^+^(!\*6,$&&>3K$C@(X]5'><+/.4WY'PW$HU*F@;J7N11>6P*U< X%QK
M*FZNP?<DZ%6R4"(C2+?P)9LM9P93Q=!@9WF)$><*!3]I@$AJ[7P1[BK4AG3[
M@!A.1;<M,>W >GZH2.P"<? 3<FHQ!X0")_'QQ:@D!M.G$[(<NIND3L>L^?6_
MRVS\&=]+7GH8%HI--#B>-QQ!";!SM<)>TX) '34R8X!+,TK&GY\LYZ%W! <H
M,CE339^_-$-$B^D:H<,0>[R43ON<"9GH 25C<L 56?%5<$ET.ROOB=PK6?T#
M=G4B0@L.<;$ZR5>X.&'G =\@61+5R-SM*"6T%9<T*O>TD-<-6F>PM.^QR1.6
M"WE*1K\XX"*K-0?%(7']$I3'Y(W\L#S#QH*J--U3RKOX<>]GF+]\.9L_J9WU
MJJ_+7YFFY)+I)%NNY3PH#79]*7RSSI?D$W8GT5ADU\47E.@_STNS!6Z=4#IU
MM%U@3\H\SVM6(:2"I7? .-@[G):D\9"T&D/!2]2(76@8ZX.7'65KE"\^21/!
MJHW*249^^N_P:&F]&PQT&MZ^BG,LY]#J7P[T[C!R2JDRZNL%E8A]T1&#*%UY
M?HA1YIP "K:J-,5M9]WWCFR(55;[#T%C?E=13;=C??H>HQH)>_T#\6ZC&B8
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M;]!WU$VR\H"?5UA\3[GS0ZTLY312# Y1M#J@$I84U%O.5/Z5K$%I)X($,"T
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MS2!(0[V&(LG)(MME9STPYLW!F[S8NY>0Z\Y+]2N@_HH+EGL<9B@[ A-,:*F
MS)8#I*@4WR-A]1$.3B!]YJLE=\^4D^".Z#/2"U48>UXKRC^TM8G(LT1P%7T$
M[9 #ED<T&7M9M3ZMX\A>Q]HH,DLB L(D$U(K4 WZ<98+:1&1X./HTS,V>X!6
MKUP9OV<YB-C[X3G*Z!<BUQ+NZ6FF>G8R;GO$DWNYR'+PP@6T9I(6\OO8P%SF
MR1C3X72^B]NI^12^Q9,.ZZ[0A.M46;A-0?=M$L/"SG_O=COF!0CO \P>U@3S
M= *Q($NV2 [JUIFW9MVHI[S'NE4VC@[PU.ECK7+,@^F-:=<_>_WZ><QNC>,P
M[9<(R"'[HSP<0@>.=DFWC"@1>+7@/&*4#!N&^#OA8.2'A5>(9][.;[MF=07-
MR1^T<U\S=<8DWSIR&L;.OW:MX]UX"_9ST :A5.97O45K+]PZ%K"XMR@[Z@V*
M%_*72J.=R84//7OV--J1U7215'X/*!BK O-N[#.C95/G55)8.TC;JUB9,V/-
MQ((QX:T5U.YZF6?AUE7M^9@&%N)P4712T-U8P:)4"5B$Z.@KS/^**%-6G'0V
MH66E/4Q5:OOZ33@F@4/597'F5/*1J+I78K.>/6N LQ@:F@0O)B2T7'=VY,>=
MI_#1=$Z@I._^>N^G%IMUEPFE;3',FB9^+E;U>_L?;'+90 Y>:'],_[_5V0C1
M=D;ZJZPH8+<Y+K+Y,E?XY*&)5G;Z^[O14;D'B^CI3S\\?_KT5;1CL1NJ 2D6
MP\9A=!+N*,0S9)A<6SUW3B[?>BP'3=H4<;A5C<8J)UCA6RW,:89UWZU;$R">
MJ=YB+GR(2"<9/=63XCX!8B&+(OT2_??@5V5)AK1OK>A/39XC;Z!F3[$JX1D^
MQD**C(L"S808Z\H:$VUZ1)H:27'9$;?="%[G8KE(^<>$>![XI$&JAY@MJ:FR
M:+6&&D93,S&FYC&BV6HYBKZ[I-KKQUY_^>E1U%_:M;V*?^M'YM\Z/ND/20:C
M=QA][!WUWO<_]H_.8*F?]?M#.-J1A^OCX S^U7HD=^61_+@5&JX#-U)GD(H&
MEB2(6"M@YZ@\DC  <LB&\?,H75Q#P"LT0XG-59AGMGSZ(N4F4:3VQ,82B'9J
M[&1AKE47*Q-NM4,?6;4E_/CP00&/??5MPQT^"Z\,'5.APTNM,EIPNFJV>Z(W
MILB^1\RHI27%47-\ELY&1I+)7<^I81$G(#=\W$)[N3=S/[\7#19^@"I2398F
M&+>)*7262_RI1K2?9\*$64PLYMOH=$E"QE:0&IXN"]<(WL!2<@+,1(:AZ*2<
M+TA*.RFR6;FLL8HK@%/8@W!CW7]M;4&Y: 1/G[%RBIHU)_>)<QV-\I*0V)0@
MR5JR\7O?FMM@&<.UMDCJSYJ29^4^7=,\V9;Z[[W8E6Q6ZF)0N#!25>E5!@^#
M;_V?)X,:N=\0X=@ *CYGH"+:+<*+2M,(?4>P?1:@KZV>W]\J&&U8/!=B:'RE
M,?;,%3:B-59DT%PAX)2+'!LJ8^*1JK7O_/[>^?B/[?P<$VO*^ ?)%4Z9\>IT
M <>_,.A.\++XC:R2"Q#0&3/C"($3)EVJ,F&A *L**C^I$MO/]YZ]:)?-_2V;
MR6;+1C%\)-%LN5C2XK'X4XPK&I!JL(AJR7\D<1%%*]A8&U1M5XOCY=ZK-[C2
MVO5Q;^LCW6Q]$(XBHI($U>1R7:Y<4$=-A1TT+N/F257"VIG5:\W#R[V?[P>6
M\OC?_@:1Q3;88-<&_?.DKJD89 6S;11Q[YM^PR@"-5W3=$'Z35+F*L?C1)76
MN!^)^F I)\-,59)CB7840KZ0MG.!M5%#]E5)H(<JPEZDDEKPIVD%APBQ5MW4
MV$V^V^(J_PQ!AB6.JD2A\$@@#H&RAH."^O\6HH6**3EV0L&EE&6SX0'0EG56
ME75><EE'*9V3BDIO<'1V&O6.#J+>P:_]X6D_ZO_:AU^U%9V[.EY?;DM819&*
M$=0$&0?@Z92:1?]*=RBIC_&OUA)[JNL0PX!W)9N%<PVAMKERI"]\!4=\L4A$
MHB4KS+^K% -2&+> Z1GP,JF2:]+;FV)5EPE'%1LH_RK)X774!KDOVH43[7U:
M0!?G^1W "QB<=TH&\"-XKW#*@%TR:N,;/G.;"+_G_;0ER%:?@4FH"H[,F<3R
M2$WC46,)$:.-A^5,5BA=2F*45RL#HA@BA#%2+ R7V$CNWJ8!QTK6+-9H64MH
M1?]R 5L^T##<#VAC,36MA@+'NZ"N)G)MNL3,P+CDDK*M#(G;1A?$M%(-0D(N
M2H**UDI IU(XMR;KBA)BAVF$F7<I%7FR,BT/FFR,N"1T<##E5:07L'@(XU*2
M7B4\7S3+:FDN"E(852D8SS$I6%A4][6T);GP-#9[\"?U1A$*Z]L? LRM4 [X
M6EJ3UD?Z>EC7BZ>/'=;U<POK>H1KV_C_K]C_WS\^>C<X "=_P/**Z/P?],YZ
M$00&9_U]!'RUWO]=>2NOMN7]'Y7%DW.$4>,/!\PV"Z?$2@XD)>5BT\IB2XKA
ME:46$4U-)NW;<(HR-0R>6P=6$ZT'8W%SO*<-<H ])%5 HIO$4YDFYAWF(,4/
M9V&"0'!$Z#S$SA*DXHEVKB]3\OQU$YHO)Y/D"R)BJ.TFC5V<AYB[O(+$.L+E
M2$J])(A#,"!]]([2(ITRLZC,$ 5+BNT7 IDE@=TB.O,_@SMPE60YLSJCXI/T
MQB/1DP4-6L'T2YT@II?&&H]!8; K9#,YJVR+ZK-1*/RW<.Y<5.42^6)9P9A_
MWQ.90OBEA<C2TL$$*%_)1:QOT@9!]VQ6MA0$G2Y@96 #&;S9_62-/3$ZK2SW
ML: PA2M_-@$U-6JN7#^F\Y/4WQ2@3^L^35(N,$U1GS#E1H<IA @X0LUDRD&8
M[$%A'UV]IYBFD#O=N$QU568$G).^CG2BKD7*<K2CQ])4"G^H4V5,8B3W6E3+
M,?\C3VH.\LCRZ/U!S<'7A3,O-F=XM[-#_&?.IL(O:=TOKI_6V0PL227Z7[O,
M!.\*ZC4GTB)SQ0D,T]^J\(Q;6,R+M5C.2&:/0C&X('RWMF?>F3HL#]<<VAK#
M*&R2JUZ*SZ)I.':-8"]<VB73L6&9^J:K5]HQGFX"8X&=@>,VFK^:(TU*$J85
MN]O!@X4/)X=JG:-H"@_=.#UP$ME''KT^*J27R,5)*&CKUOJD@6!S3I/FHDQC
M36 XX;0#]Q/Q\V?<6 U7O,I*S5GATVVVIOJ>3?66Y&&'JNW.>'^2WCV[518@
M)DT LSMYZXM.@/':9(_AKLN*92K:D-(>P,W=*S?<%#.[-J4B,QW2@/02GC+U
MHVYW?;7W(^PX;I@&SW:!7\<VN(EJ7]"9HZ";Z%'%&QG'-5Z69Q0,<>W(9W1A
M8H5EM1!=0:E]:B&@0$^W/&AM\]CZXB:7PKFX^LC*K!Y+$:71\A+U<LITD9BO
M0ZL]N;+YK"T#7)?4=UB&N'6M<Z(D'M)E08P+<-ZFZ6?+V'/^SC7KW#%?COC4
M4,X 8>EIGE1,L>H!WQC),%H32FJI,9LJTZ:()/$P1YI)DVKD05!BL3&.6'LN
MGU/1SI0Y-8]3"[L:)H 30]'@2[N.X2#.N-O2V5G=CE'GM.9IC9I':XWOVQIO
M2?I8<P8VW!#82&N5M]F#*6P%6+:!;((;=0#XY$I;E@GO_LH/( M(QKEE7* 4
M2R/GK+6A*\TM0XYLMV-[P]+\P@$P.L862X9"<12EDX-/5Z?@WR ;"1+XKQN0
MXE7 %NL<KCM1F@O>Q0A0YK6;*5O+=.=OB QGC#-@Z#P:JD9<\[&B;7Q#ZOPA
M=@H*S/7A0H$*,?9<ELH%&U&<#9=.FH(\AL<"#\DK.%",G!TK\D8]L.DY.MZM
MP,"]VX<M"7$>82E-XLA "=%9@GK_H3 Z!1^)Q4:CJ8^<N O]MHT#+HE>5E27
M(,0J\Z!_Y14&%8.+4ONX94#4;D!T.,ET8<[C!9W']L&.-([IG(-S[X!/%H@7
M5<Q^"G*,[JNMW(Q!UQCQRM$DF247G*3+23A=1)EU=7>#@3_\/?A0J:E?/'OL
M-;37CZ*&UIX;VS\WMB2'.TS! ,N)<<XZMZSK2$E!X]^0Y &;-)&U !M&LBA6
M^8..C@;R8XV=K^CN1F -_[CJ4+%I, 41P5 &9MXER=PY$P$*.]NBO. BCI97
M(C%I)B203C/2SA#1E]K2</+=-CRV)/1;7:U H!@#BM4PD.65:B'-29BD+)N3
MY[?XU/C]YG7A#"LQN(2KC.% +;CW*IS58.HY3P&/42\25&->&Y.XY?Q&,7"O
M'D_-#J[66W 3G19_$ OD+2O*&*B"%HS#DI@,^@BW:$Z&$$8/_Q!][ 9I2[*3
M)QSV]8H"8IRQ+85U)-!^#IJ\9,N<6H$*A=A$QCVZ3F)=1]%<*0[!A(/>@,T2
M;1Z*&.$IM ?J7 V^,LTJL(JZ@M#0[6%&B2RMFYG[,);5$<14"MZU+]1BF\)F
M?2#UJ^79 C>_JFAK'D'T8H. N'A3.&Z[Y^YYSVU)U](Y%U;9?9M=$/QC%2XJ
M53;D*Z&4AUN)E-3KO,I2@F3;A4CV)NQ[K^;?9]Y1VB)(&4@*D65>7L!B7: 8
MDV'EHQ.&91V5<*0+CV1J/'1H8A93'I=Y+A4"T:"B7UMT)?97Q@:5DMG>"3PB
MR=21(\)EQ"6F;-$_<A#C&\^V0I*[LMD+I.@F^[71A63WPJ&+>23GW< #%BG5
M#]V7( >PJ![0[=8Y TWF6,N2BOX4)]N9"Q4=#Y/=(AG/@'=!#B<[8BND(+CT
MB1DQ[7]P]4*X1":>(MB45-SH>R>J'^ 0WAF!LG?2O8L]YD#^B(*?%8J^I?5N
M:^/NV\9M2X$3M_0)FPBT GJ-2K9L:FM02K'NA&KFL.+IRUE-Q?&QL.47L-1@
M0TY-=M6/&>HR4&2"]8I=)(Q-3R*GD00OC<V'>NLSD]K*H4-LL5@D2*2"%[-)
M55ZQZ!\9#)3:NVG7\7VOXZWI5)+V>,_591\2$38OY9[A'INO=S$Y-MV:CQE]
MLXNIQ1#^H(_9@K57@;5_8K#VI]YPV#LZ&_3;CLP[V_H_;0N3_9$X4F _&4)!
M%2=^8IVX3,O0:T2!<_@PRZ%F)+0EYM2^+C4XHF5,N/=F^ T9$V!M'%<722&D
MX?1:M:D5_X9U1;"33NN82+D90I?RFNFZM((MN=)D5C!GRKF+;L<4VA4X5@1E
MA&MCKO P#2"C&Q:TS$P/GE^!2LH4]N79F%NV?U6@3PL&F'Y)QTN]YA3]4K@Y
MDD(]0Y-*0:FGD6,^$LP%&]0*XDPFI*Y$(2V.D;T4(O<H<Y9.UA@LQ=3J"P2F
M7[*:VT8335'9GTYE&1]H 6;S-6+1=YX#(2:AH<1J(+&&JU 903'P)ZC$G"QS
MD7B+63X<W2*25J[*RVQ$J0]+[H-*)O6B8HF9T0WKQ5GI!C]U;HW5U9,R$! ]
M"9&>@V['G826+>M/0<('>_97^!T*S,JNY(UZ:A8!-3(CRYK&(\0$(Z)Z&FR5
M&E:<=3XDTGN AP%=4T3N9:/[FURVM;$*L3$)E AT=_M:$S$I64M,;6%6A;V$
M_7$)WG1:R=BHR]K(+59&%4/^;?4K>5U7L1ZOP/)EV(%V+SO6K]?-)D.W2@S]
M;YW6!\Q ]F !'\\?.>#CQ=,6\/%7/ 4V""*WU('GQ(/K0TFOCU6A"12#!!TN
M)#NGV.Y5#"DAI2N?IIHP7N\]\T A*S7/%2RDC48?A!NR>33ZOBPG,/)%3@WD
M4;\8+V<C@H'4.AR]SKCUYRJ]B2[P\]18HQ4$%,=)C0(&&4D/!'AENITI-G R
MJ!J.]SRY1C(5U4\8,^('7.88E40(HI-:@VD#T3]#(#I4DHV.U7 :SITD!P/]
M<3%).5=K/A+J P.Z//=Z0MWV=2+6<6_HKLJ5VC(ZQ:&=2_L:Y=2]3(@R"**S
M/3L\*]U\NA>\T2[BKLPI6F@>YP!6/=6TE\SX PZN%0$ZTID-M[C=$W^&0,\2
M@#PV(;^=_$7+5TSH%%6J];AV1LCE1=V\S26<%E=9518D+I.#;<V34<EY01(W
MSJ-:VO=KE0 $+W:2*N$E\]<&=N@_!__XL(39ED)5M ^!W$)RCB0DS-T$.,K_
M_&'PCVC'%)\$-7"%;G^]RTA(Z53D(\&N>[Y8V0I%](,WMABTZ&&*;G3M]W^K
M+[@-C#?(:#B;)Q5E@]P)BU;/ES<D!S^CA*LSW9$Q57-VW-\_P'G!'@Y.LB$I
MRBCAG-7;*AM)MNV=" ,+>NZ8FC9%>G+ H%<I";Y5[_\,ZTI":$AS;O4??N5<
M\9SHR<(/S,$8C;-YGOJ/;AK3RND4TUX(!LZ0V^0B0WUD'4O;P;LX!? )X5]@
M$7HV:-@!S+^4+)DL%F7P);I'57.M)*;Y9\ ?H%071?;D-0@X,)O-R6YRQ^L"
M@QUL *6.4]..2GA7^DGO*R6(CM#?#%<TW461&02$P1V-9)WWG"R5B-FZ9OOH
M]+)<YHIK!5$UY56HMU6=+/XBQ^6&@W?ZZ>PF:+HN(G96RB4KJACN-_ZN28WV
M]-B&Z$) /IA>LUYZ0TLV][1<5F,F?U0;FHTVL8?PS\KX@$69I,H30ZY5DN5%
M3E;Q]E$1GCL2J;JTSJ3$8H3$HM@FC)+@X_*BH':J*1P""1O@D#E>5@QR\ UR
MS)HB]1AM*"'%OFX.-CJ&I*&"H&S4&R&M$^&6"+]I/E&Q3X6,GGE2:8#<W+O=
MCW2[=N<]=#D+>&=R9KM1<"'(=CH1<47A44A@=OI!'W87V=1.BS#)4,HQ@B+#
MI\87XCF?)C.($O@,2;^P##2E=/119=IYV@K/_2Z@Z>:FF]\C^\O82>LN)65'
MN,6J0092FE975W\1&W[4E8F0#2_]@"L4?^H5L4&V=TLD/E^;[26XJ47#J)@6
M)=?;IFT?V$K:;MKVQ 0F!N*AR38U!Y+$+^PV^3F$\?N/3/_H8RUL$"F520.A
MD+K7 \Y!W<<0-BJ-OGCLI=%G?^'2:&OB_O2U!(657-@V]2OJ",@;XG>8-.L!
M'HK?'\SVRP6MCWAO/N*6J,786=L<5;["[Z,SW5F=*K&-@*V:]HGIU%/Z&KH!
M+]1CHNMDO =:;_(!F-K-O<DS(M@0'/J_[0+5(+PF0E^PRU>X).@S;:KKSW74
M-@GBO^6,;5X%F40$'>+;GEL/5AWN6E^CE#&<A*IOW'21>X5[3FO;3*+=3G;;
MPUQ0FXUG(5/S]Z5JAPX?Q\$G2B-N+V^@:3GK_75^0X#'_X_["\R=MB"'8?X5
M#D/;RK>JE>]G;N4;'!WT/QX-SGYK._GNRN7Z>5N=? .8Q%FA"1O]_;D2Q)#)
M]VYB.D"[G<NDFA%5#9$?+JUZ4V3*39-TFBH]CMC?^%R?4RX6U@TF&>HA4@VN
M1!Q!BC]5EGMXA2_#@N(CX8:I19"]OD@+927YHE9W&-@X;G2O55. "+4B&>,%
MJ3 J.)^R_8?,K:A_;[.GCO,DF['&XSA-$3*"XU%*C0@B2):UJ,0WY1OM*^W3
ME1P-1Q$;KI!:'XO<<!%L/:(J>9(Q5D-[J<@8F:8+&P(+KC,<4C8:QH+!ZO8A
M8S:E$-^PUU.[=Z=R7?78NEE,?=Y%PK.O#@.<AF[GMJZ\6+5/&'TZ?._CS[C
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MP<0FSK:XC\IS?([#4-RHA',A5,;4P$T\ZAGKBZ1G!I[[+%W$#A;K*VPX4^;
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M$>I(J^SH#)'['A;NVM3$^!8$<M1H.6A!87]D6!LA&%X]=@3#CX\"P="N[16
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M]OO#'?^)ISOYX\.CJ^-?67_PZT7[IXV12NP^V]M-+1O(6!C6%7>LIV*>U/Q
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M/@J9F^"IZM<>LF?1$1]GS#'+VPLCUFO0[\TOU^_2D3G-A3A"\ S! FE RGH
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M9ZIV?K'W?1V4[TZ.3L\/7[__^NK@#]4]]+!__'KR[N3P/>]>(SCHDA4S.'E
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MSY 1C'DC)Q@;ED:*$KED9C=9$4O,%R;@(NG2]$%;/:SUL(])+B]5(.@4R S
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MR^'-04LZN,Q=G"(" [TU<"A8-D:MW/BYO9QH&)')P[DQ6M\/Q*[W8]T FE^
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M-P:7. H_]6Z5@E%><P><=FS_2!7BUSGND4AJ9PSW2EKX+]K"%X1;S28RDQS
MY"F;9#GV9RNI'PYV&:DXI\'3Q[^JY!]4:E"I!5KFE/:XI%X^LZ00/"OR>&/[
M'2J+I(.IT6S <JA4#C2?4+5@5H]^I#T[1_KK7=TZA9QYK\N0]R2BKH:G4)'6
MCAI1_S1P:EL<HG)ZCN%(U"=T+&O2@GI4W&U,?R58/OAKTO)KY6J6U0PTC5%F
M4GE]W\)W&7AB[JV&%-<(6DGX]&R23[24=K4K2_]MEWVK0;0&\5)MIT='*Z)^
MIVCW&]$XND@P_Q$1K3_%$;8S:F;4RS]A4\W5&2A_5E]1DZZ,V+LU]>>:MIU<
MK\PL8J;1I[6*;6'0 EUFK@ T6<QI!:<MA2<R"MRM[>N1I-QK7>S=3C8$4V*,
M2C>]Z=VWLDU([<L(+_F.,Q.'[U^ZB& .+O3O%IJCT\Y+&I)S[P&OWIVZPLUT
MAAQ7",T>VR0P##%*ML;T2H'W<G>G;X]#QK1.NPO?88*M[J\8O.(60TS)XC3U
M0*^$E#?1,#NB=)1.,%UX8-_#<NY,&P\#8%A*8A]"IY#S TX.P:6]1G,8A\-2
MTD &JF-"T"EJ#E9]*$L$BUDV>YMHM/EKADI3--&O&0:A^72A08TH'W 8V+\@
MKV$X^&L-N_S'Z-'^081](]0_][B%CYT,;78Y-]K*O)9Y+U5I^4J#9$ UVHM:
MEZ*%# O5N DQ;)_"K*R2&(N)%W)6$*5$@4U!X)^JMDS3R34_1V-N.5\T)9;3
M)75=3C**7K#07__C) +A^LA"N?9J+\$1889#$AR1G11*JA3(DFQ>GK2I;EOL
M7CG55?[X1*H!]89.DN_0PU*D'-T99%403_JJ=%@*Q^!.?#1HGM.CX]W]AZ:)
MH\T*+ZC 4<IRX!B[2LA/4)\2I$YB:[50Y2)/ZKF@=X_VG^"+42:M\SS]>KW?
M\+='^T^I<Q'RCPX'<)^]AR0:^*]].'2H6[/.$6#/+/K9R!#*U0WL<CYNW>39
M1K1TNC!/BV2GPTGMKR=V*[R0IF&4F< @?8,K89KM>.ACL,EA-C$//(&5:2X0
MX$!A@H]+(6VH%R YRQP_YVKH+*T2V%WT 6C.14N6?N)0AYJQ.NM^QQ31^NC^
MLVUT7Z+[S[;1_>\ZNO_</Q4S9N_I,8R$?1E+/8#'SG^ /FFBXZR>H"7&00VW
M?&','VG\9(]8!+^TT,Z4>[^]5^#'D.?Z*,9PZ/,[ID>^X=*]6+-T9:!WY>$X
M7Q:?HK=[_[471R]5/LO:^78V=</CA\'9/*M*Y.A9(?Y!LK,%_X19S_G,7ROJ
M8#?,N "=2U]S"S=PJK$(IT(4:=LETTNV[Q=S\RSW&,>J"+Z3J^02)5_B=0:$
M98JF0G LWZ5SX58I64F&+DE3VS<(TS">G__S[0KJ%3SHKJ!AC=%\)&$V7=U#
MR+*67 GMC.4\LK&MP.8SS_&H4KC#1Y>#I4^^XC01Z<3>\"<,%J/ 4\I90,D%
MSR/-\UU@Q[1: N @=-,V-S5#+L^&FTX$GZ:M*9T0YJ8F,75*&;NXNJW4::E[
MY*MZN_C,]1$(W+HRYQ'G6/#7%Y) ZAKZ]2102&*D@- C!/:(P\G5>X!U#^ '
M9:G^D!U*A(1I:=4D0]>PR*""[;&F!)AE5DDW4T%MQ7L3\7Z\2KS/3:>AL#T3
M4+_2I]1\+CMD.]EZLOW4$6R!'!DK6[$=%ZIJPBE]HTXRYS=H.])/N+A?VLDX
MO)N:QRM _P0K6)7MC C@<#&ORBI/'7@+[R#]U#[I_ KZOP9C/<@22L4#\.^H
M2&@:^8^T(GY6+-0S9+J17)["M%,A,ET/8E<R_F0XJ%6%O4/UA;THN*D&\5HY
M\0>H>-Q+X%5B\UH(#;O*B)7&BT+&00I4.%X1BS I%TN95V$7N-'S&Z=P$+/T
M>NML]XC>(UZV*6#8V923$5"61P$[@V!1JDCCCEV>TEC:@O-*$2&0V$($Q,?>
M2W6)W9=BO6F:I)AE8ZZ1@,VG_\([#@?N]<98*PT?! >=M627+F\O?Y4OF;C7
M%>I4(B(9P\VDRL9L(09(UTY#77P++%BKJ>V0 9 AT5$Y*?/:ZVK$&;(Z%HJ0
MVC" ^&DN'QYN+HDUI%VV+J5P:9[_V5(#.?L'# ;,!FPV@:^1JJ3[X]KC&;%_
M<=UMXH[&H3AA('F(532VK"CRA8E\,UXFR9=-7QXZF/=8VGS[="DX('@[X@FM
M*"U-.WM.\\@)DTHAVZ$L!S^-)DPNCR6H7_-H:$;!V*+U4]PZ#E4%]F^J,N82
MY\FM;:,RDEM*6NB+W%4@0A=WUIQ?."83M8*<PU8U8W$YB,72TU4T8X$VU>S8
M^M=2#D1AVW'N-\@I>6:^#A="QH'2 Y$M'HI+6+-VU\:&A@\>1NU_Z"P22'">
M=SC&J$0&;5(VH#7KMK1-XM\2D$@:[S@JW+;Y(>(7KMZIA2VVP8T_@0.YYO]$
M&C8)WMJ27A<KWI [7DF/<\TCZ\HPE5]I;ES+0>N<Q1WBB)J25J0>D)<0)) S
M0=,NPX2YT".1D$\M?J1WA\Z5>]$Y'H2);A9%V7XDG,TZQ..B\#P256[42] P
M9J*A"TN0*\U%1'>DZ<V$L<3OK&NX>Q,_Q-4E@.?K8$P[O&%0Z]8C&D=@E.:4
MT4>,-KI,=W2'"=4.R!S_5O%RG1SM8GV]9IG3O-GFE%_U4)F<VC>J[IA1L#X+
M]GR;!9,LV/-M%NQ[SH(]?M:U4'.5SE3?1 WQPO&I8:Q%@@ (LS_!/F896'P>
M*)C!N5=$O,WH9I_1)&%G\*,>1]PAYJ\0<9"IJ79H!(,LARD5#Y257U$H8(MP
M9Y3'SZ@SBN%(( 5GX<+U7ZN:5)K34EK:BC*BP :_DTE3]\P*MIVS*G*)UDU?
M+>N#.MU=X3?(I+2D=L1""QZ\>7?=X#;Y,N!:T+*9A;UC6O@;"KZ7_GUM Z%K
M6]GYC:E1'*WE8Y@1?80=+AAZ)G8+8'R@1F7%#%B51W F/G4LUHGIE\=E[8LJ
MJ]E8 J.QU)X<4=3'?A@\(1QCPN%1&$L%=A$>QCLJ8\IGV:]XD_Y5?%MXX#@K
M9.^1'+E14^'0[_ZV'G4ZA7@]6>>U/Q<=SXDL6IZ<NH'?S)J+VM4EO75:U3V#
ML4B] OMN$\H[S8/[#3?'B_[FP(BX"<*'MX?7K\ F>>5XT$VOWZ@*K*"__Y(<
MBG:MHPLJWIE@,J$F%;X7G19(\$_$'++&@6'H=6^JEE/'FB$R\ QL<\YA%>R0
MS8^)=J2]$C69#J!E89><O#F.WF1YGBU0Z%$)F[_>9[-Y,J)C*?! V\#'/@YE
M754YUI?!GA"F3GC(F4.D^D:\IOJN]0K\=O+XY&%8'D^DK[6Z:=)4R^2*U-7M
MLE##@2U"N&4F5(1P=<.!C?.@))4]_4>A(!VYRDD.<]V^RC\^"FY%[%.*6XXH
MO(BU-?C8XE3;V2T9"BFES 9&?J[Y0Z@?$D:KX\C).IN=\W=K_KED(!R\]WS0
MFRZ@JSM6Y1&WNT[ONOWPKEN]U\RT]S>F#_QY6Q:[_6NV,Z]G_B \\^9H6*_F
M;!C9#\SU&E5=G\3_G(TD!5SR@$V!'SU]MT[=$<?4-C%^K3P]"LM3>!O^<6=H
MPVL8/":-\'SUH](5'>-8Q [USQJUMA4Q+6*/-Q&QKP SVD#.4F'0[\L6]1(*
ML\ZQY!@!">BQC;176 0I;G0=KB<H@G<3AK(^FOYB&TV7:/J+;33]>XZF/WD2
M5H+?1NWM)".>=F.@@<>\PD*[XXK03Z+Z,W5=]_,G3V(*\F/\92PSTO/)2SX=
M),?NMK;V'N6ZSCQES85RL^EN,MT);!J,"G_OM4:HW._:V@#6UBX$Y3M*<M&_
M]CC8Z5_806C__XZ=0=]PVS_UP?QF+UX'.S47VK[LWL>B-S03AOW".((8(2$,
M)6SI?+E=$;TB7EKS3?([>\_8\KZ_$L3L!3+_'\D"Q_.+PD#L,HY>$55H')TV
M22X\PQ(=_CMLCK2<PZ 7B>YBW(L=PQT/0=F!MM@NBUZ6Y_ZRF!-B%:6=I9KM
M%M<S 1SI)-9K[G&#M=FX9+9=9$S]@;CJ&\S&9$;_S!-,)^._L#O"@JGP""U7
M5F#_\.%D$WMRU)+^*VACZFR=^WA<^$6E-&3/@O?HU@XWM3-*4JV3BP0ACS#A
MFC%+ 'W$BB#$M7B/M:W+-'J.<4,Y4A-HQHW/:];UK<7GS@CQB[ 0TX'YG[(T
MUY0/ZQ5TUM44%,];Q$#DTK$\C=H%(PFN<'U@5:1T!*D4"8?(M9.<(RO;!F%[
M;,S(%1K#(- -M/WPGY@N)=0:KCD\00^)K0:X+W?I)8^(T(48U?<>+8U%?V\+
MAN'C7B#!6E09%7=*WQ?88E05C>!-1.1I>R9@Q?8I(9Q&IGC6<>M?4@YKYK#V
M!X\)B&M'3R,/=JU:->CMCI =\=1+S[T-]L)(:!#<]J+'H40%P\@=(ZA&Z2;&
M2RFK\.KXD%BP"'LP;7&#^"2V#F-0Q(1!/#^/]A_O/1H.A#@(V6I>2E1<)RS4
M'SVDIP_W8PWE7JX@@6+(<B-$,2[O;K\%@E]&DJ1,=T-X[%P98 6=-_(&TE)$
MJE(2WQ,ES\=[89_T-#9WH\JWV$UW;C>%WA1>]NRM:H8#[%VP@AMO5I4U+,(<
MEQA5TV4)DNFQYL1=S<AEBO2I1YJCF\]+K13XZG,+@B!(#>AES,0FEN:T[VP2
MF")5V M> $%MD>B'I]P78Y?[8NA.854=[0A[YP4^UQV6[3G:?=)H=3\,9-JL
M:[]<"T1:;+ZZAT@TG3'J#F;>^O-ZAC& (4@HP8RD)DT]9DN16XCB<<H \<1"
M6+HK9A8L[E3&Z)X<N)!!;D%)E3MQ!=B-#;&?-CKK+J!(?K'P:N'.)9(FZ71N
MY^@BN=2PRGS)S44(Q1[S-_0!.#'4N)%&+S^8(*2&ID1/L+QWYXU_B/[OW_[V
MM__WA;?]P0%NH^"&^SH[?.T#-XMR[S_<AKDES+W_<!OG_B/CW,%SZ=;O<,IJ
MD+%W4M'2U3C#0:@M-.9J04:E^_*1A8\:1>60G+I?=]I#C6+N>P"G)GU5V^,C
M<%.'?@TTZ*1E1)-F8LLY/DU!GB.TLD#Q1N"F58UB.@+S8R[FJ?2AV'L<C@3M
MH]+@H6Q,SIT9?:!8#I3 1*0*BY7(5DQJ.=[J'^Z %OVRLG3R"<LFZ>S4/'W(
M&2B!3K.^2%U+QPJ3./9FG==(H<NW^O U>8CNS['F#B;=TBXXYZ,]HDF@AP/J
M?5!&.[-1E(S!WQQ%._@3SY3K#_"0AN*+,)&6@SUOGSNMQ.8Z?+!S^+]>CH19
M\8]<=F0$DI5_^=4U"3SL,,('9:;E+:X4!@@FBOV8!/O$=;9EK%T<[?$XIDUO
MYLO)I,5PQ:HV;EX9:%<Z;()I"EK$:"[#XACJ1>=U>5O?$P[5"\P!D47K"IED
M-L,(6V,:S_F3@H%J^E<=ZPD*JZU^:SA16:MP^0]LW#+6\'^J F;G+HY<O47)
MPI#>RJ:LX1WU>J,YZ?0:N0MVXY>5^7^0K/+D\F$DYXFC[+@$F.B=B7RU+]4[
M?L93GQ;F9CW!&?EM$B=)(36KSD&CM9 .Z6)L!C-^\=KAAL]>1RW3T0EBZIR=
M6KFOT).VWFGIC \<0><5=L?+72-120V[!X;/L5$*A8)CYP1-Y9E.;,\IV0*'
MAQ'^Y$S1326F(TU>@HT@;8V)SN^4XB^Z93)F4W6W3UC/)!A?GV+"SER856YH
M=DY)*E[3&LL@A@/:I(6XM_:588EQZJD)>$QES(Z_3G7US9H0,MC/%S:&C$5(
M"1..^T]AT3@].AH.+--PDD87Y40_@Y(L*F4J!I8(LZ8ZE,3-,F2>*6V!#JZA
M&1&GU95Q(UK3K)#4R3B3FCMZ'7>Y=[)&(KY2G8=K3S+)00">B\4":3H=NPQ>
M:_6[V!'8'VI6*_B=Q_0/JA+FJN(HQ^'Q.]J+$R11H+BT25B]:_5^(A)%OJ^6
MWQ,: D_(6]4V%?'$:R[HHR]=#7('5*7G: 2B&EEMLNIC6-A<I3IPIF-<#H-D
MN#Q-<FNUKQUW$L>>TT][28\(>R$2NUL=Q5KI15QOK7+76M%?WE@")ZF#NZZC
M4/1OQX3,5ANY4=_&O=:MT7DF>37'YW(/&%U'R_QH=:.-FA6V&3%/WL;LTAJ%
MNVP%'^:M_TX]TFJY,\4PA[ \[8*SMB(L-"XX&>O ;:A(38:L!XPFF_L<=ZQ[
MT3^L]:H%PQ[/CL?JB6CWK!9P#OQDDA HOC!OZL@X9]S&:UY-6'VNL^$,QYV9
M5BVNH=CC QWU="8*SRW]DL'C7G;7M:9'\*%ZO)W5#!HDIDC[UOLP.).WVVEH
M_ 4FHV.Q;&[JQ$[L]V8VPG#PQ8V$Z#8V LOL^E[<7=MJ@_6)MY;%W;<LKHFH
M[V\CZCJBOK^-J/]Y(^J&#T$3QL7FM$D"_N9MLKY4P,MG,.]LL!&0;H^T&#,W
MTB/'TMU)<:<GXG&A9&[$R=P=Z81YHQ2NSY*5XJF0HCV7,+M@GW*!8!(&J"RV
MN#GVM96/AYI$98TNYRRH?9Y;(*QO](J8R"W6G.XJ-]V+7G&?&"(AI'+D6GC4
M/$:T@#NRDXTH(3K!-N\.:$A3GB=UG0E9&6C[694@V<5.EG&_+$3W99S3+<E.
MFI?2=$O/#ETL5P<!A"[[(=5W>PU [217FHNXW,64,KR"3 P2DJ9ZO Y-/,M-
MGLT)OYI0HR'G'1 YGUWRP-#VU'222.C'O3B9#]"U\VQU /<'6\!GIHN9WW/7
MLCH*/PY"3^#>U#8CA%)<QE8 *$J*R1V)D\#2P4YKF0-RM(OCCAVA-$GTL!?W
M&<*J)10\HW4B&I3-+6A&@V8ZM/B_M<UN.=T]*R<?*9I8!XIH^LQ4EE/*\BHA
MZ<Z$VM<J!.%J*DJTS@I<;,) N(A$A"]:Q4BV( I'LM1>LO\E8:<8-1&RT4+@
M#Q!,!RZC8(N42Z5\]JJ^U]]AUV'>X.!;3O%F::LZKR58,K J$XQ;""&QI.<J
M:YPZ!F]21SV4C+\K @NU%6HMU%[U]9GP<E))$?C)ZXO";/=K4?]\9!@\M^G<
MN'!*180$U"5O=C&"M-2UN!?!:Y$B-/"%0",%-T6I"XYJ\+/CX&_XL-,/['TG
MW><\GE+F-^6A9MP9F0E:,\^^\9F&]1.H) 9W6JO?QOL3UF>7Z;*<4?%%<)92
MXR7W"\'LTPT4<=W6U 8:,Q7^E$U&9@W(/R0<E?2:+2OMN$Y;*A&@SZ5-JQ?E
M"<S@<+"#4B#4K2/WK6$@C-DF4E9X)=4@'L\1!:'R=#^RC.6L:PPO<TPDW@29
MJ_7R@%;%6@@9R!C;8&=<7X!KQR]C?M'Y 8@S&#U%5L\]\:L4^/I9JB>N4H6Z
M2IC:F::%_K6+W0S%8]>:6H\+)J37Q%2 K6AO:+Y2E"/W5746)\\^JE&/$=U,
M45D%Q1C7@#8&QQ5@N:7M+S88%Z94M'10<JW8BK;M/FRK&K5J]%@#I _'<$ ]
M-P**4:\,SS(7YTCOCOZ:2<":KP5;D-_Y(JG%3U$4AD6J8XQ%XBF=5@GRER=C
M6->2$Y(HT%/JC43&:*=+?:#Q[I2,746#\9H44'270TZIFI!^807 PRQ*'+M"
M^FF.V1$4LZ9Q@C=&Q,,D;N@A>"^A9V"J,Q]D3A JT]$P'+=+'=R!]&O2HNK.
MG"@P?CI%2C]RH!2,6ZOP^S\Q;(4<2^:91^4W-;%)\[SN[>.5@UWQR-'><'!*
MD+-N:(X,''JX_R+AF:(0.@@U_!H>QO/FTK-I GS06UG98M ?#EYBI-86/BA&
MCW\P\3O*F+#<&N;!Z&VG52F\ UQB":'98-/H?_>W&"+ 6> P+HZ%NPRZ84S-
M2[W1O@D[\S=])3 4IS(R)F;EV2S'-(O@#;:%)3HWO+%"*;O#!/+2T%;.?9/Z
MF"*=/?A3Z!/:N_!12,ZO]Q'L8BR0-LE^KDZ"B1GM1>\OJ#4/M0U>D(.&!)LZ
M@]6Y\U0.&V^D-)D\KVSS.VN&3CR%?(W,$*TGS0@_SH]%PZ34<()+A;\$I74
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MP,K'F,Y"7H,X1HP,.V7(Q;+#2(6E8DF5FA2&\\S5D^!Q,.%V\![1?8)HR.&
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M7/88=-W4)5GV'<2//#/ RM>/J#Z">=VCT'(G-2DWH;/,'R^BK'AD3F*QZ:D
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M7'7&W[O[TF89!2#GI!D[MJ34#]C-0KXLBRA92N&MXC16M)3&/+FE3P<,3[I
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M=3C[^?T,9]\9^;YYO B3L%W*V%3EV:5:S<-@R4,[<84D6AT;N%4\H!\Y#V3
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M-GW8]28D%LF!NI)[Z7''8J?]9.-0<U>1+#746,+SF8G[N_]40Z7V5'#[,F0
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MH10HZ616ZL%RH2/#ZWSYNCH%[6W3/ZHV<%W4M[XMA<+]ZVY=GE<9RG@!,6<
M/M>P;J\V4AH>9VPT).XGT");2&^G]B6<W6:B<]S8N^=U!B$,9+NT-:9D(6_X
ME&.ET>D3H&!]QG:-N-HKNI<YH$PS\9 F,\4_YI0M3=E2$V.'^XR^"+%Z%^ :
M""07M'%'C/P.,"OH2<T+]LHU%<D,S0XK8OTM*%L!YZ=^"A>#AMO%NW>KVZUN
MGW/ #>Z[H=]7JDK/(GLA1VG@JZS,:@ '69>^K5BHN&VDTG#[.C[M/M !ER";
M0WE6][<6:=K#.J; M4!T,@%@2O86)*[7#>MVWK;S +>/D=(K003N(4I@V.%/
MD7R]8W6"^N2::1])@< *]6!Q*90'!+#%AWMQOW- %- KQAV46X^<*WQ%1<#T
M0%)<"Y^T6BV$MCY@O/0TY]H 4EC.EP;$(0I!%"GL9(]%OAT&PN-55AJB.U4"
MG,K6:WS"AJ=?Z3[+99\)33CI)*\KI98H!T5W6F;5O GM5(0RQ;?-6!X_O/FV
MTR B4^A6XSYL_Z!/"<>]A!1N/2W2H<%;0S\[/='UP-WXW;1A2P:S=9!P&,HK
M%2GTOK:UQ,W5C-B[W?)8G[S<W.@+4V)"NF[J#CY;9&H2B$+:R*[]+BXT_'&G
M=>H<<9G \V2/$9U IY=.[-&;Y7FRSW'()CDB4@2LBERP+E*,BA036,^;&^R!
M!/]$PLO2Z8 U"&L.%LI.,_;@QKAG5!3(YM^[PU 7R(0#Z2[=-NM#6L(9HQ%-
MZ[")FY=S0G'-Q'>@/49W@;LP;WPVV3FA#_B)RHKA2U#(77'2 $8^-X@S+@&4
M;F?LUE'1B9OA"Z 420<AS(3:H[I,"YD(^,OK7<G%<PE;*^60\*[^#.J@,2+2
MQ1L95 (J:U'M1!P[+8J=;L3/.<Z3O,OUQ7+6JOTR>9N!YV?S9RB^(!V/) Q<
MU)DWJ>+H("-@=6?=S#1-%QNG IQ@9J+V)/>TYQ.*-K(>>B\:F,@%O2//6,[D
M!>Y(U.:&(?(:(7OIIIVW:*IBU+-DR]JU64R(WV= 6>75Z'FP:ULQ6#)!2OK>
M&[[1YIXWK(<TNB^/<%:Z?Q]2(\^Y"4;,U@-G4,HJG5Y")KO)"EK_:8W$&>(*
M_1/ "3Q^=$P-$2&?-C?\,FS)TUM2M2#-2;"5\FK[KAA(AI4)%<[6!4'65%/G
MI1OOA$=BH+02L,S, DO\*X!LH4J;!E1$#'_VV<IV<ENMG[5"]94UNY1M5JO0
MZBQ?J-^R%4^13YA631[$6>U5*IYT7_C]JU'0T[3\&(S41=8W [MB\]L];1%M
M99;M!!]E=7,"NLV6Z40<O&QP,$C79,+II*Z&<\P22Y8&^-JI^T3;B-HTM\E^
M:\;[P]2]MIL,<;AZL=8I5&FG6)CB_,B':D[2+Q230&G6$%-[0=L#./YL=EX1
M=V:7GTPB7BFGG6C^:7(F<TK>>N"P[%OJE<A*+PXQ-S-?ETIZ)%A4K]-+7P_-
M'I@9"+$5 -R:EFN:2=J97\SSE^'C'EV'C[L.^1:CP18AZ+X&?-RC[QH?=S=W
M]'.Z^3^IFY^AS2>\_!F#=P?)84G.IOMW+RW'QRR;AJ!3BX+3:7[Z'K95D<V$
MW17%H#C0:GH8E_)1>U&H/=::[8@V50V4#TK8184]CIP]Z'R@J1C%D87<S],1
M[-@8R'+G2)4O$2#+V1/<Q/Y TG$'>CB;S5M@JG:2W9FW*9"Q]N_&M8Q8S6E&
M2XK3"%8MO&BL"3H!C',*S,'@UXE+6Y1Z\Q%2R1%YWA!L%65D:5*-Y12'.IL0
M"KZ+VNKQ:_#/W$I)?$$RA_/2F+-8Y_.LH)*]45:D5]EH.XF@1#"]W8AAS8J/
M0BUH<9"?(O* +\XK-%-6XTHE"A KB:Y+'M3'#S<W>%D""PSBZ)+Z9M$<7FF*
MM&-QD-FWK'3ZEL+SW&W^1=W9F7Z/U\A[B0&4WT+5</]FVAP4_!EC5;1@C*HG
MB%*-TO<!X*5NM7LIR5U0ZAUE4\45=]GU?QF\%MN/6N0]GQ'E2H 1JN+8YC[O
M/2^2_9$-Y] +&/,X'S'N,7=3[FTMJ7:)RPHA%E,/?(NJMR)!J&)O"MR$//"K
MOM&<9H*7"T-QZL]?'E&3T[-B;("3@MVCD\.]UP?)CQX(A*;O+;M8=D,H9$(U
MY!\(R319>^H82ZA]EF=$FX/6QBS$/:J$_,'6=M NJGC9;-1NG,JVLE$-892C
MO!D651.+/$0GCV;%P@U1KL.JC&#7< *FJ,T3VU@RR12@E,"'FU1W)RJ9KK,B
MNY#\0=""06U?12XM-X.5X!&WAM;RR[OG'8B:T:E>>EF_&JBN89S:/5'&_M2B
M3A#7(/MCRA6,0=4/W".)9+@C(4X/<.$9 ^EJ[TZPRQ_QSP175MTOE0H^M]S&
MO\(@B@Q)2L$N^^.)ZJD])G!8H2J^N]U#N$7.0O]VSA NHY B3W T:CDR%$"P
MB$%\"<"YY27[=%PS+_K'2R9'#MN8CE=69W90,7<=KN-C]8X9O4</2=3BQ+=-
M3B67*718[BP\P#,V-XC."E.&[&_,E8S]A7;EY.T+>'(\1WFTQU2V"P;,?"[
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MSA5M3*]K?W_M04LX^;1_X*UN1^'<\'T&>CB"^8 "=-##%8^R,U23H,7/KI)
M<;.DOC4R33D7G30Z<FDXU#OGY!$T[J%J)?-95&12=.W&,5,"%Z;$&BH3KGM6
M[F8E^.;='MR+CE,.6?@.$/^<UWDSRODQGSCF_R7H\)N.8:5X_]-UO%_C_4^_
MXWC_9Y9O_=\MXOU/)=YO<KD$9XARE-]B5/_6<^;C^F^)RX?F9G.CW7?N%+CT
M"RTZ(/S3&,>2X,SFI=AJJ-Z?PX5Q9PRQ$$[K/%5'H5)@*Z+7Z+8#_>\VC%L:
M EV$.WIR%_&FX(%=P! D[@G;K(_08=U#(SI*#0ZSBGKY6*(&N*7CULUIF/S.
M,*BZIW/5UQHH;[3M$%$!E)*@)P=V:U@15LD=UN"',7P5YK&'9B9B;IK9.=7Q
MXD?J/6H8Q]>(X*&G3+$1>=\4>#5+*K$^,H-S84MFHG_+X!2O":^;S(<S*O#0
MTK/Y<<_"]<9J1]6A= C!^:*6UM:[AM#U4T75P>GG? '\TVV,JN"2'^>YF?;&
MA]$N#B%"MZ(^(AP+03//W2]# %*ISCAZX;<U.W L;C[C->2Q0=*"KX21=O;5
M%G)=,,#-#@ESYEE2V<6@Q!77]9#IF<T85"A2N>A]O3P[=;=2*%=)62:3; 0@
M'(SIZ]W(V'/<2CT=9*\_N.UL8:8(:5'/<(-@TBH%0>>J2^JC:6'=B(YY/\9+
M61^MF/80I.D#&"U*KI&8,#^GF-/&L6D3N5AFG-1P#;FU^4'H)1KB-:6>ULH:
M9.[>KH3BHC?XN1(RJJ0=)\9)Y\3 7FY>#^7\G*N\0#B*H^'C=(AL%F)ZV"2X
MB70IQ9^=?J:^HW'OVT?L,/3ZW1O<<AIB]W%498U0SW $+([*8AQCZ6:OL]C2
M%[ZU+$<0#'RTQZVEL%SL_*VB6VAQC'*Y?J\M5#*[_?Y^5S7T[7DGK:U-WWMP
M=79"X+P*$9UX)]!.]BD-&1BEQIV EC9(X=]A<^.TKN9PGWLY2J]I5/*W0X7:
M'?[JX79/I?5<$JCHC%CCI8/ F:2Y=$D(@2K/WM&6VO6AW4ZW4-J;&Z+&Q_5Q
MJQDQBP1*!'"O29FW.A.W:'#:E8W*6/PS]:-IWU)8UN@TC56R8;<*:>2FJ89,
MAD4B:;7+>H%;@>QCTAAJ8CL;X&WD\$@#+58KE>7O-IH'.\\H+I0L<V(S1[%U
M8&1KLL#Y:$UPCLD2XR)P/&=4.U7G3/A<Y"GC,)PUY.[AGCB,!K*M(FCOJ(FL
M,4?6K"P9 /\6U264(0]FX,Z#J#O5=L RR<DHX>2TH.Y-HQR]I3@#1@AZM)&K
MSCS>O36^8%PQ0KF7+G0MJB*JF8?EZ GD+%6OS5D=G9RKEJ!\&;F:D@]<@A*(
MDR#FA#.'15>ZS.%-:45!$4B/ #(%6D:OY2[SU'>,9/FH[>1\&4A("PS:11:]
M(I3EDU/4\/@@#\3SW7P&&,7[:O@QFS%X":-&9T1?^%%6Y8-HIO!!F"V>SKQL
M R7"W*Q%5$5T+"*Z#\1=?JJI^'&R*W0*Z&AR 4]%G%W#M%#K5[8@1T\[8Q/>
ML:MMOT4E[=\NSQD$B1"&/Q XG:#HE:@GQC"=A?J@P.Q*\6[I&5@%R>R^E3W"
M-:LR9%-#I70@3?_Z[T,&>?^]N(E$)/"*.E ?(4>K"?*!&OO%\U#2Q?FZT!T[
M$!;[E@;49#FD'J7-O!O QVP:T7(LJ-&2&[6>@(P]#H 1Y^]P'ML&!&WOQK*7
M8QYM/_L%#[#-,O37W"QQ =W$S4WUIY^$<.*;33<]6Z>;--WT;)UN^@K33<\D
MW63B'LY$$V[3/<0<H(#:\?RU^7!=[BGU:2>T-'(GP"4!3]C$\U%FP>5U<D(:
MDXX<.CIZ3$*G!U Q4!XI9+ V-_8#-Q**1<OY&/2>=193/.7_DPKD@!>Y:>6^
M3*<"<A\O\JK@0\<'IUN&;6]!NY3,-SXTWLX=2=2M&R4?F.1,.S:X(#5D\)F8
M<W>%)H8\$$NB$=U'*SXX:A?ER>$UYKE.%5V3*MHG=V0'"WFW#)%TJJ Z*ZDQ
M6!K:U<!RTJ/3D*Y%:)-P-TU6^-9EYU6%3&0KAIT-"PJ46Q IFCW4/"0*;6MQ
MCSQVH5 %6X^KB7Q[!1.Z,*[A,,NG,\X&D5,W,"CB04^3HMNTK>IU+)XYG2:^
M!075KP58+7]QZ^ '#W71+/74UG$,./N#JN$NS',;0JCYE?0]HWK&L-ZFG>!P
M &'*H=6W3&G?&MV^!'^!O$EJ(/3MB@OPE3#'1S;,V<#2U?F%SX[06^(T. -Y
MO-O#SD/R7941-.E>6E'2!"7YSF!&BB&5E(D$ VEVFHR?W'\+(\6IC4U5!&^?
M4X0=XCK)4OAWXWE!";5\F$_U*&Y#B7D7( ]F^K'+4!+4"LZRLZM^=S6*1?6V
M&+Q;;N?9UM@HC(6+P=.!Q ]ZD?GW2SI0Z5[XY#+%$BA0PHD-ZA5-C=$-F8.3
M3 1)BRVX;[-L997H,S,-,RD33L43I>3"6Q0PT4D#N(D[;:@^:^8_D7-MK:C:
M28[=Z31+"[6KNU!K'^9BJ'B/NG*&'/F^IJM=OYAR0W8<LQF(KZ-H;NL*A3#=
MH5Q4(K+TL Z(O&]X/J$^RAKJ.\;W47R9#GS 4"AC(P^T6:;70Z@I5*YS*421
M=-L8+8%H#/B)]FOKWPL*UKAT"P$0/6I2N,R(X2$^H[LM^20)A5-U4A4U+/9G
MNDP^-W])ITTK<Z7)FH'T/NT;G:Y-*#(R,YUH]*[WE;SY19NT:F:VKG59$[AF
M48P?0=$+@ N\B(9U:OLL(4R;(%<&)<DP"SEX] UL,[=V]J-5<!X\%6I &?[T
M;[I6/ M25I\E?>X[FQ4H*/2]M*JQFY*5S^@7K6/ZA3VJA]OF.3>"=2R];;:*
M!;!"KK]'?T?-@;.HRKSC]9N/5 U(&8NBQ!8:$P=I*\30=73H!KUG#%O,(0]D
M4XZT\S[M.?_-AM=_7(?7-;S^XSJ\_M6%UWUR&?T5 ER'^LX!:K/'P!H^5VZ)
MWNG11M<B>>A86P'*DWQZ),_FQ@V@/,DG1/)HX_<UE&=!INA'R13M^0)(0DI\
MH%D32BIXM7O4J3/W];Y:N!3J*R&GO>VB+3"=Y*\5X[042II*B4>#N"BY%?FL
ME7J!KS2Z 0?6UNGVUN/MK=UM8,VDOX8[XQ5=X1FJF(:&L=EU-JNV.45#CHBO
M!NZCH.F4W32V5!:S6,U+*L!9D.>!/+>2.G/>/J'?B&G-.N""ET6%/7++=!8C
MC\D3@]>9DB[P^%OSX $_MJ:.&\R#,I7ZWDYBBZ=2FV70K!:HZ_6F,OV)A=(J
M61IM#NB6&2[K(L$]Q4CI\0TF?'/#RD,*<K-0QTMJI,-V]A6$D[^,;AP_)@^2
MO7=O7Q[NHP7'[NO#DW]\@L8:T=S=LK/&EZ9J?_3M-?;0"AE?(DL+'S[T:!)F
M'..UF)Y* Q^Y(9(+B1Q+NHGT%!'$=_.J Q-=L"0+Y+X@-I35:.[(C4PK]V^+
M?:2^3@&<.6#Z+I@K148J?6A>)]'.Q-.Y)Z"Q<9YF6%1-YG\%#>-K^+E_Z^8&
M.AI/B:O"N57.NFB4'& VL]W6Z2([E8 S>$H*?12%<O-9CP?7A>\%\P!LRIL;
M3N/7I**,-_WDD;-9R==>5*C3)FA/B3%#HS8+!ZS9Z73&>$5#*X0(:>LANO8S
MIM2QXL0L"+VCR^S@F/3'C,8R>OB@E<DQ#-MB:\,A46^DF=*,G]B3*@J?!"H=
M/S\KKJ?I\NYEP;>A$!X/WV&,^2="Q&*8PGR<N!%0;L7@_A8]^5OK0GI'3,QE
MZH[7M'"J9G0E5;8^8A9/==5M?69B/KJ%;4LNL(?&,D8H =R<XM9(C;$8. WV
MV9F'OIAU.?7KXM1T5A.92@1L(8>1'*Y8'2,,K8I"OA]5$Z)4BV<=ZQAF?L&"
MKQ<DRL8[-\5Y%O>Y)M3\9:6E,,4-$F E= Q3!:1#9C$@LIW@0K=OX9ZXJ,/A
M>J6C="9M/7=.-A2\ WJM2"_'<RQY9(6LI"2[OE7H.;E<5VI\7+L <8^2"T$R
MD?_6N2*Z7QOWYQ-[_!)AH[M1KR7 YI5( D(K&90XN3D+-23!FH;I)BUE^K==
M5R!T_24(0)Q60F.K*V1M%QB+P6Q2<$MK";]P5_<+2E7\M$Y5:*KBIW6JXK.G
M*E;<9M15]&TU@^Y 9>"(23N<XWWJM))UQ"BVVCX7V#TO'Q!A4MK140"">%=^
MH<>V0/4D/9X:3AZ$'[Q9$Z.T X= E][@WMVS/ZV]MU_3GU9=5(S-'3DYCIR\
MY*1\.[6B+,*M-1LD"'G/(EI>2]XM<5D3#6T6=!TS#8P,#Z<AP>]M0^9&>)>V
M3H\YXG)3('1\DR>"9=AZL1V]>U21[.3?QR@"N6MX_3CVW->#&AWW]K:IZ9K[
MBWG-LP= G+N9+9)F-A_E&3?5V],/3X!(;5I<FX90DPL[.'- %9'[VXE;"4)8
M]C%K+FB/?>^&^XJ2^TE5XHVW#^T?BE]>43J'8"IM!-A6H(.!H*#HQ W-&?8>
MRU//32-R\YOLCZ&SP,^$H[Q&M;='Q:6M'&6XC+,X=(GO93*>4P+H--/^,0CX
MU:G;DI0R1:/(&5?X<@&M5)!:8+*3+V/<MY2"'X9@60>]BCAH7P_%I\G+4S(:
M##1YD)Q7EX , DDT8-4NP5RF>LTG4W1-U&J'OC%)8) 9)WK/#TL*,+K@3H-Q
M/E%?U[R' /HH\KDE"$7.3;*2(^=H>J7+:9C=G3J;5EF9TH:ER=XVT?04;>)'
MT>.,%[X()(ZJ9+2?<'-0Y, [4CW($ .-(K(S<!#2F/W4RXN,["H-I%&IP9JJ
M6-I+$GL%CH,E\^^/]ZHL!$. X9MS?:G/T3\?MLBZ%6QH/ VP'RU*4&04;K@O
MMJ^)G[M]XY:H9$KK>9.%^+@D%EB]\MI3*@!K"=<MH5X?HT2GV(C-9=J$ 9U>
M=7H"D2[>VV;5%K]9C"4&C"R]<!LV<$4O6FHD>@6,,>#M#MFHLXCX6QI^&NR[
M^:K+Y$8MB?MVD\T,*>ZT=]?YZ@J4#U)$8\'PY9F=/B*()6YNC%N3')F%.@!N
M;3)K[.!TGX9V!4N?WN+'TCN*\/K-\^F"EU_GR4A'HU$3U$FC32A&4K"T,S$M
M&[?XA3QJT0_:K6"=D38 ZT'>2+D/H>=MHH#(4]5,K6:J9<!1ZCR8.J7&N^:(
M[OV]&_@#/H"U/8W[ !BKBAF_0P_?;?3Y:;*T)L$RSQC87L#*< _)I-. (SD#
MC\NX/*\F 1-OU(@VZ#@E PX=/.3 :@&*E_AA:"E1@,T&A.9USG@KA/KXE(Q2
M:Q:*K&C@N#KHVF-[R=' _!4$^Z*67)Y WITWJ*8DD^6*CI_W6=V0[5,I$7RS
M6('WL:G$H\87V.G+3P(W$J.T8ZJ[Z'Y$+K+>]V[?7\3;7KHYGU[UBP$:S/3N
MMW1(DXYM,\GJ,Q!>(O0PXCUM(7\#ZB+=L,X^3<N/=)'D.YC_-[]PEVUN-.[,
M'$KSL;E4S/8_G>](FQ8F$!E3Z30'S_\X)Q]4\BQ4J58.^1IWH]G<=P?P]R!;
MP1L. .J'!@]R.3^_GW"19H*[B^E<V D@4T, 2(1N40;:9;0T+;OB/!7W(>/R
M)J]\"<L5D\R&A;-*: 7EXY4-_:;4&/1BV\^WM5^DKI*;:ZM[#U9_57L4@WC)
M1*$,1K&$KJ9>D1J)$+ G.HJYP64H7&0[VU=7<[$U&[<=D(F3%ZJ6\/VA< 4W
MLS,N8/?\%Y=Z*?[D3UO43]6H:/'S5LHK_+S.*VA>X>?O.*_P.>+--P<N/M9F
MU72"L>+><4/ZX<6O+:BWA?[A#+)^*37GI&BJ8KT"%KK;0F@5VM+ ?BTQ'?T.
M_B^&@E! :3()N.NY6\MMP([I?%)29C]*G*N*;SH%LPE;)5$R7THZHO+7@_&8
MJR V-_93[E#(B(WHRV2?46?,5E*"!1Q,!K:=:00'8:9MX>;QT9<8J[B ;46(
M>>(F4E.S@@@4Y#/F2&&3+!"RX%WK+-#BZU*D)L(<B+ME+CLM%ZEQ,W#AZ+T8
M,(6(SG2*!)KY*57^FEJ T.C+4*BH&/B1,';4OY9O>>B9[0TWJ)*H9ZC#A:78
M7$W0!C9ME;VT^IMI6UD&R!:<I2_]7R(!'1D>4ZZ>CDM"T<J(J7+0]I;T<D1S
MT/BV6U&XA<NKQ\M>]5O+ZM]!8SU1C07\\.;&48;Y%C3SOG=TUIQG'7SG"12'
M%SKOD95.47/7HJBQ@\2"LS],N]R6 9KWL%@.S[/1O,ANR2WS(V?R-C>X,F>]
M@!$0-&1D]1 D[<\.H6+42&TT1(N<LCO:L])Q K3C5=S@=);S(<JB^L9-N9"R
MA; _Q>.IW*@U2'D3]N+[9%/Z+\A)WT[J460H#0<ZY]+TE,)!(>D!;G;+!^9*
M$Z6\1.'1=TA]]XK\HZUL&ZE+<HA->\2HB3<_](_ BCLM4$HY:B%&_0&K3CHY
MYJVSR%PBO-A1:C%#XDNZH+@#MJJG%?>K6!QX]X\-8M7*MZRW<@0A7M@CM,^P
MLW+ZZ4T[Q.)YU_29=GU-HZD'4:%5)D$/+)-!4B\BPI'=,S8OC8Y-O#LY8B4)
M('F;+URDOHRBOI^2!\G1P?NC@^.#MR>[)X?OWAXGNV_WD]]WCXYVWYX<'ARO
M:_Q66NR??(W?FSE84F%Y6@N=#=#?T]J]+E ?G6H_SSC&O[SD7S9]=?A<$9AZ
M)''L8Z[+EB*S-I\YYZ])G-4)Y^TL+=$0<A#:EFE&08 41"OH@9.:0\HZ*"&9
M^JC%K]3+A$-1T_6(+* LP-G7Z)$V,-QXI+E4J9.@@X2T79:H+:8D^<KEFR:4
M'DHCX><.W?-'#(^)#1+IUCW*!0"*RZKQNJ@C,J.)*Y*,TB:?P8[Q!L[0AXDH
M/ 2N-*J!\XU&N7F(ND3H25CDU)J $EO+$N?K-8CL'^Y='\3?SSEM8Y[AC &1
M,L?<1^$T<^;(V%L)!NAB<$:GN7"A@@K.-$)UUV=!'T<;2?(:6%[:2>OEBNJ@
M*.9X*[F/&[4&2D0N0!LH-?D@U#1E#("4]"V<Q5'&H52I!^;^)8SP<&N/8]0T
MW7->23Y3C]$0%GHT6JH<?=2!Q7./N&\H?4JL&C(J=JV9+61 "%$*^YT)H2LC
M1;@E/,$UDU<H#"JE!?V+:H1<+J77XV/D(JO-H#X!6.&;I1?[99U;T]S:+]]Q
M;NU+J=FY74UA66UNG'E-X:V+E'6KA-D&WL\%DGC('/I.!4^F:HJ"XMY7?#BM
ME!/Q@<&J+%-, ]0>.V\Z'Y(6@SBX\0^2P+_1-HBIO5/)W5T1(\J@?7/"UBC'
M<H0G'_1C:)A%U4!C2)<#BY<&-&MT@B@K&1,0V8^!\:FIZ5LP&>(GP@#FI_)+
M=A".X'Z>>:9G6SS51R[6QN;ZT31?>##BS_23-:4<PM6K>,H^:K3$3_;A)CC(
M:S<X<H-W&\\1&(<+.F5;5)<@*X&]ETJ+ZVM89;0XANCCJ+XF>?7FO?YP0!2$
M8<DYUUXHM39AF<0%![-W(]3*HSC#ZI;_)!N>EU51G5UI@[CMA3]P6W-<9WS?
M89&EM19'%+G[K5.EYVZ",T!ZW=$XGYS6V/*DL:2Q#;0H-C))U[1JFDR($XB8
M;;VG([]YB81U\&58_FI*A4US6FI$1[J]H-_7%4EF?X.*Y)>=)7Q,F?$?URL5
M>==+5JH4@(L)TGO2SQ8[ 2"'TH^*L+F!0%!L#MN0BGY!"W_!@7W:4G*YVX!+
M>EG!KN%!]8,P!@(W.L]/\QEGI@]?/WCT$__*?(J? 4P[M;^RU$2$$FFYJQUD
MBPV[K0E&KPT-+)&UV;D6%"='K&\#7*"Z,5S 5OPZ5XTU@XT3(*S7K>2]++G^
M2RG.&1 ;V-86!-EWT %+OB&N).+FHU0&PO1%2FTJR/X;)?,I=X"1!F:^),MW
MS<(?_U%6EP]^JRY-:U'W_#?2LZ81"'<$J&"8=_30^(7#??3N T.:N;EQW3-O
M/3OK/6 =NF5[H.IJ&*R*F^DSJ&-3'!5#!2^Y;$$6IN&BFV@S!4"^=;NX:.AF
M?01%=RY#;:Y7/&((7[+B?@E]K+.;W#^#2Y.DZMAS?:HO(0D^>+S@9IN;#4O:
M1D[PCJB9X]R0A@5"2__U>GUU?<^NLZ J;>E)ZTI9"^XPF%'P^-H]/SM'I5M6
M"N&E+Z8;L"U6"S$U?4-9S,V-LQK[,K!(2#M24PG^,2^9!7X(O$96GBFW16!C
MCKF8!Q+#R1%R;QHRWG <U,UY/EU$RDRQHAX:[ #$'5!0/25IS/Y(P20[\*!H
MC,?494D02_%E/"\,T(U^0RZC\&)1(15]L+F!.#["!X>_"A87M9YX:%Y*+&U:
M5^X7(-]&3;X4;97.%1$R:JW4"J35N&3HSG1,'T=)Q>G-X<P<SV@KR;;$H7H"
MH!E*43<WWA'=KH:K)*+FZ5=\0ECI';8'GAQ?>7-H01+/<+I(B0_Z5+A2B7-^
M9"D _\9M8S7$IQ>VK^N]C ?2VUA6%*$(&4O_NL'*2AF0IP_7&1#)@#Q]N,Z
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M^"G>,^4N)L#40;-6-NX5FKV1V%/,K4/A(K&:7NSLI2J[?#)-A]I%'OBP]FU
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MA'3I)580S.XI952)2SF4%R$ %!>HD7/&CZ3'9.$A_ 2G9UE 4^- +J(.J5L
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M6;Q->MSNOFSG/>7P).\FN#3*O?F2>=2RL,J_R-W$P9LN:1M1"7UW%U#\.OR
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M^6XO<[F!K:W!*JKLBJD$ ]L9!(S=-UWAA"R^.F, H5P%LAW%%KA[X)E:&=*
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M),N48F*/8^>;67T1;'<I!2N[$/-(>$=RE+\Q]G7D]=2H>YFF'OX%4$L#!!0
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M6 (4A\8(]<E(8 P5H3J/CW0-[0'WC-[R&_?BGD-KC_P'4$L! A0#%     @
M\8%N5+\-'XOB,@  I)8! !H              ( !     &5A,34V-SDP+7,Q
M83)?:&5L:7AA8W$N:'1M4$L! A0#%     @ \8%N5*@(#2!*$   =5X  !P
M             ( !&C,  &5A,34V-SDP97@Q,"TQ,%]H96QI>&%C<2YH=&U0
M2P$"% ,4    " #Q@6Y4IO9,W^+%  #Z2 4 '               @ &>0P
M96$Q-38W.3!E>#$P+3$Q7VAE;&EX86-Q+FAT;5!+ 0(4 Q0    ( /&!;E1[
MP(?8O0L  $I#   <              "  ;H) 0!E83$U-C<Y,&5X,3 M,3)?
M:&5L:7AA8W$N:'1M4$L! A0#%     @ \8%N5&J; XV##P  "%D  !P
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2      D "0!^ @  ]B@"

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
